{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/rafael/.conda/envs/IA_TexT/lib/python3.8/site-packages/umap/distances.py:1063: NumbaDeprecationWarning: \u001B[1mThe 'nopython' keyword argument was not supplied to the 'numba.jit' decorator. The implicit default value for this argument is currently False, but it will be changed to True in Numba 0.59.0. See https://numba.readthedocs.io/en/stable/reference/deprecation.html#deprecation-of-object-mode-fall-back-behaviour-when-using-jit for details.\u001B[0m\n",
      "  @numba.jit()\n",
      "/home/rafael/.conda/envs/IA_TexT/lib/python3.8/site-packages/umap/distances.py:1071: NumbaDeprecationWarning: \u001B[1mThe 'nopython' keyword argument was not supplied to the 'numba.jit' decorator. The implicit default value for this argument is currently False, but it will be changed to True in Numba 0.59.0. See https://numba.readthedocs.io/en/stable/reference/deprecation.html#deprecation-of-object-mode-fall-back-behaviour-when-using-jit for details.\u001B[0m\n",
      "  @numba.jit()\n",
      "/home/rafael/.conda/envs/IA_TexT/lib/python3.8/site-packages/umap/distances.py:1086: NumbaDeprecationWarning: \u001B[1mThe 'nopython' keyword argument was not supplied to the 'numba.jit' decorator. The implicit default value for this argument is currently False, but it will be changed to True in Numba 0.59.0. See https://numba.readthedocs.io/en/stable/reference/deprecation.html#deprecation-of-object-mode-fall-back-behaviour-when-using-jit for details.\u001B[0m\n",
      "  @numba.jit()\n",
      "/home/rafael/.conda/envs/IA_TexT/lib/python3.8/site-packages/umap/umap_.py:660: NumbaDeprecationWarning: \u001B[1mThe 'nopython' keyword argument was not supplied to the 'numba.jit' decorator. The implicit default value for this argument is currently False, but it will be changed to True in Numba 0.59.0. See https://numba.readthedocs.io/en/stable/reference/deprecation.html#deprecation-of-object-mode-fall-back-behaviour-when-using-jit for details.\u001B[0m\n",
      "  @numba.jit()\n"
     ]
    }
   ],
   "source": [
    "import matplotlib as mpl\n",
    "import pandas as pd\n",
    "from nltk.tokenize import word_tokenize\n",
    "from nltk.stem import WordNetLemmatizer\n",
    "from sklearn.decomposition import PCA, TruncatedSVD, IncrementalPCA, KernelPCA, SparsePCA, FastICA, FactorAnalysis\n",
    "import umap.umap_ as umap_\n",
    "import hdbscan\n",
    "from sklearn.utils import shuffle\n",
    "from sklearn.discriminant_analysis import LinearDiscriminantAnalysis\n",
    "from sklearn.manifold import TSNE, LocallyLinearEmbedding, Isomap, SpectralEmbedding, MDS\n",
    "import matplotlib.patches as mpatches\n",
    "import re\n",
    "from sklearn.metrics import calinski_harabasz_score, davies_bouldin_score\n",
    "from sklearn.random_projection import SparseRandomProjection\n",
    "from unidecode import unidecode\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "from numba.core.errors import NumbaDeprecationWarning, NumbaPendingDeprecationWarning\n",
    "import warnings\n",
    "from sklearn.cluster import KMeans\n",
    "from sklearn.metrics import pairwise_distances\n",
    "import nltk\n",
    "import numpy as np\n",
    "from matplotlib import pyplot as plt\n",
    "import os\n",
    "import shutil\n",
    "from sklearn.metrics import silhouette_samples, silhouette_score\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.tokenize import word_tokenize\n",
    "warnings.simplefilter('ignore', category=NumbaDeprecationWarning)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-05-24T14:17:28.719958306Z",
     "start_time": "2023-05-24T14:17:12.102575378Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "outputs": [],
   "source": [
    "def extract_top_n_words_per_topic(tf_idf, count, docs_per_topic, n=20):\n",
    "    words = count.get_feature_names_out()\n",
    "    labels_ = list(docs_per_topic.Topic)\n",
    "    tf_idf_transposed = tf_idf.T\n",
    "    indices = tf_idf_transposed.argsort()[:, -n:]\n",
    "    top_n_words = {label: [(words[j], tf_idf_transposed[i][j]) for j in indices[i]][::-1] for i, label in enumerate(labels_)}\n",
    "    return top_n_words\n",
    "\n",
    "def extract_topic_sizes(df):\n",
    "    topic_sizes = (df.groupby(['Topic'])\n",
    "                   .Doc\n",
    "                   .count()\n",
    "                   .reset_index()\n",
    "                   .rename({\"Topic\": \"Topic\", \"Doc\": \"Size\"}, axis='columns')\n",
    "                   .sort_values(\"Size\", ascending=False))\n",
    "    return topic_sizes\n",
    "\n",
    "\n",
    "def c_tf_idf(documents, m, ngram_range=(1, 1)):\n",
    "    count = CountVectorizer(ngram_range=ngram_range).fit(documents)\n",
    "    t = count.transform(documents).toarray()\n",
    "    w = t.sum(axis=1)\n",
    "    tf = np.divide(t.T, w)\n",
    "    sum_t = t.sum(axis=0)\n",
    "    idf = np.log(np.divide(m, sum_t)).reshape(-1, 1)\n",
    "    tf_idf = np.multiply(tf, idf)\n",
    "\n",
    "    return tf_idf, count\n",
    "\n",
    "def map_labels_to_colors(labels,cmap_):\n",
    "    cmap = plt.get_cmap(cmap_)\n",
    "    num_labels = np.max(labels) + 1\n",
    "    colors = cmap(np.linspace(0, 1, num_labels))\n",
    "    # print(colors)\n",
    "    return colors[labels]\n",
    "\n",
    "\n",
    "def gera_comparacao(list_preprossing_,cluster_):\n",
    "    docs_df = pd.DataFrame(list_preprossing_,columns=[\"Doc\"])\n",
    "    docs_df['Topic'] = cluster_\n",
    "    docs_df['Doc_ID'] = range(len(docs_df))\n",
    "    docs_per_topic=docs_df.groupby([\"Topic\"],as_index=False).agg({\"Doc\":' '.join})\n",
    "    tf_idf, count = c_tf_idf(docs_per_topic.Doc.values, m=len(list_preprossing_))\n",
    "    top_n_words = extract_top_n_words_per_topic(tf_idf, count, docs_per_topic, n=5)\n",
    "    topic_sizes = extract_topic_sizes(docs_df)\n",
    "    # print(top_n_words)\n",
    "    legends=[top_n_words[i][0] for i in top_n_words]\n",
    "    return  legends\n",
    "\n"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-05-24T14:17:28.740235085Z",
     "start_time": "2023-05-24T14:17:28.734376184Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package stopwords to /home/rafael/nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n",
      "[nltk_data] Downloading package punkt to /home/rafael/nltk_data...\n",
      "[nltk_data]   Package punkt is already up-to-date!\n",
      "[nltk_data] Downloading package wordnet to /home/rafael/nltk_data...\n",
      "[nltk_data]   Package wordnet is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "\n",
    "nltk.download('stopwords')\n",
    "nltk.download('punkt')\n",
    "nltk.download('wordnet')\n",
    "stopwords_ = set(stopwords.words('portuguese'))\n",
    "\n",
    "\n",
    "def preprocess_text(text):\n",
    "    # Conversão para minúsculas\n",
    "    text = text.lower()\n",
    "    # Remoção de pontuações\n",
    "    text = re.sub(r'[^\\w\\s]', '', text)\n",
    "    # Remoção de caracteres especiais, preservando letras acentuadas\n",
    "    text = re.sub(r'[^a-zA-Z0-9áéíóúÁÉÍÓÚâêîôûÂÊÎÔÛàèìòùÀÈÌÒÙãõñÃÕÑçÇ\\s]+', '', text)\n",
    "    text = unidecode(text)\n",
    "    return text"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-05-24T14:17:29.128482620Z",
     "start_time": "2023-05-24T14:17:28.753825838Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['promestrieno promestrieno promestrieno indicado tratamento alteracoes troficas disturbios vulva vagina causadas reducao falta estrogenio organismo promestrieno tambem indicado acelerar cicatrizacao lesoes vagina colo utero periodo posparto normal poscirurgia apos terapias locais agentes fisicos voce nao deve utilizar promestrieno seguintes casos hipersensibilidade alergia conhecida promestrieno qualquer componentes formulacao amamentando utiliza produtos espermicidas historico suspeita cancer mama historico suspeita tumor maligno estrogeno dependente tal cancer endometrial sangramento vaginal causa desconhecida hiperplasia endometrial crescimento excessivamente anormal endometrio nao tratada antecedente quadro tromboembolismo venoso formacao coagulo dentro veia impedindo circulacao sangue tai trombose venosa profunda formacao coagulo sanguineo veia embolia pulmonar formacao coagulo pulmao disturbios trombofilicos diagnosticados tai deficiencia proteina c proteina s antitrombina vide item 4 devo saber ante usar medicamento doenca tromboembolica doenca coagulacao sangue arterial ativa recente tal angina dor peito infarto miocardio doenca hepatica doenca figado aguda historico doenca hepatica funcao hepatica nao retornado normalidade porfiria doenca genetica rara manifesta atraves problemas pele eou complicacoes neurologicas medicamento contraindicado uso homens medicamento nao deve utilizado mulheres gravida possam ficar gravida durante tratamento creme estrogenos simple venda sob prescricao medica genericos'\n",
      " 'ampicilina ampicilina ampicilina indicada tratamento diversas infeccoes causadas microorganismos sensiveis medicamento sao infeccoes trato urinario infeccoes urinarias infeccoes trato respiratorio amidalites sinusites pneumonia infeccoes trato digestivo biliar infeccoes intestinais vesicula biliar infeccoes localizadas sistemicas generalizadas especialmente causadas germes grupo enterococos haemophilus proteus salmonella coli infeccoes bucais extracoes dentaria infectadas outras intervencoes cirurgicas ampicilina contraindicada pacientes historia reacoes hipersensibilidade alergia penicilinas classe antibioticos onde ampicilina enquadra eou demais componentes formulacao tambem nao deve administrada pacientes sensiveis cefalosporinas outra classe antibioticos devido ocorrencia reacao alergica cruzada medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista capsula dura penicilina amplo espectro retencao so pode vendido retencao receita genericos'\n",
      " 'dejavu citrato sildenafila dejavu citrato sildenafila indicado tratamento disfuncao eretil entende sendo incapacidade atingir manter erecao suficiente desempenho sexual satisfatorio dejavu citrato sildenafila eficaz necessario estimulo sexual uso dejavu citrato sildenafila contraindicado pacientes hipersensibilidade conhecida farmaco qualquer componente formula demonstrado dejavu citrato sildenafila potencializa efeito hipotensor nitratos uso agudo cronico estando portanto contraindicada administracao pacientes usando concomitantemente qualquer forma doadora oxido nitrico nitratos organicos nitritos organicos tanto uso frequente quanto uso intermitente vide item 6 interacoes medicamentosas coadministracao inibidores pde5 incluindo sildenafila estimuladores guanilato ciclase tai riociguate contraindicada vez pode potencialmente levar hipotensao sintomatica medicamento contraindicado uso pacientes tratamento medicamentos contenham qualquer forma doadora oxido nitrico nitratos organicos nitritos organicos medicamento contraindicado uso mulheres medicamento contraindicado menores 18 ano comprimido revestido vasodilatadores venda sob prescricao medica prescricao medica'\n",
      " 'cefadroxilacapsuladura cefadroxila cefadroxila indicada tratamento infeccoes causadas bacteria sensiveis eficacia cefadroxila manifestase melhora estado geral paciente incluindo regressao febre sinai sintomas infeccao cefadroxila nao deve utilizada caso voce apresente alergia intolerancia cefadroxila qualquer outro componente produto tambem nao deve utilizado caso voce apresente alergia penicilina antibioticos classe cefalosporinas ante utilizacao verifique voce possui antecedentes alergicos especialmente componentes formulacao medicamento nao deve utilizado mulheres gravida orientacao medico cirurgiaodentista informe medico cirurgiaodentista voce fazendo uso algum outro medicamento capsula dura antibioticos sistemicos simple retencao so pode vendido retencao receita genericos'\n",
      " 'cogmax oleo soja veiculo bisglicinato magnesio dimagnesio malato bitartarato colina oleo peixe veiculo agua purificada veiculo bisglicinato zinco selenio metionina acetato dl alfa tocoferol pantotenato calcio cianocobalamina cloridrato piridoxina mononitrato tiamina acido folico colecalciferol gelificante gelatina umectante glicerina emulsificante lecitina soja glaceante cera abelha corantes amarelo tartrazina dioxido titanio oxido ferro preto verde rapido fcf cogmax formulacao exclusiva base minerais vitaminas desenvolvida atuar manutencao saude mix exclusivo minerais aminoacidos quelatados cogmax aliado conjunto vitaminas atuam sinergia maximo aproveitamento organismo gestantes nutrizes criancas ate 3 tres ano somente devem consumir produto sob orientacao nutricionistas medico capsula dura medicamento isento prescricao isento prescricao suplemento alimentar'\n",
      " 'trisk daptomicina trisk daptomicina utilizado adultos 18 ano criancas 1 17 ano tratamento infeccoes pele partes mole complicadas tambem utilizado adultos 18 ano idade criancas 1 17 ano tratamento infeccoes sanguineas adultos infeccoes tecido reveste parte interna coracao incluindo valvula cardiacas causadas bacteria staphylococcus aureus medicamento nao utilizado tratamento pneumonia infeccao inflamacao tecido pulmonar voce nao deve usar medicamento voce alergico hipersensivel daptomicina qualquer outro ingrediente deste medicamento aplicar voce informe medico enfermeiro voce acha alergico certeza solicite recomendacoes medico enfermeiro po liofilizado solucao injetavel antibioticos sistemicos simple retencao so pode vendido retencao receita hospitalar'\n",
      " 'itraconazol itraconazol itraconazol medicamento utilizado tratamento infeccoes fungicas micoses vagina pele boca olhos unhas orgaos internos nao utilize itraconazol voce alergico itraconazol qualquer componentes medicamento voce gravida menos medico saiba voce gravida decida voce precisa tomar itraconazol voce idade fertil voce deve tomar precaucoes contraceptivas adequadas ter certeza nao engravidara enquanto tomando itraconazol itraconazol permanece organismo algum tempo apos termino tratamento voce deve continuar medidas contraceptivas ate proxima menstruacao apos final tratamento itraconazol voce possui insuficiencia cardiaca tambem chamada insuficiencia cardiaca congestiva icc itraconazol pode agravar doenca caso medico decida voce deva utilizar itraconazol voce condicao procure auxilio medico imediatamente voce falta ar ganho peso inesperado inchaco pernas fadiga nao usual comecar acordar durante noite voce tambem nao deve utilizar certos medicamentos enquanto utilizando itraconazol existem muitos medicamentos interferem itraconazol vide item 4 devo saber ante usar medicamento interacoes medicamentosas medicamento contraindicado uso pacientes insuficiencia cardiaca medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiao dentista capsula dura antimicoticos sistemicos venda sob prescricao medica genericos'\n",
      " 'don5mg cloridrato donepezila don cloridrato donepezila indicado tratamento sintomatico demencia alzheimer intensidade leve moderadamente grave grave diagnostico demencia alzheimer deve realizado acordo criterios cientificos aceitos dsm iv icd10 don cloridrato donepezila contraindicado pacientes conhecida hipersensibilidade cloridrato donepezila derivados piperidina qualquer excipiente usado formulacao categoria c risco gravidez portanto medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido revestido retencao so pode vendido retencao receita prescricao medica'\n",
      " 'tamisasemparar gestodeno etinilestradiol tamisa 30 parar gestodeno etinilestradiol contraceptivo oral uso continuo indicado prevencao gravidez cocs nao devem utilizados mulheres apresentem qualquer seguintes condicoes trombose venosa profunda historia anterior atual tromboembolismo historia anterior atual doenca cerebrovascular arterialcoronariana valvulopatias trombogenicas disturbios trombogenicos trombofilias hereditarias adquiridas cefaleia sintomas neurologicos focais tai aura diabetes alteracoes vasculares hipertensao nao controlada carcinoma mama conhecido suspeito outra neoplasia estrogenio dependente conhecida suspeita adenoma carcinoma hepaticos doenca hepatica ativa desde funcao hepatica nao retornado normal sangramento vaginal etiologia esclarecer pancreatite associada hipertrigliceridemia severa historia anterior atual gravidez confirmada suspeita hipersensibilidade qualquer componentes tamisa 30 parar gestodeno etinilestradiol gravidez categoria risco x medicamento nao deve utilizado mulheres gravida possam ficar gravida durante tratamento dragea anticoncepcionais venda sob prescricao medica prescricao medica'\n",
      " 'tadalafila20mg tadalafila medicamento indicado tadalafila indicado tratamento disfuncao eretil nao devo usar medicamento tadalafila nao indicado homens nao apresentam disfuncao eretil tadalafila nao deve usado pacientes alergicos tadalafila qualquer componentes comprimido tadalafila nao deve administrada pacientes utilizando medicamentos contendo nitratos tai propatilnitrato sustrate isossorbida monocordil cincordil isordil nitroglicerina nitradisc nitroderm tt nitronal tridil dinitrato isossorbitol isocord nao ha recomendacoes advertencias especiais quanto uso tadalafila idosos medicamento contraindicado uso mulheres comprimido revestido vasodilatadores venda sob prescricao medica genericos'\n",
      " 'corretal capecitabina medicamento indicado cancer mama corretal capecitabina combinacao docetaxel indicado tratamento pacientes cancer mama metastatico apos falha quimioterapia citotoxica antraciclina corretal capecitabina monoterapia indicado tratamento pacientes cancer mama metastatico resistente regime quimioterapia paclitaxel antraciclina resistente paclitaxel pacientes terapia adicional antraciclina nao indicada pacientes receberam dos cumulativas 400 mgm2 doxorrubicina equivalente definese resistencia progressao doenca vigencia tratamento resposta inicial recorrencia ate 6 me termino tratamento adjuvante antraciclina regime contenham antraciclina cancer colorretal corretal capecitabina indicado tratamento adjuvante pacientes cancer colorretal duke c estagio iii submetidos resseccao completa tumor primario casos preferencia terapia fluoropirimidinas capecitabina demonstrou nao inferioridade 5fulv 5 fluoruracila acido folinico refere sobrevida livre doenca embora capecitabina quimioterapia combinada prolonguem sobrevida global quimioterapia combinada demonstrado melhor sobrevida livre doenca comparada 5fulv medico deve considerar resultados prescrever corretal capecitabina monoterapia tratamento adjuvante cancer colorretal duke c corretal capecitabina indicado tratamento primeira linha pacientes cancer colorretal metastatico casos preferencia terapia fluoropirimidinas quimioterapia combinada demonstrado beneficio sobrevida comparado monoterapia 5fulv comparacao capecitabina combinacao oxaliplatina 5fulv combinacao oxaliplatina assegurar seguranca manutencao vantagem sobrevida nao adequadamente estudada corretal capecitabina combinado oxaliplatina combinado oxaliplatina bevacizumabe indicado tratamento primeira linha cancer colorretal metastatico corretal capecitabina tambem pode combinado oxaliplatina corretalbulavpsv9 versao 09 versao altera versao 08 tratamento segunda linha cancer colorretal metastatico pacientes previamente tratados irinotecano combinacao regime fluoropirimidina terapia primeira linha cancer gastrico corretal capecitabina indicado tratamento primeira linha pacientes cancer gastrico estagio avancado desde associada compostos platina cisplatina oxaliplatina corretal capecitabina contraindicado pacientes hipersensibilidade conhecida capecitabina quaisquer excipientes formula produto corretal capecitabina contraindicado pacientes apresentam historia reacoes graf inesperadas terapia fluoropirimidinas hipersensibilidade conhecida fluoruracila corretal capecitabina contraindicado pacientes conhecida ausencia completa atividade enzimatica dpd diidropirimidina desidrogenase corretal capecitabina nao deve administrado concomitantemente sorivudina analogos quimicamente relacionados brivudina vide item 6 interacoes medicamentosas medicamento contraindicado uso pacientes insuficiencia renal grave depuracao creatinina inferior 30 mlmin existirem contraindicacoes qualquer agentes combinacao agente nao deve utilizado categoria risco gravidez d medicamento nao deve utilizado mulheres gravida orientacao medica informe imediatamente medico caso suspeita gravidez comprimido revestido venda sob prescricao medica oncologia'\n",
      " 'cloridratodememantina cloridrato memantina medicamento indicado cloridrato memantina indicado tratamento doenca alzheimer moderada grave nao devo usar medicamento nao tomar cloridrato memantina voce alergico cloridrato memantina qualquer outro componente formulacao veja composicao medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiao dentista comprimido revestido retencao so pode vendido retencao receita genericos'\n",
      " 'linezolida linezolida linezolida indicada tratamento infeccoes presumidas comprovadamente causadas bacteria sensiveis vide espectro acao item 3 caracteristicas farmacologicas infeccoes bacterianas destacam associadas bacteremia concomitante exemplo 1 pneumonia adquirida ambiente hospitalar servicos relacionados assistencia saude incluindo relacionadas ventilacao mecanica comunitario 2 infeccoes pele partes mole complicadas incluindo pe diabetico osteomielite concomitante nao complicadas 3 infeccoes enterococicas incluindo causadas cepas enterococcus faecium enterococcus faecalis resistentes vancomicina medicamento ativo somente contra bacteria grampositivas linezolida nao atividade contra patogenos gramnegativos exigida terapia gramnegativa especifica caso confirme suspeite patogeno gramnegativo concomitante vide item 5 advertencias precaucoes item 3 caracteristicas farmacologicas linezolida contraindicada pacientes apresentam hipersensibilidade linezolida qualquer componentes formula linezolida tambem contraindicada pacientes utilizando qualquer medicamento inibidor monoaminoxidases b ex fenelzina isocarboxazida ate duas semanas uso qualquer destes medicamentos menos pacientes monitorados quanto potencial aumento pressao sanguinea linezolida nao deve administrada pacientes hipertensao nao controlada feocromocitoma tireotoxicose eou pacientes utilizando algum seguintes tipos medicamentos agentes simpatomimeticos acao direta indireta ex pseudoefedrina fenilpropanolamina agentes vasoconstritores ex epinefrina norepinefrina agentes dopaminergicos ex dopamina dobutamina vide item 6 interacoes medicamentosas medicamento nao deve administrado pacientes sindrome carcinoide eou pacientes utilizando algum seguintes medicamentos inibidores recaptacao serotonina antidepressivos triciclicos agonistas receptor serotonina 5ht1 triptanos meperidina buspirona vide item 6 interacoes medicamentosas menos sinai eou sintomas sindrome serotoninergica cuidadosamente observados pacientes solucao injetavel antibioticos sistemicos simple retencao so pode vendido retencao receita hospitalar'\n",
      " 'ibandronatodesodiomonoidratado ibandronato sodio monoidratado medicamento indicado tratamento osteoporose enfraquecimento ossos posmenopausa finalidade reduzir risco fraturas vertebrais voce nao devera tomar medicamento conhecida hipersensibilidade alergia ibandronato sodio demais componentes formula produto paciente hipocalcemia baixo nivel calcio sangue nao corrigida tal acontece varios bisfosfonatos voce nao devera tomar medicamento anormalidades esofago demora esvaziamento esofagico estenose estreitamento esofago acalasia ausencia relaxamento esofago voce nao devera tomar medicamento nao conseguir ficar pe sentado durante menos 60 minutos medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiao dentista comprimido revestido venda sob prescricao medica genericos'\n",
      " 'sulbactamsodicaampicilinasodica sulbactam sodico ampicilina sodica medicamento sulbactam sodico ampicilina sodica injetavel indicado infeccoes causadas microrganismos suscetiveis indicacoes comuns sao infeccoes trato respiratorio inferior superior incluindo sinusite infeccao seios face otite medium infeccao ouvido medio epiglotite infeccao epiglote parte garganta pneumonia bacterianas infeccoes pulmonares causadas bacteria infeccoes trato urinario pielonefrite infeccao rins infeccoes intraabdominais incluindo peritonite infeccao peritonio camada recobre orgaos internos abdominais colecistite inflamacao vesicula biliar endometrite infeccao endometrio camadas utero celulite pelvica infeccao pele tecido subcutaneo regiao pelvica sepse bacteriana disseminacao bacteria partir foco infeccao atraves sangue infeccoes pele tecidos mole infeccoes osso articulacoes infeccoes gonococicas causadas bacteria gonococo sulbactam sodico ampicilina sodica injetavel tambem pode administrado perioperatorio momentos ante incisao cirurgica reduzir incidencia infeccoes feridas cirurgicas pacientes submetidos cirurgia pelvica abdominal casos regiao operada possa contaminada bacteria trabalho parto cesarea sulbactam sodico ampicilina sodica injetavel pode usado reduzir chance infeccao posoperatoria uso sulbactam sodico ampicilina sodica injetavel contraindicado caso voce historia reacao alergica qualquer penicilina qualquer componente formula nao ha contraindicacao relativa faixas etarias medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista po solucao injetavel antibioticos sistemicos simple retencao so pode vendido retencao receita hospitalar'\n",
      " 'hemolenta cloreto sodio sulfato magnesio heptaidratado hemolenta solucao eletrolitica base composicao solucao dialisante apos aditivacao obrigatoria solucao hemolenta agente tampote preferencialmente bicarbonato sodio calcio necessario cloreto magnesio potassio eou glicose solucao utilizada procedimentos hemodialise venovenosa continuum cvvhd terapia indicada pacientes lesao renal aguda estao hemodinamicamente instaveis pacientes acidentadostraumatizados nao toleramsuportam hemodialise convencional devido quadro hipotensao arterial acentuada necessidade remocao grandes quantidades liquidos excesso compostos nitrogenados ureia creatinina potassio forma lenta concentracao agente tampote bicarbonato sodio calcio adicionada solucao hemolenta alem concentracao cloreto magnesio potassio eou glicose serem adicionados necessario ficara criterio medico especialista acordo estado clinico cada paciente considerando concentracao hemolenta ante aditivacao especificacao final solucao dialisante relacionadas solucao dialisante hemolenta apos aditivacao obrigatoria agente tampote bicarbonato sodio calcio hipopotassemia hipocalemia alcalose metabolica nestes casos sugerese reducao nivel bicarbonato solucao dialisante relacionadas terapia hemodialise venovenosa continuum cvvhd anticoagulacao sistemica risco hemorragia pressao arterial insuficiente acesso vascular medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista categoria c medicamento nao deve utilizado mulheres gravida orientacao medica solucao hemodialise produtos hemodialise venda sob prescricao medica hospitalar'\n",
      " 'paracetamolfosfatodecodeina paracetamol fosfato codeina medicamento indicado medicamento paracetamol fosfato codeina indicado alivio dores grau moderado intenso decorrentes traumatismo entorses luxacoes contusoes distensoes fraturas posoperatorio posextracao dentaria neuralgia lombalgia dores origem articular condicoes similares nao devo usar medicamento nao utilize paracetamol fosfato codeina voce apresenta alergia conhecida paracetamol codeina qualquer outros componentes medicamento codeina contraindicada dor criancas abaixo 12 ano codeina contraindicada tratamento dor posoperatoria criancas adolescentes abaixo 18 ano submetidas tonsilectomia eou adenoidectomia medicamento paracetamol fosfato codeina contraindicado metabolizadores ultrarrapidos cyp2d6 convertem codeina metabolito ativo completamente rapido outras pessoas individuos podem apresentar sinai overdosetoxicidade incluindo sintomas tai sonolencia extremum confusao respiracao superficial pode fatal medicamento contraindicado uso maes amamentando medicamento contraindicado menores 12 ano medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido analgesicos narcoticos retencao so pode vendido retencao receita genericos'\n",
      " 'cloridratodemetilfenidato cloridrato metilfenidato cloridrato metilfenidato utilizado tratamento transtorno deficit atencaohiperatividade transtorno deficit atencaohiperatividade tdah transtorno hipercinetico disturbio comportamento criancas adolescentes cerca 3 criancas sofrem deste transtorno torna incapazes ficarem paradas eou concentrar tarefas determinado periodo tempo criancas transtorno podem ter dificuldades aprender fazer tarefas escolares podem frequentemente tornar dificil lidar tanto escola quanto casa adultos tdah frequentemente dificuldade concentrar costumam sentir inquietos impacientes desatentos ficam entediados facilidade podem ter dificuldades organizar vida pessoal trabalho paciente crianca voce adolescente medico prescreveu cloridrato metilfenidato parte programa tratamento tdah incluira tambem usualmente terapia psicologica educacional social voce alguma duvida sobre funciona cloridrato metilfenidato porque medicamento receitado voce pergunte medico cloridrato metilfenidato tambem utilizado tratamento narcolepsia narcolepsia disturbio sono pacientes narcolepsia vivenciam repetidos ataques sonolencia durante dia apos noite adequada sono narcolepsia deve diagnosticada medico atraves padrao registrado sonovigilia nao tome cloridrato metilfenidato voce alergico hipersensivel metilfenidato qualquer outro componente medicamento listado inicio desta bula voce achar pode alergico peca orientacao medico sofre ansiedade tensao agitacao algum problema tireoide problemas cardiacos ataque cardiaco batimento cardiaco irregular dor peito angina insuficiencia cardiaca doenca cardiaca nasceu problema coracao pressao sanguinea alta hipertensao estreitamento vasos sanguineos doenca arterial oclusiva pode causar dor bracos pernas tomando medicamento chamado inibidor monoamino oxidase imao utilizado tratamento depressao tomado imao ultima duas semanas vide item 4 devo saber ante usar medicamento ingestao concomitante outras substancias pressao ocular aumentada glaucoma tumor glandula adrenal chamado feocromocitoma fala movimentos corporeos incontrolaveis sindrome tourette qualquer outro membro familia portador desta sindrome voce acha algum casos acima aplicase voce informe medico tomar cloridrato metilfenidato comprimido retencao so pode vendido retencao receita genericos'\n",
      " 'cloridratodedexmedetomidina cloridrato dexmedetomidina cloridrato dexmedetomidina sedativo indutor estado calmo indicado uso pacientes ventilacao mecanica durante tratamento intensivo unidade terapia intensiva salas cirurgia procedimentos diagnosticos cloridrato dexmedetomidina contraindicado pacientes alergia conhecida dexmedetomidina qualquer excipiente formula medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista solucao injetavel hipnoticos retencao so pode vendido retencao receita hospitalar'\n",
      " 'escsolucaooral oxalato escitalopram esc oxalato escitalopram indicado tratamento prevencao recaida recorrencia depressao tratamento transtorno panico agorafobia tratamento transtorno ansiedade generalizada tag tratamento transtorno ansiedade social fobia social tratamento transtorno obsessivo compulsivo toc esc oxalato escitalopram contraindicado pacientes apresentam hipersensibilidade escitalopram qualquer componentes ver composicao tratamento concomitante imao inibidores monoaminoxidase nao seletivos irreversiveis contraindicado devido risco sindrome serotoninergica agitacao tremor hipertermia etc ver item 6 interacoes medicamentosas tratamento concomitante pimozida contraindicado combinacao escitalopram imaoa ex moclobemida reversiveis linezolida imao nao seletivo reversivel contraindicada devido risco sindrome serotoninergica ver item 6 interacoes medicamentosas esc oxalato escitalopram contraindicado pacientes diagnosticados prolongamento intervalo qt sindrome congenita qt longo esc oxalato escitalopram contraindicado uso concomitante medicamentos causam prolongamento intervalo qt ver item 6 interacoes medicamentosas fertilidade gravidez lactacao gravidez categoria risco b dado clinicos utilizacao oxalato escitalopram durante gravidez sao limitados estudos animais mostraram toxicidade reprodutiva ver item 2 resultados eficacia estudos animais nao usar esc oxalato escitalopram durante gravidez menos necessidade clara avaliado cuidadosamente riscobeneficio uso deste medicamento recemnascidos devem observados uso maternal escitalopram continuou ate estagios avancados gravidez particularmente terceiro trimestre escitalopram usado ate proximo dia nascimento efeitos descontinuacao recemnascido sao possiveis esc oxalato escitalopram usado durante gravidez nao interromper abruptamente descontinuacao devera gradual seguintes reacoes observadas recemnascidos apos uso isrsisrn ultimos me gravidez dificuldade respiratoria cianose apneia convulsoes instabilidade termica dificuldade alimentacao vomitos hipoglicemia hipertonia hipotonia hiperreflexia tremor agitacao irritabilidade letargia choro constante sonolencia dificuldade dormir efeitos tambem podem indicativos sindrome serotoninergica retirada abrupta medicamento durante gravidez maioria casos tai complicacoes comecam imediatamente brevemente 24 horas apos parto dado epidemiologicos sugerem uso isrs durante gravidez especialmente final gravidez pode aumentar risco hipertensao pulmonar persistente recemnascido hppn risco observado aproximadamente 5 casos cada 1000 gestantes populacao geral 1 2 casos hppn ocorrem cada 1000 gestantes lactacao escitalopram excretado leite materno mulheres fase amamentacao nao devem tratadas escitalopram situacoes onde nao possivel retirar medicamento devido gravidade quadro clinico materno substituir aleitamento materno leites industrializados especificos recemnascidos fertilidade estudos animais mostraram citalopram pode afetar qualidade esperma ver item 2 resultados eficacia estudos animais relatos casos humanos alguns isrss mostraram efeito qualidade esperma reversivel ate momento nao observado impacto fertilidade humana medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista solucao retencao so pode vendido retencao receita prescricao medica'\n",
      " 'quet hemifumarato quetiapina adultos quet hemifumarato quetiapina indicado tratamento esquizofrenia monoterapia adjuvante tratamento episodios mania associados transtorno afetivo bipolar episodios depressao associados transtorno afetivo bipolar tratamento manutencao transtorno afetivo bipolar i episodios maniaco misto depressivo combinacao estabilizadores humor litio valproato monoterapia tratamento manutencao transtorno afetivo bipolar episodios mania mistos depressivos adolescentes 13 17 ano quet hemifumarato quetiapina indicado tratamento esquizofrenia criancas adolescentes 10 17 ano quet hemifumarato quetiapina indicado monoterapia adjuvante tratamento episodios mania associados transtorno afetivo bipolar quet hemifumarato quetiapina contraindicado pacientes hipersensibilidade conhecida qualquer componente formula prescricao medica'\n",
      " 'pantoprazolpo pantoprazol sodico sesquihidratado medicamento indicado tratamento ulcera peptica gastrica duodenal ulcera causada acido estomago contato revestimento estomago inicio intestino esofagites refluxo moderadas graf doenca causada volta conteudo estomago esofago tratamento sindrome zollingerellison outras doencas causadoras producao exagerada acido estomago via oral nao recomendada criterio medico pantoprazol sodico sesquihidratadointravenoso iv tambem indicado tratamento hemorragia digestiva alta complemento terapia endoscopica prevencao ressangramento profilaxia sangramento agudo ulcera estresse pantoprazol sodico sesquihidratado iv nao deve usado individuos apresentem alergia hipersensibilidade conhecida pantoprazol demais componentes formula benzimidazois substituidos categoria b risco gravidez medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista po liofilizado solucao injetavel antiacidos antiulcerosos venda sob prescricao medica hospitalar'\n",
      " 'dexfer ferripolimaltose dexfer ferripolimaltose indicado sindromes ferropenicas latentes moderadas anemia ferroprivas devido subnutricao eou carencias alimentares qualitativas quantitativas anemia sindromes disabsortivas intestinais anemia ferropriva gravidez lactacao anemia hemorragias agudas cronicas onde conveniente suplementacao fatores hematologicos dexfer ferripolimaltose contraindicado casos hipersensibilidade sais ferro qualquer componentes produto toda anemia nao ferropenicas particularmente causadas acumulo ferro incapacidade utilizacao tai hemocromatose hemosiderose anemia falciforme anemia hemolitica anemia provocada chumbo anemia sideroacrestica talassemia anemia tumores infeccoes deficiencia ferro anemia associadas leucemia aguda cronica retocolite ulcerativa dexfer ferripolimaltose nao deve utilizado pacientes doencas hepatica agudas doencas gastrintestinais anemia nao causadas deficiencia ferro incapacidade utilizacao categoria risco gravidez categoria b medicamento nao deve utilizado mulheres gravida orientacao medico cirurgiaodentista forma farmaceutica solucao oral contraindicada menores 1 ano forma farmaceutica comprimido revestido contraindicada menores 12 ano comprimido solucao gotas xarope vitaminas venda sob prescricao medica prescricao medica'\n",
      " 'meropenem meropenem trihidratado meropenem trihidratado indicado tratamento seguintes infeccoes adultos criancas causadas unica multiplas bacteria sensiveis tratamento empirico ante identificacao microrganismo causador infeccoes trato respiratorio inferior infeccoes urinarias incluindo infeccoes complicadas infeccoes intraabdominais infeccoes ginecologicas incluindo infeccoes posparto infeccoes pele anexos meningite inflamacao membranas cerebro medula espinhal septicemia doenca sistemica causada propagacao microrganismos toxinas atraves sangue tratamento empirico incluindo monoterapia inicial infeccoes presumidamente bacterianas pacientes neutropenicos baixo numero neutrofilos sangue infeccoes polimicrobianas causadas varios microrganismos devido amplo espectro atividade bactericida contra bacteria grampositivas gramnegativas aerobias anaerobias meropenem eficaz tratamento infeccoes polimicrobianas fibrose cistica meropenem intravenoso sido utilizado eficazmente pacientes fibrose cistica infeccoes cronicas trato respiratorio inferior tanto monoterapia quanto associacao outros agentes antibacterianos patogeno nao sido sempre erradicado nestes tratamentos voce nao deve utilizar medicamento apresentar alergia meropenem carbonato sodio anidro ante iniciar tratamento meropenem trihidratado informe medico voce reacao alergica qualquer outro antibiotico incluindo penicilinas outros carbapenemicos outros antibioticos betalactamicos medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista po solucao injetavel antibioticos sistemicos simple venda sob prescricao medica hospitalar'\n",
      " 'rivaroxabana10mg rivaroxabana rivaroxabana usado prevenir formacao coagulos sangue veias apos cirurgia substituicao articulacao joelhos quadril medico prescreveu medicamento porque apos operacao voce risco aumentado ter coagulo sangue rivaroxabana indicado tratamento trombose veias profundas prevencao trombose veias profundas embolia pulmonar recorrentes adultos rivaroxabana indicado tratamento embolia pulmonar prevencao embolia pulmonar trombose veias profundas recorrentes adultos voce nao deve utilizar rivaroxabana voce alergico hipersensivel rivaroxabana qualquer outro componente formula componentes produto estao listados inicio bula voce sangramento requer cuidados especiais exemplo sangramento intracraniano sangramento gastrintestinal voce doenca hepatica grave lev aumento risco sangramento voce gravida amamentando nao use rivaroxabana fale medico qualquer eventos acima aplicar voce comprimido venda sob prescricao medica genericos'\n",
      " 'dicloridratodebetaistina dicloridrato betaistina medicamento indicado sindrome meniere caracterizada 3 tres principais sintomas vertigem sensacao tontura malestar acompanhado nausea vomito zumbido ouvidos perda dificuldade audicao sensacao tontura causada parte ouvido interno controla equilibrio nao funciodo corretamente chamada vertigem vestibular nao tome dicloridrato betaistina voce alergico hipersensibilidade betaistina qualquer componentes produto veja composicao medico informar voce possui tumor glandula adrenal chamado feocromocitoma nao tome medicamento alguma situacoes acima aplica voce voce nao certeza fale medico farmaceutico ante tomar dicloridrato betaistina medicamento nao deve utilizado mulheres gravida orientacao medica comprimido antivertiginosos venda sob prescricao medica genericos'\n",
      " 'ciprofloxacino ciprofloxacino adultos tratamento infeccoes complicadas nao complicadas causadas microrganismos sensiveis ciprofloxacino trato respiratorio muitos microrganismos p ex klebsiella enterobacterproteus colipseudomonas haemophilus moraxella legionella staphylococcus reagem muita sensibilidade ciprofloxacino maioria casos pneumonia nao necessitam tratamento hospitalar causada streptococcus pneumoniae ness casos ciprofloxacino nao medicamento primeira escolha ouvido medio otite medium seios paranasais sinusite especialmente causadas pseudomonas staphylococcus olhos rins eou trato urinario eferente orgaos reprodutores inclusive inflamacao ovarios tuba uterinas anexite gonorreia infeccoes prostata prostatite cavidade abdominal p ex trato gastrintestinal trato biliar peritonio pele tecidos mole ossos articulacoes infeccao generalizada septicemia infeccoes risco infeccao profilaxia pacientes sistema imunologico comprometido exemplo pacientes tratamento medicamentos inibem defesas imunologicas naturais organismo pacientes numero reduzido globulos brancos sangue descontaminacao intestinal seletiva pacientes sob tratamento imunossupressores ciprofloxacino nao eficaz contra treponema pallidum causador sifilis criancas adolescentes 5 17 anospara infeccao aguda fibrose cistica disturbio metabolico hereditario aumenta producao viscosidade secrecoes bronquios trato digestivo causada p aeruginosa nao possibilidade outros tratamentos injetaveis eficazes nao recomenda ciprofloxacino outras indicacoes antraz inalacao apos exposicao adultos criancas terapia imediata tratamento antraz apos inalacao bacilos antraz bacillus anthracis nao use ciprofloxacino seguintes situacoes alergia hipersensibilidade substancia ativa ciprofloxacino medicamentos contendo outras quinolonas qualquer componente formula sinai alergia podem incluir coceira vermelhidao pele dificuldade respirar inchaco mao garganta boca palpebra uso concomitante tizanidina relaxante muscular uso concomitante teofilina outros produtos contenham cafeina usando medicamentos conjunto pode aumentar riscos efeitos colaterais graf categoria risco c medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista solucao infusao antibioticos sistemicos simple venda sob prescricao medica hospitalar'\n",
      " 'olanzapinacomprimido olanzapina medicamento indicado olanzapina indicada tratamento agudo manutencao esquizofrenia outros transtornos mentais psicoses adultos quais sintomas positivos exemplo delirios alucinacoes alteracoes pensamento hostilidade desconfianca eou sintomas negativos exemplo afeto diminuido isolamento emocionalsocial pobreza linguagem sao proeminentes olanzapina alivia tambem sintomas afetivos secundarios esquizofrenia transtornos relacionados olanzapina eficaz manutencao melhora clinica durante tratamento continuo pacientes adultos responderam tratamento inicial olanzapina indicada monoterapia combinacao litio valproato tratamento episodios mania aguda mistos transtorno bipolar pacientes adultos sintomas psicoticos ciclagem rapida olanzapina indicada prolongar tempo episodios reduzir taxas recorrencia episodios mania mistos depressivos transtorno bipolar nao devo usar medicamento medicamento nao deve usado pacientes alergicos olanzapina qualquer componentes formulacao medicamento medicamento nao deve usado mulheres gravida amamentando orientacao medica informe imediatamente medico caso suspeita gravidez comprimido antipsicoticos retencao so pode vendido retencao receita genericos'\n",
      " 'amalfi isotretinoina isotretinoina indicada tratamento formas graf acne nodulocistica conglobata acne risco cicatrizes permanentes quadros acne resistentes terapeuticas anteriores antibioticos sistemicos agentes topicos categoria risco gravidez x estudo animais mulheres gravida farmaco provocou anomalias fetais clara evidencia risco feto maior qualquer beneficio possivel paciente medicamento nao deve utilizado mulheres gravida possam ficar gravida durante tratamento nao satisfacam criterios contracepcao exigidos vide item gravidez lactacao atencao risco mulheres gravida causa graf defeitos face orelhas coracao sistema nervoso feto isotretinoina contraindicada seguintes casos gravidez mulheres gravida possam ficar gravida durante tratamento menos pacientes satisfacam todos criterios contracepcao exigidos vide item gravidez lactacao mulheres periodo lactacao hipervitaminose preexistente vide item reacoes adversas pacientes fazem uso concomitante tetraciclinas derivados vide item advertencias precaucoes pacientes valores lipidicos sanguineos excessivamente elevados vide item advertencias precaucoes isotretinoina tambem contraindicada pacientes hipersensibilidade conhecida isotretinoina algum componentes isotretinoina contem oleo soja portanto contraindicada pacientes alergicos soja isotretinoina nao deve administrada pacientes alergicos parabenos usados conservantes capsula mole medicamento contraindicado uso pacientes insuficiencia hepatica vide item advertencias precaucoes capsula mole antiinflamatorios venda sob prescricao medica prescricao medica'\n",
      " 'amoxicilinacapsula amoxicilina trihidratada medicamento amoxicilina trihidratada antibiotico eficaz contra grande variedade bacteria indicado tratamento infeccoes bacterianas causadas germes sensiveis acao amoxicilina entretanto medico pode receitar medicamento outro uso desejar informacoes pergunte medico medicamento nao pode administrado ingerido pessoas alergicas amoxicilina outros antibioticos penicilanicos antibioticos similares chamados cefalosporinas voce ja reacao alergica erupcoes pele tomar antibiotico deve conversar medico ante usar amoxicilina trihidratada medicamento nao deve usado mulheres gravida orientacao medica cirurgiaodentista capsula dura venda sob prescricao medica genericos'\n",
      " 'atorvastatinacalcica atorvastatina calcica medicamento indicado atorvastatina calcica comprimidos revestidos indicado tratamento hipercolesterolemia aumento quantidade colesterol sangue isolada hipercolesterolemia associada hipertrigliceridemia aumento niveis sanguineos outro tipo gordura hipercolesterolemia associada reducao niveis sanguineos hdl tipo colesterol hipercolesterolemia associada hipertrigliceridemia associado tambem reducao niveis sanguineos hdl inclusive hipercolesterolemias transmissao geneticafamiliar familiar homozigotica disbetalipoproteinemia etc resposta dieta outras medidas nao farmacologicas inadequadas atorvastatina calcica indicada prevencao secundaria instituida evento evitar ocorra novamente sindrome coronaria aguda doenca musculo cardiaco recebe menor fluxo sangue atorvastatina calcica tambem pode usada prevencao complicacoes cardiovasculares vasos sanguineos coracao pacientes doenca cardiovascular dislipidemia preexistente multiplos fatores risco tabagismo hipertensao diabetes hdl baixo historia familiar doenca cardiaca precoce atorvastatina calcica indicada tratamento pacientes doenca cardiaca coracao coronariana vasos coracao reduzir risco complicacoes infarto miocardio nao fatal acidente vascular cerebral derrame fatal nao fatal procedimentos revascularizacao desobstrucao arteria hospitalizacao insuficiencia cardiaca congestiva doenca musculo cardiaco nao consegue bombear sangue corpo angina dor peito devido problemas coracao vasos nao devo usar medicamento atorvastatina calcica contraindicada pacientes apresentam hipersensibilidade qualquer componente formula doenca hepatica figado ativa elevacoes persistentes inesperadas transaminase sericas enzimas figado excedendo 3 vezes limite superior normalidade durante gravidez lactacao amamentacao mulheres idade fertil nao utilizando medidas contraceptivas evitar gravidez eficazes atorvastatina calcica deve administrada adolescentes mulheres idade fertil somente gravidez altamente improvavel desde pacientes sido informadas potenciais riscos feto medicamento contraindicado menores 10 ano idade atorvastatina calcica nao deve utilizada mulheres gravida possam ficar gravida durante tratamento comprimido revestido antilipemicos venda sob prescricao medica genericos'\n",
      " 'anginorub cloridrato benzidamina tratamento aftas dor dente dor inflamacao garganta sintomas resfriado gripe amigdalites faringites laringites dor postraumatica apos procedimentos odontologicos otorrinolaringologicos bucomaxilofaciais uso adulto pediatrico acima 6 ano anginorub cloridrato benzidamina nao deve utilizado pacientes alergia cloridrato benzidamina demais componentes formula medicamento contraindicado menores 6 ano nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista pastilha antiinflamatorios produtos orofaringe anestesicos locais medicamento isento prescricao isento prescricao'\n",
      " 'preni prednisolona preni prednisolona indicado agente antiinflamatorio imunossupressor patologias cujos mecanismos fisiopatologicos envolvam processos inflamatorios eou autoimunes tratamento condicoes endocrinas glandulas composicao esquemas terapeuticos algumas neoplasia preni prednisolona contraindicado uso pacientes alergicos prednisolona qualquer outro componente formula pacientes infeccoes fungicas sistemicas infeccoes nao controladas comprimido venda sob prescricao medica prescricao medica'\n",
      " 'prednisolona3 fosfato sodico prednisolona medicamento indicado medicamento indicado agente antiinflamatorio imunossupressor patologias cujos mecanismos fisiopatologicos envolvam processos inflamatorios eou autoimunes tratamento condicoes endocrinas glandulas composicao esquemas terapeuticos algumas neoplasia nao devo usar medicamento medicamento contraindicado uso pacientes alergicos prednisolona qualquer outro componente formula pacientes infeccoes fungicas sistemicas infeccoes nao controladasanismo todo solucao glicocorticoides sistemicos venda sob prescricao medica genericos'\n",
      " 'rivaxa rivaroxabana rivaroxabana indicada prevencao tromboembolismo venoso tev pacientes adultos submetidos cirurgia eletiva artroplastia joelho quadril rivaroxabana indicada tratamento trombose venosa profunda tvp prevencao trombose venosa profunda tvp embolia pulmonar ep recorrentes adultos rivaroxabana indicado tratamento embolia pulmonar ep prevencao embolia pulmonar ep trombose venosa profunda tvp recorrentes adultos rivaroxabana contraindicada pacientes hipersensibilidade rivaroxabana qualquer outro componente produto ver composicao pacientes sangramento ativo clinicamente significativo exemplo sangramento intracraniano sangramento gastrintestinal ainda pacientes doenca hepatica associada coagulopatia risco sangramento clinicamente relevante incluindo pacientes cirroticos child pugh b c ver item 3 caracteristicas farmacologicas propriedades farmacocineticas nao estabelecidas seguranca eficacia rivaroxabana mulheres gravida dado animais mostram rivaroxabana atravessa barreira placentaria portanto uso rivaroxabana contraindicado durante toda gravidez ver itens 5 advertencias precaucoes gravidez lactacao 3 caracteristicas farmacologicas dado seguranca preclinicos nao estabelecidas seguranca eficacia rivaroxabana mulheres lactantes dado animais indicam rivaroxabana secretada leite materno portanto rivaroxabana so pode administrado descontinuada amamentacao ver itens 5 advertencias precaucoes gravidez lactacao 3 caracteristicas farmacologicas dado seguranca preclinicos comprimido revestido antitrombotico anticoagulantes prescricao medica'\n",
      " 'celecoxibe celecoxibe celecoxibe indicado tratamento sintomatico osteoartrite lesao cronica articulacoes junta artrite reumatoide inflamacao cronica junta causada reacoes autoimunes sistema defesa corpo agride engano si proprio alivio sintomas espondilite anquilosante doenca inflamatoria cronica atinge articulacoes coluna quadris ombros alivio dor aguda posoperatorio cirurgia ortopedica odontologica doencas musculoesqueleticas entorse tornozelo dor joelho coxa alivio dismenorreia primaria colica menstrual alivio lombalgia dor costa medicamento nao deve usado pacientes 1 tido crise asma doenca pulmonar crisis chiado urticaria alergia pele reacoes alergicas apos uso acido acetilsalicilico outros antiinflamatorios poi ha risco alergia uso celecoxibe 2 doenca hepatica figado grave eou insuficiencia renal grave reducao importante funcionamento rins 3 dor relacionada cirurgia revascularizacao miocardio cirurgia ponte veia safena arteria mamaria desobstrucao coronaria medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista capsula dura venda sob prescricao medica genericos'\n",
      " 'dopo levonorgestrel dopo levonorgestrel contraceptivo emergencia pode usado prevenir gravidez tomado dentro 72 horas tres dia apos coito desprotegido acidente contraceptivo contraceptivo emergencia dopo levonorgestrel indicado apos qualquer ato coito desprotegido incluindo nenhum contraceptivo usado metodo contraceptivo possa ter falhado incluindo ruptura deslizamento emprego incorreto camisinha desalojamento rompimento remocao antecipada diafragma tampao falha interrupcao coito ex ejaculacao vagina genitalia externa calculo incorreto metodo periodico absiliencia expulsao diu pilulas contraceptivas orais regulares omitidas tres dia ciclo casos estupro excecao gravidez existente nao ha nenhuma contraindicacao medica conhecida uso dopo levonorgestrel contracepcao emergencia nao recomendado uso mulher gravidez confirmada primariamente porque nao serum eficaz gravidez nao puder excluida dopo levonorgestrel pode administrado paciente deve ciente tratamento nao serum eficaz ja gravida caso sangramento vaginal anormal nao diagnosticado doencas hepatica vesicula biliar ictericia gravidica carcinoma mama carcinoma ovario utero historia dopo levonorgestrel deve administrado apos consideracao cautelosa relacao riscobeneficio'\n",
      " 'pantoprazolcomprimido pantoprazol sodico sesquihidratado medicamento indicado tratamento ulcera peptica duodenal ulcera causada acido estomago contato revestimento inicio intestino ulcera peptica gastrica ulcera causada acido estomago esofagites refluxo moderadas graf doenca causada volta conteudo estomago esofago adultos pacientes pediatricos acima 5 ano esofagites leves recomendase pantoprazol sodico sesquihidratado 20 mg tratamento sindrome zollingerellison outras doencas causadoras producao exagerada acido estomago erradicacao helicobacter pylorus bacteria responsavel formacao ulceras finalidade reducao taxon recorrencia ulcera gastrica duodenal causadas microrganismo neste caso deve associado doi antibioticos adequados vide item 6 devo usar medicamento nao devo usar medicamento pantoprazol sodico sesquihidratado nao deve usado individuos apresentem alergia hipersensibilidade conhecida pantoprazol benzimidazolicos substituidos demais componentes formula terapia combinada erradicacao helicobacter pylorus pantoprazol sodico sesquihidratado nao deve administrado pacientes problemas moderados graf figado rins vez nao existe experiencia clinica sobre eficacia seguranca terapia combinada exemplo amoxicilina claritromicina ness pacientes medicamento contraindicado menores 5 ano idade medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido venda sob prescricao medica genericos'\n",
      " 'alprazolam alprazolam alprazolam indicado tratamento transtornos ansiedade nao deve administrado substituicao tratamento apropriado psicose quadro delirios alucinacoes sintomas ansiedade podem incluir forma variavel tensao medo apreensao intranquilidade dificuldade concentracao irritabilidade insonia dificuldade dormir eou hiperatividade neurovegetativa respiracao curta superficial sufocacao palpitacoes aumento batimentos coracao mao frias suadas boca seca tontura enjoo diarreia gas rubores vermelhidao rosto calafrios necessidade urinar vezes dificuldades engolir mudancas tom voz etc resultando manifestacoes corporais variadas alprazolam tambem indicado tratamento transtornos ansiedade associados outras condicoes abstinencia alcool tratamento transtorno panico agorafobia medo espacos abertos meio multidao cuja principal caracteristica crise ansiedade inesperada ataque repentino apreensao intensa terror medo voce alguma vez ja apresentou reacao alergica alprazolam outros benzodiazepinicos qualquer componente formula produto nao use alprazolam alprazolam tambem nao deve usado caso voce miastenia gravis doenca nervos musculos resulta fraqueza muscular glaucoma angulo estreito agudo aumento pressao dentro olhos medicamento contraindicado menores 18 ano idade comprimido ansioliticos simple venda sob prescricao medica abuso deste medicamento pode causar dependencia genericos'\n",
      " 'naire bilastina naire bilastina indicado tratamento sintomatico rinoconjuntivite alergica intermitente persistente urticaria bilastina nao deve usada casos hipersensibilidade conhecida bilastina demais componentes formula medicamento contraindicado faixa etaria 0 12 ano comprimido antihistaminicos sistemicos venda sob prescricao medica prescricao medica'\n",
      " 'bupxl cloridrato bupropiona xl cloridrato bupropiona indicado tratamento episodios depressivos maiores prevencao recaidas recorrencias episodios depressivos apos resposta inicial satisfatoria cloridrato bupropiona contraindicado pacientes hipersensibilidade conhecida bupropiona qualquer componente formula bupropiona contraindicada pacientes diagnostico epilepsia outros disturbios convulsivos diagnostico atual previo bulimia anorexia nervosa vez observada alta incidencia convulsoes nestes pacientes bupropiona administrada cloridrato bupropiona nao deve administrado pacientes tratados qualquer outro medicamento contenha bupropiona vez incidencia convulsoes dosedependente contraindicada administracao concomitante inibidores monoaminoxidase imaos uso associado bupropiona dentro ate 14 dia apos interrupcao tratamento imaos cloridrato bupropiona contraindicado pacientes processo descontinuacao abrupta uso sedativos alcool medicamento contraindicado menores 18 ano categoria d risco gravidez medicamento nao deve utilizado mulheres gravida orientacao medica informe imediatamente medico caso suspeita gravidez antidepressivos retencao so pode vendido retencao receita prescricao medica'\n",
      " 'azitromicinasuspensaooral azitromicina azitromicina dihidratada po suspensao oral indicada tratamento infeccoes causadas bacteria sensiveis azitromicina infeccoes trato respiratorio inferior bronquios pulmoes superior nariz faringe laringe traqueia incluindo sinusite infeccao seios face faringite inflamacao faringe amigdalite inflamacao amigdalas infeccoes pele tecidos mole musculos tendoes gordura otite medium infeccao ouvido medio aguda doencas sexualmente transmissiveis nao complicadas homem mulher devido clamidia gonorreia tipos bacteria tambem indicado tratamento cancro lesao pele devido haemophilus ducreyi especie bacteria infeccoes ocorrem junto sifilis doenca sexualmente transmissivel devem excluidas azitromicina dihidratada nao deve usada voce historia hipersensibilidade reacoes alergicas azitromicina eritromicina qualquer antibiotico macrolideo classe antibioticos pertence azitromicina cetolideo outra classe antibioticos qualquer componente formula po suspensao diluente antibioticos sistemicos simple retencao so pode vendido retencao receita genericos'\n",
      " 'astrosolucaooral azitromicina astro azitromicina dihidratada po suspensao oral indicado infeccoes causadas organismos suscetiveis infeccoes trato respiratorio inferior incluindo bronquite pneumonia infeccoes pele tecidos mole otite medium aguda infeccoes trato respiratorio superior incluindo sinusite faringitetonsilite penicilina farmaco escolha usual tratamento faringite devido streptococcus pyogenes incluindo profilaxia febre reumatica azitromicina geralmente efetiva erradicacao estreptococo orofaringe porem dado estabelecem eficacia azitromicina subsequente prevencao febre reumatica nao estao disponiveis momento doencas sexualmente transmissiveis homem mulher astro azitromicina diidratada indicado tratamento infeccoes genitais nao complicadas devido chlamydia trachomatis tambem indicado tratamento cancro devido haemophilus ducreyi infeccoes genitais nao complicadas devido neisseria gonorrhoeae resistencia multipla infeccoes concomitantes treponema pallidum devem excluidas astro azitromicina diidratada contraindicado individuos hipersensibilidade azitromicina eritromicina qualquer antibiotico macrolideo cetolideo qualquer componente formula prescricao medica'\n",
      " 'ferrovitan colina ferro zinco cobre selenio vitamina acido folico vitamina d suplemento vitaminicomineral elaborado auxiliar bom funcionamento organismo criancas idade acima 6 me ate 10 ano produto nao deve usado criancas menores 6 seis me idade nao indicacao expressa medico nutricionista aleitamento materno evita infeccoes alergias recomendado ate 2 doi ano idade alergicos contem derivados amendoim pode conter soja vitaminas isento prescricao'\n",
      " 'cloridratodeciprofloxacino cloridrato ciprofloxacino indicacoes cloridrato ciprofloxacino sao seguintes adultos tratamento infeccoes complicadas nao complicadas causadas microrganismos sensiveis ciprofloxacino trato respiratorio muitos microrganismos p ex klebsiella enterobacter proteus coli pseudomonas haemophilus moraxella legionella staphylococcus reagem muita sensibilidade cloridrato ciprofloxacino maioria casos pneumonia nao necessitam tratamento hospitalar causada streptococcus pneumoniae ness casos cloridrato ciprofloxacino nao medicamento primeira escolha ouvido medio otite medium seios paranasais sinusite especialmente causadas pseudomonas staphylococcus olhos rins eou trato urinario eferente orgaos reprodutores inclusive inflamacao ovarios tuba uterinas anexite gonorreia infeccoes prostata prostatite cavidade abdominal p ex estomago intestino trato gastrintestinal trato biliar membrana serosa reveste internamente paredes abdome peritonio pele tecidos mole ossos articulacoes infeccao generalizada septicemia infeccoes risco infeccao profilaxia pacientes sistema imunologico comprometido exemplo pacientes tratamento medicamentos inibem defesas imunologicas naturais organismo pacientes numero reduzido globulos brancos sangue eliminacao seletiva bacteria intestino durante tratamento medicamentos inibem sistema imunologico organismo descontaminacao intestinal seletiva pacientes sob tratamento imunossupressores cloridrato ciprofloxacino nao eficaz contra treponema pallidum causador sifilis criancas adolescentes 5 17 ano infeccao aguda fibrose cistica disturbio hereditario aumenta producao viscosidade secrecoes bronquios trato digestivo causada pseudomonas aeruginosa nao possibilidade outros tratamentos injetaveis eficazes nao recomenda cloridrato ciprofloxacino outras indicacoes antraz inalacao apos exposicao adultos criancas reduzir incidencia progressao doenca apos inalacao bacilos antraz bacillus anthracis nao use cloridrato ciprofloxacino seguintes situacoes alergia hipersensibilidade substancia ativa ciprofloxacino medicamentos contendo outro derivado quinolonico qualquer componente formula veja item composicao sinai alergia podem incluir coceira vermelhidao pele dificuldade respirar inchaco mao garganta boca palpebra uso concomitante tizanidina relaxante muscular porque pode causar efeitos adversos queda pressao arterial sonolencia medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido venda sob prescricao medica genericos'\n",
      " 'mesilatodeimatinibe mesilato imatinibe mesilato imatinibe indicado pacientes adultos pediatricos acima 2 ano leucemia mieloide cronica lmc cromossomo philadelphia positivo ph recem diagnosticada tratamento anterior pacientes adultos leucemia mieloide cronica lmc cromossomo philadelphia positivo crise blastica fase acelerada fase cronica apos falha intolerancia terapia alfainterferona tratamento pacientes adultos pediatricos acima 1 ano leucemia linfoblastica aguda lla ph cromossomo philadelphia positivo recentemente diagnosticada integrados quimioterapia uso pacientes hipersensibilidade substancia ativa qualquer excipientes contraindicado categoria risco gravidez d medicamento nao deve utilizado mulheres gravida orientacao medica informe imediatamente medico caso suspeita gravidez comprimido revestido antineoplasicos venda sob prescricao medica oncologia'\n",
      " 'antara levetiracetam 1 indicacoes medicamento indicado monoterapia tratamento crisis focaisparciais generalizacao secundaria pacientes partir 16 ano diagnostico recente epilepsia antara levetiracetam indicado terapia adjuvante tratamento crisis focaisparciais generalizacao secundaria adultos adolescentes criancas idade superior 6 ano epilepsia crisis mioclonicas adultos adolescentes criancas idade superior 12 ano epilepsia mioclonica juvenil crisis tonicoclonicas primarias generalizadas adultos adolescentes criancas 6 ano idade epilepsia idiopatica generalizada hipersensibilidade principio ativo outros derivados pirrolidona qualquer excipientes categoria risco gravidez c medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido revestido retencao so pode vendido retencao receita prescricao medica'\n",
      " 'sinotcomprimido amoxicilina trihidratada sinot amoxicilina trihidratada antibiotico amplo espectro indicado tratamento infeccoes bacterianas causadas germes sensiveis acao amoxicilina amoxicilina penicilina nao deve administrada pacientes historico hipersensibilidade antibioticos betalactamicos cefalosporinas penicilinas po suspensao antibioticos sistemicos simple retencao so pode vendido retencao receita prescricao medica'\n",
      " 'pitavastatinacalcica pitavastatina medicamento indicado terapia complementar dieta reduzir niveis elevados colesterol total colesterol ruim ldlc apolipoproteina b triglicerides aumentar niveis colesterol bom hdlc pacientes adultos excesso substancias gordurosas sangue medicamento so deve usado resposta dieta restrita gorduras saturadas colesterol outras medidas nao farmacologicas inadequadas pitavastatina calcica contraindicada pacientes hipersensibilidade conhecida qualquer componente desse produto doenca hepatica figado ativa mulheres gravidasou idade fertil mulheres amamentando coadministracao ciclosporina exemplo sandimmun neoral eritromicina medicamento nao deve utilizado mulheres gravida possam ficar gravida durante tratamento comprimido revestido antilipemicos venda sob prescricao medica genericos'\n",
      " 'gesicoduo 375 mg cloridrato tramadol 3250 mg paracetamol gesico duo cloridrato tramadol paracetamol indicado dores moderadas severas carater agudo subagudo cronico medicamento contraindicado pacientes demonstraram previamente hipersensibilidade tramadol paracetamol qualquer componente formula deste produto opioides casos intoxicacoes agudas alcool hipnoticos narcoticos analgesicos acao central opioides psicotropicos pacientes tratamento inibidores monoaminoxidase mao tratados agentes ultimos 14 dia pacientes depressao respiratoria significativa vide item 5 advertencias precaucoes comprimido revestido analgesicos narcoticos retencao so pode vendido retencao receita'\n",
      " 'bicertoiv cetoprofeno bicerto iv cetoprofeno medicamento antiinflamatorio analgesico antitermico sendo indicado tratamento inflamacoes dores decorrentes processos reumaticos doencas podem afetar musculos articulacoes esqueleto traumatismos lesao interna externa resultante agente externo dores geral desta forma bicerto iv cetoprofeno pode utilizado tratamento dor pre posoperatorio outras patologias dolorosas bicerto iv cetoprofeno nao deve utilizado seguintes casos pacientes historico reacoes hipersensibilidade alergia intolerancia cetoprofeno crisis asmaticas doenca pulmonar caracterizada contracao vias respiratorias ocasiodo falta ar outros tipos reacoes alergicas cetoprofeno acido acetilsalicilico outros antiinflamatorios nao esteroidais aines diclofenaco ibuprofeno indometacina naproxeno nestes pacientes relatados casos reacoes anafilaticas severas reacao alergica grave imediata raramente fatais vide item 8 quais male medicamento pode causar pacientes ja ulcera pepticahemorragica lesao localizada estomago eou intestino pacientes ja sangramento perfuracao gastrintestinal estomago eou intestino relacionada uso aines paciente hemorragia gastrintestinal cerebrovascular qualquer outro sangramento ativo pacientes insuficiencia severa reducao acentuada funcao orgao coracao figado eou rins mulheres terceiro trimestre gravidez medicamento contraindicado uso pacientes insuficiencia coracao figado eou rins severa pacientes historico reacoes hipersensibilidade cetoprofeno acido acetilsalicilico outros antix0002inflamatorios nao esteroidais aines pacientes ja ulcera pepticahemorragica medicamento contraindicado faixa etaria pediatrica medicamento nao deve utilizado mulheres gravida 3 trimestre gestacional orientacao medica cirurgiaodentista informe imediatamente medico cirurgiaodentista caso suspeita gravidez solucao infusao antiinflamatorios venda sob prescricao medica hospitalar'\n",
      " 'rebrive sugamadex sodico rebrive sugamadex sodico usado acelerar recuperacao musculos efeitos relaxantes musculares apos cirurgia relaxante muscular utilizado brometo rocuronio brometo vecuronio medicamento contraindicado uso pessoas apresentam alergia hipersensibilidade sugamadex sodico quaisquer componentes formula produto informe anestesiologista algum des casos aplica voce solucao injetavel venda sob prescricao medica hospitalar'\n",
      " 'amplacilina ampicilina forma anidra amplacilina ampicilina indicada tratamento diversas infeccoes causadas microorganismos sensiveis medicamento sao infeccoes trato urinario infeccoes urinarias infeccoes trato respiratorio amidalites sinusites pneumonia infeccoes trato digestivo biliar infeccoes intestinais vesicula biliar infeccoes localizadas sistemicas generalizadas especialmente causadas germes grupo enterococos haemophilus proteus salmonella coli infeccoes bucais extracoes dentaria infectadas outras intervencoes cirurgicas amplacilina ampicilina contraindicada pacientes historia reacoes hipersensibilidade alergia penicilinas classe antibioticos onde ampicilina enquadra eou demais componentes formulacao tambem nao deve administrada pacientes sensiveis cefalosporinas outra classe antibioticos devido ocorrencia reacao alergica cruzada medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista capsula dura penicilina amplo espectro retencao so pode vendido retencao receita'\n",
      " 'cetoprofenocomprimido cetoprofeno cetoprofeno medicamento antiinflamatorio analgesico antitermico sendo indicado tratamento inflamacoes dores decorrentes seguintes casos processos otorrinolaringologicos sinusites inflamacao mucosa nasal otites inflamacao ouvido faringites inflamacao faringe laringites inflamacao laringe amigdalites inflamacao garganta processos ginecologicosobstetricos anexites processo inflamatorio envolve trato genital feminino parametrites inflamacao parametrio pelvico endometrites inflamacao endometrio dismenorreia dor menstrual processos urologicos colica nefretica dor lombar decorrente obstrucao total parcial rins ureteres orquiepididimites inflamacao testiculo prostatites inflamacao prostata processos odontologicos periodontites inflamacao perda tecidos conjuntivos envolvem sustentam dentes pulpites inflamacao polpa dentaria abscessos acumulo pu tecidos orgaos espacos circunscritos normalmente associado sinai infeccao extracoes dentaria processos reumaticos artrite reumatoide inflamacao cronica articulacoes espondilite anquilosante inflamacao vertebra gota doenca reumatica caracterizada acumulo cristais acido urico junto articulacoes eou outros orgaos condrocalcinose deposito sais calcio articulacoes reumatismo psoriatico tipo artrite associada alteracao pele sindrome reiter tipo artrite pseudoartrite lupus eritematoso sistemico doenca apresenta manifestacoes pele coracao rins articulacoes outras esclerodermia doenca autoimune pode ter varias manifestacoes endurecimento pele periarterite nodosa tipo inflamacao ocorre arteria osteoartrite doenca articular degenerativa progressiva periartrite escapuloumeral inflamacao tecidos redor articulacao ombro bursites inflamacao bursa pequena bolsa contendo liquido envolve articulacoes capsulite adesiva inflamacao caracterizada perda movimentos ombro sinovites inflamacao membrana envolve articulacoes tenossinovites inflamacao bainha tendao tendinites inflamacao tendoes epicondilites doenca resultante esforco nao usual braco lesoes ortopedicas contusoes esmagamentos lesao causada trauma direto pressao fraturas entorses lesao ligamento musculo deslocamento fratura luxacoes deslocamento qualquer parte corpo normalmente articulacao posicao normal dores diversas nevralgia cervicobraquial dor associada lesao nervos regiao pescoco axila cervicalgia dor regiao pescoco lombalgia dor regiao lombar dor ciatica dor causada compressao nervo ciatico posoperatorios diversos enxaqueca dor cabeca intensa aura sintomas precedem enxaqueca variam consideravelmente pacientes afetando principalmente visao audicao cetoprofeno nao deve utilizado seguintes casos pacientes historico reacoes hipersensibilidade alergia intolerancia cetoprofeno crisis asmaticas doenca pulmonar caracterizada contracao vias respiratorias ocasiodo falta ar outros tipos reacoes alergicas cetoprofeno acido acetilsalicilico outros antiinflamatorios nao esteroidais aines ex diclofenaco ibuprofeno indometacina naproxeno nestes pacientes relatados casos reacoes anafilaticas severas reacao alergica grave imediata raramente fatais vide 8 quais male medicamento pode causar pacientes ja ulcera pepticahemorragica lesao localizada estomago eou intestino pacientes ja sangramento perfuracao gastrintestinal estomago intestino relacionada uso aines pacientes insuficiencia severa reducao acentuada funcao orgao coracao figado rins mulheres terceiro trimestre gravidez medicamento contraindicado uso pacientes insuficiencia coracao figado rins severas pacientes historico reacoes hipersensibilidade cetoprofeno acido acetilsalicilico outros antiinflamatorios nao esteroidais aines pacientes ja ulcera pepticahemorragica medicamento contraindicado faixa etaria pediatrica medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista informe imediatamente medico caso suspeita gravidez comprimido venda sob prescricao medica genericos'\n",
      " 'trimusk cafeina carisoprodol diclofenaco sodico paracetamol trimusk cafeina carisoprodol diclofenaco sodico paracetamol indicado tratamento reumatismo formas inflamatoriodegenerativas agudas cronicas crise aguda gota estados inflamatorios agudos postraumaticos poscirurgicos exacerbacoes agudas artrite reumatoide outras artropatias reumaticas osteoartrites estados agudos reumatismo tecidos extraarticulares quadros lombalgias lombociatalgias trimusk cafeina carisoprodol diclofenaco sodico paracetamol indicado coadjuvante processos inflamatorios graf decorrentes quadros infecciosos trimusk cafeina carisoprodol diclofenaco sodico paracetamol contraindicado casos ulcera peptica atividade hipersensibilidade quaisquer componentes formula discrasias sanguineas diateses hemorragicas trombocitopenia disturbios coagulacao porfiria insuficiencia cardiaca hepatica renal grave hipertensao grave contraindicado pacientes asmaticos quais sao precipitadas crisis asma urticaria rinite aguda antiinflamatorios nao esteroidais trimusk cafeina carisoprodol diclofenaco sodico paracetamol contraindicado pessoas fazem uso isocarboxazida eou fenelzina eou tranilcipromina risco aumento pressao arterial medicamento contraindicado uso pediatrico nao use outro produto contenha paracetamol nao indicado criancas abaixo 14 ano excecao casos artrite juvenil cronica comprimido relaxantes musculares venda sob prescricao medica prescricao medica'\n",
      " 'zolpidemhemitartaratode5mgsublingual hemitartarato zolpidem medicamento indicado hemitartarato zolpidem indicado tratamento insonia pode ocasional transitoria cronica nao devo usar medicamento voce nao deve utilizar hemitartarato zolpidem casos hipersensibilidade zolpidem qualquer outro componente formula insuficiencia hepatica severa funcao alterada figado insuficiencia respiratoria aguda severa historico comportamento complexo sono sonambulismo apos utilizar zolpidem outros medicamentos tratamento insonia eszopiclona zaleplon medicamento contraindicado faixa etaria pediatrica comprimido hipnoticos retencao so pode vendido retencao receita genericos'\n",
      " 'cefadroxila cefadroxila cefadroxila indicada tratamento infeccoes causadas bacteria sensiveis eficacia cefadroxila manifestase melhora estado geral paciente incluindo regressao febre sinai sintomas infeccao cefadroxila nao deve utilizada caso voce apresente alergia intolerancia cefadroxila qualquer outro componente produto tambem nao deve utilizado caso voce apresente alergia penicilina antibioticos classe cefalosporinas ante utilizacao verifique voce possui antecedentes alergicos especialmente componentes formulacao informe medico cirurgiaodentista aparecimento reacoes indesejaveis nao use medicamento conhecimento medico pode perigoso saude po suspensao antibioticos sistemicos simple retencao so pode vendido retencao receita genericos'\n",
      " 'altiva cloridrato fexofenadina medicamento antihistaminico destinado tratamento manifestacoes alergicas tai sintomas rinite alergica incluindo espirros obstrucao nasal prurido coriza conjuntivite alergica febre feno urticaria altiva contraindicado uso pacientes hipersensibilidade componentes formula medicamento contraindicado menores 12 ano comprimido revestido antihistaminicos sistemicos medicamento isento prescricao isento prescricao'\n",
      " 'iban iban ibandronato sodio monidratado iban ibandronato sodio indicado tratamento osteoporose posmenopausa finalidade reduzir risco fraturas vertebrais subgrupo pacientes risco escore t 30 dp colo femur iban ibandronato sodio tambem demonstrou reduzir risco fraturas nao vertebrais tratamento osteoporose osteoporose pode confirmada achado baixo indice massa ossea escore t 20 dp presenca historico fratura osteoporotica baixo indice massa ossea escore t 25 dp ausencia fratura osteoporotica preexistente documentada iban ibandronato sodio contraindicado pacientes conhecida hipersensibilidade iban ibandronato sodio demais componentes formula produto pacientes hipocalcemia nao corrigida assim todos bisfosfonatos indicados tratamento osteoporose hipocalcemia preexistente deve corrigida ante inicio terapia iban ibandronato sodio tal acontece varios bisfosfonatos iban ibandronato sodio contraindicado pacientes anormalidades esofago demora esvaziamento esofagico estenose acalasia vide item 5 advertencias precaucoes iban ibandronato sodio contraindicado pacientes nao conseguem ficar pe sentados durante menos 60 minutos vide item 5 advertencias precaucoes medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista iban medicamento classificado categoria b risco gravidez comprimido revestido venda sob prescricao medica prescricao medica'\n",
      " 'norelbin ditartarato vinorelbina norelbin ditartarato vinorelbina indicado agente unico quimioterapia combinada cancer pulmao nao pequenas celulas cancer mama metastatico hipersensibilidade conhecida vinorelbina outros alcaloides vinca qualquer outro constituinte formulacao contagem neutrofilos 1500 mm3 infeccao grave atual recente ultima 2 semanas contagem plaquetas 100000mm3 gravidez lactacao vide item 5 advertencias precaucoes associacao vacina contra febre amarela medicamento nao deve utilizado mulheres gravida orientacao medica informe imediatamente medico caso suspeita gravidez solucao injetavel antineoplasicos venda sob prescricao medica oncologia'\n",
      " 'selene etinilestradiol acetato ciproterona tratamento disturbios androgenodependentes mulher tai acne principalmente formas pronunciadas naquelas acompanhadas seborreia inflamacoes formacoes nodulos acne papulopustulosa acne nodulocistica casos leves hirsutismo sindrome ovarios policisticos sop tratamento acne selene deve usado terapia topica tratamentos antibioticos sistemicos nao considerados adequados embora medicamento selene tambem funcione contraceptivo oral nao deve utilizado exclusivamente mulheres contracepcao sim reservado apenas mulheres necessitam tratamento condicoes androgenodependentes descritas recomendase ainda tratamento retirado 3 4 ciclos apos condicao indicada ter sido resolvida selene nao continuado unicamente fornecer contracepcao oral medicamentos contendo combinacoes estrogenioprogestogeno nao devem utilizados presenca qualquer seguintes condicoes listadas abaixo presenca historico processos tromboticostromboembolicos arteriais venosos exemplo trombose venosa profunda embolia pulmonar infarto miocardio acidente vascular cerebral presenca historico sintomas eou sinai prodromicos trombose exemplo ataque isquemico transitorio angina pectoris alto risco trombose arterial venosa veja item 5 advertencias precaucoes historico enxaqueca sintomas neurologicos focais diabetes mellitus comprometimento vascular hepatopatia grave enquanto valores funcao hepatica nao retornarem normal uso medicamentos antivirais acao direta contendo ombitasvir paritaprevir dasabuvir combinacoes destes medicamentos ver item 6 interacoes medicamentosas presenca historico tumores hepaticos benignos malignos diagnostico suspeita neoplasia malignas influenciadas esteroides sexuais exemplo orgaos genitais mama sangramento vaginal nao diagnosticado uso concomitante contraceptivo hormonal suspeita diagnostico gravidez lactacao hipersensibilidade substancias ativas qualquer componentes meningioma historico meningioma qualquer condicoes citadas anteriormente ocorrer primeira vez durante uso medicamentos contendo combinacoes estrogenioprogestogeno utilizacao deve descontinuada imediatamente produto nao indicado pacientes sexo masculino 5 comprimido revestido venda sob prescricao medica prescricao medica'\n",
      " 'tamisa15 gestodenoetinilestradiol tamisa 15 gestodeno etinilestradiol indicado contraceptivo oral embora tendo eficacia bem estabelecida ha casos gravidez mulheres utilizando contraceptivos orais contraceptivos orais combinados nao devem utilizados mulheres apresentem qualquer seguintes condicoes trombose venosa profunda historia anterior atual tromboembolismo historia anterior atual doenca vascular cerebral arterial coronariana valvulopatias trombogenicas disturbios ritmo cardiaco trombogenicos trombofilias hereditarias adquiridas cefaleia sintomas neurologicos focais tai aura tamisa15com revvpsv03 diabetes envolvimento vascular hipertensao nao controlada carcinoma mama conhecido suspeito outra neoplasia estrogeniodependente conhecida suspeita adenoma carcinoma hepaticos doenca hepatica ativa onde funcao hepatica nao retornado normal sangramento vaginal etiologia esclarecer pancreatite associada hipertrigliceridemia severa historia anterior atual gravidez confirmada suspeita hipersensibilidade qualquer componentes tamisa 15 gestodeno etinilestradiol contraceptivos orais combinados sao contraindicados uso concomitante certos medicamentos antivirais contra virus hepatite c hcv ombitasvir paritaprevir ritonavir dasabuvir vide item 5 advertencias precaucoes neoplasia hepaticadoenca hepaticahepatite c item 6 interacoes medicamentosas medicamento contraindicado uso homens tamisa 15 gestodeno etinilestradiol medicamento classificado categoria x risco gravidez portanto medicamento nao deve utilizado mulheres gravida possam ficar gravida durante tratamento comprimido revestido anticoncepcionais venda sob prescricao medica prescricao medica'\n",
      " 'atenololclortalidona atenolol clortalidona medicamento indicado atenolol clortalidona indicado controle hipertensao pressao alta nao devo usar medicamento voce nao deve utilizar atenolol clortalidona seguintes situacoes alergia atenolol clortalidona qualquer componentes formulacao batimentos lentos coracao bradicardia comprometimento importante funcao coracao bombear sangue tecidos choque cardiogenico pressao arterial baixa baixa hipotensao alteracao metabolica onde ph sangue baixo acidose metabolica problemas graf circulacao arterial periferica extremidades bloqueio cardiaco segundo terceiro grau tipo arritmia causa bloqueio impulsos eletricos coracao sindrome nodo sinusal doenca local origem impulsos eletricos coracao portadores feocromocitoma tumor benigno glandula adrenal suprarrenal nao tratado insuficiencia cardiaca descompensada durante gravidez amamentacao comprimido venda sob prescricao medica genericos'\n",
      " 'delabaxi delafloxacino meglumina delabaxi delafloxacino meglumina indicado adultos tratamento infeccoes graf pele tecidos mole causadas microrganismos sensiveis delafloxacino delabaxi delafloxacino meglumina contraindicado pacientes hipersensibilidade alergia delafloxacino qualquer componente formula produto delabaxi tambem contraindicado pacientes hipersensibilidade alergia outros antibioticos tipo fluoroquinolona nao utilizar medicamento historia previa disturbios tendinosos relacionados administracao fluoroquinolonas po liofilizado solucao injetavel antibioticos sistemicos simple venda sob prescricao medica hospitalar'\n",
      " 'olmesartanamedoxomila olmesartana medoxomila olmesartana medoxomila indicado tratamento pressao arterial alta pressao cujas medidas acima 140 mm hg pressao alta sistolica 90 mm hg pressao baixa diastolica voce nao deve usar medicamento durante gravidez alergico sensivel qualquer componente deste produto voce nao deve usar produto diabetico utilizando alisquireno primeiro trimestre gestacao medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista segundo terceiro trimestres gestacao medicamento nao deve utilizado mulheres gravida orientacao medica informe imediatamente medico caso suspeita gravidez comprimido revestido antihipertensivos venda sob prescricao medica genericos'\n",
      " 'bicerto cetoprofeno bicerto cetoprofeno medicamento possui atividade antiinflamatoria analgesica antitermica indicado tratamento processos otorrinolaringologicos sinusites otites faringites laringites amigdalites processos ginecologicosobstetricos anexites parametrites endometrites dismenorreia processos urologicos colica nefretica orquiepididimites prostatites processos odontologicos periodontites pulpites abscessos extracoes dentaria processos reumaticos artrite reumatoide espondilite anquilosante gota condrocalcinose reumatismo psoriatico sindrome reiter pseudoartrite lupus eritematoso sistemico esclerodermia periarterite nodosa osteoartrite periartrite escapuloumeral bursites capsulites sinovites tenossinovites tendinites epicondilites lesoes ortopedicas contusoes esmagamentos fraturas entorses luxacoes algias diversas nevralgia cervicobraquial cervicalgia lombalgia dor ciatica posoperatorios diversos enxaqueca aura sintomas precedem enxaqueca variam consideravelmente pacientes afetando principalmente visao audicao bicerto cetoprofeno nao deve utilizado seguintes casos pacientes historico reacoes hipersensibilidade cetoprofeno crisis asmaticas outros tipos reacoes alergicas cetoprofeno acido acetilsalicilico outros antiinflamatorios nao esteroidais nestes pacientes relatados casos reacoes anafilaticas severas raramente fatais vide 9 reacoes adversas pacientes ulcera pepticahemorragica historico pacientes historico sangramento perfuracao gastrintestinal relacionada uso aines pacientes insuficiencia cardiaca hepatica renal severas terceiro trimestre gravidez medicamento contraindicado uso pacientes insuficiencia cardiaca hepatica renal severas pacientes historico reacoes hipersensibilidade cetoprofeno acido acetilsalicilico outros aines pacientes ulcera pepticahemorragica historico medicamento contraindicado faixa etaria pediatrica categoria risco gravidez d medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista informe imediatamente medico caso suspeita gravidez prescricao medica'\n",
      " 'domperixsuspensaooral domperidona medicamento destinado tratamento sindromes dispepticas frequentemente associadas retardo esvaziamento gastrico refluxo gastroesofagico esofagite sensacao empachamento epigastrico saciedade precoce distensao abdominal dor abdominal alta eructacao flatulencia nausea vomitos azia queimacao epigastrica regurgitacao conteudo gastrico nausea vomitos origem funcional organica infecciosa alimentar induzidas radioterapia tratamento medicamentoso antiinflamatorios antineoplasicos indicacao especifica sao nausea vomitos induzidos agonistas dopaminergicos usados tratamento doenca parkinson ldopa bromocriptina domperix domperidona contraindicado pacientes hipersensibilidade conhecida domperidona qualquer excipientes domperix domperidona nao deve utilizado sempre estimulacao motilidade gastrica possa perigosa exemplo presenca hemorragia gastrintestinal obstrucao mecanica perfuracao domperix domperidona tambem contraindicado pacientes tumor hipofisario secretor prolactina prolactinoma administracao concomitante domperix domperidona inibidores potentes cyp3a4 demonstraram causar prolongamento intervalo qt tai claritromicina eritromicina itraconazol cetoconazol oral posaconazol ritonavir saquinavir telitromicina telaprevir voriconazol contraindicada vide itens 5advertencias precaucoes 6 interacoes medicamentosas domperix domperidona contraindicado pacientes insuficiencia hepatica moderada severa vide item 3 caracteristicas farmacologicas propriedades farmacocineticas medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista suspensao venda sob prescricao medica prescricao medica'\n",
      " 'trokgpomada dipropionato betametasona sulfato gentamicina trokg dipropionato betametasona sulfato gentamicina indicado alivio manifestacoes inflamatorias dermatosis sensiveis corticosteroides complicadas infeccao secundaria causada bacteria sensiveis gentamicina suspeita tai infeccoes dermatosis incluem psoriase dermatite alergica contato eczema dermatite atopica neurodermatite circunscrita liquen simple cronico liquen plano intertrigo eritematoso disidrose pompholyx dermatite seborreica dermatite esfoliativa dermatite solar dermatite estase pruridos anogenital trokg dipropionato betametasona sulfato gentamicina contraindicado pacientes apresentam hipersensibilidade betametasona gentamicina qualquer componente formula produto trokg dipropionato betametasona sulfato gentamicina tambem contraindicado pacientes portadores infeccoes cutaneas causadas virus fungos tuberculose pele trokg dipropionato betametasona sulfato gentamicina nao indicado uso oftalmico medicamento contraindicado menores 2 ano pomada antiinfecciosos topicos associacoes medicamentosas retencao so pode vendido retencao receita prescricao medica'\n",
      " 'praivaiv cloridrato moxifloxacino praiva cloridrato moxifloxacino solucao infusao indicado tratamento seguintes infeccoes causadas bacteria sensiveis pneumonia adquirida comunidade pac incluindo pac causada bacteria resistentes alguns antibioticos infeccoes complicadas pele anexos inclusive infeccoes pe diabetico infeccoes intraabdominais complicadas incluindo infeccoes causadas varias bacteria abscessos streptococcus pneumoniae multirresistente incluindo isolados conhecidos s pneumoniae resistente penicilina cepas resistentes doi seguintes antibioticos penicilina cim 2 gml cefalosporinas 2a geracao exemplo cefuroxima macrolideos tetraciclinas trimetoprimasulfametoxazol devemse considerar recomendacoes relacionadas uso apropriado agentes antibioticos praiva cloridrato moxifloxacino nao deve administrado pessoas conhecida alergia moxifloxacino qualquer componente formulacao antibioticos mesma classe quinolonas tambem contraindicado durante gravidez amamentacao medicamento contraindicado menores 18 ano idade'\n",
      " 'molieri20 drospirenona etinilestradiol contraceptivo oral efeitos antimineralocorticoide antiandrogenico beneficiam tambem mulheres apresentam retencao liquido origem hormonal sintomas tratamento acne vulgaris moderada mulheres buscam adicionalmente protecao contraceptiva contraceptivos orais combinados cocs nao devem utilizados presenca condicoes listadas abaixo qualquer destas condicoes ocorrer primeira vez durante uso cocs utilizacao deve descontinuada imediatamente presenca historia processos tromboticostromboembolicos arteriais venosos exemplo trombose venosa profunda embolia pulmonar infarto miocardio acidente vascular cerebral presenca historia sintomas eou sinai prodromicos trombose p ex episodio isquemico transitorio angina pectoris alto risco trombose arterial venosa veja item 5 advertencias precaucoes historia enxaqueca sintomas neurologicos focais diabetes mellitus alteracoes vasculares doenca hepatica grave enquanto valores funcao hepatica nao retornarem normal insuficiencia renal grave insuficiencia renal aguda uso medicamentos antivirais acao direta contendo ombitasvir paritaprevir dasabuvir associacoes destes medicamentos veja item 6 interacoes medicamentosas presenca historia tumores hepaticos benignos malignos diagnostico suspeita neoplasia malignas dependentes esteroides sexuais p ex orgaos genitais mama sangramento vaginal nao diagnosticado suspeita diagnostico gravidez hipersensibilidade substancias ativas qualquer componentes produto comprimido revestido anticoncepcionais venda sob prescricao medica'\n",
      " 'hormus undecilato testosterona reposicao testosterona hipogonadismo masculino primario secundario carcinoma androgeniodependentes prostata glandula mamaria homem hipercalcemia acompanha tumores malignos tumores hepaticos atuais previos hipersensibilidade substancia ativa qualquer excipientes uso hormus undecilato testosterona contraindicado mulheres medicamento contraindicado uso mulheres solucao injetavel androgenos simple retencao so pode vendido retencao receita prescricao medica'\n",
      " 'cloridratoderemifentanila cloridrato remifentanila medicamento indicado produzir manter anestesia durante cirurgias inclusive coracao alivio dor imediatamente apos operacao medicamento tambem indicado promover alivio dor sedacao pacientes mecanicamente ventilados respiram ajuda aparelhos unidade terapia intensiva uti uso deste medicamento nao indicado caso voce hipersensibilidade conhecida remifentanila outros compostos semelhantes qualquer componente formulacao ver item composicao medico nao deve administrar medicamento via epidural tipo anestesia injecao aplicada costa serve principalmente aliviar dores parto medicamento tambem nao pode usado via intratecal espaco duas membranas revestem cerebro chamado espaco subaracnoide administracao cloridrato remifentanila deve feita somente via intravenosa interior veia medicamento contraindicado menores 1 ano idade gravidez lactacao medico somente deve utilizar medicamento mulheres gravida beneficios potenciais mae superarem possiveis riscos feto deve cuidado administracao deste medicamento mulheres amamentando medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiao dentista durante tratamento paciente nao deve dirigir veiculos operar maquinas poi habilidade atencao solucao injetavel venda sob prescricao medica hospitalar'\n",
      " 'prysma eszopiclona prysma eszopiclona indicado tratamento insonia adultos prysma eszopiclona contraindicado pacientes hipersensibilidade conhecida eszopiclona algum componente formula medicamento contraindicado faixa etaria pediatrica menores 18 ano devese ter cautela uso produto criancas jovens menos 18 ano vez nao estabelecidas seguranca eficacia uso eszopiclona pacientes precaucoes advertencias pacientes idosos acima 65 ano medicamento contraindicado faixa etaria acima 65 ano vez nao estabelecidas seguranca eficacia uso prysma eszopiclona pacientes associacao alcool eou outros medicamentos prysma eszopiclona nao deve ingerido junto alcool eou outros medicamentos possam causar sonolencia prysma eszopiclona nao deve usado pacientes doenca hepatica grave historia abuso alcool drogas gravidez lactacao categoria risco gravidez c medicamento nao deve utilizado mulheres gravida periodo aleitamento orientacao medica cirurgiaodentista habilidade dirigir operar maquinas devido propriedades farmacologicas efeitos sistema nervoso central snc prysma eszopiclona pode afetar adversamente habilidade dirigir operar maquinas sendo risco pode aumentado ingestao concomitante alcool nao deve portanto dirigir veiculos operar maquinas ingestao concomitante prysma eszopiclona alcool durante tratamento paciente nao deve dirigir veiculos operar maquinas poi habilidade atencao podem prejudicadas hipnoticos retencao so pode vendido retencao receita prescricao medica comprimido revestido'\n",
      " 'ciprofibrato ciprofibrato ciprofibrato nao deve utilizado seguintes casos insuficiencia hepatica figado severa insuficiencia renal rins severa gravidez lactacao associacao outros fibratos exemplo clorfibrato bezafibrato genfibrozila fenofibrato alergia ciprofibrato qualquer componente produto devido presenca lactose medicacao contraindicada pacientes deficiencia lactase galactosemia sindrome ma absorcao glicose galactose medicamento indicado adjunto dieta outros tratamentos nao farmacologicos exemplo exercicio reducao peso seguintes casos tratamento hipertrigliceridemia severa isolada elevacao gordura sangue hiperlipidemia mista aumento colesterol sangue estatina outro tratamento eficaz sao contraindicados nao sao tolerados comprimido antilipemicos venda sob prescricao medica genericos'\n",
      " 'novafibra polidextrose inulina oligofrutose po fibras alimentares auxiliam funcionamento intestino consumo deve associado alimentacao equilibrada habitos vida saudaveis alergicos pode conter derivados leite vaca soja ovo medicamento isento prescricao isento prescricao'\n",
      " 'cloridratodeparoxetina cloridrato paroxetina cloridrato paroxetina indicado tratamento adultos apresentam algumas condicoes abaixo transtorno depressivo maior anteriormente outros antidepressivos nao sido eficazes comportamento obsessivo compulsivo incontrolado ataques panico inclusive causados fobia pavor lugares abertos agorafobia ansiedade generalizada sensacao muita ansiedade nervosismo situacoes rotineiras inclusive situacoes exigem contato social ansiedade seguida evento traumatico transtorno estresse postraumatico acidente carro assalto desastre natural enchente terremoto cloridrato paroxetina nao indicado tratamento criancas adolescentes menores 18 ano ver item 4 devo saber ante usar medicamento cloridrato paroxetina contraindicado pacientes alergia conhecida droga qualquer componente formula voce nao deve tomar cloridrato paroxetina tempo outros medicamentos antidepressivos chamados inibidores mao antibiotico chamado linezolida azul metileno so passe usar cloridrato paroxetina duas semanas apos ter deixado tomar tipo medicacao mesma forma voce so deve iniciar tratamento inibidores mao demais citados duas semanas apos ter deixado usar cloridrato paroxetina voce tambem nao deve tomar cloridrato paroxetina tempo tioridazina pimozida normalmente usados tratar esquizofrenia ver item 4 devo saber ante usar medicamento voce nao certeza usando inibidores mao medicamentos base tioridazina pimozida consulte medico ante iniciar tratamento cloridrato paroxetina medicamento nao deve utilizado mulheres gravida orientacao medica informe imediatamente medico caso suspeita gravidez durante tratamento paciente nao deve dirigir veiculos operar maquinas poi habilidade atencao podem prejudicadas medicamento contraindicado menores 18 ano idade comprimido revestido antidepressivos retencao so pode vendido retencao receita genericos'\n",
      " 'sinotpo amoxicilina trihidratada sinot amoxicilina trihidratada antibiotico amplo espectro indicado tratamento infeccoes bacterianas causadas germes sensiveis acao amoxicilina amoxicilina penicilina nao deve administrada pacientes historico hipersensibilidade antibioticos betalactamicos penicilinas cefalosporinas comprimido antibioticos sistemicos simple retencao so pode vendido retencao receita prescricao medica'\n",
      " 'olmesartanamedoxomilahidroclorotiazida olmesartana medoxomila hidroclorotiazida olmesartana medoxomila hidroclorotiazida indicado tratamento pressao arterial alta pressao cujas medidas acima 140 mm hg pressao alta sistolica 90 mm hg pressao baixa diastolica voce nao deve usar olmesartana medoxomila hidroclorotiazida alergico sensivel qualquer componente deste produto outros medicamentos derivados sulfonamida grupo antibioticos semelhanca substancia hidroclorotiazida durante gravidez sofrer insuficiencia renal grave diminuicao quantidade urina anuria voce nao deve usar produto diabetico utilizando alisquireno primeiro trimestre gestacao medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista segundo terceiro trimestres gestacao medicamento nao deve utilizado mulheres gravida orientacao medica informe imediatamente medico caso suspeita gravidez comprimido revestido venda sob prescricao medica genericos'\n",
      " 'ventus furoato mometasona ventus furoato mometasona indicado tratamento rinite alergica polipos nasais rinossinusite tratamento complementar episodios agudos rinossinusite medicamento contraindicado uso pessoas hipersensibilidade furoato mometasona qualquer componentes medicamento contraindicado menores 2 ano solucao venda sob prescricao medica prescricao medica corticosteroides nasais'\n",
      " 'cloridratoamitriptilina cloridrato amitriptilina medicamento indicado medico receitou cloridrato amitriptilina tratar seguintes condicoes depressao enurese noturna urinar cama noite cloridrato amitriptilina possui propriedades ansioliticas sedativas calmantes nao devo usar medicamento voce nao deve tomar cloridrato amitriptilina alergicoa qualquer componentes deste medicamento recebendo tratamento depressao medicamentos inibidores monoaminoxidase imao recebendo tratamento cisaprida sofrido infarto coracao ultimos 30 dia gravidez categoria risco c medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido revestido antidepressivos retencao so pode vendido retencao receita genericos'\n",
      " 'nitazoxanida nitazoxanida nitazoxanida indicada tratamento seguintes infeccoes gastroenterites virais provocadas rotavirus norovirus helmintiases provocadas nematodeos cestodeos trematodeos enterobius vermicularis ascaris lumbricoides strongyloides stercolaris ancylostoma duodenale necator americanus trichuris trichiura taenia spp hymenolepis amebiase tratamento diarreia amebiase intestinal aguda disenteria amebiana causada complexo entamoeba histolyticadispar giardiase tratamento diarreia causada giardia lamblia giardia intestinalis criptosporidiase tratamento diarreia causada cryptosporidium parvum blastocistose balantidiase isosporiase causadas respectivamente blastocistis hominis balantidium coli isospora belli nitazoxanida nao deve administrada seguintes situacoes diabetes doencas hepatica doenca renal hipersensibilidade qualquer componentes formula medicamento contraindicado menores 1 ano po suspensao antiparasitarios venda sob prescricao medica genericos'\n",
      " 'leg desloratadina leg desloratadina indicado alivio sintomas rinite alergica espirro rinorreia prurido congestao nasal prurido ocular lacrimejamento vermelhidao olhos prurido palato tosse leg desloratadina tambem indicado alivio sinai sintomas urticaria medicamento contraindicado uso pacientes hipersensibilidade substancia ativa qualquer componentes comprimido comprimido revestido xarope antihistaminicos sistemicos antialergicos antitussigenos simple medicamento isento prescricao isento prescricao'\n",
      " 'turnosl hemitartarato zolpidem turno sl hemitartarato zolpidem indicado tratamento insonia ocasional transitoria cronica medicamento contraindicado seguintes casos hipersensibilidade zolpidem qualquer componentes formula insuficiencia respiratoria severa aguda insuficiencia hepatica severa pacientes ja apresentaram comportamento complexo sono apos utilizarem zolpidem outros medicamentos tratamento insonia eszopiclona zaleplona medicamento contraindicado faixa etaria pediatrica medicamento contraindicado uso pacientes insuficiencia respiratoria severa eou aguda medicamento contraindicado uso pacientes insuficiencia hepatica severa medicamento contraindicado uso mulheres gravida gravidez categoria risco gravidez categoria c medicamento nao deve utilizado mulheres gravida orientacao medica medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido hipnoticos retencao so pode vendido retencao receita prescricao medica'\n",
      " 'pantocalpo pantoprazol sodico sesquihidratado medicamento indicado tratamento ulcera peptica gastrica duodenal ulcera causada acido estomago contato revestimento estomago inicio intestino esofagites refluxo moderadas graf doenca causada volta conteudo estomago esofago tratamento sindrome zollingerellison outras doencas causadoras producao exagerada acido estomago via oral nao recomendada criterio medico pantocal intravenoso iv pantoprazol sodico sesquihidratado tambem indicado tratamento hemorragia digestiva alta complemento terapia endoscopica prevencao ressangramento profilaxia sangramento agudo ulcera estresse pantocal pantoprazol sodico sesquihidratado iv nao deve usado individuos apresentem alergia hipersensibilidade conhecida pantoprazol demais componentes formula benzimidazois substituidos categoria b risco gravidez medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista po liofilizado solucao injetavel antiulcerosos venda sob prescricao medica hospitalar'\n",
      " 'doceuno docetaxel trihidratado medicamento destinado tratamentos cancer mama adjuvante doceuno docetaxel trihidratado associacao doxorrubicina ciclofosfamida indicado tratamento adjuvante pacientes cancer mama operavel linfonodo positivo doceuno docetaxel trihidratado associacao doxorrubicina ciclofosfamida indicado tratamento adjuvante pacientes cancer mama operavel linfonodo negativo fatores alto risco tamanho tumor 2 cm idade 35 ano status receptor hormonal negativo tumor grau 2 3 doxorrubicina ciclofosfamida seguida doceuno docetaxel trihidratado associacao trastuzumabe acth indicado tratamento adjuvante pacientes cancer mama operavel cujos tumores superexpressam her2 doceuno docetaxel trihidratado associacao trastuzumabe carboplatina tch indicado tratamento adjuvante pacientes cancer mama operavel cujos tumores superexpressam her2 cancer mama metastatico doceuno docetaxel trihidratado associacao doxorrubicina indicado tratamento pacientes cancer mama localmente avancado metastatico nao receberam terapia citotoxica previa condicao doceuno docetaxel trihidratado monoterapia indicado tratamento pacientes cancer mama localmente avancado metastatico apos falha terapia citotoxica quimioterapia previa deve ter incluido administracao antraciclina agente alquilante doceuno docetaxel trihidratado associacao capecitabina indicado tratamento pacientes cancer mama localmente avancado metastatico apos falha quimioterapia citotoxica terapia previa deve ter incluido administracao antraciclina doceuno docetaxel trihidratado associacao trastuzumabe indicado tratamento pacientes cancer mama metastatico cujos tumores superexpressam her2 previamente nao receberam quimioterapia doenca metastatica cancer pulmao naopequenas celulas doceuno docetaxel trihidratado indicado tratamento pacientes cancer pulmao nao pequenas celulas localmente avancado metastatico apos falha quimioterapia previa doceuno docetaxel trihidratado associacao cisplatina indicado tratamento pacientes cancer pulmao naopequenas celulas irressecavel localmente avancado metastatico nao recebido previamente quimioterapia condicao vide item 9 reacoes adversas item 3 caracteristicas farmacologicas propriedades farmacodinamicas cancer ovario doceuno docetaxel trihidratado indicado tratamento carcinoma metastatico ovario apos falha quimioterapia primeira linha subsequente cancer prostata doceuno docetaxel trihidratado associacao prednisona prednisolona indicado tratamento pacientes cancer prostata metastatico resistente castracao doceuno docetaxel trihidratado combinacao terapia privacao androgenica adt prednisona prednisolona indicado tratamento pacientes cancer prostata metastatico hormoniosensivel adenocarcinoma gastrico doceuno docetaxel trihidratado associacao cisplatina fluoruracila indicado tratamento pacientes adenocarcinoma gastrico avancado incluindo adenocarcinoma juncao gastroesofagica nao receberam quimioterapia previa doenca avancada cancer cabeca pescoco doceuno docetaxel trihidratado associacao cisplatina fluoruracila indicado tratamento inducao pacientes carcinoma celulas escamosas cabeca pescoco localmente avancado cavidade oral orofaringe hipofaringe laringe doceuno docetaxel trihidratado contraindicado pacientes historia reacoes hipersensibilidade severas docetaxel polissorbato 80 pacientes contagem neutrofilica basal 1500 celulasmm3 contraindicacoes outros farmacos tambem sao aplicaveis associados docetaxel trihidratado medicamento contraindicado uso pacientes pediatricos medicamento contraindicado uso mulheres gravida medicamento contraindicado uso pacientes insuficiencia hepatica severa categoria risco gravidez d medicamento nao deve utilizado mulheres gravida orientacao medica informe imediatamente medico caso suspeita gravidez solucao injetavel antineoplasicos venda sob prescricao medica oncologia'\n",
      " 'sulfatodepolimixinab sulfato polimixina b medicamento indicado tratamento infeccoes agudas causadas pseudomonas aeruginosa infeccoes trato urinario meninges sangue infeccoes causadas seguintes microrganismos drogas menor potencial toxico sao ineficazes contraindicadas h influenzae especificamente infeccoes meninges escherichia coli especificamente infeccoes trato urinario aerobacter aerogenes especificamente caso bacteremia klebsiella pneumoniae especificamente caso bacteremia medicamento nao deve utilizado casos hipersensibilidade alergia polimixinas gravidez lactacao seguranca uso droga durante gravidez nao estabelecida portanto uso so deve feito nestes casos avaliandose fator riscobeneficio medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista po liofilizado solucao injetavel antibioticos sistemicos simple venda sob prescricao medica hospitalar'\n",
      " 'bissulfatodeclopidogrel bissulfato clopidogrel bissulfato clopidogrel indicado prevencao secundaria apos ocorrencia eventos aterotromboticos exemplo infarto agudo miocardio im infarto coracao acidente vascular cerebral avc derrame morte vascular pacientes adultos apresentaram im avc recente condicao conhecida doenca arterial periferica doenca vasos sanguineos membros sindrome coronaria aguda pacientes sindrome coronaria aguda sca angina instavel tipo severo dor peito im incluindo tanto controlados clinicamente quanto submetidos intervencao coronaria percutanea colocacao stent protese arteria coracao bissulfato clopidogrel nao deve utilizado caso voce apresente alergia intolerancia clopidogrel qualquer outro componente produto tambem nao deve utilizado caso voce apresente ulcera peptica lesao estomago hemorragia intracraniana sangramento dentro cerebro comprimido revestido venda sob prescricao medica genericos'\n",
      " 'acidozoledronico5mg acido zoledronico medicamento indicado tratamento osteoporose mulheres posmenopausa reduzir incidencia fraturas quadril vertebrais nao vertebrais aumentar densidade mineral ossea prevencao osteoporose mulheres osteopenia posmenopausa prevencao fraturas clinicas apos fratura quadril homens mulheres posmenopausa tratamento aumentar densidade ossea homens osteoporose tratamento prevencao osteoporose induzida glicocorticoides tratamento doenca paget osso medicamento contraindicado uso pacientes hipocalcemia vide advertencias precaucoes pacientes insuficiencia renal grave clearance creatinina 35 mlmin vide advertencias precaucoes gravida lactantes vide gravidez amamentacao pacientes hipersensibilidade principio ativo qualquer excipientes produto qualquer bisfosfonato medicamento pertence categoria d risco gravidez medicamento nao deve utilizado mulheres gravida orientacao medica informe imediatamente medico caso suspeita gravidez solucao injetavel antineoplasicos venda sob prescricao medica'\n",
      " 'subtrax sulfametoxazol trimetoprima subtrax sulfametoxazol trimetoprima somente deve usado beneficio tratamento superar qualquer risco possivel consideracoes devem feitas quanto agente bacteriano efetivo suscetibilidade bacteria in vitro varia geograficamente tempo situacao local deve considerada seleciona antibioticoterapia medicamento indicado tratamento infeccoes causadas microrganismos sensiveis associacao trimetoprima sulfametoxazol tai infeccoes trato respiratorio otites exacerbacoes agudas quadros cronicos bronquite sinusite tratamento profilaxia primaria secundaria pneumonia pnemocystis jirovecii adultos criancas otite medium criancas ha boa razoes preferir combinacao antibiotico simple infeccoes trato urinario renais cistites agudas cronicas pielonefrites uretrites prostatites cancroides infeccoes genitais homens mulheres inclusive uretrite gonococica infeccoes gastrintestinais incluindo febre tifoide paratifoide tratamento portadores colera medida conjunta reposicao liquidos eletrolitos diarreia viajantes causada escherichia coli enterotoxicogenica shiguelose cepas sensiveis shigella flexneri shigella sonnei tratamento antibacteriano indicado infeccoes pele tecidos mole piodermite furunculos abscessos feridas infectadas outras infeccoes causadas grande variedade microrganismos tratamento possivelmente combinacao outros antibioticos osteomielite aguda cronica brucelose aguda nocardiose blastomicose sulamericana actinomicetoma subtrax sulfametoxazol trimetoprima contraindicado casos lesoes graf parenquima hepatico pacientes insuficiencia renal grave caracterizada depuracao creatinina 15 mlmin vide item 8 posologia modo usar mesma forma subtrax sulfametoxazol trimetoprima contraindicado pacientes historia hipersensibilidade sulfonamida trimetoprima qualquer componentes formulacao subtrax sulfametoxazol trimetoprima nao deve utilizado combinacao dofetilida vide item 6 interacoes medicamentosas medicamento contraindicado uso prematuros recemnascidos durante primeiras seis semanas vida comprimido trimetoprima associacao sulfa retencao so pode vendido retencao receita prescricao medica'\n",
      " 'algestonaacetofenidaetatodeestradiol algestona acetofenida etato estradiol medicamento algestona acetofenida etato estradiol indicado prevenir gravidez sendo contraceptivo anticoncepcional injetavel base hormonios uso dose unica mensal medicamento algestona acetofenida etato estradiol pode tambem indicado controle irregularidades menstruais tratamento problemas hormonais falta estrogeno progesterona voce nao deve usar algestona acetofenida etato estradiol apresentar seguintes condicoes alergia qualquer componentes produto gravida suspeita gravidez amamentando menos 6 semanas apos parto cancer mama suspeita doenca maligna mama orgao genital dores cabeca graf recorrentes inclusive enxaqueca sintomas neurologicos hipertensao pressao alta grave acima 180110 mmhg doencas vasculares apresentar historico recente antigo trombose venosa profunda embolia pulmonar ambo tratamento anticoagulante problemas recentes antigos falta irrigacao sanguinea coracao incluindo infarto miocardio doenca valvula coracao diabetes comprometimento rins olhos nervos outros problemas circulacao sanguinea diabetes ha 20 ano lupus eritematoso sistemico tipo reumatismo presenca historico doencas figado incluindo cirrose grave tumores malignos figado hepatite ativa ictericia colestatica amarelamento pele gravidez ictericia uso anticoncepcional hormonal previo incluindo coceira grave gravidez passado cirurgia grande porte exija tempo repouso sangramento uterino vaginal anormal tabagismo intenso fumar 15 cigarros dia idade acima 35 ano medicamento contraindicado durante gravidez medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiao dentista solucao injetavel anticoncepcionais venda sob prescricao medica genericos'\n",
      " 'bedoze cloridrato hidroxocobalamina medicamento indicado tratamento deficiencia vitamina b12 quadros clinicos quais reposicao vitamina b12 adequado medicamento indicado tratamento disturbios metabolicos pacientes acidemia metilmalonica homocistinuria hipersensibilidade substancia ativa cobalaminas cobalto qualquer excipientes vitaminas venda sob prescricao medica prescricao medica injetavel'\n",
      " 'mesilatodedoxazosina mesilato doxazosina hiperplasia prostatica benigna hpb aumento benigno prostata mesilato doxazosina indicado tratamento sintomas hiperplasia prostatica benigna hpb doenca caracterizada aumento benigno prostata assim tratamento reducao fluxo urinario associada hpb mesilato doxazosina pode administrado pacientes hpb hipertensos sofram pressao alta normotensos pressao normal nao sao observadas alteracoes clinicamente significativas pressao sanguinea pacientes normotensos hpb pacientes hpb hipertensao apresentam ambas condicoes tratadas efetivamente mesilato doxazosina monoterapia unico remedio tratando duas doencas hipertensao pressao altamesilato doxazosina indicado tratamento hipertensao pode utilizado agente inicial controle pressao sanguinea maioria pacientes pacientes controle adequado unico agente antihipertensivo mesilato doxazosina pode administrado associacao outros medicamentos pressao alta tai diureticos tiazidicos betabloqueadores antagonistas calcio agentes inibidores enzima conversora angiotensina medico prescrevera melhor opcao tratamento caso nao utilize mesilato doxazosina voce alergia doxazosina outros tipos quinazolinas prazosina terazosina qualquer outro componente deste medicamento amamentando prostata aumentada hiperplasia prostatica benigna pressao baixa apresenta historia condicao conhecida hipotensao ortostatica forma pressao baixa faz voce sentir tonto atordoado levanta prostata aumentada juntamente seguintes condicoes qualquer tipo congestao bloqueio trato urinario infeccao cronica trato urinario pedras bexiga incontinencia urinaria transbordamento ausencia vontade urinar anuria organismo nao produz urina problemas renais comprimido antihipertensivos venda sob prescricao medica genericos'\n",
      " 'tramadolcloridratode2 cloridrato tramadol medicamento indicado cloridrato tramadol indicado alivio dor intensidade moderada grave nao devo usar medicamento voce nao deve tomar cloridrato tramadol voce alergico cloridrato tramadol qualquer componente medicamento intoxicacao aguda alcool pilulas dormir analgesicos outras drogas psicotropicas medicamentos afetam humor emocoes voce tambem tomando inibidores mao certos medicamentos usados tratamento depressao tomado ultimos 14 dia ante tratamento cloridrato tramadol voce epiletico crisis convulsao nao estao controladas adequadamente tratamento substituto abstinencia narcoticos solucao analgesicos narcoticos retencao so pode vendido retencao receita genericos'\n",
      " 'turno1 hemitartarato zolpidem turno hemitartarato zolpidem destinado tratamento curta duracao insonia dificuldade dormir pode ocasional eventual transitoria passageira cronica dura ha tempo turno hemitartarato zolpidem nao deve utilizado pacientes hipersensibilidade alergia intolerancia zolpidem qualquer outro componente formula medicamento tambem nao deve utilizado pacientes insuficiencia respiratoria severa eou aguda dificuldade respiratoria insuficiencia figado severa reducao funcao figado pacientes apresentaram comportamento complexo sono apos tomar medicamento medicamento contraindicado faixa etaria pediatrica medicamento contraindicado uso pacientes insuficiencia respiratoria aguda eou severa medicamento contraindicado uso pacientes insuficiencia hepatica severa medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido revestido hipnoticos venda sob prescricao medica prescricao medica'\n",
      " 'calnate poliestirenossulfonato calcio calnate poliestirenossulfonato calcio indicado tratamento hiperpotassemia concentracao alta maior normal potassio sangue circulante casos insuficiencia renal diminuicao funcao rins calnate poliestirenossulfonato calcio nao deve utilizado pacientes problemas paratireoides glandulas produzem paratormonio hormonio regula metabolismo calcio problemas doencas sangue mieloma multiplo sarcoidose doenca causa conhecida acumulamse granuloma pequenos nodulos tecidos carcinoma metastatico possam apresentar insuficiencia renal elevada taxon calcio sangue pacientes calculo renal elevada taxon calcio sangue qualquer origem tambem nao devem utilizar calnate poliestirenossulfonato calcio medicamento nao deve utilizado mulheres gravida orientacao medica informe imediatamente medico caso suspeita gravidez po suspensao venda sob prescricao medica hospitalar'\n",
      " 'azitromicinacomprimido azitromicina dihidratada azitromicina dihidratada indicado tratamento infeccoes causadas bacteria sensiveis azitromicina infeccoes trato respiratorio inferior bronquios pulmoes superior nariz faringe laringe traqueia incluindo sinusite infeccao seios face faringite inflamacao faringe amigdalite inflamacao amigdalas infeccoes pele tecidos mole musculos tendoes gordura otite medium infeccao ouvido medio aguda doencas sexualmente transmissiveis nao complicadas genitais homens mulheres causadas bacteria chlamydia trachomatis neisseria gonorrhoeae tambem indicado tratamento cancro lesao pele devido haemophilus ducreyi especie bacteria infeccoes ocorrem junto sifilis doenca sexualmente transmissivel devem excluidas azitromicina dihidratada contraindicado voce historia hipersensibilidade reacoes alergicas azitromicina eritromicina qualquer antibiotico macrolideo classe antibioticos pertence azitromicina cetolideo outra classe antibioticos qualquer componente formula comprimido antibioticos sistemicos simple retencao so pode vendido retencao receita genericos'\n",
      " 'desve succinato desvenlafaxina monoidratado medicamento indicado tratamento transtorno depressivo maior tdm medicamento nao indicado uso nenhuma populacao pediatrica hipersensibilidade succinato desvenlafaxina monoidratado cloridrato venlafaxina qualquer excipiente formulacao desvenlafaxina inibidor recaptacao serotonina noradrenalina medicamento nao deve usado associacao inibidor monoaminoxidase imao minimo 14 dia apos descontinuacao tratamento imao base meiavida succinato desvenlafaxina monoidratado devese esperar minimo 7 dia apos interrupcao succinato desvenlafaxina monoidratado ante iniciar imao iniciar succinato desvenlafaxina monoidratado paciente sendo tratado imao reversivel linezolida pacientes cujo azul metileno intravenoso sido administrado tambem contraindicado razao aumento risco sindrome serotonina vide item 8 posologia modo usar item 5 advertencias precaucoes succinato desvenlafaxina monoidratado medicamento classificado categoria c risco gravidez portanto medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido revestido liberacao prolongada antidepressivos retencao so pode vendido retencao receita prescricao medica'\n",
      " 'acetilcisteinagranulado acetilcisteina medicamento indicado medicamento expectorante indicado dificuldade expectorar ha muita secrecao densa viscosa tai bronquite aguda bronquite cronica exacerbacoes piora quadro clinico complicacoes enfisema pulmonar doenca cronica caracterizada comprometimento pulmoes pneumonia inflamacao pulmoes bronquios colapsoatelectasias pulmonares fechamento bronquios mucoviscidose doenca hereditaria produz muco espesso tambem conhecida fibrose cistica tambem indicado intoxicacao acidental voluntaria paracetamol nao devo usar medicamento acetilcisteina contraindicada pacientes alergicos acetilcisteina eou demais componentes formulacoes medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista medicamento contraindicado criancas menores 2 ano nao ha contraindicacoes tratamento overdose paracetamol acetilcisteina granulado expectorantes balsamicos mucoliticos medicamento isento prescricao genericos'\n",
      " 'zina dicloridrato levocetirizina zina dicloridrato levocetirizina indicado tratamento sintomas associados enfermidades alergicas rinite alergica sazonal incluindo sintomas oculares rinite alergica perene urticaria cronica idiopatica zina dicloridrato levocetirizina contraindicado pacientes historia hipersensibilidade levocetirizina cetirizina qualquer outro componente formulacao hidroxizina qualquer derivado piperazinico zina dicloridrato levocetirizina contraindicado pacientes insuficiencia renal grave clearance creatinina inferior 10 mlmin pacientes estao sendo submetidos dialise medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido revestido antialergicos medicamento isento prescricao'\n",
      " 'escodt oxalato escitalopram esc oxalato escitalopram indicado tratamento prevencao recaida recorrencia depressao tratamento transtorno panico agorafobia tratamento transtorno ansiedade generalizada tag tratamento transtorno ansiedade social fobia social tratamento transtorno obsessivo compulsivo toc esc oxalato escitalopram contraindicado pacientes apresentam hipersensibilidade escitalopram qualquer componentes ver composicao tratamento concomitante imao inibidores monoaminoxidase nao seletivos irreversiveis contraindicado devido risco sindrome serotoninergica agitacao tremor hipertermia etc ver item 6 interacoes medicamentosas tratamento concomitante pimozida contraindicado combinacao escitalopram imaoa ex moclobemida reversiveis linezolida imao nao seletivo reversivel contraindicada devido risco sindrome serotoninergica ver item 6 interacoes medicamentosas esc oxalato escitalopram contraindicado pacientes diagnosticados prolongamento intervalo qt sindrome congenita qt longo esc oxalato escitalopram contraindicado uso concomitante medicamentos causam prolongamento intervalo qt ver item 6 interacoes medicamentosas fertilidade gravidez lactacao gravidez categoria risco bos dado clinicos utilizacao oxalato escitalopram durante gravidez sao limitados estudos animais mostraram toxicidade reprodutiva ver item 2 resultados eficacia estudos animais nao usar oxalato escitalopram durante gravidez menos necessidade clara avaliado cuidadosamente riscobeneficio uso deste medicamento recemnascidos devem observados uso maternal escitalopram continuou ate estagios avancados gravidez particularmente terceiro trimestre escitalopram usado ate proximo dia nascimento efeitos descontinuacao recemnascido sao possiveis esc oxalato escitalopram usado durante gravidez nao interromper abruptamente descontinuacao devera gradual seguintes reacoes observadas recemnascidos apos uso isrsisrn ultimos me gravidez dificuldade respiratoria cianose apneia convulsoes instabilidade termica dificuldade alimentacao vomitos hipoglicemia hipertonia hipotonia hiperreflexia tremor agitacao irritabilidade letargia choro constante sonolencia dificuldade dormir efeitos tambem podem indicativos sindrome serotoninergica retirada abrupta medicamento durante gravidez maioria casos tai complicacoes comecam imediatamente brevemente 24 horas apos parto dado epidemiologicos sugerem uso isrs durante gravidez especialmente final gravidez pode aumentar risco hipertensao pulmonar persistente recemnascido hppn risco observado aproximadamente 5 casos cada 1000 gestantes populacao geral 1 2 casos hppn ocorrem cada 1000 gestantes dado observacionais indicam risco aumentado menos 2 vezes hemorragia posparto apos exposicao isrs irsn me anterior nascimento ver advertencias precaucoes reacoes adversas lactacao escitalopram excretado leite materno mulheres fase amamentacao nao devem tratadas escitalopram situacoes onde nao possivel retirar medicamento devido gravidade quadro clinico materno substituir aleitamento materno leites industrializados especificos recemnascidos fertilidade estudos animais mostraram citalopram pode afetar qualidade esperma ver item 2 resultados eficacia estudos animais relatos casos humanos alguns isrss mostraram efeito qualidade esperma reversivel ate momento nao observado impacto fertilidade humana medicamento nao deve utilizado mulheres gravida orientacao medica cirurgiaodentista comprimido orodispersivel antidepressivos retencao so pode vendido retencao receita prescricao medica']\n"
     ]
    }
   ],
   "source": [
    "name_types = {\n",
    "                \"ativo_indicacao_contra_indicacao_classes\":[0,1,2,3]\n",
    "}\n",
    "lnp_models = [\n",
    "                     'distiluse-base-multilingual-cased-v2',\n",
    "]\n",
    "\n",
    "df_train = pd.read_csv(\"./medicamentos_reduzidos\")\n",
    "# df_train = pd.read_excel(\"./medicamentos.xlsx\")\n",
    "\n",
    "df_train.head()\n",
    "color_maps = 'tab20'\n",
    "lemmatizer = WordNetLemmatizer()\n",
    "figsize=(20,10)\n",
    "list_preprossing=np.empty(0)\n",
    "\n",
    "for row in df_train.itertuples():\n",
    "    value=' '\n",
    "    for data in row[1:]:\n",
    "        value +=' '+str(data)\n",
    "    # print(value)\n",
    "    #     lemmas = nlp(preprocess_text(value.replace('nan','')))\n",
    "    # for lemma in lemmas:\n",
    "    #     print(lemma[\"lemma\"])\n",
    "    # print(preprocess_text(value.replace('nan','')))\n",
    "\n",
    "    # lemmatized_tokens = [lemmatizer.lemmatize(token) for token in filtered_tokens]\n",
    "    # filtered_text = ' '.join(filtered_tokens)\n",
    "    # list_preprossing = np.append(list_preprossing,filtered_text)\n",
    "    # break\n",
    "    # tokens = tokenizer.tokenize(preprocess_text(value.replace('nan','')))\n",
    "    # print(tokens)\n",
    "    tokens = word_tokenize(preprocess_text(value.replace('nan','')))\n",
    "    filtered_tokens = [token for token in tokens if token.lower() not in list(stopwords_)]\n",
    "        # print(filtered_tokens)\n",
    "    lemmatized_tokens = [lemmatizer.lemmatize(token) for token in filtered_tokens]\n",
    "    filtered_text = ' '.join(lemmatized_tokens)\n",
    "        # print(filtered_text)\n",
    "    list_preprossing = np.append(list_preprossing,filtered_text)\n",
    "\n",
    "\n",
    "print(list_preprossing)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-05-24T14:17:31.218133235Z",
     "start_time": "2023-05-24T14:17:29.135863716Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "outputs": [
    {
     "data": {
      "text/plain": "Batches:   0%|          | 0/4 [00:00<?, ?it/s]",
      "application/vnd.jupyter.widget-view+json": {
       "version_major": 2,
       "version_minor": 0,
       "model_id": "6d445d66707f4056a4802bb0a1049b90"
      }
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "corpus_embeddings = SentenceTransformer(lnp_models[0]).encode(list_preprossing,show_progress_bar=True)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-05-24T14:17:47.503740890Z",
     "start_time": "2023-05-24T14:17:31.219186420Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "outputs": [],
   "source": [
    "umap = umap_.UMAP(n_neighbors=2,n_components=2,metric='cosine')\n",
    "reduce_embedding_umap=umap.fit_transform(corpus_embeddings)\n",
    "kmeans = KMeans(n_clusters=7,n_init='auto').fit(reduce_embedding_umap)\n",
    "result = pd.DataFrame(reduce_embedding_umap,columns=['x', 'y'])\n",
    "reduce_embedding = reduce_embedding_umap\n",
    "result['labels'] = kmeans.labels_\n",
    "centroids = kmeans.cluster_centers_"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-05-24T14:32:11.960642691Z",
     "start_time": "2023-05-24T14:32:08.139048693Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "outputs": [
    {
     "data": {
      "text/plain": "<Figure size 2000x1000 with 1 Axes>",
      "image/png": "iVBORw0KGgoAAAANSUhEUgAACF4AAAM7CAYAAAB5wMZfAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAAEAAElEQVR4nOzdd3yN5//H8dfJXhIrSIzEptQusUet2qpma9booqqqtWqvtpTqt4sSqoPSpTYVu5QqatTesUkikX1+f9y/hEhIQuLOeD8fj/PIyX1f93U+J8mddb/P57JYrVYrIiIiIiIiIiIiIiIiIiIiIpJqNmYXICIiIiIiIiIiIiIiIiIiIpJZKXghIiIiIiIiIiIiIiIiIiIi8ogUvBARERERERERERERERERERF5RApeiIiIiIiIiIiIiIiIiIiIiDwiBS9EREREREREREREREREREREHpGCFyIiIiIiIiIiIiIiIiIiIiKPSMELERERERERERERERERERERkUdkZ3YBmVFsbCwXL14kR44cWCwWs8sRERERERERERERERETWa1WQkJC8Pb2xsbm7mteo6KiiImJMbEyEREReRS2trbY29uneLyCF4/g4sWLFC5c2OwyREREREREREREREQkAzl37hyFChUiODiYa9euERERYXZJIiIi8ogcHR3Jmzcv7u7uyY5V8OIR5MiRAzB+gUrJB1menKioKNauXUvTpk1TlUCSLCooCBYtgrlz4eRJ8PaGzp2hSxcoU8bs6iQNZOhz/upVWLYMvv8e/vkHcuaErl1hwAAoWtTs6kQyrQx93otImtM5L5K96JwXyV50zktWExwcTOHChcmRIwfBwcFcuHABNzc38ubNi729vbpni4iIZCJWq5WoqCiCgoK4cOECQLK5AAUvHkHcL0ju7u4KXmQwUVFRuLi44O7urj/YsrOjR+GTT8DfHyIjoWNHmDMH6tcHW1uzq5M0lKHPeXd3GDbMuB06ZHw9fv01fPEFtG4Nb74JDRuC/ugWSZUMfd6LSJrTOS+SveicF8ledM5LVmWxWLh27Rpubm4UKlRIgQsREZFMytnZmRw5cnD+/HmuXbuWbC7A5qF7RUQyC6sVtm6FNm2gdGlYsgSGDIEzZ+Dbb6FRI4UuxDxPPQUffADnzsGXXxodWJ59FipVMr4+o6LMrlBERERERERERNJAdHQ0EREReHh4KHQhIiKSyVksFjw8PIiIiCAqmWs5Cl6ISOYWGwu//AK1a0PdusYF7fnz4exZGD8evLzMrlDkLhcX6NcP9u+HDRugYEF46SUoUQJmzYLbt82uUEREREREREREHkNsbCyAOrmIiIhkEXE/02NiYh46TsELEcmcrFZYuRIqVoT27cHeHn7/3big3asXODmZXaHIg1ksRheWlSth3z5jGZyhQ8HX1whgREaaXaGIiIiIiIiIiDwGdbsQERHJGlL6M13BCxHJfHbvNi5at2wJefPC9u2waZPxvo2+rUkmU6ECLFwIJ07A888bS+SULQuLFxsdXURERERERERERERERCRD0xVKEck8Tp6Erl3hmWfg6lVYsQL++ANq1jS7MpHHV6QIfPUVHDgA5cpBly5QowYEBJhdmYiIiIiIiIiIiIiIiDyEghcikvFduwaDB0OZMrB5M3z9tbE8Q4sWxpINIlnJU0/Bb78ZXVxsbKBhQ6Oby7//ml2ZiIiIiIiIiIiIiIiIJEHBCxHJuKxWowNA8eIwfz6MGwfHjkGfPmBra3Z1IumrXj34809YsgSOHoWKFWHgQAgNNbsyERERERERERERERERuYeCFyKSMZ07B82awYAB0LEjHD8Ow4eDi4vZlYk8ORaL8fV/8CB89JHR7aVCBdiyxezKRERERERERERERERE5P8peCEiGYvValxcLl8eDh+G1ath7lzw9DS7MhHzODjAW2/B/v3g7Q316xvvh4WZXZmIiIiIiIiIiIiIiEi2p+CFiGQc589DixbQty+88AL8+6/R9UJEDCVKQEAAzJgBX3wBlSrBtm1mVyUiIiIiIiIiIiIiIpKtKXghIhnDt98aXS7274cVK4yuFx4eZlclkvHY2sLgwbBvn9EJpm5dGDoUIiPNrkxERERERERERERERCRbUvBCRMwVEwPvvAMvvQStWxtdLlq0MLsqkYyvVCnYvBk+/BA++cToDnPjhtlViYiIiIiIiIiIiIiIZDsKXoiIeUJCoH17Y9mEWbNg4ULIlcvsqkQyD1tbePtt+OMPI7RUowb895/ZVYmIiIiIiIiIiIiIiGQrCl6IiDnOnIHatSEgAH7/HQYNAovF7KpEMqc6dWDnTnBwMMIX69aZXZGIiIiIiIiIiIiIiEi2oeCFiDx527dD9epw+zbs2AHPPWd2RSKZX7FixvlUq5ZxTn32mdkViYiIiIiIiIiIiIiIZAsKXojIk/Xbb9CwIZQqZbxCv1w5sysSyTrc3Y1zbOBAeP11GDYMrFazqxIREREREREREREREcnS7MwuQESykYAA6NQJWrWC774DR0ezKxLJeuzs4OOPwdcXBg8GDw8YOdLsqkRERERERERERERERLKsDNfxYvfu3YwfP56mTZtSqFAhHB0dcXNzo1SpUvTu3ZutW7emar5Vq1bRvn37+LkKFSpE+/btWbVqVTo9AxFJ0p490KYN1Kun0IXIk/DmmzB+PIwaBZ9/bnY1IiIiIiIiIiIiIiIiWVaG6nhRr149tmzZkmh7ZGQkx44d49ixY/j7+9OjRw/mzJmDg4PDA+eKjY2lf//+fP311wm2X7hwgQsXLvDLL7/Qt29fvvzyS2xsMlz+RCRrOXIEmjeHp56Cn35S6ELkSRk1Cq5fN5YdyZULunQxuyIREREREREREREREZEsJ0MFLy5evAiAt7c3HTt2pG7duhQpUoSYmBh27NjB9OnTuXDhAgsXLiQqKorvvvvugXONHDkyPnRRuXJlhg0bRvHixTlx4gQffPABe/fuZe7cuXh6ejJ58uQn8vxEsqWzZ6FJE8ifH1auBDc3sysSyT4sFpgxA27cgO7djWVHnnvO7KpERERERERERERERESylAwVvChTpgyTJ0+mQ4cO2NraJtjn5+dH9+7dqV27NkePHuX777/nlVdeoV69eonmOXr0KB999BEA1apVY/PmzTg7OwPwzDPP0KZNG+rXr8/u3bv58MMP6dOnDyVKlEj/JyiS3dy5Y1zktbODtWshd26zK5IUslqtnD59mmPHjnH69GkuXbpEaGgoUVFR5MiRg5w5c1K6dGkaNGiAi4uL2eXKw9jYwNdfQ1AQdOgAu3ZB+fJmVyUiIiIiIiIiIiIiIpJlZKjgxe+///7Q/Xnz5mX69Om0bt0agKVLlyYZvJg5cybR0dEAzJ49Oz50EcfFxYXZs2dTs2ZNoqOj+fjjj/nf//6XRs9CROKNHAknTsDff4O3t9nVyEPcuXOH7du3ExAQwKYtm9i7dy+3g28DYLGx4OjuiI2TDRY7C7HhsUTdjiI6PBoHRwcaNmxIq5ataN26NT4+PiY/E0mSvT388ANUqwY9e8KffxrbRERERERERERERERE5LFlqOBFSjRs2DD+/okTJxLtt1qt/Prrr4DRQcPPzy/Jefz8/ChdujT//fcfv/76K59++ikWiyV9ihbJjjZtgpkz4aOP4KmnzK5GklGpSiWOHjmKQw4HnEo54dLEhTw+eXD0csQ+lz0Wu4TfH61WKxGBEdzed5sd/+5g3VvrGPzWYN4e8jZjxoxRF4yMyNkZFiwAPz+YPBnGjDG7IhERERERERERERERkSwh0wUvIiIi4u/fvxwJwKlTp7h48SIA9evXf+hc9evX57///uPChQucPn2aokWLpm2xItlVSAj07g116sCbb5pdjaRAYGAgnq08yfd8Piw2yYfQLBYLTt5OOHk7wXMQcyeG62uv89HHH7FqzSo2rNuAp6fnE6hcUqVaNaMTzcSJ0KoVVK1qdkUiIiIiIiIiIiIiIiKZXqYLXmzatCn+ftmyZRPtP3ToUPz9MmXKPHSue/cfPnxYwQuRtPLOO3DlCqxfD0kEpCRjsnW1TRC6iL4dTURgBJGXIokOjib2TixYwNbFFueizjgXd8bG3sY41tmWfG3z4V7FnaMfHaV+w/rs+WtPoqWeJAMYNQqWLzeWHNm9G5yczK5IREREREREREREREQkU8tUwYvY2FimTp0a/36nTp0SjTl//nz8/UKFCj10vsKFC8ffP3fu3APHRUREJOi0ERwcDEBUVBRRUVHJFy5PTNznQ58XE23fDgsXGsuMFC4M+lxkCk5OTthH2ROxO4KQwyFEnYoiLDAsfr97TndyuOUAK9y6eYugsCDsHO1wLu1M3lZ5cS5sBCwcCzviOMyRU5NPMW/ePHo1b05scDA2Li7Y+/hgSeMgjs75R+TvD/XqwbRpMGKE2dWIpIrOe5HsRee8SPaic14ke9E5L1mNvpZFRESyt0wVvPj444/ZtWsXAM8//zxVk2iRHhISEn/fzc3tofO5urrG3799+/YDx02ZMoVx48Yl2r527VpcXFySrVuevHXr1pldQvb2/ffG25Urza1DUmzOl3PuvtP4MSfLCXxr3F3/7793tx858pgTP5jO+UewYIHxVuepZFI670WyF53zItmLznmR7EXnvGQVYWFhyQ8SERGRLCvTBC82bdrEe++9B0C+fPn4/PPPkxwXHh4ef9/BweGhczo6Osbfv3PnzgPHDR8+nCFDhsS/HxwcTOHChWnatCnu7u4pql+ejKioKNatW0eTJk2wt7c3u5zs58gRqFEDvvwSunQxuxpJhfnz5xMTE0Pz5s2T7RZ0r6ioKN566y0WfbuIYuOK4ZjX+L4afiGckxNPMjZ/AVrc+33SxgZ7b28Kf/kF9vnzP3bdOucfw7lzULGi0fWiXz+zqxFJMZ33ItmLznmR7EXnvEj2onNespq4TtkiIiKSPWWK4MXBgwdp37490dHRODk58eOPP5IvX74kxzrds1Z9ZGTkQ+e9d/kQZ2fnB45zdHRMENKIY29vrz8KMih9bkzyySeQMyd07gz6+Gcq/fv3f6Tj7O3t+WDoUH5c/AMXV17Eu4c3AJaCFmyLWFh14Sqt7/v+GXv6NIH9+lP055+wued79uPQOf8IihWDli1hxgwYMADSeBkYkfSm814ke9E5L5K96JwXyV50zktWoa9jERGR7M3G7AKSc+rUKZo2bcrNmzextbXlhx9+oF69eg8cnyNHjvj7D1s+BCA0NDT+fnLLkohIMi5fhm++gYEDIZluM5I1hO7YwZk+L3OxdRu62tkTtOUm1lhr/H77Ao4ExkYnPjAmhshTpwheueoJVitJGjIETpyA334zuxIREREREREREREREZFMK0MHLy5evEjjxo25ePEiFouFefPm0bZt24cec2+L/PPnzz907Llz5+LvFy5c+PGKFcnuvvjCeMX8gAFmVyLpKDYykqDfV3CmR0/O9u5D2I4dAJR2dCImykrM7Zj4sbbOtoTExiQ9kY0NNxZ98yRKloepXh3q1IGPPza7EhERERERERERERERkUwrwy41cu3aNZo0acLJkycBmD17Nj169Ej2uKeeeir+/pEjRx469t79ZcuWfcRKRQSAVaugTRvIndvsSiQdxISGcu3zL7j1ww/E3ttNyGp0uAi3xgJgcbDE74oOiSafzQOWr4iNJeLQYayRkVjUIcVcPXtC//4QHAzu7mZXIyIiIiIiIiIiIiIikulkyI4XQUFBNGvWjEOHDgEwdepUXn/99RQdW7RoUby9vQHYtGnTQ8du3rwZgIIFC+Lr6/voBYtkd+Hh8PffUKuW2ZVIGgvZtIkTbdpwtGo1bsydmzB0cY+1t0NwzueArZMRtLDGWAn7J4Qaji4PnT82MirNa5ZUqlXLCNDs2mV2JSIiIiIiIiIiIiIiIplShgtehIWF0bJlS/7++28ARo4cybvvvpvi4y0WS/xyJEeOHOHPP/9Mctyff/4Z3/Gibdu2WCyWJMeJSArs3QtRUVCzptmVSBqJDQvj1AsdOT/gFSKPHkt60P93uzgaEc4fIbfJ1TJv/K7QI6FEhsbQPEeOBz6GxdERG9eHBzPkCShTBnLmhAf8vBQREREREREREREREZGHy1DBi8jISNq3b8+2bdsAePPNN5k4cWKq5xk8eDC2tsarrgcOHMidO3cS7L9z5w4DBw4EwM7OjsGDBz9e4SLZ3Y4d4OwMFSuaXYk8BmtMDGF//03QypVcrl4D799+wy4q6Y4UdlFRFD55ks2XL9PrwjmcCjiSs2ZOAGKjY7nywyWKOTlS3skp6QeztcW9dWuF3jICGxuoUcM4j0VERERERERERERERCTV7Mwu4F5du3Zl7dq1ADRq1IiXX36Zf//994HjHRwcKFWqVKLtpUqV4p133mHq1Kns3r2b2rVr8+6771K8eHFOnDjBtGnT2Lt3LwDvvPMOJUuWTJ8nJJJd7NgB1aqBvb3ZlcgjiI2I4MbChdxc9C3Rly+D1UqxU6fYFRXJP6dPcSN3bmJtjDBbFFZuR0XxX9AttmIl7NZN3Cu44dO3EDYONsSExnBhznkiL0QwtXCRBwcrYmLI3a3rE3yW8lA1a8InnxhdTBSGERERERERERERERERSZUMFbz46aef4u//8ccfVKhQ4aHjfXx8OH36dJL7Jk2axJUrV5g3bx579+6lS5cuica8/PLLj9RRQ0Tuc/gwNGxodhWSSlGBgdz8YTG3liwh5ubNuzssFs4WLsxLZ05yNiYWy41r8btsbCzYOdrgUNqFHOXc8CrvhrOvM9ZYKzc23eDaksvYhMcy26sg5Z2cH/jYed94A6ennkrPpyepUakS3LgBV65A/vxmVyMiIiIiIiIiIiIiIpKpZKjgRVqysbHh66+/pkOHDnz11Vf89ddfXLt2jbx58/LMM88wYMAAnnvuObPLFMkawsIgRw6zq5AUirl9m0uj3yd49Wqjw0ESou3tCbe1xbNlLvI///AL8YHfB3J9zXUAWrm7M9TXk3x2SXQ/sViw2Nvj+eab5O7T+7Gfh6QhNzfjbViYuXWIiIiIiIiIiIiIiIhkQhkqeGF9wAXAx9GiRQtatGiR5vOKyD3CwsD5wd0NJOOIDQ3lTPceRPz33wNDF3GsKVxxIvJCRPx9Nxsb7Pn/Ay0WbD09sc+fH9scOXBrUB+Ptm2x9fB41PIlvbi4GG9DQ82tQ0REREREREREREREJBPKUMELEcmkLCm8Qi9PXGxkJJHHjxN75w62uXJz45tvjNBFbGyKjg87FsbV36/Gv2+xt2DrYouTjxNOhZ2wWCz4DPUl5k4MNwNusuzXKyw/E8zIfF50LFeOoksWY5szZzo9O0kzcSEcGxtz6xAREREREREREREREcmEFLwQkcfn7KwlCjKY6KtXubHwG24uXkxscPDdHRZLsp0u4lR0dGbX8TAijobFHxNhhTv/f7ijhx0ulXKQu2FunH2dyftcXnLWzsmlxZcYse0COYe+zasKXWQOceevOteIiIiIiIiIiIiIiIikml7aKiKPz80N7r24L6YKP3qUk+3ac/3rrxOGLiDFoQuAz/Lm4yo23IyxctnWnr2FinDLzp47wCpbW7riivOftzk57gRXfrmC1WrFzt2Ogn0LkrtRbga9O4x9+/al7ZOT9BH3deLqam4dIiIiIiIiIiIiIiIimZCCFyLy+MqXh7//NrsKAaJv3uRsnz7E3LqV4uVEkmIXFYXPubM4REURaW/PmcJFuOPswpnCRbCxt6d5TAxfhoWxzrswb3gX5MovV+KXJLFYLBToWgCHfA6MGj0qjZ6ZpKu//4Z8+cDT0+xKREREREREREREREREMh0FL0Tk8dWsaVy4jYgwu5Js79biJcTcuAkxMY8+idVKkXPnEoQuou3tAYj+//cj7e1xiIqidPgdZv33H0OGDOHGyhvEhBqPa2Nvg3s9d9asWUNQUFBaPDVJTzt2GOexxWJ2JSIiIiIiIiIiIiIiIpmOghci8vj8/CAyUl0vTGaNieHmd989VqcLACwWrubNS4S9Q4LQRfzjeHlxe/x4rKVKYfvxx1hcXXnnnXewxFi4selG/DiPZzyIiozit99+e7x6JH3FxMCuXcZ5LCIiIiIiIiIiIiIiIqmm4IWIPL6KFcHJCf780+xKsrXoK1eIvnIlTeYKcXfnZNGi8aELjw4d8F26lJJbt1Bq6xZyv/celgMHoHNnAAoUKMDzzz9P6F+h8XPY57bHtYgrW7duTZOaJJ0cPAi3bxsdL0RERERERERERERERCTVFLwQkcfn4ADVqoEusJvKmtZLvVgs2Li6ku+9d/GaOAHn8uWwy5v37n4HhwTDy5YpS/St6ATbbNxtuHbtWtrWJWlr2zawtTXOYREREREREREREREREUk1O7MLEJEsonVrGD0aLl2CAgXMriZbss2TBywWsFofey7HMmXI3f0l3Fu0wMbZOUXHREVFYbG1JNwYA46Ojo9dj6QTqxXmzoVnnwVXV7OrERERERERERERERERyZTU8UJE0ka/fmBvD599ZnYl2ZZtjhy41a9vdC94RM5VqlDof59S7JefydmhQ4pDFwD/7PsHu1wJ83yxwbEUUBAn49q8Gf7+G4YMMbsSERERERERERERERGRTEsdL0QkbeTKBX36GMGL4cMhFRfsJe3k6v4StwMCkh9osWDj5kYR//lEX7oEgEPRojgWK/ZIj3v06FFWrliJV0+v+G0xYTGEXwnHx8fnkeaUJ2DGDChXDpo2NbsSERERERERERERERGRTEsdL0Qk7QweDDdvwsKFZleSbbnWqkWu7i89fJDFAhYLBWfMwLlcOcIrVMCpXr1HDl1YrVYmTZqEg4cDOWvljN8e9FcQ1hgrHTp0eKR5JZ0dPQrLlxvdLiyW5MeLiIiIiIiIiIiIiIhIkhS8EJG0U6wYtG8PH38MMTFmV5MtWSwW8o8YQd7XXwc7u4QX1G2Mb/m2uXNTZO4c3OrWAaBEyRIUL1GcL7/8kjt37qTq8W7fvs3rr7/OwoULydMuDzYOd3+shGwLoVHjRhQqVOjxn5ikvRkzIF8+ePFFsysRERERERERERERERHJ1LTUiIikrffeg+rVYfp0GDbM7GqyJYvFgufAN8j10osE/fQToTt3Ehsahp1nXtyfa0GORg2x2NvHjw8OCibCOYJXXn2FwW8NpmWLljRv3pxKlSpRrlw5nO9bNubSpUv88ccfbNiwgd9+/42bt27i1cOL3A1yx48J2R9CyNEQXh738hN73pIKO3fCnDkwdSo4OppdjYiIiIiIiIiIiIiISKam4IWIpK1q1WDoUBg9Glq0gPLlza4o27LLlYs8L79MnpeTDz/keS4PrmVdCd4VzJq/17Dsp2VgNfY5uziTwz0HNjY2hISEEBoSCoBrYVecKjpRvGlxHDwd4ueKvBJJ4FeBNH+uOZ06dUqX5yaPISwMevSAqlXhrbfMrkZERERERERERERERCTTU/BCRNLe+PGwcqVxcXfnTrinu4JkXI75HPFs5YlnK09iI2IJPx9OxMUIYsJijBsx5HDKQe7cuXEt44qdR+IfIbcP3ybwq0AKFSjEd99+h42NVrTKcEaOhLNnYe9eYzkaEREREREREREREREReSy64iIiac/JCRYsAD8/mDgRxo0zuyJJRvjZcKJvR2PnZvxYsHG0waW4Cy7FXZI91hpr5c7pO9zYcINb225Ru25tlv24jFy5cqV32ZJaAQEwcyZ8/DGUKWN2NSIiIiIiIiIiIiIiIlmCghcikj6qVoVRo2DCBGjZEqpXN7sieYBmzzVjzao13Nx4E9cSrjiVdMKlhAuOBR1xyOOAxdaS6JioW1Hc/vc2tw/c5s6hO0SGROKRy4M5c+bQp08fdbrIiIKCoHdvqF8fBg0yuxoREREREREREREREZEsQ8ELEUk/I0bAqlXQujVs3QolS5pdkSRh9crVBAYG8ttvv7F27Vo2b9vM2RVnAbCxtcEhhwO2zrZggZg7MUSFRRETEQNApSqVaDmoJc2bN6dGjRrYa1mZjOnOHeM8vHULNmwABWNERERERERERERERETSjIIXIpJ+7O1h+XKoWxeaNIFt26BgQbOrkiR4eXkxYMAABgwYgNVq5dy5cxw9epTjx49z9epVbt++TXR0NB4eHnh4eFCgQAEaNmxIvnz5zC5dkhMVBZ06we7dsH49FCtmdkUiIiIiIiIiIiIiIiJZioIXIpK+PD1h3TqoXRuaNoXNmyFPHrOrkoewWCwUKVKEIkWK0LhxY7PLkccRGwt9+sCaNUYIqlYtsysSERERERERERERERHJctRrXETSX+HCRvji6lVo0QJu3za7IpGsz2qFt96Cb7+Fb76BZs3MrkhERERERERERERERCRLUvBCRJ6M0qVh9Wo4fBjatoWQELMrEsm6rFYYPRo++QQ+/xw6dza7IhERERERERERERERkSxLwQsReXKqVDGWO/jrL2PpkTNnzK5IJOsJD4eXXoJJk+DDD2HAALMrEhERERERERERERERydIUvBCRJ6t+fdixw1hupHp12L7d7IpEso5Ll6BBA/jpJ1i8GIYONbsiERERERERERERERGRLE/BCxF58sqVg507oVQpaNgQFi0yuyKRzG/fPiPMdPYsbN4MnTqZXZGIiIiIiIiIiIiIiEi2oOCFiJjD0xPWr4du3aB7dxg5EmJjza5KJHP67Tdj+R5PT2Mpn2eeMbsiERERERERERERERGRbEPBCxExj6MjzJsHH3wAU6ZAixZw/rzZVYlkHuHhMGwYtGsHzZoZnS4KFjS7KhERERERERERERERkWxFwQsRMZfFAu+8AytXwoEDUL48+PuD1Wp2ZSIZ286dULkyzJplBJd+/BFcXc2uSkREREREREREREREJNtR8EJEMobmzeHff6FtW+jdG1q3hosXza5KJOOJiIDhw6FWLXBzg7//hnffBRv9SBcRERERERERERERETGDrtKISMaRKxcsWAC//QZ79kC5cvDNN+p+IRLnr7+gShWYPh0mTIAdO4zzREREREREREREREREREyj4IWIZDytW8PBg9CyJfToYXTBOHHC7KpEzBMcDO+9BzVrgpOTEUwaMQLs7MyuTEREREREREREREREJNtT8EJEMqbcuWHRIvj5Z+Mic9myMHgwXLtmdmUiT05kJHz6KZQoAbNmwZgx8Oef8PTTZlcmIiIiIiIiIiIiIiIi/0/BCxHJ2Nq1g2PHYOxYmDcPiheHKVMgLMzsykTSj9UKS5cay4gMGgStWsHRozB6NNjbm12diIiIiIiIiIiIiIiI3EPBCxHJ+FxcjGUVTpyAXr2MV/2XKmUEMWJizK5OJG1t3mwsKdKxI5QsCf/8Y3ytFy5sdmUiIiIiIiIiIiIiIiKSBAUvRCTz8PQ0lls4fBjq1IGXX4ZKleCXXyA21uzqRB7PP/9A27ZQvz5ER8OGDbByJVSoYHZlIiIiIiIiIiIiIiIi8hAKXohI5lO8OPzwA+zcCXnzQvv2xpIM8+ZBRITZ1YmknNVqBCyaNYPKleHAAfjuO9i1Cxo1Mrs6ERERERERERERERERSQEFL0Qk86peHTZuhK1boXRpowNGsWIwbRrcuGF2dSIPFhUF338PzzwDjRvDlStG4OLoUejaFWz041lERERERERERERERCSz0JUdEcn8atc2lhs5dAiaN4f334dCheCVV4xtIhnF1aswaRL4+kK3bpAzJ6xZA3//bQQu7OzMrlBERERERERERERERERSScELEck6ypaFr7+Gs2dh+HD49VdjCZImTYzuAmFhZlco2VFsLAQEQK9eULgwTJwILVvC/v2wfj00bQoWi9lVioiIiIiIiIiIiIiIyCPSS2tFJOvJnx9Gj4Z334WlS+Gzz4zuAjlyQMeO0L071Kun5RwkfR05At98A4sWGWGgYsVg7Fjo1w/y5DG7OhERERERSYrVChERcPu2Ed6PjjbC1A+7Wa3G35dJ3SyWu/cdHMDNDVxdwd7e7GcqIiIiIiIiaUjBCxHJuhwcjMBFt25w/LhxAXzhQpg3D4oUMQIY3btD6dJmVypZxbVr8MMPRuBi1y5jKZHOnY2vs1q11NlCRERERCQ9REUZy/pdvmy8DQkxghOhocYttfdjY9O/Znv7uyEMV9fU3/fwMF50kD8/5MqlFxaIiIiIiIiYTMELEckeSpQwug2MGQPbtxsBjE8/hUmToHp16NEDnn8evLzMrlQym9BQWL3aCFusWGFse+45+PFHaNUKnJzMrU9EREREJDMKD4crV4wwRXK3GzeSnsPO7sHBBXd34++/h4UcXFyMgMSDOljE3cDoehHX/eJBnTEiIu6GO+4Ne9wfALl1Cy5cSDoYYrUm/Tzz5TNucWGMB93y5gVb23T7tImIiIiIiGRXCl6ISPZisUDt2sZt1ixYvty4YD54MLzxBlSrZlwsb90aKldWhwJJ2pkz8Pvvxm3jRuMfqNWqwYwZ0KULeHqaXaGIiIiISMZ15w6cOgUnTsDJk8btwgW4eRMGDYJChYzQxf3y5LkbIChQACpWNO7fGzjIl88IVbi6Gl0QsxKr1fjYhYYa4Yx7wyf3hlSOH4dt24z7t28nnMNiMcIX94YxCheG4sXv3goVUjhDREREREQklRS8EJHsy8kJOnY0btevw6pVRhBjxgyjO4a3N7RsaQQxGjc2Xu0k2VNMDOzceTdsceCA8aqyevVg6lTja6RECbOrFBERERHJGKxW42+skyeNcEXcLe79CxfujnVygmLFoGBBY0lIgGHDjDDz/Z0a7O3NeT4ZhcVi/F3q4mJ8fEqWTP6YsLDEwYx7b+fPGyGNc+fuLrFibw++vgnDGMWLG5+nYsX0t7GIiIiIiEgSFLwQEQHjlVMvvWTcoqJg61YjhLF8OcyZY/wzsFEj4wJ7w4ZQurS6YWR1ly7Bpk2wcqVxu3bN+Dpp2RJGj4amTY11lUVEREREsiOr1bhYf+xYwlBF3C04+O7YvHmNC/bFixvh5Xsv5Ht53V2uIyrK+N170CCFLNKKiwsULWrcHiYy0ujsd+/n8MQJ42+iefOMThtxvLzufv7uDWaUKgW5c6fv8xEREREREcmgFLwQEbmfvb0RrmjY0Oh+cfSo0eVg+XIYONDofuDpCXXqQN26xq1SJaMDgmROVqvxT8UtW+7ejh839pUvD/36GaGbGjXUcldEREREsp/wcDh4EP75B/btM97u3w9BQcZ+GxujW0Xx4vDMM9C5c8JwhQLLGZ+Dg9FBI6kuGlarEUy/v3PJ0aNG58irV++OLVzYWAKmYkXj7+SKFY2vg7hwjYiIiIiISBalq4QiIskpVQqGDDFuISGwYwds3mxcnB8+HCIiwM0Nata8G8SoUQOcnc2uXB4kJsZYLuTeoMWlS0YXk6efhmbNYOJE43Pp7W12tSIiIiIiT87ly3fDFXFv//vP+B3aYjH+PqpUCZ57DipUMN738TEu3EvWZLEYXS68vIwXINwvJMQIYxw6ZHzN7NtndMkIDDT2u7oaXyv3hjGeftrYLiIiIiIikkUoeCEikho5chhLTDRtarwfEQG7d9+9eD99Orz/vtE1495/KlWqZPyjyd3dzOqzp8jIu/8AjPvn8d9/G6/Os7c3XpHXs6cRsqhdG3LmNLtiEREREZH0Fx1tdCy49/fkffuMQDIY4fIKFaBBA3jzTeNvmvLljaUrRO6VI8fdLhddu97dfuXK3a+rf/4xlvScM+duiKdkycR/N3t7a1lPERFJkQu37nAzNNLsMpKUy9WBgjmzx4vyfH19ATh9+vRjzWOxWKhfvz4BAQEpGj927FjGjRvHxo0badCgwWM9tohIWlHwQkTkcTg6Ghfra9eG994z/oH0779GCGP3buO2YIGxVjEYbXbvb7vq46N/LKWVa9cS/mNv3z44fPjux794cePj/s47xiu1qldXZxIRERERyR5u3oRt2+6GxvfuNZYQAWOZkEqVjCX24v5WKVpUy0PI48mXD5o0MW5xwsMTB+M//BBu3TL2581rdJCM6yZZrZq6qYiISCIXbt2h0UcBRETHml1KkhztbPhjaIPHDl8sWrSILVu2sGfPHg4cOEBkZCTz58+nV69eaVOomC42Npb//e9/fPXVVxw/fhw3NzcaN27MpEmTKFasWKrmOnr0KKNGjeKPP/4gNDSUUqVK8corr/DKK69gue/6wz///MOSJUvYs2cPf//9N9euXUtV8AVINGdyrFYrp0+fpmjRog8dd/PmTXKm4MWRDRo0YNOmTQQGBlKgQAGAJOd3dnYmZ86clC1bltq1a9OzZ0+KFy+eaL6AgAAaNmz4wMfz8PDgVtzvrCIPoOCFiEhasrW9G6yIExkJR44k/MfS7Nlw/bqx38MDypS5uwbyvWshe3kplHG/W7furi186pTxsWvd2gi8XLhgjHF2Nl6d5+cHAwYY/zh++mnjlVgiIiIiItnBhQsJl9b791+wWqFgQeOCdqdOd8PguXKZXa1kF05OUKWKcYtjtcLZs8bfynv3GgGhCRMgNNT42+7eIEbNmkY3FhERydZuhkZm2NAFQER0LDdDIx87eDFq1CjOnDlD3rx58fLy4syZM2lUYcZz+PBhXLJhZ7UBAwYwd+5cypUrx6BBg7h48SJLlixh7dq1/Pnnn5QsWTJF8xw6dIhatWpx584dOnXqhLe3NytWrOC1117j0KFDzJ49O8H4X375hSlTpuDg4ECpUqW4du1aqmsfM2ZMom0zZ84kKCgoyX33Kl68OC+99FKS+5ycnFJdy8Pmj4iI4MqVK+zatYsJEyYwefJkhg0bxqRJk5IMj1StWpVWrVqlS12S9Sl4ISKS3hwcjBBAhQrQvbuxzWqFixfvhjGOHjWCBAEBxvY4zs5GAOPeMIavL+TPf/fm6GjCk0on0dFG14rLl43b+fN3QxZxt5s3744vUAC++ALy5DGWC6lQwfjncYkSRghGRERERCQ7sFqNvynuDVqcOmXsK1XKuGA9dKjx1tdX4W7JWCwWoxOkjw+0aWNsi442/laO+3r+/HMjjGFrC5Ur3w1i1KkDnp6mli8iIpJe5s6dS8mSJfHx8WHq1KkMHz7c7JLSTZkyZcwu4YnbuHEjc+fOpV69eqxbtw6H/+/y1a1bN1q0aMEbb7zBmjVrUjTXq6++SlBQECtXruS5554DYMKECTRu3JhPP/2Ubt26UbNmzfjxHTt2pE2bNjz99NNcv34dLy+vVNc/duzYRNv8/f0JCgpKct+9SpQokeyYx/Gg+bdu3Ur37t2ZMmUKtra2TJgwIdGYatWqpWttkrUpeCEiYgaLxXilWcGC0KJFwn1hYcY/SeOCBidPGm9XrDC2xy2bEcfDw2jhem8Y496bhwe4uhqvCnJ1vXvf0TH9/uEaGWm8Oinudvu28TYkxFjnNy5Yce/tyhUjdGG1Jvw4FSpkhE4qVoT27RN2BXFzg5Urwd8f7O3T57mIiIiIiGQ00dFGiDvuovTWrcbv0zY2RhC5TZu7F6Xz5ze7WpHUs7MzlhmpVg3eesv4O/HIkbtf8z/9BB9/bIwtU+ZuEKNuXS3nKSIiWUbjxo3TZJ7kloS4f/mSbdu2MXnyZHbs2EFYWBi+vr507tyZd999N0VdKcaOHcu4cePYuHEjJ06cYObMmRw7dow8efLQqVMnxo8fT477OhNbLJYkl7o4d+4cw4YNY82aNURGRlK1atUkL5bfa/PmzXz44Yfs2LGDkJAQihQpQufOnRkxYkSC+uOWlhgzZgxNmzZl5MiR7N69GycnJzp27Mj06dNxdnZmxYoVTJw4kf379+Pm5kbPnj2ZPHkydnaPd4l1zpw5gBGQcLhnabXnnnuOBg0asHbtWs6ePUuRIkUeOs/Ro0fZvHkzDRs2jA9dADg4ODBhwgQaNGjAnDlzEgQvypUr91i1Z1Z16tRh9erVVKxYkQ8++ID+/ftTuHBhs8uSLETBCxGRjMbFBcqVM273i4m5G1JIKrxw+TIcO2a8vXoVYh/Scs/GJmEQI+6+nZ2x7/6b1WrMd+8tJsYIitwbrggNTRwOuV+uXAnDIeXKJXw/Lkji5fXwjh7JPY6IiIiISFYRGGiEsX//Hf74wwg1OzoayzD063d3GQZ3d7MrFUl7FguULWvc+vc3tp07l7DLy/9fvKBwYXjuOWNJykaNjL+xRUREsgF/f3969+5Nz5498ff3j9/+oGUfPv/8c65cuZIgjPDjjz/StWtXHB0d6dy5M/ny5WPt2rWMHz+eNWvWEBAQkOIlF2bMmMGGDRvo3LkzLVu2ZP369cycOZM///yTzZs3Y5/MC+kCAwOpWbMmFy5coFmzZlSpUoXDhw/TpEkTGjZs+MDn9Prrr5MzZ05at25Nvnz52L17N5MmTWLjxo1s3LgxQcgBYOfOnUybNo1mzZoxYMAANm7cyOeff05wcDCtW7emV69etG3blpo1a7JixQo+/PBD3NzceP/99xPM4+vry5kzZzh16hS+vr7JfnwCAgJwdXWldu3aifY1a9aMgIAANm3aRPe4LtoPmQegadOmifbVqVMHV1dXNm3alGw92UXp0qXp1KkT33zzDb/88gsDBw40uyTJQhS8EBHJTGxtwdvbuCUnJgauX4fg4MSdJx52PyYmccAiNjZhCMNiuXvfxSXpjhoPuu/paSy/IiIiIiIiD2a1wt9/G0GL33+H3buN379r1YL33oP69Y1uAFlp6UGR1ChcGLp1M25g/P27bRts3GicM199BU5O8OyzRgijZUujo6KIiEg2k9SyCdOmTePKlSu0bduWF154AYDg4GD69euHnZ0dO3bsoEKFCgBMnjyZbt26sXjxYj788ENGjx6dosdds2YNf/31V/w8VquVl156ie+++45PPvmEt99++6HHDx8+nAsXLjBx4kRGjhwZv/2rr75iwIABicYfOnSIQYMGUaFCBTZs2ECePHni98Ut1TJ79uxEj7t69Wp++eUX2rZtC0BUVBTVqlXju+++Y82aNWzevJlnnnkGgHHjxlGiRAlmzZrF8OHDkw2PPEhoaCiBgYGUL18e2ySWzC5ZsiQAx44dS3auuDFxx9zL1taWokWLcujQIaKjox+7S0daOX78eJJfl82bN8fPzy/dH79BgwZ88803/PXXX4n27d69O8naunTpki2XxJHUyRhnmIiIpD1bW6NzRL58ZlciIiIiIiIpERoKGzYYF41XrICLF42lA5s3h8GDjbf3/ANZRO6RJ4+xzE6bNsYyJEePwvLlxvn0+uvwyivGUjytWhlBjGrVjDCTiIhIFtG+fXv8/Pzw8PB46LiffvqJ4cOHU6VKFb799lts/v/n4a+//kpQUBCvvvpqfFgCwMbGhg8++IBly5bh7++f4uBFjx49EsxjsViYPHkyixcvxt/f/6HBi8jISBYvXky+fPkSjevbty8fffRRolDCl19+SXR0NLNnz04QugAYNmwYM2bM4Pvvv080X8OGDeNDFwD29va88MIL7N+/n9atW8eHLgBy5MhBq1atmDdvHufPn6do0aLx+zZs2EBUVBQFCxZM9mMTFBQE8MDPlfv/d7GLG/e4c8XGxhISEkKuXLmSne9JOHHiBOPGjUu0PWfOnE8keOH9/y9svXbtWqJ9e/bsYc+ePYm2V6pUScELSZaCFyIiIiIiIiIiZjl7NuESIuHhUKoUdOliXByuXRse8ZV0ItlaqVLw9tvG7eZNWLPGOM/+9z+YONF4kULLlkYQo0kTuG+teRERkczGw8Mj2dDF7t276d69O97e3ixfvhxXV9f4fXv37gWMbgD3K1KkCMWKFePo0aOEhISQIwU/N+vWrZtom4+PD4ULF+bgwYNERkYmWvYjzn///Ud4eDiNGjVKtLSJjY0NtWvXThS8+PPPPwGj08aGDRsSzWlvb8+RI0cSba9UqVKibV5eXsnuu3jxYoLgRfHixZN8LpJYs2bNWL169UPH+Pv7c/r06QTb2rVrl+TnJC0NGDCAL774Il0fQ7IuBS9ERERERERERJ6U2FjYtevuEiL79hnd6urVg0mTjIvApUqZXaVI1pIrlxFm6tIFoqNhxw7j/Fu+HObPN5bDbNDgbjeMFKzLLiIiktmcO3eO1q1bY7FYWL58efyr/uMEBwcDkD9//iSP9/Ly4ujRowQHB6coePGgefLnz8/p06cJCQlJ1JkiTlwXh3wP6Oac1Nw3btwAYNKkScnWdq+47hL3iluS42H7oqKiUvU494oLyDyoo0Xc5yK5IE1K57JYLCn6nGUk/v7+bNq0KcE2X1/fNAleXLx4EQBPT8/HnkvkXgpeiIiIiIiIiIikt6NH4ZtvjNuZM5A7N7RoAcOHQ7NmkDOn2RWKZA92dlC3rnGbNg1OnDC6zixfbnTHGDQIatWCHj2gUycjtCEiIpLJhYSE0KpVK65cucLPP/9M5cqVE42JCxlcvnw5yTkuXbqUYFxyHjTP5cuXkw0CxIUJrly5kuK54+pKaTDETK6urnh5eXHq1CliYmKwtbVNsD+um0fJkiWTnStuzP0dQABiYmI4deoURYsWjQ+MZBYBAQHpPve9y8iIpAUtZCgiIiIiIiIikh6uX4fPPgM/PyhdGmbPhqZNISAALl82QhidOyt0IWKm4sWNsMW6dXDtGnz7Lbi7w2uvQYEC0LEj/PYbPMarWkVERMwUExNDly5d2L9/Px9++CFt2rRJclxcGCOpC97nzp3jxIkTFCtWLMWhhi1btiTadubMGc6dO0e5cuUeuMwIQKlSpXBycmL37t2Eh4cn2BcbG8v27dsTHVOjRg3g7pIjGV39+vUJDQ1l27ZtifatWbMGgHr16qVoHoC1a9cm2rd161ZCQ0PjxwgcPXqUJUuW4OjoSPv27c0uR7IYBS9ERERERERERNJKRAT8/DO0bw9eXsYFXU9PWLIELl2Cr76C+vWNV92LSMbi7g7dusGqVXD+PEyZAseOQdu24O1tnM+7d4PVanalIiIiiQQFBXHkyBECAwMTbB88eDArV66kf//+DBky5IHHt23bFg8PD+bPn8/Bgwfjt1utVt59912io6Pp1atXiutZuHAh+/fvTzDPiBEjiImJSXYeR0dHOnXqxJUrV5g+fXqCfXPnzuXo0aOJjnnttdews7Nj4MCBnD17NtH+W7dusXfv3hTXn1onTpzgyJEjKV6CpH///gCMHj2ayMjI+O2rVq0iICCApk2b4uPjk+CYI0eOcOTIkQTbSpcuTb169di4cSOrVq2K3x4ZGcno0aMB6Nu37yM9p6xm27ZtNGvWjIiICN577z0KFixodkmSxeivfBERERERERGRx2G1ws6dRgeLH36AGzegalX48EPo2hUesDa1iGRgXl4wZIhx27/fOL8XLTI615QtayxF8uKLULiw2ZWKiEgWNXfuXLZu3QrAgQMH4rfFdaSoU6dOggvqP//8M71796Znz574+/sDsGvXLj799FOcnZ3x9PRk7NixiR6nXbt2VKpUCXd3d+bMmUPXrl2pUaMGnTt3xtPTk/Xr17Nnzx6qV6/OO++8k+L6mzVrRs2aNenSpQuenp5s2LCB3bt34+fnx8CBA5M9furUqWzYsIFRo0axdetWKleuzOHDh1m5ciVNmzZN1OGhfPnyfPbZZ7z66quULl2aFi1aULx4cUJCQjh58iSbNm2iV69efPHFFyl+Dqnx7LPPcubMGU6dOoWvr2+y4xs2bEjfvn2ZO3cuVapUoWXLlgQGBrJ48WJy587N7NmzEx1TtmxZwAix3Ouzzz6jdu3atGvXjs6dO+Pl5cWKFSs4ePAgb7zxBrVq1Uow/siRI0ydOhWAO3fuxG+7NxAT9zWUGR0/fjz+az0yMpIrV66wa9cuDhw4gK2tLaNGjWLMmDHmFilZkoIXIiIiIiIiIiKP4vRp40LswoXGq+ILFoR+/aB7dyhXzuzqRCStVKhgBKmmTIENG4wQxvjxMGIENGxohDCefx4y+HryIiKSuWzdupUFCxYk2LZt27YES1Mk18kgLCwMMC6uT5o0Kckxvr6+VKpUCYCOHTtSoEABpkyZwk8//URYWBi+vr6MHj2ad999FycnpxTXP2TIENq0acPMmTM5fvw4uXPn5s0332TChAkPXWYkjpeXF9u3b2fYsGGsWbOGzZs3U7VqVdatW8cff/yR5NIa/fr1o1KlSsyYMYPNmzezfPlyPDw8KFKkCG+99RY9e/ZMcf1PwpdffsnTTz/NV199xaxZs3Bzc6N9+/ZMmjSJ4sWLp3iecuXKsXPnTkaNGsWKFSsIDQ2lVKlS/O9//+PVV19NNP7SpUuJvrYuX76cYFtmDl6cOHGCcePGAeDs7EzOnDkpU6YMo0ePpmfPnqn62IqkhsV6fyxKkhUcHIyHhwdBQUG4u7ubXY7cIyoqipUrV9KiRQvs7e3NLkdE0pnOeZHsR+e9SPaic14ypKgoWLYMvvgCNm0CV1fo0MG48NqgAdjaml1hpqVzXjKVkBDje8HChRAQAM7OxveCN96A6tXNri5T0DkvWU3cdYOrV69y9epVihYtmqqL1JJyF27dodFHAUREx5pdSpIc7Wz4Y2gDCuZ0NrsUU4wdO5Zx48axceNGGjRoYHY5IiKPLTw8nFOnTiX7s10dL0REREREREREknP1KsyZA599BhcuGCGLb76B9u2N8IWIZC85ckCvXsbt7Fn49lvje8Q334CfH7z5phHEUKBARCTNFczpzB9DG3AzNNLsUpKUy9Uh24YuRESyMwUvREREREREREQeZP9+mDXLuKhqscBLL8GgQfD002ZXJiIZRZEiMHw4DBsGK1YY3zO6dgVvb3jtNejfHzw9za5SRCRLKZjTWeEGERHJUGzMLkBEREREREREJEOJjTUunjZsCBUrwpo1MGYMnDtnvKJdoQsRSYqtLbRpAxs2GKGtFi1g4kQoXBhefhkOHza7QhERERERSScKXoiIiIiIiIiIAERGwoIFUKECtGoFd+7A4sVw6pTxava8ec2uUEQyi6efNoJa58/D2LGwejU89RS0bQvbt5tdnYiISLoZO3YsVquVBg0amF2KiMgTpeCFiIiIiIiIiGRvISEwYwYULw69ekHRorB5M+zYAZ06gb292RWKSGaVJw+89x6cPAnz5sGxY1C7NtSpA7/9ZnTYERERERGRTE/BCxERERERERHJnoKCYPRoKFLEuDDauDH8+y8sXw5164LFYnaFIpJVODpC797G95jffjO2tW0L5cvDokUKYIiIiIiIZHIKXoiIiIiIiIhI9hIRAbNmGR0uZsyAl182Xo0+fz6UK2d2dSKSldnYQOvWsHUrbNsGJUtC9+5QtSqsW2d2dSIiIiIi8ogUvBARERERERGR7CE2Fn74AcqWhSFD4Pnnjbb/H30EhQqZXZ2IZDe1asGvvxoBDFdXaNoUmjWDf/4xuzIREREREUklBS9EREREREREJOvbuBGqV4euXeHpp+HAAfjqK/D2NrsyEcnuatWCLVvg55/hzBmoUgV69DDui4iIiIhIpqDghYiIiIiIiIhkXQcOQIsW0KgR2NnB5s3GK8yfesrsykRE7rJYoF07+Pdf+PxzWLsWSpeGd96BmzfNrk5ERERERJKh4IWIiIiIiIiIZD3nz0OfPlCxorGcyI8/wo4dULeu2ZWJiDyYnR0MGADHj8Pw4UYIo3hxmD4dwsPNrk5ERERERB5AwQsRERERERERyTqCgoyLlSVLwu+/w+zZcOgQvPCC8YpyEZHMwM0NxowxAhhdusC77xodMBYtgthYs6sTEREREZH7KHghIiIiIiIiIpmf1QrffWe8MvyTT2DoUOOC5euvg7292dWJiDyaAgXgs8/g4EGoWhW6d4caNYwlSUREREREJMNQ8EJEREREREREMrfLl6FDB3jxRWjc2FhaZMIEcHc3uzIRkbRRujT89BNs3QphYUYIY8oUiI42uzIREXOE34LgCxnzFn7L7I9OhuPv74/FYsHf3z9TP4aIyMPYmV2AiIiIiIiIiMgjW7zY6GphYwNLlxoBDBGRrKp2bdizB8aOhVGj4Oefwd8fnnrK7MpERJ6c8FuwfTrEZtDwmY0d1HobnHI+8hQXLlzgxx9/ZOXKlRw5coRLly6RO3duateuzbBhw6hRo0ba1Wsii8VC/fr1CQgIMLsUuUdgYCCjRo1i5cqV3Lx5Ex8fH3r06MGwYcOwT2U3wW+//ZZZs2Zx8OBBHBwcqF27NuPHj6dKlSqJxi5atIgtW7awZ88eDhw4QGRkJPPnz6dXr14peix/f3969+6d4tp69uyJv78/Y8eOZdy4cQ8c17ZtW3755Zdk5zt9+jRFixalWbNmrF69On77/fPb2NiQI0cO8uXLR8WKFWnRogWdOnXC1dU10Zy9evViwYIFD3zMN998k5kzZyZbmzwZCl6IiIiIiIiISOZz9Sq89poRtujYEf73P/D0NLsqEZH05+QEU6dC+/bQqxdUrgzjx8Pbb4Od/t0rItlAZGjGDV2AUVtk6GMFL2bPns20adMoXrw4TZs2xdPTk2PHjvHLL7/wyy+/8N1339G5c+e0qzmdtW/fHj8/P7y8vMwuRZJx6dIlatSowfnz52nfvj0lS5Zk06ZNjBo1il27dvHLL79gsVhSNNekSZMYNWoUPj4+vPLKK4SEhPDDDz9Qq1YtNmzYQO3atROMHzVqFGfOnCFv3rx4eXlx5syZVNVeqVIlxowZk2Db6dOnWbBgARUrVqRdu3aJxt+rQ4cOlC9fPtG8ZcqUSVUdD3Lv/MHBwZw+fZqAgACWLl3K+++/zzfffEODBg2SPPbll1+mUKFCibb7+fmlSW2SNvSbuIiIiIiIiIhkLkuXGqGL2Fij40WnTmZXJCLy5NWoAX//DWPGwPDhd7tfpNHFARERMU/16tUJCAigfv36CbZv2bKFZ599lldffZV27drh6OhoUoWp4+HhgYeHh9llSAq8++67nDt3js8//5xXXnkFAKvVSrdu3fjhhx/44Ycf6Nq1a7LzHDt2jLFjx1KqVCl27doV//l/7bXX8PPzo1+/fvz777/Y2NjEHzN37lxKliyJj48PU6dOZfjw4amqvVKlSonCFAEBASxYsIBKlSoxduzYhx7/wgsv0KVLl1Q9ZmokNX9ERAQzZ85kxIgRtGrViu3bt1OhQoVEx/bt21chi0zAJvkhIiIiIiIiIiIZwLVr0KWL0eGibl04eFChCxHJ3pyd4YMPYOtWuHkTKlWCjz6CmBizKxMRkcfw/PPPJwpdANStW5eGDRty8+ZNDhw4kKo5f/31V5599lly5cqFk5MT5cuX56OPPiLmvp8ZsbGxzJ07l+rVq5M7d26cnZ0pVKgQrVu3TnJJkM2bN9OuXTvy58+Po6MjhQsX5vnnn2fr1q3xY/z9/bFYLPj7+wPGxfC4rgmbNm3CYrHE3+LGBAUFMW3aNOrXr4+3tzcODg54e3vTo0cPTpw4karnvm3bNlq2bEnu3LlxcnKiTJkyjBkzhrCwsERjLRYLDRo04Pz583Tt2pW8efPi4uJC7dq1Wb9+faLxvXr1wmKxcPLkSaZPn85TTz2Fo6Nj/PIYFy9eZMyYMfj5+ZEvXz4cHR3x9fXltdde48qVKw+d76OPPqJUqVI4Ozvz1FNP8cMPPwAQGRnJyJEj8fX1xcnJiQoVKrBq1apUfUySEhISwuLFiylWrBgDBgxI8DGZOnUqAHPmzEnRXPPnzyc6OpqRI0cmCN1UqlSJrl27cvjw4QRfIwCNGzfGx8fnsZ9HZuLo6Mi7777L+++/T2hoKO+9957ZJcljUPBCRERERERERDK+n3+GcuVg3Tr4/nuj60X+/GZXJSKSMdSqBf/8A6+/DsOGGeG0o0fNrkpERNKBvb09AHb3LS8VF26Iu+B/r+HDh9OuXTv+++8/nn/+eV577TWcnZ155513Er0Cf/jw4fTr148bN27QrVs3Bg8eTKNGjTh48GCi4MGsWbNo0KAB69ato0mTJrz99ts0atSIffv2sXTp0gc+B19f3/glIXx8fBgzZkz8La5jweHDh3n//fdxdnamffv2DB48mGrVqvHdd99RvXr1FC9D8eOPP1K/fn0CAgJo164dgwcPxsXFhfHjx9OoUSPCw8MTHXPz5k1q167NsWPH6Nu3L127dmXfvn00b96cX375JcnHGThwIJMnT6ZatWoMHjyYp59+GjCCKdOnTyd//vx07dqVgQMHUrx4cT7//HNq1qxJUFBQkvMNGTKE6dOn06BBA3r16kVgYCDdunVjzZo1PP/883z//fe0bNmSF198kWPHjtG2bdtEgZS4gMuDlq+4344dO4iIiKBJkyaJlhPx8fGhdOnSbNu2LVFYJylxIZ2mTZsm2tesWTPACN2I4e2338bFxYU1a9Y88GtCMj4tNSIiIiIiIiIiGVd4OLz6qtE+v21b+OILKFDA7KpERDIeZ2eYPh3at4fevaFiRfjf/6BPH7MrExGRNHL27FnWr1+Pl5dX/IX95Kxbt46pU6fSrFkzli1bhqurK2AsH/Haa6/xxRdfsGzZMjp06AAYyz14e3uzf/9+XFxcEsx148aN+Pv79u1jyJAheHl5sW3bNnx9feP3Wa1WAgMDH1iTr68vY8eOZdy4cfH371e2bFkCAwPJnTt3gu0bN26kcePGTJw4MdnuC8HBwfTr1w87Ozt27NgRv4TD5MmT6datG4sXL+bDDz9k9OjRCY7bv38/3bp1Y9GiRfEBhDfffJNnnnmG/v3706xZM5ydnRMds3fvXooUKZJge6NGjbh06RJubm4Jti9cuJCePXvy6aefMnLkyES1Hz58mP379+Pp6QlA7969qVGjBl26dKF8+fIcOHAg/nPZrFkzOnfuzKxZs/jkk08e+jF5mGPHjgFQsmTJJPeXLFmS//77jzNnzlCsWLFk53Jzc6NAEn+7xc0f93gZxdKlSzly5Eii7e+99x5OTk7p+thubm5UrVqVLVu2sGfPHho1apRg/9y5c1m9enWCbU5OTuqQkcEoeCEiIiIiIiIiGdPly8YFxL17jeBFjx5w3yuvRETkPnXqwL598Oab8PLLcOgQTJsGtrZmVyYiIo8hKiqK7t27ExERwbRp07C97/t6+/bt8fPzS7CsA8Cnn34KwFdffRV/oR7uLh/x5Zdf8v3338cHLwAcHBwSzQ8kCEF8+eWXxMbGMnHixAShi7i5vb29H/m5AomeR5yGDRtSrly5JJf9uN+vv/5KUFAQr776anzoAsDGxoYPPviAZcuW4e/vnyh4YWtry+TJkxN0fahQoQLdu3fn66+/ZuXKlQk+XgDvvPNOotAFQL58+ZKsrXv37gwcOJD169cnGbwYOXJkfOgCoHr16hQrVoyTJ08yadKkBJ/LDh06YG9vz759+xLMUb16dQ4fPpwoQPMgcZ0WHvSxd3d3TzAuubke9NxTM8+TtGzZMpYtW5Zo++DBg9M9eAHEnzPXrl1LtO/rr79OtM3Dw0PBiwxGwQsRERERERERyXj274fWrSEyEjZtgurVza5IRCTzcHGBr76Cp5+Gt96C//6D776DHDnMrkxERB5BbGwsvXr1YvPmzfTr14/u3bsnGuPh4ZHkBfM///wTV1dX5s2bl+Tczs7OCV7l36VLFz777DPKly9Ply5daNiwITVr1kzU4WHXrl1A0ktJpJWAgABmzpzJzp07uXbtGtHR0fH7HBwckj1+7969AEkutVGkSBGKFSvG0aNHCQkJIcc9PyOLFCmCj49PomPq1q3L119/zd69exMFL6o/5O+Vn376iS+//JK///6bmzdvJliq4+LFi0keE7fkyr28vLw4efJkon22trbky5cv0VwuLi6UKVPmgXVJQt9//32ipXfudevWLWbOnJloe1IdW9Lajh078PPzS/fHkcej4IWIiIiIiIiIZCzLl0O3blCihHG/UCGzKxIRyXwsFhg0CEqVgs6doXZt43tqEheSREQk44qNjaVPnz589913vPTSS3zxxRepOv7GjRtER0czbty4B44JDQ2Nvz9r1iyKFi3K/PnzmThxIhMnTsTJyYlOnToxffp08ubNCxjdCiwWC15eXo/2xJLx448/0rlzZ9zc3GjWrBm+vr64uLhgsVjw9/fnzJkzyc4RHBwMQP78+ZPc7+XlxdGjRwkODk4QvHjQ+LjtSXVqeNAx06dPZ+jQoXh6etK0aVMKFSoUH2KZOXMmERERSR4X1xXiXnZ2dg/dFxUVleRcKRUX3HlQJ4q4j+eDOmLcP1dazJOR3Lp1K8nzKK2CF3HBmXs7nUjmouCFiIiIiIiIiGQMVivMmAHvvAPt2sE338A9LXRFROQRNG8OO3ZAq1ZG96Cff4ZatcyuSkREUiA2NpbevXuzcOFCunbtir+/PzY2Nqmaw93dHYvFkuTyBUmxs7Nj6NChDB06lIsXL7Jp0ybmz5/PwoULuXTpEmvWrAEgZ86cWK1WAgMDKViwYKqfW3LGjh2Lk5MTe/bsoWTJkgn2/fDDDymaIy6gcPny5ST3X7p0KcG4OA8aH7c9qcCAJYklEaOjo5kwYQJeXl78888/CZbesFqtfPDBByl4Fk9O3Mf52LFjSe4/duwYDg4OSS6pktRcO3bs4NKlSxQoUCDRPPc+Xmbh6+uL1WpNl7lv377Nnj17sLW1pUqVKunyGJL+UvfdWUREREREREQkPURGQt++MHQovPceLF2q0IWISFp56inYtQtKl4aGDY1gm4iIZGj3hi46d+7MN998g62tbarnqVGjBtevX3/gxfSH8fb2pmvXrqxevZoSJUqwfv167ty5A9xdWmPt2rWpnjeOjY1NgmU37nXixAnKli2b6OJ8YGAgJ0+eTNH8lStXBowlS+537tw5Tpw4QbFixRJ0uwA4e/Zskh01tmzZkmDe5Fy7do2goCBq1qyZIHQBsHv37viPZUbh5+eHg4MD69atSxQwOHPmDP/99x+1a9eO77zxMPXr1weS/vqIC+/EjRGjM0pYWBjPPfdcpusEIncpeCEiIiIiIiIi5rp2DZo0gUWLYOFCmDwZUvlKPhERSUbevLBuHbz4IvToASNGQGys2VWJiEgS4pYXWbhwIR07dmTRokXJhi6CgoI4cuQIgYGBCbYPGjQIgD59+nD9+vVEx126dInDhw8DEBERwfbt2xONCQ0N5fbt29jb28d33HjllVewtbVl1KhRiUIKVqs1ftmEh8mdOzfnz59Pcp+Pjw/Hjx9P0H0iPDycV199NcVLarRt2xYPDw/mz5/PwYMHE9T37rvvEh0dTa9evRIdFxMTw4gRIxKED/bv388333yDp6cnLVq0SNHj58uXD2dnZ/7++2/CwsLit9+8eZOBAwemaI7HERYWxpEjRzh79myKxru7u9OlSxdOnjzJl19+Gb/darUyfPhwAPr165fgmAd93fXu3Rs7OzsmTZqUYMmRf/75h++//56yZctSp06dR31qWUZERAQffPAB48ePx83NjSlTpphdkjwGLTUiIiIiIiIiIuY5fNhofx8SAn/8AbVrm12RiEjW5egIX38NZcvCu+/CkSNa1klEJAMaP348CxYswM3NjVKlSjFx4sREY9q1a0elSpXi3//555/p3bs3PXv2xN/fP3578+bNGT16NBMmTKBEiRI0b94cHx8frl+/zvHjx9myZQsTJ06kbNmy3Llzh9q1a1OqVCmqVq1KkSJFuH37Nr///juXLl1i6NChODo6AvD0008zc+ZMBg0aRLly5WjXrh0+Pj5cunSJzZs307JlS2bOnPnQ59moUSOWLFlCu3btqFy5Mra2trRp04YKFSowcOBABg4cSOXKlXnhhReIjo6O78RQsWJF9u3bl+zH0d3dnTlz5tC1a1dq1KhB586d8fT0ZP369ezZs4fq1avzzjvvJDquQoUKbN26lWeeeYbGjRtz9epVFi9eTHR0NF999RXOzs7JPjYYHT1ee+01pk+fTsWKFWndujXBwcGsWrUKHx8fvL29UzTPo9q1axcNGzakfv36SXb9SMrUqVPZuHEjr732GuvXr6dEiRJs2rSJP//8k9atW9OlS5cE4x/0dVeqVCnGjh3LqFGjqFixIh06dCAkJCR+mZg5c+YkWjZn7ty5bN26FYADBw7Eb4urvU6dOvTt2/cRPhIZw9KlSzly5AhgLC1y6tQpNm/ezLVr1yhcuDCLFi2ifPnyJlcpjyPDBS+uXLnCrl272LVrF3/99Rd//fVXfALv/pP2Qfz9/endu3eKHm/+/PlJptlEREREREREJJ0dOQL160O+fLBhA/j6ml2RiEjWZ7HAO+8Yy4506wZt28Lvv4OTk9mViYikjIMr2NhBbLTZlSTNxs6o8TGcPn0aMC7OTpo0Kckxvr6+CYIXDzN+/Hjq1avHJ598woYNG7h16xZ58uShaNGijB07lhdffBEAV1dXpk2bxoYNG9iyZQtXrlwhV65clC5dmilTpiS66P7GG29Qvnx5pk+fzqpVq7h9+zb58uWjRo0adOrUKdm6Zs2aBcAff/zB8uXLiY2NpVChQlSoUIHXX38de3t7Zs+ezZw5c8iZMyctW7ZkypQpdOzYMUXPG6Bjx44UKFCAKVOm8NNPPxEWFoavry+jR4/m3XffxSmJn3+5cuVixYoVDB06lDlz5hAWFkblypUZN24cTZo0SfFjA0yZMoXcuXPj7+/PZ599Rv78+enatStjx47NkBfZvby82LlzJ6NGjWLFihUsX74cHx8fJkyYwLBhw7BYLCmea+TIkfj6+jJz5kw+//xzHBwcqFu3LhMmTKBKlSqJxm/dupUFCxYk2LZt2za2bdsW/35mDl4sW7aMZcuWYWNjg5ubG/ny5aNBgwa0bNmSTp064eLiYnaJ8pgs1vsX6THZw07YjBK8CA4OxsPDg6CgINzd3VN1rKSvqKgoVq5cSYsWLbC3tze7HBFJZzrnRbIfnfci2YvO+Szu1CmoWxdy5oRNmyBPHrMrEpPpnBcxwaZN0Lw5NG0KS5fCEzz3dM5LVhN33eDq1atcvXqVokWLJnlBV9JI+C2IDDW7iqQ5uIJTTrOrkEdksVhS1SFCRLK+8PBwTp06lezP9gzX8eJeRYoUoUyZMqxdu/aR51izZs1DW/UUKlTokecWERERERERkUdw8SI0bmy8unrdOoUuRETMUr8+/PwztGkDPXsay47Y2ppdlYhI8pxyKtwgIiIZSoYLXrz//vs888wzPPPMM+TPn5/Tp09TtGjRR56vVKlS+KpVqYiIiIiIiEjGcO2aEbqIjIStW8HLy+yKRESyt+bN4fvvoVMncHWFr74yliMREREREZEUy3DBi3HjxpldgoiIiIiIiIikh6AgaNYMrl+HLVvAx8fsikREBKBDB5g3D3r1ghw5YPp0hS9ERERERFIhwwUvRERERERERCQLCguDli3h5EnYtAlKlTK7IhERuVfPnnD7NrzxBri7w9ixZlckIiLyxFmtVrNLEJFMSsELEREREREREUlfViv06QN798Iff0CFCmZXJCIiSXn9dQgOhhEjjIBct25mVyQiIiIikinYmF1Aeuvduzfe3t44ODiQN29e/Pz8GDVqFBcuXDC7NBEREREREZHs4aOPYPFi8PeHGjXMrkZERB7mvfegRw/o2xf++cfsakREREREMoUsH7wICAggMDCQqKgorl+/zs6dO5k0aRIlSpTgyy+/NLs8ERERERERkaxt3TrjIt7w4dCxo9nViIhIciwW+OILeOopaNcOrl0zuyIRERERkQwvyy41UqxYMZ5//nlq1qxJ4cKFATh58iTLli1j6dKlhIeH88orr2CxWOjfv/9D54qIiCAiIiL+/eDgYACioqKIiopKvychqRb3+dDnRSR70Dkvkv3ovBfJXnTOZwGnT0PPntCqFbz/PuhzKQ+hc14kA7Gzgx9/hPr1oXt3+OknY1sa0jkvWY2+lkVERLI3i9VqtZpdxMOcPn2aokWLAtCzZ0/8/f2TPSYoKAh3d3csFkuS+3///Xeef/55oqKicHFx4cSJExQoUOCB840dO5Zx48Yl2v7dd9/h4uKSsiciIiIiIiIiIiIiIiJZUlhYGN26dePq1atcvXqVokWL4uTkZHZZIiIi8pjCw8M5depUsj/bs2THCw8Pj4fub9WqFe+//z6jR48mLCyMr7/+mpEjRz5w/PDhwxkyZEj8+8HBwRQuXJimTZvi7u6eZnXL44uKimLdunU0adIEe3t7s8sRkXSmc14k+9F5L5K96JzP5GbNgrFjYfVqqFHD7GokE9A5L5JBjR8Pn3wCmzZBuXJpNq3Oeclq4jpli4iISPaUJYMXKdG/f3/ef/99rFYrmzZtemjwwtHREUdHx0Tb7e3t9UdBBqXPjUj2onNeJPvReS+Sveicz4T+/RdGjoTBg6FOHbOrkUxG57xIBjNqFPz6K/TqBbt2gYNDmk6vc16yCn0di4iIZG82Zhdglnz58pEnTx4ALly4YHI1IiIiIiIiIllEVBT06AElS0ISy3aKiEgm4+gICxfCwYNG9wsREREREUkk2wYvACwWi9kliIiIiIiIiGQtn34K+/bBggWgdc1FRLKGSpXg/fdh6lQ4csTsakREREREMpxsu9TI1atXuXbtGgDe3t4mVyMiIiIiIiKSBVy/brwaun9/qFrV7GpERCQtvfMOzJsHw4bBb7+ZXY2IZHNRFy8SffOm2WUkyS5XLuyz+XWn06dPU7RoUXr27Im/v3/89gYNGrBp0yasVqt5xYmIpJNsG7z46quv4r+x169f3+RqRERERERERLKA8eMhJkZLjIiIZEVOTjBtGnTuDBs2wLPPml2RiGRTURcvcqL5c1gjI80uJUkWBweKr171WOGL8PBwRowYwe7duzl+/Dg3btwgZ86cFC9enL59+/LSSy9hb2+fhlVnfbGxsfzvf//jq6++4vjx47i5udG4cWMmTZpEsWLFUjXX0aNHGTVqFH/88QehoaGUKlWKV155hVdeeSVRt/1vv/2WpUuXsn//fq5cuYLVasXHx4emTZsydOhQChYsmOzjpbaDv9VqjQ+/PMzNmzfJmTNnsvPFBWYCAwMpUKAAQJLzOzs7kzNnTsqWLUvt2rXp2bMnxYsXTzRfQEAADRs2fODjeXh4cOvWrWTrEsloslzw4vTp09y8eZPKlSs/cMzvv//O+P9fj9DZ2ZnevXs/qfJEREREREREsqb//oPPPoOJEyFfPrOrERGR9NCxI8ycCW+/DXv2gK2t2RWJSDYUffNmhg1dAFgjI4m+efOxghe3b9/m888/p3r16rRs2RJPT09u3rzJqlWr6NOnDz/88AOrVq3CxsYmDStPfwsXLiQsLMyUxx4wYABz586lXLlyDBo0iIsXL7JkyRLWrl3Ln3/+ScmSJVM0z6FDh6hVqxZ37tyhU6dOeHt7s2LFCl577TUOHTrE7NmzE4z/4YcfOHbsGH5+fnh5eWG1Wvnnn3+YNWsW/v7+bN26lXLlyj30MceMGZNo28yZMwkKCkpy372KFy/OSy+9lOQ+pzRYGvLe+SMiIrhy5Qq7du1iwoQJTJ48mWHDhjFp0qQkwyNVq1alVatW6VKXiBkyXPBi69atHD9+PP79uOVAAI4fP56gJRFAr169Erx/+vRpGjZsSM2aNWndujUVK1Yk3///w+fkyZMsXbqUpUuXxne7+Oijj1KUJhMRERERERGRhxg7Fry94c03za5ERETSi8UCM2ZAzZrw44/QpYvZFYmIZEm5c+cmKCgIBweHBNujo6Np0qQJa9euZdWqVbRs2dKkCh9NkSJFTHncjRs3MnfuXOrVq8e6deviP67dunWjRYsWvPHGG6xZsyZFc7366qsEBQWxcuVKnnvuOQAmTJhA48aN+fTTT+nWrRs1a9aMH//jjz8mGST4+uuv6du3L2PHjuXHH3986GOOHTs20TZ/f3+CgoKS3HevEiVKJDvmcTxo/q1bt9K9e3emTJmCra0tEyZMSDSmWrVq6VqbyJOW4YIXc+fOZcGCBUnu27ZtG9u2bUuw7f7gRZwdO3awY8eOBz6Oi4sLH3/8Mf3793/kWkVEREREREQEOHvWuAA3c6bRil4kizhz5gyzZs0iJiYmTebLmzcvo0aNSnW7aJEMxc8PGjeG6dONZUf09SwikuZsbGwShS4A7OzsaN++PQEBAQlexPwwsbGxzJs3L36JjTt37pAnTx4qV67M22+/TYMGDRKMnz9/Pl988QUHDx4EoFy5crz66qtJXo+LiYnho48+Ys6cOZw/f55ChQrx8ssv07lz5yRriVuyIu7F0XGio6P55JNPWLBgAUePHsXBwYEqVaowZMgQWrdunaLn+TBz5swBjIDEvR/X5557jgYNGrB27VrOnj2bbDDk6NGjbN68mYYNG8aHLgAcHByYMGECDRo0YM6cOQmCFw/q3tCxY0f69u2b4s9jZlOnTh1Wr15NxYoV+eCDD+jfvz+FCxc2uyyRdJXhghePq2rVqixatIgdO3awe/duAgMDuXbtGtHR0eTKlYty5crx7LPP0rdv3/hOGCIiIiIiIiLyGD75BHLkgAe8OEIks/rtt9/4+OOPKeSZeG3q1AqPDOVa0CX69Omj7quS+Q0ZAi1awJYtUK+e2dWIiGQbsbGxrF69GoDy5csn2Ofv70/v3r3p2bNngu7xw4cP54MPPqB48eJ069aNHDlycOHCBbZu3cr69esTBC8GDRrE7NmzKViwIC+//DIAy5Yto3fv3uzdu5dZs2YleMz+/fszb948ihYtyuuvv054eDgzZsxg+/btKX5OVquVF154gV9//ZVSpUrx+uuvExoayuLFi2nTpg0zZszgrbfeSnCMr68vZ86c4dSpU/j6+ib7GAEBAbi6ulK7du1E+5o1a0ZAQACbNm2ie/fuyc4D0LRp00T76tSpg6urK5s2bUq2HoAVK1YAiT+PWUnp0qXp1KkT33zzDb/88gsDBw40uySRdJXhghf+/v6JlhNJjRw5cvDiiy/y4osvpl1RIiIiIiIiIpK04GCYMwdeew3c3MyuRiTNOdg78t7zXz32PAfP7uTzVSPSoCKRDKB5c3jqKaPrhYIXIiLpJjIyksmTJ2O1Wrl+/TobNmzgyJEj9O7dm2effTZFc8ydOxdvb2/279+Pi4tLgn03btyIv79582Zmz55N2bJl2bFjBx4eHoCxzIWfnx+ffPIJL7zwAnXr1gWMEMK8efOoWLEi27Ztw9XVFYARI0ZQqVKlFD/Hb775hl9//ZX69euzdu3a+I4Uw4cPp2rVqgwbNoy2bdtSrFixFM95r9DQUAIDAylfvjy2traJ9pcsWRKAY8eOJTtX3Ji4Y+5la2tL0aJFOXToENHR0djZJbwEu2TJEg4dOkRYWBgHDx5kzZo1FC1alPHjxz/K00qx48ePJ7mcR/PmzfHz80vXxwajy8k333zDX3/9lWjf7t27k6ytS5culClTJt1rE0lrGS54ISIiIiIiIiKZyMKFEBYGb7xhdiUiIvKkWCxG14t+/eDUKSha1OyKRESypMjISMaNGxf/vsViYejQoUyZMiXR2Pbt2+Pn5xcfmLiXg4NDkqGD3Llzx99fsGABYAQt7p0jV65cjBkzhhdffBF/f//44MXChQsBeP/99+NDFwAFCxbkzTffZPTo0Sl6jnGP+8EHHyRYBqRIkSK89dZbjBw5km+//TbBfBs2bCAqKipFXcSCgoIAkvy4ALi7uycY97hzxcbGEhISQq5cuRLsW7JkCcuWLYt/v1q1avzwww8UTeefoSdOnEjwNRQnZ86cTyR44e3tDcC1a9cS7duzZw979uxJtL1SpUoKXkimpOCFiIiIiIiIiDy6H34wXvmspRMkm9h3aitXgy6k+rjLt86mQzUiJurcGQYOhB9/hGHDzK5GRCRLcnNzw2q1Ehsby8WLF1m+fDkjRoxgx44drFy5Mj40AEYYIKlAQJcuXfjss88oX748Xbp0oWHDhtSsWRNnZ+cE4/bu3QuQYOmROA0bNgTgn3/+id+2b98+gPggxr2S2vYge/fuxcXFherVq6focQGKF3/8ZeCetKVLlwJw69Yt9u7dy8iRI6latSo//fQTjRo1SrfHbdasWfzyNA/i7+/P6dOnE2xr165dqjqXPIoBAwbwxRdfpOtjiDxJCl6IiIiIiIiIyKM5fx62bTO6XohkEwsDpmKxASdHx1QfW6J4iUSvfhTJtNzcoEULWLJEwQsRkXRmY2NDoUKFePXVV8mbNy+dOnVi0qRJTJs2LdljZ82aRdGiRZk/fz4TJ05k4sSJODk50alTJ6ZPn07evHkBCA4OxsbGBk9Pz0Rz5M+fH4vFQnBwcPy2oKAgbGxs4o+/f3xKBQcHU7hw4ST3eXl5xY95VHFhlAd1tIib+0FdLFI7l8ViIUeOHA+cI2fOnDRs2JDVq1dTunRpevTowalTp7C3t0/28dOLv78/mzZtSrDN19c3TYIXFy9eBEjy60okq7ExuwARERERERERyaSWLQMHB2jTxuxKRJ4Yq9XKtGlTuXnrZqpvx44fS7S2ukim1rEj7NkDJ0+aXYmISLbRtGlTAAICAlI03s7OjqFDh3Lw4EEuXLjAd999R926dVm4cCEvvvhi/Li4ZTKuXr2aaI4rV65gtVoTddiIjY1NcgmJy5cvp/j5uLu7c+XKlST3Xbp0KX7Mo3J1dcXLy4tTp04RExOTaP+xY8cAKFmyZLJzxY2JO+ZeMTExnDp1iqJFi2Jnl/zr3t3d3fHz8+PChQscP3482fHpKSAgAKvVmuDWq1evNJsb4JlnnkmT+UQyMgUvREREREREROTR/PgjNG0KKXh1mIiIZEEtW4KzM/x/+3QREUl/cR0EHqVDgre3N127dmX16tWUKFGC9evXc+fOHQAqV64MJB3oiNt2bweEihUrArBly5ZE45Pa9iCVK1cmLCyMXbt2pehxH0X9+vUJDQ1l27ZtifatWbMGgHr16qVoHoC1a9cm2rd161ZCQ0Pjx6TE43wuM4OjR4+yZMkSHB0dad++vdnliKQ7BS9EREREREREJPXu3IGdO4028yKSSOztcKIOXSQ84Ajh6w8Rsek/ov67hPVOpNmliaQdNzeoVw9S+KprERFJmUOHDhEWFpZoe1hYGEOGDAGgxX2/hwcFBXHkyBECAwPjt0VERLB9+/ZE84SGhnL79m3s7e2xsTEuFfbs2ROAcePGJVpSZNy4cQnGAHTv3h2A8ePHExoaGr/9woULzJo1K8XPNW7O4cOHExUVFb/93LlzzJgxAzs7uwSdOQBOnDjBkSNHEox/mP79+wMwevRoIiPv/i62atUqAgICaNq0KT4+PgmOOXLkCEeOHEmwrXTp0tSrV4+NGzeyatWq+O2RkZGMHj0agL59+8ZvDwkJ4b///kuypnnz5rFr1y5KlixJiRIlUvQ8MpNt27bRrFkzIiIieO+99yhYsKDZJYmku+R73YiIiIiIiIjcw2q1suuXJfy1/Gci7xj/DHRwdqFaq/b4Pd/Z5Orkidm9G6KjoWZNsysRyVCsVivRhy4Sc/YGWADr/2+PiiHm5FViTl7FrkQ+bEvkw2KxmFqrSJqoWRNmzYLYWLDR6/xERNLCkiVLmDFjBnXq1MHX1xd3d3cuXLjAqlWruH79OnXr1uWtt95KcMzPP/9M79696dmzJ/7+/gDcuXOH2rVrU6pUKapWrUqRIkW4ffs2v//+O5cuXWLo0KE4OjoCRseHgQMHMnv2bMqXL0+HDh2wWq0sW7aM8+fPM2jQoARdIRo2bEjv3r2ZP38+Tz/9NO3btyciIoLFixfj5+fH77//nqLn2r17d3766Sd+/fVXKlSoQKtWrQgNDWXx4sXcuHGD6dOnU6xYsQTHPPvss5w5c4ZTp07h6+ub7GM0bNiQvn37MnfuXKpUqULLli0JDAxk8eLF5M6dm9mzZyc6pmzZsoDxu929PvvsM2rXrk27du3o3LkzXl5erFixgoMHD/LGG29Qq1at+LHXr1+nbNmyVKtWjTJlylCwYEFu3rzJX3/9xd9//427uzsLFixI0ccpozp+/Dhjx44FjADKlStX2LVrFwcOHMDW1pZRo0YxZswYc4sUeUIUvBAREREREZEUO3twP0snjMJqjU2wPSL0NtsWf8P2Jd/SYdQEfMpXNKlCeWK2bwdXVyhf3uxKRExnjbUSe+M2sXeiiL14C+uN/3/VpzXp8dHHr2AF7Evmf2I1iqSbmjVh7Fg4ehTKlDG7GhHJBuxy5cLi4IA1MmN2kbI4OGCXK9djzdGqVSsuXrzI9u3b2bFjB7dv38bDw4MKFSrQpUsX+vTpg51d8pf4XF1dmTZtGhs2bGDLli1cuXKFXLlyUbp0aaZMmUKXLl0SjP/kk0+oXLkyn3/+OV999RUA5cqVY/z48fTu3TvR/HPmzKFUqVLMmTOHTz/9lEKFCjFkyBA6deqU4uCFxWJh6dKlzJo1iwULFjB79mwcHByoUqUKQ4YMoU2bNimaJzlffvklTz/9NF999RWzZs3Czc2N9u3bM2nSJIoXL57iecqVK8fOnTsZNWoUK1asIDQ0lFKlSvG///2PV199NcFYT09PRo8eTUBAAOvWreP69es4ODjg6+vLW2+9xZAhQyhUqFCaPD+znDhxIr4jirOzMzlz5qRMmTKMHj2anj17pupjK5LZWaz3R7UkWcHBwXh4eBAUFIS7u7vZ5cg9oqKiWLlyJS1atMiya2KJyF0650WyH533Iua6eOww3496J0Vju4z/kIKlyz7W4+mcz+DatYPgYPjjD7MrkSwiI57zs2fPZujb7zCjz8r4bUPmteTDj6YxaNAgYiOjiD5ymdjLQRAd+5CZkuZQrxQ2ro5pWbLIkxcUBLlywddfQxIX5R4kI57zIo8j7rrB1atXuXr1KkWLFsXJycnssrKsqIsXib550+wykmSXKxf23t5mlyEiImkkPDycU6dOJfuzXR0vREREREREJEWWTnw/xWOXTR7NoAVL07EaMd2//xrhC5FsKDYiihPr/uLY7n1cDwnC3taO3DncyZXDgxIFfXC0d0h+EgvEnLuBTRmv9C9YJD15eECJEnDggNmViEg2Yu/trXCDiIhkKApeiIiIiIiISLICj/1HVPidFI+PCg/n4tHDeJd6vK4XkkFZrXD+PBQpYnYlIk9cZFQ4bw0bylsP2O/i6Eyjyn48V70uzarVpWDeBywnYoWYi7ewV/BCsoLCheHCBbOrEBERERExjYIXIiIiIiIikqyNC+ek/hj/Obw4eUY6VCOmu3YNIiIgk69HLPIoGpR/HoCS3hXxyu2Lm1NOYmKjCYsI4fadWxy/dIBDp/9k5c6JWLHSq+nzjO81iLweSaz1HhXzhKsXSSeFC8PRo2ZXISIiIiJiGgUvREREREREJFlht26l/pjg1B8jmcT588bbwoXNrUMkHVljYokNCTc6vNzjhdqvJzk+h3NO8ucsTHGvp2lWuRu3w4P469h6Fgcs5Ket6/h66ERa1miQ8CA7m3SqXuQJK1QI/vjD7CpEREREREyjv+5EREREREQkWbZ2qc/t29jZp0MlkiEEBhpvvbREgmQ91vAoog4HErHhMDHnbiQ5JiLqDpdunuH05cOcvHSQy7fOERGVcDkmNycPGj7dgdGd/fHxLE/H8W/y3YbldwdYwCZvjvR8KiJPjrf33Z8NIiIiIiLZkDpeiIiIiIiISLKKVq3OjYvnU3dMparpVI2YLiLCeOvsbG4dImks9nY4kTtPQVQ03NPo4k5kKP+e+ZPD5/7i5OUDXAu+lOhYexs7yhZ+hsrFG1DepybODq4A5HDORd+m4/h+8wz6f/w+JQr6UL1MBbCCnU+eJ/XURNKXkxNER0NsLNjotX4iIiIikv3ot2ARERERERFJVr1uPVN9TP3ufdKhEskQoqONt7a25tYhkoasUTFE7kocuoiMjmT0os4s+GMyd6LP8mLjpszpN5SNuT3ZBxwANgGTXV1xsL3Jgj+mMGpRZ7YfWYn1/5cpsbHY0KXOYArlLcHLH43iTkQ4Nl4e2OR0MeOpiqS9uM5YUVHm1iEiIiIiYhJ1vBAREREREZFk2djYUrJGLY7t3J6i8cWr+WFrqz85s6y4wEVsrLl1iKShmAs3ISI6wbanihTnKZ+SvFC3KS81aUthzwLx+yylK+A4tEf8+zXGzOaNpypx9kogk7/7ggVrp3Pl1jna+Q0AwNbWju4N3mXqsv7M37aCt1q//2SemMiTEBNjvFUgT0RERESyKXW8EBERERERkRRpM2QE+YuVSHacp28x2r0z6glUJKaxtzfeRkaaW4dIGrFarcScuZ5oe4NKNdjz+TKGdxuQIHTB1UvYfzQiwVj7j0bA1UsUyefFF4PH8WH/Yazft4SdR9fGjymQy4cyhaqxdNs6LLb6t5xkIXGdLhS8EBEREZFsSn/hiYiIiIiISIq9NGUmz7TpgK29Q6J9tvYOVGv1PD2mfWJCZfJE5cljvL12zdw6RNJKTCzWsBQGia5ewuHdPthcOk9sgUJEfLSQ2AKFsLl0Hod3+8DVSwC80e4lWvs1ZMO+xfFLjgBUKdaAHTu2c/78+fR4JiLmuHoV8uYFi8XsSkRERERETKG+ryIiIiIiIpIq9V7sTb0Xe3PhvyOc/mc3Vqz4VqxCoTLlzC5NnpTChY23585B+fLm1iKSFmKtyY+BRKGLyGnzwLMAkdPmxW93eLePsT2/F2+89jrNerzAicADlPCuAMDTPjWxs7Nn2bJlvPnmm+n4pESeoPPn7/5sEBERERHJhhS8EBERERERkUdSsHQZCpYuY3YZYoYCBcDGxgheiGQF9rZgY3l4ACMqCocR/RKFLoBE4QvHMa/CoX9p4lSOEuNKsv2/lfHBC2dHN7xz+3LkyJEn8MREnpBz56BQIbOrEBERERExjYIXIiIiIiIiIpI69vZG+EJLJUgWYbFYsC2Yi5jzN+BB2Qt7e6Jfeh27Rf8jcvKcu6GLOD6FiV2xBkvX9ljGjwdnJwDqN6jHHyu2JRjq6ujBlStX0uGZiJjk/HmoVcvsKkQkGwm+doU7wcFml5EkZ3d33PPmM7sMERF5whS8EBEREREREZHUK1kSDh40uwqRNGNbJDcx5248dExs/eZE1nrWCB/9P4u7E3blCmKb08XYcOAAODjE78+dOzehESEJ5nFxdOf6tetpV7yImaKi4OhR6NHD7EpEJJsIvnaFeYMHEBMVZXYpSbK1t6fPzC8VvhARyWZszC5ARERERERERDIhPz/480+wPmRpBpFMxMbdGbvSBZIfaG8PTnbYlsiHY8MyONYueTd0AQlCFwAhISE4Obgm2BYbG4O9gz0iWcK+fXDnDtSsaXYlIpJN3AkOzrChC4CYqKh06cYxbdo0LBYLFouFP//8M83nl6T99ddftGjRgpw5c+Lq6oqfnx9LlixJ9TwRERGMHz+ekiVL4uTkhLe3N/3790+yC1pYWBjTp0+nW7dulClTBhsbGywWC6dPn07x4/Xq1Sv+6yUlN39/fwAaNGjw0HEzZ85M0eP7+/tjsViYOnVqgu33z29vb0+ePHmoVKkSL7/8MqtXryY2NjbJOX19fR9a2y+//JLij49IelDHCxERERERERFJvZo1Ydo0OHcOihQxuxqRNGFXzBPsbIj+7xJE3/MPXwvGEiSOdtg/XQhbzxwpnvOfvf+Q0zlvgm23wq5S3qtq2hQtYrYdO4xAUuXKZlciIpJl/fvvv4wZMwZXV1dCQ0PNLifb2LhxI82aNcPJyYkuXbqQI0cOli1bRufOnTl37hxvv/12iuaJjY2lbdu2rFmzBj8/Pzp06MCxY8eYO3cuGzZs4M8//8TT0zN+/JUrVxg6dCgAPj4+5MqVixs3Ht6Z7X7t2rXD19c3wbaAgAA2bdpE27ZtqVSpUoJ997//9ttv4+bmlmhePz+/VNXxIHHzx8bGcuvWLQ4fPsy3337LvHnzqFWrFt9//z1Fkvg709bWllGjRiU5Z5kyZdKkNpFHpeCFiIiIiIiIiKRe3Cubd+xQ8EKyFLsiebAtmIuYwCBir4UYAQwHW2zze2CTLwcWiyXFcx04cIA/d/5Jn8bvx2+LtcYSeOMUTz/dKx2qFzHBjh1QpQo4OZldiYhIlhQVFUXPnj2pVKkSJUuWZNGiRWaXlC1ER0fTr18/bGxs2Lx5c3ww4f3336d69eqMGDGCF154AR8fn2TnWrBgAWvWrKFr1658++238b9PfvHFF7z66quMGjWKL7/8Mn583rx5Wbt2LVWrViV37tw0b96cNWvWpKr+du3a0a5duwTbxo4dy6ZNm2jXrh29evV66PFDhw6lQIEUdIN7REnNf+3aNQYNGsT3339Ps2bN2L17N66uCTvH2dnZMXbs2HSrS+RxaKkREREREREREUm9fPmgZEn44w+zKxFJcxZbG+wK5cKhUhEcqvniUKEwtvndUxW6APj888/J6ZaHir6147ddvnmW8Mg7VKhQIa3LFnnyYmMhIABq1052qIiIPJpJkyZx8OBB5s2bh62t7SPP8+uvv9K0aVPy5MmDk5MTvr6+dO/enX///Td+zNGjRxk2bBhVqlSJH1eqVCnee+89bt++nWjOuGUjoqKiGDt2LL6+vjg6OlKqVCk+++yzJOuwWq3Mnz+funXrkjNnTlxcXChZsiQDBgzg7NmzCcaGhIQwZswYypUrh7OzMzlz5qRZs2Zs3br1gbWEh4czatQoihcvjr29/SNfpP/jjz84ceIE3bp1S9ANwsPDgxEjRhAZGcmCBQtSNNecOXMAmDJlSoLfJwcMGECxYsX49ttvuXPnTvx2Nzc3mjRpQu7cuR+p9swqb968LFq0iEaNGnHkyBH+97//mV2SSKooeCEiIiIiIiIij6ZdO/j5Z4iONrsSkTR3+vRpgh9jffYNGzYwd85capVuha3t3aazO/5bRe5cuWnQoEEaVClisu3bITAQ2rc3uxIRkSzp77//ZtKkSYwZM4annnrqoWP9/f2xWCxJdjJ4++23adeuHXv27KFdu3a89dZb1KlTh/Xr17N+/fr4cT/99BNff/01xYoVo2fPnrzyyivkzp2badOm0aRJE6KiopJ87K5duzJv3jyaNWvGyy+/zI0bN3j99dfjAwdxYmNj6dSpE3369OHUqVN07dqVgQMHUqVKFZYsWcLff/8dP/bGjRvUrFmT8ePHkytXLl555RU6dOjAnj17aNiwIb/88kuStXTo0AF/f38aNmzIm2++SdGiRQGj24PFYklxECMgIACApk2bJtrXrFkzADZt2pTsPOHh4ezcuZPSpUsn6o5hsVho0qQJoaGh7N69O0V1ZXU2NjaMHDkSgMWLF5tcjUjqaKkREREREREREXk0nTrBhx/Cpk3w7LNmVyOSpmr61SQ0NIzX33iN1157jcKFC6fouNjYWObNm8fAgYMo6V2JZpW7xe8Li7jNX8fX0f/Vvjg6OqZX6SJPzpIl4O0NtWqZXYmISJYTERFBjx49qFSpEsOGDXvkeX7//XdmzJjB008/zcaNG8mTJ0/8vujoaK5fvx7/fvfu3RkyZAgODg4J5hg/fjxjxoxhyZIlvPjii4ke4/z58/z777+4u7sD8Oabb1K+fHmmT59Ov3794sd99tlnLF26lGeffZbly5fj7Owcv+/OnTsJuj4MHDiQgwcPMmfOHPr27Ru/fcqUKVSrVo3+/fvTvHlznO5b6urixYvs37//sbtFHDt2DICSJUsm2legQAHc3NzixzzMiRMniI2NTXKee+c/duwYdevWfYyK09ZHH32Em5tbgm0FChTglVdeSffHrl27NnZ2dvzzzz9ER0djZ3f3cnZ0dHSS4ZkyZcrQpUuXdK9N5GEUvBARERERERGRR1O1Kvj6wo8/KnghWc7t27fJ6VyAmR9/wtSpU6lW7RnatGlN5cqVqVChAvnz548PT0RERPDXX3/x448/8uOSpQReukitMi14odbrCbpd/LjtE7Cx8uabb5r1tETSTmwsLFsGL7wANmqsLCKS1t5//32OHTvGnj17UrTESPv27fHz88PDwyPB9rglP2bNmpUgdAFgZ2dH/vz5498vWLBgknO/8cYbjBkzhvXr1ycZvJgyZUp86AKgdOnS1K5dm02bNhESEkKOHDnia7G1teXzzz9PELoAcHZ2jt927do1Fi9eTKNGjRKELgDy5cvHO++8w6BBg1i/fj2tWrVKsH/cuHFJhi7eeOMNunTpQt68eZN8jvcLCgoCSPTxjOPu7h4/5nHnuXdcRjF9+vRE2ypWrPhEgheOjo7kyZOHy5cvc+PGDfLlyxe/LyYmhnHjxiU6pm3btgpeiOkUvBARERERERGRR2OxGF0vvv4aZs6E+15tJpLZVS/ZhJqlm3PgzA72nd7K1MkfEBZ+d31zB3sHLDY2RESEA5ArhycVferStUYDihUol2CuLYeW89exDSxatCjF3TNEMrSAALh4ETp2NLsSEZEsZ8eOHXz00UeMHTuW8uXLp+gYDw+PJC/u79q1C0dHR+rXr5/sHFarlfnz5+Pv78+///5LUFAQsbGx8fsvXryY5HFVq1ZNtK1QoUIA3Lp1ixw5cnD79m0OHz5MiRIlHtj9Ic5ff/1FTEwMERERSXY3iOs0ceTIkUTBi+rVqyc5Z968eVMcuhAIDAykQIECD9z/zz//JFruxdfXN8mlbtKSo6Mj4eHh6foYIo9KwQsREREREREReXR9+xrLjXz7Lbz8stnViKQ5Z0c3qpdqQvVSTbBardy8fYXAm6cJDQ/mTmQosdYYXB3dyevujW/+sthYEr7yPyY2hrV7v2PFbn9ef/11unXr9oBHEslkZs6EcuWgdm2zKxERyVKio6Pp2bMnFSpU4L333nvs+YKCgihYsCA2KehONGjQID799FMKFy5MmzZt8PLyiu/wNW7cOCIiIpI87t5uF3Hilof4P/buO6zK+v/j+POwl4ILBffAbWouzAHkKkdqlpqVIy23mVZqX039pZll5S4VV1aONDP3KHGl5i73wo0DByrIPr8/7kCPoKKCh/F6XNd9Aff43O/D4SCe+3W/P3FxcYl1wIO7atzr2rVrAGzZsoUtW7Y8cL/w8PAk6+7t4PE0EkIsD+pEcfPmTXLkyJEq49y7X0axd+/eJJ0n/Pz8UiV4ERUVxdWrV7G1tX3qKWNEniUFL0RERERERETkyfn4wCuvwDffwDvvGF0wRDKJ8MibxJvjE8MUJpOJnNnykjPbo9/QN5vNHDz7N0t2TCPk6imGDRvGp59+ikmvEckMjhyBpUuNjkf6mRYRSVW3b99O7Ojg4OCQ7D41a9YEYPHixbRo0eKh43l4eHDx4kXi4+MfGr64fPkykyZN4rnnnmPr1q24uLgkbrt48WKy0zs8joRgwfnz5x+5b0KQo3///owZM+axzpNaf2sldOU4duxYko4eFy9e5Pbt2w/srnGvYsWKYWNjk/ic3i9h/aO6gKQ3HTt2TLPuFlu2bCE2NpYqVaokBnhEMgL9tIqIiIhIuhETGcnhvzZy+dQJ4mPjyJ7HkzJ1/Mme2/PRB4uIiPX06wd+frB6Nbz0krWrEUkV+QsUYPWen9h2dAXF81WkcJ5SFMxTEk/3AmR3yZmks4XZbOZmxDWOXtjD4XO7OHZxD9duXqFunbos+WYBVatWtdIjEUkDY8dC3rzw5pvWrkREJNNxdHSk8wM6yW3cuJFjx47xyiuvkCdPHooUKfLI8apXr86KFSvYsGEDAQEBD9zv5MmTmM1m6tevbxG6ANi0adNjPYbkuLm5UbZsWY4cOcKxY8ceGjSoVq0aJpOJrVu3PvV5n5Sfnx+jRo1izZo1tG3b1mLb6tWrE/d5FGdnZ6pXr862bds4ffo0hQsXTtxmNptZu3Ytrq6u+lvxP/Hx8YwcORKAN954w8rViDweBS9ERERExOrM8fFsXTSXncsWExMZiY2trbHebGbz/DmUqOpLg/d6Ye/s8oiRRETEKurUgapVYfRoaNRIdz9LprBv317++usv1qxZQ1DQBlbu/YHIyDsA2Nnak83FAwd7R2xMNkRE3Sb8zi1i42IAqFD+OTq9257GjRsTEBCgLheSuVy6BLNnwyefwH/t50VEJPU4OzsTGBiY7LaOHTty7NgxBg0ahK+vr8W2sLAwQkJCcHd3x8vLK3F9z549WbFiBe+//z5BQUEWUzfExsZy9epV8ubNmxgI+Ouvvyy6Y5w7d45BgwalymPr2bMnPXv2pEePHvz+++84OzsnbouMjCQiIoKcOXOSL18+Wrduzfz58/nqq6/48MMPk/w9tX37dipUqJAkJPIgoaGhhIaGkjt3bnLnzv3I/evVq0exYsX4+eef6dOnD5UqVQKM7/Pnn3+Og4MD7du3tzgmJCSEsLAwvLy8LKYOee+999i2bRuDBg3ip59+SnwsU6ZM4eTJk7z33nsW34usKjQ0lD59+vDnn39StmxZunfvbu2SRB6LghciIiIiYlVms5mVk7/l0Kb1ievi/5v/M8GJXdu58r9gWg8f/azLExGRlDCZYMgQaN4cVq6Exo2tXZHIU3N0dCQgICDxztDY2FiOHj3KyZMnOXXqFFevXiUiIoK4uDg8PDzw8PAgX7581KlTJ9XmFhdJlz79FJycoEcPa1ciIiL3WLx4MZ06daJDhw7MmjUrcX3jxo358MMPGTNmDD4+PrRs2RJPT0/Onz/PH3/8wYcffkjfvn3x8vKiVatWLFq0iKpVq1KvXj0uXbrEsmXLqFevHidOnHjqGrt3786GDRtYsGABPj4+vPLKK2TPnp0zZ86wevVqpk+fnjh1yuTJkzly5Agff/wxc+bMoWbNmnh4eHD27Fl27tzJsWPHCAkJSXHwYuLEiQwfPpyhQ4cybNiwR+5vZ2dHYGAgjRo1om7durRt25Zs2bKxaNEiTp8+zZgxY5J0HBk0aBCzZ89m5syZFtNwdOjQgfnz5zN37lyCg4Px8/Pj+PHj/PrrrxQtWpQRI0YkOf+HH35IaGgoAP/++2/iOjc3NwC6dOlC7dq1U/TY06MxY8bg5uZGfHw8N2/e5ODBg2zatInIyEhq1arF3LlzU/zciqQXCl6IiIiIiFX9++cai9BFcszx8dwMvcwf07/DpmSFZ1SZiIg8lmbNICAA+veHBg3A3t7aFYmkKjs7O8qWLUvZsmWtXYqI9fz7LwQGwjffwD13TIuIPEvO2bNja29PXEyMtUtJlq29Pc7Zs1u7DAtfffUVNWvWZOLEiSxcuJDIyEi8vLx48cUXadCgQeJ+s2bNokiRIixatIgJEyZQqFAh+vXrx4ABA1i4cOFT12EymZg3bx4NGzYkMDCQH374AbPZTP78+WndujVVqlRJ3Ddnzpz89ddfTJw4kfnz5/PTTz8RHx9Pvnz5qFixIkOGDElR54qnERAQwObNmxk6dCjz588nJiaGChUqMHr0aNq0aZPicWxsbFiyZAlffPEFc+bM4dtvvyVnzpx07tyZESNGkCdPniTHLFy4kNOnT1usW7RoUeLn/v7+GTp48fXXXwPG39jZsmWjUKFCtGvXjtatW9OgQYPEjisiGYnJbDabrV1ERnPz5k3c3d0JCwsjezr7xzOri4mJYcWKFTRu3Bh7vcknkunpNS+SsUSE3WDjzzO5cioYs9mMu2dearVtz9KvP+fahfPAo/8sNdnZU7x1R73uRbII/VufAe3ZA1WqwMSJuhNaHpte8yLpnNlsTCd16hTs3w8ODk81nF7zktkkXDe4cuUKV65coWjRojg5OVm7rEzrZuhl7ty8ae0ykuWcPTvZc3tauwwREUklkZGRBAcHP/LfdnW8EBEREZE0FRsdxS8jBnPhyCGL9VdOB3N8x7bHGsuktLuISPpWuTJ07AhDh0LbtrobWkQkM1mxAtauhd9+e+rQhYjI08qe21PhBhERSVf0zrWIiIiIpInrFy/w58wpjHu7VZLQhYiIZGIjR0JsLPTube1KREQktVy/Dl27QsOG8Mor1q5GRERERCTdUccLEREREUl1+9auYN3074x2xKnKlMrjiYhIqvPyMqYaeestaNkSXnvN2hWJiMjTev99uH0bAgPBpL/JRURERETup44XIiIiIpKqDm78k3WBk9MgdAFmc3yqjykiImmgXTt49VXo3h0uXbJ2NSIi8jQWL4Y5c2D8eChY0NrViIiIiIikSwpeiIiIiEiqiY2O5s9ZU9JsfFtbNWwTEckQTCb47jvj43vvpUkYT0REnoGLF40pRpo3h7fftnY1IiIiIiLploIXIiIiIpJqjm7fQlR4eNoMbjJR4cWGaTO2iIikPk9PoyX977/DF19YuxoREXlc0dHw+utgawtTpmiKERERERGRh1DwQkRERERSTfCenZhs0uJPTBPFnq/GC63fTIOxRUQkzbzyCgwZAv/7H6xYYe1qRETkcXzwAWzfDosWQd681q5GRERERCRdU69mEREREUk1URHhmOPjn/h4F3d3IsLCLNZly5Wb5xs35/nGrxAX9+Rji4iIlQwbBnv2QLt2sGMH+PhYuyIREXmUGTNg8mSj08ULL1i7GhERERGRdE/BCxERERFJNU6ubphsbJ44fPH26AlEhd/m8ulg4mNjyZ47DwXKlE/soqHghYhIBmRjAz/+CNWrQ4sWsGULeHhYuyoREXmQv/6C7t3hvfeMRUREREREHknBCxERERFJNcWr+nJoc9ATHetdqgxuOXLiliMnuQoUSt3CRETEutzd4bffoFYtaNwY1qwBNzdrVyUiIvfbu9f4Pe3rC+PHW7saEREREZEMIy0m4BYRERGRLKpENV+cs7s/9nFuOXPx+pCRaVCRiIikG2XKwKpV8O+/RueLyEhrVyQiIvc6fBgaNjSmhFq6FBwdrV2RiIiIiEiGoeCFiIiIiKQaWzs7GrzbM8X7m2xsKF7Vly4TpmNn75CGlYmISLpQvTosW2ZMN9K6NcTEWLsiEREBCA6G+vXB09MIyWXPbu2KREREREQyFE01IiIiIiKpyqf6CzTp8xErJ32LOT4Os9mcZB9HV1cqN2qGb6s22NrZW6FKERGxGj8/WLwYXnkFOnSAOXPA1tbaVYmIZF0XLhihC2dnWLsWcuWydkUiIo9kvhONOTrO2mUky+Rgi8lZN5c8S0FBQQQEBDB06FCGDRv2RGOYTCb8/PwICgpK1dpEJOtQ8EJEREREUl3pWn4ULPcc//65hv3r1xB+4zo2tnbkK1GSyi81o9jzVbGx0UU2EZEs66WXYO5co+uFqytMnQomk7WrEhHJekJDoUEDiI6GzZvBy8vaFYmIPJL5TjRRG49CfNIbPdIFGxOOdUs+dfiiSJEinD59OtltCgjI44iKimL06NHMmTOHs2fPkjNnTpo2bcqIESPw9PR8rLF27NjB0KFD+euvv4iJiaFChQr069eP1q1bJ9l3/PjxrF69mgMHDnDlyhXs7e0pXLgwLVu2pE+fPuTMmfOh5zp16hRFixZNcW2FCxfm1KlTiUGcB3F3d+fGjRspGrNIkSJcvHiRyHumykxufFdXV3LkyEH58uXx8/Ojffv2eHt7Jxlv1qxZdOrU6YHnq1ixInv37k1RbZL+KHghIiIiImnC1SMHvq+2wffVNtYuRURE0qNWrWDGDOjYEeztYfx4sNPbFCIiz0xICDRpYoQvNm2CwoWtXZGISIqYo+PSb+gCIN6MOToOk/PTD+Xu7k7fvn2TrC9SpMjTD56JVK9enUOHDpE7d25rl5LuxMfH07x5c1avXo2vry+tWrXi2LFjBAYG8scff7Bt2zby5MmTorHWr19Po0aNcHJyom3btmTLlo1FixbRpk0bzp49S//+/S32nz59OmAEhfLly0dkZCTbt29n+PDhzJgxg7///pt8+fI98HweHh4MHTo0yfrhw4cn+9rw8PCw+LpKlSo0bdo0yfFOTk4peryPcu/4ERERXLx4kb/++otVq1YxfPhwvvzyS3r37p3ssfXq1aN27dpJ1j/s+yHpn97REBERERF5mJgYCA+H27eNj/d+nty68HCIioL4+OQXABubpIvJBA4Oxp3fbm7Gx3s/T26dq6txjO4SF5GMqkMH4/dst24QHAzz5oG7u7WrEhHJ/PbsMaZ8io+HdeugZElrVyQiIsnw8PB44qkzshIXFxdKly5t7TLSpdmzZ7N69WreeOMNfvrpJ0z/vYf0/fff0717dwYPHsyUKVMeOU5sbCzvvvsuNjY2bNy4kUqVKgHw6aefUr16dT755BNee+01Ct8T5Ny+fXuyIYchQ4YwYsQIvv76a7766qsHnvNBP//Dhw9P0WujatWqafr6edD4S5YsoXPnzvTp0wdXV1feeeedJPvUr1+fgQMHplltYh021i5AREREROSZio2Fixdh3z5YswbmzIGvv4aPPzYuAL70ElSuDN7e4OhoBBty5ICCBaF0aahSBfz8oHFjo0V+p07Qrx+MHg2zZsGKFUab5u3bYdcu4zwHDsCRI3D8uLEcOWKs27fP2Gf7dvjrL1i92qhnzBijns6doU0baNoU/P2hWjUoWxYKFTLm3nZyMurLmxeee85oE/3mm5b1rFwJu3fD+fPGxU0RkfSmSxdYtQq2bYOaNeHkSWtXJCKSuS1eDLVrQ758sGMHVKhg7YpEROQZ2LhxI82aNSN37tw4Ojri4+PD4MGDiYiISLLvokWL8PPzw9PTEycnJ7y9valfvz6LFi1K3Mff3x+TyfTApWPHjhZjnj59ms6dO5M/f34cHBwoUKAAnTt35syZM0nOnzB2ZGQkAwcOpFChQjg5OVGmTBkmTJiA2WzZ8SQoKAiTyZTsRfDLly/Tv39/SpUqhbOzMzlz5qRGjRqMGTMmRd+30NBQ+vbtS9GiRXF0dMTT05PWrVuzf//+JPt27NgRk8lEcHAw48ePp3Tp0jg6OlK4cGGGDx9OfMINOf8JCwtj9OjR+Pn54e3tjYODA97e3rRv354TJ06kqL5HmTZtGgCjRo1KDF0AdO3alWLFivHTTz9x586dR47z559/cuLECdq1a5cYugCjK8snn3xCdHQ0s2fPtjjmQZ0lXn/9dQCOHz/+uA8nQ2jevDkLFy4EYMCAAYSHh1u5InlW1PFCRERERDKXW7eMi3YnTlh+vHABLl0yWinf9x90smUzwguensZHX1/jY+7cRneJR3WdsLdPm8cSGwsREQ/vtnH7Nly9ajy2S5fg3DkjzHHpEiQ3X2XOnMbj9PKCYsWgePG7H4sXN0ImIiLPWv36RvCiWTOoXh1+/RXq1rV2VSIimYvZbIRzBw2C1183QrouLtauSkREHiIqKopZs2Zx4cIFsmfPTrVq1ahRo0ay+wYFBREQEICfnx9BQUEW27777jt69uyJh4cHzZo1w9PTk507dzJy5EjWr1/P+vXrcXBwSNy3R48eeHl50bJlS3LlysXFixf5+++/Wbx4Ma1atQKMkIG/v3+SOlauXMnff/+Nyz3/xhw9epTatWtz5coVmjVrRrly5di/fz8zZsxg6dKlbN68mZLJdF9q3bo1e/bsSTznokWL6NOnD6dOneLrr79+5PfvyJEjBAQEEBISQu3atWnRogXh4eEcOHCAzz//nA8//PChx1+5coWaNWty4sQJ/P39adu2LcHBwSxcuJDly5ezevXqZKeL+Oijj9iwYQNNmzalUaNG/PbbbwwbNozo6GhGjhyZuN+hQ4f49NNPCQgIoGXLlri6unL48GF+/vlnli9fzu7duy06SACJ4Yn7wyfJSZjao1SpUsmO06BBA6ZMmcLOnTupU6fOQ8dK+Jlq2LBhkm2NGjUCYMOGDY+sCWD58uUAlC9fPkX7Z0T+/v7UqVOHTZs28eeff9KsWTNrlyTPgIIXIiIiIpLxXLoEp07dDVbcu1y5cnc/N7e7wYKAAMtwRcLi6Zl+33C2s4Ps2Y3lSURFweXLxvcr4WPCcuGC0XHj11/h+vW7x+TIYRnEuDeYUaCAMS2KiEhaKFXKCF+89poRxJgyxegqJCIiTy8qCt591+iu9umnMHSo/q4TEckALl68SKf7/iauVq0ac+fOpXjx4ika4+DBg/Tp04fnnnuOP/74g1y5ciVu++KLLxg0aBATJkygf//+AAQGBuLg4MDevXvx9PS0GOvq1auJn9/f0QJg06ZNjBo1imLFivF///d/ieu7devGlStXmDJlCu+9917i+smTJ9OzZ0+6d+/OH3/8kWS8o0ePsn//ftz/m45w+PDh1KhRg2+//ZY33niDqlWrPvSxv/XWW4SEhDB16lTeffddi23nzp176LFgdCs4ceIEgwYN4vPPP09cv2LFCpo0aUKnTp04cuQINvf9m7p7927++ecfvLy8AGNqDR8fHyZMmMDQoUMTQy5lypQhJCSEnDlzWhy/fv166tevz4gRIxI7VjyJEydOEB8fj4+PT7LbE9YfO3bskcGLY8eOWRxzr3z58uHm5pa4z/2mTp3KhQsXuHXrFrt37yYoKIjKlSvTr1+/x3k4j23nzp3JdkFp27btM5maxt/fn02bNrFjx44kwYt169YRGRmZ5Jhu3bqRL1++NK9N0oaCFyIiIiKSfoWHw7//GgGBvXvh0CH44ANjDuqENoheXkYooGRJePlly8BA7txwTxvFLMfR0ZgipWDBh+93/XrSEMvJk8YF0LNn73YIcXSEcuWgYkWoVMn4WLEieHik9SMRkawiZ05j2qWePeGdd4zf+6NGga2ttSsTEcm4Ll+Gli2Nrmg//wxvvGHtikREJAU6depEnTp1KF++PG5ubhw9epRvvvmGOXPmUK9ePf7991+yZcuWuH/16tU5dOiQRacJgClTphAbG8uECRMsQhcAH3/8Md988w1z585NDF4A2NvbY59Md8/7j7/X8ePHadmyJS4uLixfvpzcuXMDcObMGdavX0/ZsmWThB+6devGhAkT+PPPPzl79iwF73v/YsiQIYmhCzCmtRg8eDBvv/02s2fPfmjw4u+//2bnzp3UrVs3yXkBChQo8MBjAaKjo5k7dy65cuVi8ODBFtsaN25MgwYNWLt2LVu2bEkSWhgyZEhi6AIgd+7cNG/enNmzZ3PkyBEq/DfN172P7V4BAQGUK1eOdevWJdl26NChh9Z9r7CwsIeeJ/t/N/ok7Pe0Yz1onKlTp7Jr167Erxs2bMicOXPIkcZdV3ft2mVx3gSVKlV6JsELb29vwJiu5n5//PFHsmGjFi1aKHiRgSl4ISIiIiLWZzYbHRj27r0bsti3D44dM7bZ2kKZMlClirH/3Ll3OzGk124VGUmOHMb3NuH7e6+oKKO7yIkTxvPxzz/Gc/Pzz8Y2gMKF7wYxEj4WLZq1Qy8i8uTs7Y1uF2XLQv/+cOQI/PST0cVIREQez7//GtM4RUbChg3wgPb0IiKS/gwdOtTi60qVKvHDDz8AMGfOHKZNm2bRMcDFxSXZi8nbtm0DYPXq1cle6LW3t+fw4cOJX7dt25aPP/6Y8uXL065dOwICAqhdu3biRfrkXL9+nSZNmhAWFsaqVass6ti7dy8Afn5+idNkJLCxsaFu3bocPnyYvXv3JgleJNeFIWHdnj17HlgPGMELSH5qjJQ4fPgwkZGRBAQEJAmzgBGOWLt2LXv37k1SZ5Vk3l9JCHrcuG9a2KCgIMaOHcv27dsJDQ0lNjY2cVtCZ4x7PYvAQGrbuXMnYAQQtm7dysCBA3n++edZsWIFzz33XJqdt2vXrnz//fcP3Wfs2LFJnpOOHTtSpEiRNKsLYNSoUQwcODBNzyHPnoIXIiIiIvLsXb8OW7bA5s2wc6cRtEhoV+nubly8f+klGDjQuIhftiw4OUFMDKxYAY0bGxfmJO05Ohrt/0uVslwfG2tcDL03LPPdd3enesmWzXjunn8eateGOnVAiX0RSSmTCfr2NboZtW0LtWrB778bQS8REUmZZcuM7hbFixu/QwsVsnZFIiKSCrp27cqcOXPYsmVLiqZquHbtGgAjR45M0fgffvghuXLl4rvvvuPrr79mzJgx2NnZ0aRJE7799luKFi1qsX9MTAyvvvoqR48eZerUqdSrV89i+82bNwHImzdvsudL6AyRsN+9kjsmYd2jujQkbM+fP/9D93uQp6k7uZCKnZ1xSTYuLi5x3S+//EKbNm1wc3OjUaNGFClSBBcXF0wmE7NmzeL06dNPVHuChO4UD/peJdT+oC4WjzvWozpY5M6dm2bNmlGpUiV8fHx499132b59+yPPnZbGjh2b5Pvs7++fKsGLCxcuAJAnT56nHksyBgUvRERERCTtnT8PmzbdXfbvNzpZeHsbd9316XO3W0KhQuqUkBHY2RnTjpQrB2++aawzm+HiRcuuJcuWwfjxxvYSJaBuXSOEUaeO0bFEz7WIPEzjxrB1q3G3dsWK8O230LGjfneIiDzM7dswYABMngzNm8OPP6prkIhIJpIwhUd4eHiK9k8IAdy8edNiapIHMZlMvPPOO7zzzjtcvXqVTZs2MXfuXBYsWMCxY8f4559/sL1nKsCuXbsSFBRE//79k53SI+H8ly5dSvZ8Fy9etNjvXpcuXaLQfcHBhHEeFRbw+G9a1PPnzz90vwd5mrpTatiwYTg5ObFr1y58fHwsts2bN++Jx01QrFgxbGxsOHbsWLLbE9bff+7kJOxz7NixJB09Ll68yO3bt6levXqK6ipYsCBlypRhx44dREREJNtR5Fk5depUmo0dFBQEQLVq1dLsHJK+2Fi7ABERERHJZMxmoxNCYCB06GBcXC9QwLjbbu1aqFYNZs40pq44dw5+/RU+/dR4U7hwYV1My8hMJvDyututZO5c43k+fx7mzYNGjYwOJ++8Y4Qw8ueHNm1g4kQjpHHPXR8iIonKlYNdu6BFC+P3R9Omxu8VERFJKigInnsOZs2CCROMv7UVuhARyVQSOgSk9I78Gv9NM5Uw5cjjyJUrFy1atGD+/Pm8+OKLHDx4kOPHjyduHzVqFDNnzqR58+Z8+eWXyY5RqVIlADZu3IjZbLbYZjab2bhxo8V+99q0adMD11WuXPmhtSeEANasWfPQ/R6kdOnSODk5JYYD7pdwUT25ulPqxIkTlClTJknwISQkhJMnTz7xuAmcnZ2pXr06R44cSdLVwWw2s3btWlxdXalateojx/Lz8wOS/36uXr3aYp+UCAkJwWQyWYR4MpMNGzawadMmPD09efHFF61djjwjCl6IiIiIyNMLDYU5c4yL6PnyQenS0LXr3Tmlf/kFQkLg6FGYPv1uIEMhi6zB29syYHH1qtEJo317OHsW+vUzup3kymX8vHz/vbFeRCRBjhzGRcSlS2HPHihfHmbPNsJ+IiIC4eHQuzcEBBih53/+gV69wEZv/4qIZESHDx9O9mL/4cOHGTBgAADt2rWz2BYREcHhw4c5c+aMxfoePXpgZ2dH7969k2wDuHHjBnv27En8OigoKElAIiYmJnHKEicnJwAWLlzI//73P55//nl++uknbB7wb06hQoUICAjgwIEDzJgxw2Lb1KlTOXToEC+++CIFCxZMcuxnn31mMbVFWFgYI0aMwGQy0aFDh2TPl6BatWpUq1aNjRs3Mm3atCTbH9UJw8HBgTfeeIPQ0FBGjRplsW3VqlWsXr2aEiVKUKtWrYeO8zCFCxfm+PHjFl01IiMj6d69OzExMckec/jwYQ4fPpzic7z33nsADBo0yOJ5nTJlCidPnuTNN9/E2dk5cX1MTAyHDx/mxIkTFuPUq1ePYsWK8fPPP7N3797E9WFhYXz++ec4ODjQvn37xPUhISHJfo/NZjPDhg3j0qVL1KtXD0dHxxQ/loxi6dKltGrVCoDRo0dbtaOHPFuaakREREREHp/ZDAcOGBfAli0z2sCbzUY3iy5djGkkataEFMwRKRnHzdArbPghkEunThAfG4eLuzvVXmlFqZp1Hm+gHDmgSRNjAbhzB7ZvN6ah+eMP4yJB9+7GtALNmhl3t1erpgsHImL8Pti/H95/35hyZOFCmDLFCHiJiGRVGzdCp05G0HncOAUuREQygXnz5vHNN99Qt25dChcujKurK0ePHmXFihXExMQwaNAg6tata3HM33//TUBAAH5+fondGADKly/P5MmT6d69O6VKlaJx48YUL16cW7ducfLkSTZs2EDHjh35/vvvAWjRogXZs2fH19eXwoULExMTw9q1azl48CCvvfYahQsXBqB9+/aYzWaef/55vvrqqySPoVKlSrRo0QKA7777jtq1a/Puu++ydOlSypYty4EDB/j999/JkycP3333XbLfh5IlS1K+fPnEi9iLFi3i3Llz9OvXL0VdGn766Sf8/f157733mDNnDjVr1iQyMpIDBw6wZ88erl69+tDjR48ezYYNGxgxYgR//fUXNWrU4NSpU/zyyy+4uLgwc+bMBwZOUqJ379707t2bypUr89prrxEbG8vatWsxm81UrFiRffv2JTmmTJkyAEnCMQ/SoUMH5s+fz9y5cwkODsbPz4/jx4/z66+/UrRoUUaMGGGx//nz5ylTpgyFCxe2mIbDzs6OwMBAGjVqRN26dWnbti3ZsmVj0aJFnD59mjFjxlh0YTly5AgNGjTA19cXHx8f8ubNS2hoKJs2beLIkSN4e3szadKkx/+mpSM7d+5k2LBhgBGYCQkJ4a+//uL48eM4OzszadIkOnbsaNUa5dlS8EJEREREUiYy0mhdvGyZsZw+Da6u0KCBMa1I48ZGtwvJdOJiY1jwf59w4cghi/W3rl5h2djRrP5+PC0HDKVg2fJPdgJnZ/D3N5YhQ+D6dVi92vg5mzQJRowAT08jqNG0qfEzl4J5aUUkk8qZ0+iy9NprRnel8uVh/Hh48011UhKRrCU8HD75xPgdWKsWrFoFKZijXURE0r+AgAAOHTrEnj172LRpExEREeTOnZvGjRvTo0cPGjZs+Fjjvfvuu1SqVIlvvvmGjRs3snTpUtzd3SlUqBAffPCBRfeIUaNGsWrVKv7++2+WLl2Kq6srxYsX57vvvqNz586J+925cweAwMDAZM/ZoUOHxOBFqVKl2LlzJ8OHD2fVqlUsX76cPHny0KlTJ4YOHZoY5rjfggULGDp0KHPnzuXSpUsULVqU8ePH06tXrxQ9bh8fH3bv3s2oUaNYunQpY8eOxc3NDR8fHwYPHvzI4/PkycP27dv57LPPWLJkCZs2bcLd3Z0WLVowdOhQypd/wvdB/tOzZ0/s7e2ZMGEC06ZNw8PDgyZNmjBq1Chef/31pxo7gY2NDUuWLOGLL75gzpw5fPvtt+TMmZPOnTszYsQI8uTJk+KxAgIC2Lx5M0OHDmX+/PnExMRQoUIFRo8eTZs2bSz2LV26NP369WPDhg0sW7aM69ev4+zsjI+PD0OGDKFv377kzJkzVR6jtezatYtdu3YB4OLiQs6cOSlXrhxdunShffv2eHl5WblCedZM5pRGoiTRzZs3cXd3JywsjOzZs1u7HLlHTEwMK1asoHHjxtjb21u7HBFJY3rNizwD167B4sXGBfC1a403dwsXvtuFwM8P/msx+Szodf/sxcfFMaNvV8IuX3zEniZafzqSguWeS90CYmONjioJgZ+DB8HBwQhpNG0Kr74K+fOn7jkl3dBrXh7p6lWjtf7cudC8uTFVkUKAGZZe8yKPYfNmo8vFuXPw+efQpw9ksDnS9ZqXzCbhusGVK1e4cuUKRYsWTZySQVKX+U40URuPQnw6vbxlY8KxbklMzg7WriTD8vf3Z8OGDSnu6iAikpYiIyMJDg5+5L/t6nghIiIiIpaio2HlSvjhB+NCd0yMMW3I4MHGhe5y5XRHcRaybvrkFIQuAMz8Ono47/+wKHULsLMzpq6pUwdGj4YTJ2D5cuNns39/Y7qB+vWhfXto2dLowiIiWUeuXPDzz0b3i27djH+jJkyAN97Qv1UikjlFRBh/l48dC76+xt9EpUpZuyoRkWfK5OyAY92SmKPjrF1KskwOtgpdiIhkQQpeiIiIiAiYzbBjhxG2mDfPuIO4cmXjQnfbtrp7OIsym80c2rg+xfvHRkVxcOOflK37YtoVVby4cUdnnz4QFgYLFxo/t2+/bYQuWrUyQhj+/hnurk8ReQqvvmoEtHr1MqYcmToVvvwSqle3dmUiIqkjLs6YZmnIELhyxfgd98EH+ntHRLIsk7MDJmdrVyEiInKXjbULEBERERErOn0aRo6EMmWgRg1jWpF33oF//oHdu6FvX4UusrDjO7cRGxP9WMfsWPprGlWTDHd36NwZNmyAkydhwABjWpL69Y0pcQYONKYmEZGsIU8emD/f6IoTGmr8u9amjdEpR0QkozKbYdUqIxTdqZPR5eLff+HDDxW6EBERERFJRxS8EBEREclq7tyBWbMgIACKFDHmhK5WDdasgTNnjLvnKlSwdpWSDoSeOf3Yx0TcDEuDSlKgaFHjDtAjR4zwxSuvGHe8lysHVavC+PFw44Z1ahORZ6txY9i3D6ZPhy1bjHDh++8bd4iLiGQku3dDgwbw8stG4HTrVvjlF/DxsXZlIiIiaSooKAiz2WztMkREHouCFyIiIiJZxblz8MknULCg0dXC1tYIYFy8aLQtbtBAd82JBTt7+8c+xsbGyj9DJpNxJ+jkyRASAr/+avzM9+8P+fNDjx5w+LB1axSRtGdra/xbd/QoDB9u/HtXvLgRNoyIsHZ1IiIPFxxsTJtUpQqcPw9LlsDGjcbfOCIiIiIiki4peCEiIiKS2W3darRaL1IEJk6Et94yLkStWwcdOkC2bNauUNKpopWrPvYxuQoWSoNKnpCjI7RsaUyhc/YsfPQRLFpk3P3+0kuwciXEx1u7ShFJSy4uMGiQMd3IO+/AsGHGneLTp0NcnLWrExGxdPWqERYtXRr+/NPo3vXvv0YnL5PJ2tWJiIiIiMhDKHghIiIikhnFx8Pvv0OtWvDCC7BnD3z7rXHH3NixUKKEtSuUDCB3wcJky5X7sY7xb98ljap5SvnyGRdcz5yBH36A0FBjOoLnnjO+jo62doUikpZy5zb+/Tt8GOrWhS5doGJFWL4c1MJYRKztzh1jur/ixY2wxeDBcPw4vPsu2NlZuzoREREREUkBBS9EREREMpOoKJg5E8qXh+bNwcbGCGAcPgy9e6u7hTy2Ou06pnjf3AULk7tAOup4kRxHR3j7bdixw2jZXayY0fmleHH45hu4dcvaFYpIWipWDObOhb//hjx5oGlTCAgwfh8ogCEiz1pUlNGBp1Qp+N//jM50J07AkCHg6mrt6kRERERE5DEoeCEiIiKSGcTFGfPXlyhhtFIvWRK2bIFNm6BZMyOAIfIEytT2p2rTlo/cz8XdgzdGjHkGFaUSkwnq1DGCSfv3Q/36MHAgFC4MY8ZAZKS1KxSRtFStmtHGf/lyuHYN/PyMDlGLF2sKIhFJe2Fh8NVXRhisSxeoUQMOHjSmBfT0tHZ1IiIiIiLyBPQOvIiIiEhGZjbDypVQuTJ06mRcNDp4EH77zfhcJBX4vd2Zl3p8gKtHjiTbbGxtKelbm/cmzcTBydkK1aWCcuWMTjEnT0LbtkYAo1QpmDNHF2BFMjOTyZhyaN8+WLYMHBzg1VehTBkIDDTuRBcRSU0hITBgABQqZHS4eOkl42/3X34BHx9rVyciIiIiIk9BkwSKiIiIZFS7dsHHHxt37NatC9u3Q/Xq1q5KMqlyfvUo51ePSyePc3znduJiosmZvyBl676ITWbpqFKgAEyeDO+/D598Au3bG9OPfPklNGhg7epEJK2YTNCkibFs22a85t97z2j1//77xuc5c1q7ShHJyA4eNP6mmDMHnJygWzfj94u3t7UrExERERGRVJJJ3iEVERERyUKCg6FdO6haFS5ehKVLIShIoQt5JvIWK0Gt1m9S981OlPevn3lCF/cqVQoWLTKm63F1hYYNjWXvXmtXJiJpzdcXfv0VDh0ypuoaOtQIZXXrBgcOWLs6EclI4uONbjoNGxrdtVasgM8+gzNnYPRohS5ERERERDKZTPguqYiIiEgmdfUq9OtnXBQOCoJp04z26E2bGnfrikjqeuEF2LQJFi82LpI8/zy8/TacPm3tykQkrZUqBVOnGq/9QYNgyRIoX97ofrN0qaYhEpEHu3kTxo2DkiWNANeNG/Djj3DqlNGtzt3d2hWKiIiIiEga0FQjIiIiIhnBwoXQowdERhp33/bta9yJLyJpy2SCFi2MgNP06cbr79dfjTtVe/SAzNjxQ0TuypvXmHJkwAD45RfjYuorr0Dx4tCrF7z1FuTObe0qRSQ9OHDACGzNnAl37sBrrxlTi/j6KiQtIpIGIiMvEB1zzdplJMvBPidOTumns1FQUBABAQEMHTqUYcOGPdVYx44d4+OPP2bbtm1cunSJ7Nmzc+PGDYYNG8bw4cNZv349/v7+qVK3iEhGo+CFiIiISHoWGmpc2Jk/H1q2hO++My4CicizZWcHXbsa0/wMHAi9exvTkcyYAUWLWrs6EUlrDg7w5pvGsm0bjB8PH31kLE2aGN1wmjYFR0drVyoiz9KlSzB3rhGw2L0bcuUy/kbo0QPy57d2dSIimVZk5AW2bqtPfHyUtUtJlo2NIzV916Va+GLx4sVMnjyZ3bt3Ex4ejpeXF76+vnz55ZcULFgwVc6REnFxcbRo0YLjx4/z9ttvU6BAAZycnJ7Z+eXhjh49yuDBg/nzzz8JDw+nZMmSdOvWjW7dumF6jBBofHw8kyZNYurUqRw/fhw3Nzfq16/PyJEjKVasWJL9J0yYwO7du9m1axcHDx4kLi7usQI4CaGdlEoIEHXs2JHZs2c/cL/333+fsWPHPnK8hGBS165d+f777xPX3z++ra0t2bJlw8vLi8qVK9OyZUteeeUVHBwckozp7+/Phg0bHnjOb7/9lr59+z6yNsl4FLwQERERSa8WLzbmlI+NhZ9/hrZtdbeciLVlywaTJkGrVvDOO1ChAnz1lRHKUPcLkazB19dYxo2DefPghx+MO9tz5IA2baB9e93hLpKZRUbC778br/1Vq4x//5s2hcGDoXFjBbBERJ6B6Jhr6TZ0ARAfH0V0zLWnDl6YzWa6devG1KlTKV68OG3btiVbtmxcuHCBDRs2cPr06RQFL6pXr86hQ4fI/ZSd2oKDgzl48CDvvvsuU6dOfaqxJHUdPHiQF154gTt37tC6dWu8vb1Zvnw5PXr04ODBg0yYMCHFY3Xt2pXAwEDKlStHnz59uHDhAgsWLGDNmjVs27YNHx8fi/379OkDgJeXF3ny5OHixYuPVXtyAY29e/eyZMkS/Pz8kmy//+vOnTtToECBJGP4+vo+Vh0PkjC+2Wzm5s2bHDt2jKVLl/Lzzz9TpkwZ5s2bx3PPPZfssf3798fNzS3NapP0R8ELERERkfTm6lXo08cIW7zyCkyZAvnyWbsqEbnXiy/Cv/8ad7v36GF0v5g+HQoXtnZlIvKs5Mlj3NneuzccPGjc8f7jj/D991CihNEF4623IJm7wkQkgzGbYfNm43W+YAGEhUGNGkb3mzZtjE4XIiIiqWz8+PFMnTqVHj16MH78eGxtbS22x8bGpmgcFxcXSpcu/dT1XLhwAQBv7/QzjYoYunfvTlhYGCtWrODll18G4LPPPqN+/fpMnDiRdu3aUbNmzUeOs379egIDA6lbty5r165N7ObQrl07GjduTK9evVi9erXFMcuWLaNKlSrky5ePbt26MWXKlMeq3d/fP0mYYtasWSxZsgR/f/9HTo/TpUuXNA0yJDf+rVu3GDp0KN9++y0NGzZk9+7dyb4uPvzwQ/LpPd0sRbdkiYiIiKQnv/8O5cvDihXGG7u//abQhUh6lS2bcYF19Wo4etR47U6dalycEZGspWxZGDUKTp2CP/6AWrXgyy+heHGoWxcCA40LtSKSsRw/DkOH3n0tr1ljhK2OHDGmHerRQ6ELERFJE3fu3GH48OEUK1aMcePGJQldANjZpeze6qCgIEwmU5IL2EWKFKFIkSLcvn2b999/H29vbxwdHXnuuedYuHBhkn39/PwAGD58OCaTKdkx7zdjxgyaN29OkSJFcHJyImfOnDRq1Ij169c/tM6//vqLgIAAsmXLRp48eejRowd37twBYPny5dSsWRNXV1fy5s3Lxx9/nCSEEhYWxujRo/Hz88Pb2xsHBwe8vb1p3749J06cSLZWs9nMzJkzqVOnDh4eHri4uODj40PXrl05c+ZM4n67du2iV69elC9fHnd3d5ydnalQoQJffPEFMTExyY69f/9+WrdujaenJ46OjhQtWpS+ffty9erVh37/UuLo0aNs3LiRgICAxNAFgIODA5999hkA06ZNS9FYCft99tlnFlNovPzyy/j7+7NmzRqL7wVAkyZNsly4IFu2bHzzzTd07NiRS5cuMWLECGuXJOmEghciIiIi6UFsLPTtC82bQ9WqcOCAcZes2pSLpH8NGxrdL9q2NaYcee01CA+3dlUiYg22tkZHnFmz4NIlI0Tp7Gz8bsib17gzfvlyeMAbsiKSDly7ZgQrX3gBfHzg22+N13VQEJw8CZ99BiVLWrtKERHJ5NasWcP169dp0aIFcXFx/Prrr3zxxRd8//33HD9+PNljZs2ahclkomPHjik+T0xMDA0bNmTNmjW0atWKt956ixMnTtC6dWvWrFmTuF/fvn3p0KEDAH5+fgwdOpShQ4cmO03EvXr27MmlS5eoX78+H3zwAU2bNmXr1q3Ur1+fJUuWJHvM9u3bqVevHu7u7nTt2pVChQrx3Xff8e677zJ//nxee+01ChcuTNeuXfHw8OCrr77i888/txjj0KFDfPrppzg7O9OyZUv69u1L1apV+fnnn6levTqnT5+22D8+Pp7WrVvzzjvvEBwczBtvvEHv3r15/vnnWbBgAbt3707cd9q0aSxevJgKFSrQtWtXOnfujNlsZtCgQbRt2zbJ49m8eTM1atRg8eLF1KtXj379+lG4cGHGjRtHjRo1CA0Ntdj/cZ/HoKAgABo2bJhkW+3atXF1dWXDhg0pHsvV1ZVatWol2daoUSOAFI+VFQwZMgSABQsWYNZNOIKmGhERERGxvrAw44Lt2rUwYQL07KnAhUhG4+4O06ZBkyZGaKpOHaODTTLzjIpIFuHqavw+eOstOH/emELshx+gaVPInRsaN4ZmzYzwVvbs1q5WJGs7dQqWLTOW9euNUHSjRjB3rjH1n4uLtSsUEZEsZteuXQDY2try3HPPcfTo0cRtNjY2fPDBB4wZM+apz3PhwgWqVatGUFCQxbQS9evX55tvvkm8mN+3b1+CgoKYPXt2iqZ/SHDw4EGKFi1qsS4kJISqVavy0Ucf0bx58yTHrFq1it9++y1xW0xMTGJoYvXq1WzcuJFq1aoBRveNEiVKMG7cOAYNGoS9vT0AZcqUISQkhJw5c1qMvX79eurXr8+IESMsukBMnjyZhQsXUq9ePZYuXYqzs3Pitjt37iR22wD45JNPmDRpkkUXErPZTJcuXZgxYwZbtmxJDC7Ex8fTsWNHIiIiWLVqVWJ4AeDjjz/mq6++YsCAAUyfPj1F38/kHDt2DAAfH58k22xtbSlatCgHDx4kNjb2oV1SwsPDCQkJoXz58sl2WEkYP+F86UVgYCCrVq2yWOfk5MTAgQPT/NzFihWjYMGCnD17luDgYIrdN83kmDFjcHNzs1iXMCWLZE4KXoiIiIhY08mTxgWYCxdg5Upo0MDaFYnI02jRArZsMS6mVqtmhC/+e0NIRLKw/Pnho4/gww9h3z6YP9+4wPvDD2Bvb0xh0LSp8bujeHFrVyuS+cXFwfbtsHSp8Vrcvx/s7MDPz5gmqE0bTfcnIiJWdfnyZQC++eYbnn/+ef7++2/KlCnDnj17eO+99/j6668pXrw43bt3TzymZcuW+Pr64u7u/ljn+vbbby2mlahXrx6FCxdmx44dT/047g9dAHh5edGqVSsmTJjA6dOnKVy4sMX2gIAAi0CGvb09r732Gv/88w/NmjVLDF2AMeVD06ZNmTFjBufOnUs834O+BwEBAZQrV45169ZZrJ88eTK2trZ89913FqELAGdnZ4t1hQoVSjKuyWSiZ8+ezJgxg3Xr1iUGL7Zs2cKJEyd4+eWXLUIXAJ9++inTp0/n559/5rvvvkt8Dh73eQz7b0rDB+2fPXt24uPjuXXrFjly5Hiqce7dL71ILrTi7u7+TIIXAN7e3pw9e5bQ0NAkwYuvv/46yf4VK1ZU8CITU/BCRERExFo2boRXX4UcOYw5okuXtnZFIpIaKlaEv/+Gli2Ni6mzZ0Pr1tauSkTSA5MJKlUyllGjLO+yHzAAPvjA+HsgIYTxwgvGxWAReXphYbB6tfF6W7ECrl69231m6FAjAP2YF6pERETSSnx8PAAODg789ttveHt7A1CnTh1++eUXKlasyNdff20RvHB3d3/s0IWHh0ey4YgCBQqwdevWp3gEhpMnTzJq1Cj+/PNPzp8/T1RUlMX2CxcuJAleVKpUKck4Xl5ej9x24cIFi8cSFBTE2LFj2b59O6GhocTGxiZuuzdocvv2bQ4dOkSJEiWS7Rpxv+joaCZOnMi8efM4fPgwt2/ftphm4sKFC4mf79mzByDZKVnc3NyoWrUqa9as4ciRI1SoUAF4sucxK9u6dSu+vr4P3H7q1ClmzZplsc7Dw4O+ffumbWEY3V3yKcybpeh/7yIiIiLWMHOmMd977dqwcCHc1/pQRDK4fPmMVuVduhh3zR46BJ9+qmmERMRSkSLQq5ex3L4N69YZd+DPmQNjxoCHB7z8shHCeOklI6wpIil37NjdcNPGjcYUIhUqGH+HN20K1atDMq20RURErC3hwnvVqlUTQxcJypcvT7FixTh+/Dg3btzAw8Pjqc9zPzs7u8Twx5M6fvw41atX5+bNmwQEBNCsWTOyZ8+OjY0NQUFBbNiwIUkQA+52Vri/nkdti4mJSVz3yy+/0KZNG9zc3GjUqBFFihTBxcUFk8nErFmzOH36dOK+CR0c8ufPn6LH9dprr7F06VJKlixJmzZt8PT0xN7enhs3bjBu3DiLx3Tz5k0A8ubNm+xYCaGRhP2eRMJz+KBOFDdv3sRkMpEtW7anHufe/TKKU6dOMXz4cIt1hQsXTrXgRULQJk+ePKkynmRsCl6IiIiIPEtmM/zvf8Zdru++C5MmGS3GRSTzcXIyLp6WKQODB8ORI8a0Arp7XUSS4+ZmTFfUogXEx8OuXXenQZg717g4XKuWcbG4cWMoW1ZhLpH7RUbC1q2wfLnx2jlyBBwc4MUXYdw4aNIE7rurVkREJD0qVaoUwANDFQnr79y581TBi7T07bffcv36debMmcNbb71lsa1bt25s2LAhzc49bNgwnJyc2LVrV5IuFvPmzbP4OiFIcP78+UeOu2PHDpYuXUqjRo1Yvnw5tvcEOLdt28a4ceMs9k8Iily6dCnZ8S5evGix35NIeHzHjh1Lsi0uLo7g4GCKFi2aGFB5EFdXV7y8vAgODiYuLs7isd07fkq6gqQn/v7+Fh1JUtPJkyc5e/YsefLkoUiRImlyDslYbKxdgIiIiEiWMmKEEbr46iuYMkWhC5HMzmQywlYLFsAvvxgdMJ7yriERyQJsbKBaNfi//4Pdu+HsWZg8GbJnN7rnlC8PefIYIY2vvzamN7rnDj+RLCMsDFauhE8+gTp1jKlCXnwRfvrJ+Pq334wpRVauhB49FLoQEZEMIyAgAIBDhw4l2RYTE8Px48dxdXVN13fZnzhxAoDmzZtbrDebzWzZsiXNz12mTJkkIYGQkBBOnjxpsc7NzY2yZcsSHBycbHjh/nEBmjRpkiSYsGnTpiT7V65cGTCmPblfeHg4O3fuxNnZOTFo8yT8/PwAWLNmTZJtmzdvJjw8PHGflIwVHh6e7POzevVqAOrWrfvEtWY2n332GQBt2rTBpFC8kA6DF5cvX2bZsmV8+umnvPzyy+TOnRuTyYTJZKJjx46PPd7KlStp2bIlBQoUwNHRkQIFCtCyZUtWrlyZ+sWLiIiIPMykScbFkhEj4MMPdZeqSFby+utGt4sffoD+/Y3uNyIiKVWgALz3ntEB4+pVWLsWevaEmzdhyBCoUcOYlqR+fRg+HP78EyIirF21SOq7eNEIMvbpA5UrG9P1NW4M06dD3rzw5ZdGWOn8eZg2DZo3N7rJiIiIZDDFixenYcOGHD9+nMDAQIttX3zxBTdu3KBly5YWXQzCwsI4fPgwISEhz7rcZBX+L/C4efNmi/VffPEF+/fvT/NzHz9+3KLTRGRkJN27d7eYkiRBz549iYuLo0ePHty5c8diW2RkJNeuXUscF5I+pgMHDjBq1Kgk49aqVYvixYuzcuVK1q1bZ7FtxIgRXL16lTfeeAMHB4fE9Y/7PJYqVYq6deuyfv16i2uf0dHRDBkyBIAuXbpYHBMaGsrhw4cJDQ21WP/ee+8BMGTIEKKjoxPXr1y5kqCgIBo2bJj4PcjKbt++Tf/+/Zk1axZeXl588skn1i5J0ol01+P2QfMcPa74+Hjee+89pk+fbrH+/PnznD9/nt9++40uXbowZcoUbGzSXf5EREREMpuffzbmb//gA+OOPBHJet54A65fNy6W5splTD8iIvK4XFyMgEX9+sbX0dHGtCSbNhnL2LEwbJgxrVGVKsZd/3XqQO3axkVqkYzCbIaTJ+/+bG/cCMePG9uKFTN+rnv1Mj76+CjULCIimc7kyZN54YUXePfdd/ntt98oXbo0e/bs4c8//6Rw4cJ89dVXFvsvXryYTp060aFDB2bNmmWdou/RrVs3Zs6cSatWrWjdujW5cuVi27Zt7N69myZNmrB8+fI0O3fv3r3p3bs3lStX5rXXXiM2Npa1a9diNpupWLEi+/bts9i/e/fubNiwgQULFuDj48Mrr7xC9uzZOXPmDKtXr2b69Om0aNGC6tWrU716dRYsWEBISAi+vr6cOXOG33//nSZNmrBw4UKLcW1sbJg1axaNGjWicePGvP766xQuXJitW7cSFBRE8eLF+eKLLyyOeZLncfLkydSqVYsWLVrQpk0bvLy8WL58OQcOHKBXr1688MILFvtPnDiR4cOHM3ToUIYNG5a4PiAggC5duhAYGMjzzz9PkyZNCAkJYf78+eTMmZMJEyYkOfcXX3zB4cOHAdi6dWviuoTaW7RoQYsWLVL0ONKjwMBAVq1ahdls5tatWxw7dowNGzZw69YtypUrx7x58/Dy8rJ2mZJOpLvgxb0KFSpE6dKlk22P8yj/+9//EkMXlStX5uOPP6Z48eKcOHGCL7/8kj179hAYGEiePHn4/PPPU7t0ERERkbtWrIAOHYxlzBi9KSySlfXoYdytPmSIEb7o3t3aFYlIRufgADVrGsvHHxvTGR04cPdi9dy5xt8fYExRkhDE8PWFIkX0d4mkH9HRxs/uli13f35DQoyf0QoVoFEjo3NcnTrg7W3takVExIoc7HNiY+NIfHyUtUtJlo2NIw72Tx94LV68ODt37uTTTz9l1apVrFmzhnz58tGzZ08+/fRTPD09U6HatFO5cmXWrFnD4MGD+fXXX7G1teWFF15gy5Yt/P7772kavOjZsyf29vZMmDCBadOm4eHhQZMmTRg1ahSvv/56kv1NJhPz5s2jYcOGBAYG8sMPP2A2m8mfPz+tW7emSpUqANja2rJs2TIGDhzIqlWr2LFjBz4+PowZM4aXX345SfACoHbt2mzbto3/+7//Y82aNYSFheHt7c3777/P4MGDyZ0791M/3nLlyrF9+3YGDx7M8uXLCQ8Pp2TJkkyaNInuj/m+w5QpU6hQoQJTp05l3LhxuLm50bJlS0aOHEnx4sWT7L9q1So2bNhgsS5hWhKAIkWKZOjgRcK1ZltbW7Jly4a3tzevvPIKLVq0oHnz5thrGmm5h8lsTl89bocOHUq1atWoVq0aefPm5dSpUxQtWhQgxemuo0ePUq5cOWJjY6latSobN27E2dk5cXtERAR+fn7s3LkTOzs7Dh06RIkSJVJc482bN3F3dycsLIzs2bM/9mOUtBMTE8OKFSto3LixftmJZAF6zUuGsHkzNGhgvFG8cKFx96k8Mb3uJVMwm43uN+PHG3PQv/GGtStKt/SaF0kFZjOcOnX3QvamTXDkiLHN3R2eew4qVoRKlYyP5crBPe+hPEt6zWchV6/Cvn2wd+/dj4cOQUwM2NtD1apQt64RsnjhBciRw9oVSxrQa14ym4TrBleuXOHKlSsULVoUJycna5eVaUVGXiA65pq1y0iWg31OnJwUEhQRySwiIyMJDg5+5L/t6e6d/+HDhz/1GGPHjiU2NhaACRMmWIQuAFxcXJgwYQI1a9YkNjaWb7/9lkmTJj31eUVEREQsnDoFTZsad6DOm6fQhYgYTCb45htj2pH27aFwYeOikohIWjCZoGhRY2nf3lh3+bIxPUnCRe+1a2HSJCOkYWsLpUrdDWIkhDJSaWpYyWLi443pQe4PWZw/b2x3dja6WdSoAV27Gj9vzz9vtfCPiIhkHE5O3go3iIhIupLp3v03m80sWbIEgNKlS+Pr65vsfr6+vpQqVYojR46wZMkSJk6ciEntNUVERCS1xMdDp07GnaSLF4PuchGRe9nYwPTpcPSoMQ3R3r3g6mrtqkQkq/D0hJdfNpYEERGwf7/lxfHff4fbt43tefMmDWOULKlgqdx1+zb8+69lyOLffyE83Nju5WX83Lz99t2fJR8fI+wjIiIiIiKSwWW6/x0HBwdz4cIFAPz8/B66r5+fH0eOHOH8+fMWU5qIiIiIPLWJEyEoCP74wwhfiIjcz84OZs82Lj4NGmRMPSIiYi0uLlC9urEkiI+H4GDLMMa8efDll8Z2R0coVgyKF7dcihUzOmw4OlrjkUhaCguDEycsl5MnjY9nztztmlKmjPHvW6tWd0MWefJYu3oREREREZE0k+mCFwcPHkz8vHTp0g/d997thw4dUvBCREREUseRIzBgAPTuDS++aO1qJJ2KjY3l66+/TgwN369jx45Urlz5GVclz1zJkvDFF/D++9CihX5niEj6YmNzN0zRqtXd9deuwT//GMvx48ZF99WrjQvw0dHGPiYTFCiQNJCR8HmOHNZ5TPJw8fFw4YJloOLe5dq1u/u6u999PqtXN/5Nq1QJypZV6EZERERERLKcTBe8OHfuXOLnBQoUeOi+BQsWTPz87NmzaVaTiIiIZCGxsdCxIxQsaFxMFXmAsWPHMmjgQEomM71E8J07mM1mBS+yil69jCmJOnUyWrJnz27tikREHi5nTvD3N5Z7xcfD+fNJOyHs2we//grXr9/dN0cOyzBG/vzGdCb29kaYw9vb+H2oaWFTT1wcXL0Kly5ZLqdP332ugoMhMvLuMQnhmfLloXlzyyBNjhx6fkRERERERP6T6YIXt27dSvzczc3tofu63vMm9+2EOUuTERUVRVRUVOLXN2/eBCAmJoaYmJgnLVXSQMLzoedFJGvQa17SpW+/NS6crlplXDjQz2eqyiyv++PHj/P5iBF09vLm/WTabr954Ty2trYZ/nHKYwgMhJo14eOPYcIEa1eTbmSW17xIlpIvn7HUqpV0240bcOqUcXE/YTl1ChYtgosXibGzgxkziKldG+7cMbomeHoaU1TkyWN8nvD1vZ/nyWOEAGxsnvGDTQdiYiA0FK5cgcuXjeXezxO+vnLF2C8+3vJ4V1cj9FK0KLz0kvGxaFEoUsRYHta5IjY2LR+ZZAH6d14yG/0si4iIZG2ZLngReU8q38HB4aH7Ot7zn8c7d+48cL9Ro0YxfPjwJOvXrFmDi4vLE1QpaW3t2rXWLkFEniG95iVdKVUKfvrJuJtwxQprV5NpZYbX/czZswE4kcy2//vv4wr9DGUt06YZH/W8J5EZXvMicg9HRyhd2liSsXbGjJSNc+uWsZw8mYrFZXAeHsbi4/PkY8TF3e1aIvIM6N95ySwiIiKsXYKIiIhYUaYLXjg5OSV+Hp0wr+gD3NvFwtnZ+YH7DRo0iH79+iV+ffPmTQoWLEjDhg3JrjbA6UpMTAxr166lQYMG2NvbW7scEUljes1LujNkCMyaBYcPG3cPSqrLDK/7qVOn8tFHHzGlQEEqOztzIzYWBxsTLja2ifu8eeE8L771Fl9++aUVK5VnLj4efH2Ni2U//WTtatKFzPCaF5GUS/Fr3myG8PCkHR0SPg8Pv7tERFh+nbAuLu7RBTk7g62t0UkjYTGZLL9OWBcfbyxm893P713MZoiONpZHcXAw/pZ0dQUXl+Q/z579wd1AHnEjkkh6oX/nJbNJ6JQtIiIiWVOmC15ky5Yt8fOHTR8CEB4envj5w6YlcXR0tOiOkcDe3l7/KUin9NyIZC16zUu6cPMmfPcddOtm3GUoaSqjvu6Dg4MZ8NFHtHB0pKqNDeF3Imhz5gz+zs4Mzpsvcb+oO3eIi4vLkI9RnlKPHtC1K3z+OZQoYe1q0o2M+poXkSeTote8g4MxvUipUo9/ArMZoqLuBjFu37b8eO/ncXHJhyjuX2drm3wo495whoMDuLndDU8kfH7vOldXY7o6kSxE/85LZqGfYxERkawt0wUvChQokPj5uXPnHrrv2bNnEz8vWLBgmtUkIiIiWcCMGcbdk717W7sSSafMZjPvvvMO7mYz/fLkAWDclVAuREUR8bD50yVreest+N//YOxYmDjR2tWIiGROJhM4ORlLrlzWrkZEREREREQyARtrF5DaypYtm/j54cOHH7rvvdvLlCmTZjWJiIhIJhcba1wkbdMG7gmBitxr+vTp/BEUxPDceXC1sWXfnTv8dOM6JpPJ2qVJeuLsbHS9mDkTrl2zdjUiIiIiIiIiIiKSApkueFG0aFG8vb0B2LBhw0P33bhxIwD58+enSJEiaV2aiIiIZFa//gqnT0P//tauRNKpc+fO0b9vX151d6eWqyvRZjNDQ6/wfOXKVKtSxdrlSXrTo4fR2n7KFGtXIiIiIiIiIiIiIimQ6aYaMZlMNG/enO+++47Dhw+zbds2fH19k+y3bdu2xI4XzZs3152GIiIi8uS++w78/aFyZWtXIumQ2WzmvXffxSk2lo+9jIDwjGtXOREZya6ZM+nRtauVK5R0x9MT3n7b+N0ycKDREl9EREREREQS3Y6JJTIu3tplJMvJ1gY3+0x3+U1ERB4hU/7m79u3L1OnTiUuLo7evXuzceNGnJ2dE7ffuXOH3v/Nv25nZ0ffvn2tVKmIiIhkeNHRsHUrjBpl7Uoknfrpp59YuWoVE/PnJ7utLSejovj+2jU+/OgjKlasaO3yJL165RUIDDS66ag7n4iIiIiISKLbMbH8evoycWZrV5I8WxO8WthT4Ys01rFjR2bPnk1wcPATdbWfNWsWnTp1YubMmXTs2DFxfcJYp06deuS+IiL3SndTjWzevJlZs2YlLgsXLkzcdvz4cYtts2bNSnaMkiVL8tFHHwGwc+dOatWqxfz589m5cyfz58+nVq1a7Ny5E4CPPvoIHx+fNH9cIiIikknt3QtRUVCzprUrkXTo0qVLvN+rF02yZ+dFt2zEm80MvXKZQoULM3ToUGuXJ+lZQte+rVutW4eIiIiIiEg6ExkXn25DFwBxZp66G8esWbMwmUwPXerVq5dKFUtmc/ToUVq3bk3u3LlxdnamYsWKfPfdd5jNj/fCiY+PZ8KECVSoUAFnZ2fy5MnDG2+8wcmTJ5PsO2zYsEf+zHbu3Pmh50vJGPcuw4YNA4wQzsP2S+kN+EFBQZhMJrp162ax/v7x7ezsyJEjB2XLluXNN99k4cKFREdHJzumv7//Q2sbO3ZsimqTjCHdxe0CAwOZPXt2stu2bNnCli1bLNY9KFk2cuRILl++zIwZM9izZw9t27ZNsk/nzp0ZMWLEU9csIiIiWdjWreDgoGlGJFm9evSAO3f4pGAhAH4Ju8Gu8HD+nD7doiObSBJ58kCJEsbvmDfesHY1IiIiIiIi8gxVqlTpgTdsLFy4kAMHDtCoUaNnXFX6MmrUKAYOHEj+/Pmf6PiWLVvi6+uLl5dXqu5rbQcPHuSFF17gzp07tG7dGm9vb5YvX06PHj04ePAgEyZMSPFYXbt2JTAwkHLlytGnTx8uXLjAggULWLNmDdu2bbO4sd3f3/+B4wQGBnL+/PlH/swmN8bevXtZsmQJfn5+Sbbf/3Xnzp0pUKBAkjF8E25ueUoJ45vNZm7evMmxY8dYunQpP//8M2XKlGHevHk899xzyR7bv39/3Nzc0qw2SR/SXfAitdjY2DB9+nRatWrF1KlT2bFjB6GhoeTOnZtq1arRtWtXXn75ZWuXKSIiIhnd1q1QpQo4Olq7EklnFi5cyMJff+Ubb29y2NlxKSaGb65do3PnzgQEBNzd8THvNpAspGZNdbwQERERERHJgipVqkSlSpWSrI+OjmbixInY2dnRoUOHZ19YOuLl5fVUQQh3d3fc3d1TfV9r6969O2FhYaxYsSLxOuhnn31G/fr1mThxIu3ataNmCjr3rl+/nsDAQOrWrcvatWtxcHAAoF27djRu3JhevXqxevXqxP39/f2TDU5cunSJkSNHkitXLlq0aPHQcyY3xqxZs1iyZAn+/v6JHS4epEuXLmkaZEhu/Fu3bjF06FC+/fZbGjZsyO7du/H29k5y7Icffki+fPnSrDZJH9LdVCOzZs3CbDaneHmUxo0b89tvv3H+/HmioqI4f/48v/32m0IXIiIikjq2bdM0I5LE1atX6dmtGw2yZaORWzbMZjOfXbmCq4cHX3311d0dz56Ff/6xXqGSvvn6GtMZ3blj7UpEREREREQkHfjtt9+4evUqTZs2JW/evCk6JiwsjNGjR+Pn54e3tzcODg54e3vTvn17Tpw4kWT/hOkegoKCmDlzZuI0E0WLFmX8+PEAmM1mvv76a0qVKoWTkxM+Pj788MMPyZ4/NDSUvn37UrRoURwdHfH09KR169bs378/cR+z2Uzjxo0xmUzMnz/f4niz2czLL7+cZFvC9A+nTp1Kcs6NGzfSokUL8ubNi6OjIwULFuTVV19l8+bNifskTOcya9asR34PH7SvyWTC39+fS5cu0aFDh8SpPXx9fQkKCkoyzq5du+jVqxfly5fH3d0dZ2dnKlSowBdffEFMTMwj63iUo0ePsnHjRgICAiyugzo4OPDZZ58BMG3atBSNlbDfZ599lhi6AHj55Zfx9/dnzZo1nDlz5pHjzJ49m9jYWN5++22LcTKLbNmy8c0339CxY0cuXbqkmRayuHQXvBARERHJMC5dgtOnFbyQJPr26UPUzZsM9syLyWRi7e1b/HnrJhMmTyZHjhzGTmfPgr8/REZatVZJx2rWhNhY2LXL2pWIiIiIiIhIOhAYGAgYd97fLyEc0LFjR4v1hw4d4tNPP8XZ2ZmWLVvSt29fqlatys8//0z16tU5ffp0sucaO3YsH3zwAc8//zzvvfceMTExvP/++wQGBtKrVy+++uor6tSpwzvvvMPVq1fp0KEDGzdutBjjypUr+Pr6Mm7cOIoUKUK/fv148cUX+fXXX6lRo0ZiEMJkMjFz5kw8PT3p2rWrRU1jx45l1apVdOzYkTZt2jzyezRu3Dj8/f1Zu3YtDRo0oH///rz44ovs27ePhQsXPvL4x3Xjxg1q167NgQMHePvtt3n11VfZuXMnjRo1sgiXgBFmWLx4MRUqVKBr16507twZs9nMoEGDaNu2bZKxH/ScPkhC2KNhw4ZJttWuXRtXV1c2bNiQ4rFcXV2pVatWkm0JU4akZKzp06cDyf/MZiZDhgwBYMGCBSlqHCCZU6adakREREQkzV2+bHwsWNC6dUi6smzZMn78+We+yOdFHjs7bsbFMfLSJV5xcaFV9erGTgmhi5MnNU2NPFjC75YrV6xbh4iIiIiIiFjd6dOn+eOPPyhQoAAvvfRSio8rU6YMISEh5MyZ02L9+vXrqV+/PiNGjEi2C8KmTZvYvXs3xYoVA4ypEkqUKMGHH35I3rx5+ffff8mTJw8AHTp0wNfXlzFjxlC3bt3EMQYMGMCJEycYNGgQn3/+eeL6FStW0KRJEzp16sSRI0ewsbEhb968zJ49m8aNG9OuXTs2btzIv//+y8CBA/Hx8WHChAmPfKz79u2jX79+eHl5sWXLFooUKZK4zWw2ExISkuLvW0rt27ePHj16MGHCBGxsjPvdX3zxRbp06cLEiRP5/vvvE/f95JNPmDRpEra2thZ1denShRkzZrBly5Zkgw4pdezYMQB8fHySbLO1taVo0aIcPHiQ2NhY7OwefIk4PDyckJAQypcvb1FrgoTxE873IJs2beLo0aP4+vpSrly5x3koTyQwMJBVq1ZZrHNycmLgwIFpfu5ixYpRsGBBzp49S3BwcOLrJsGYMWNwc3OzWJcvXz66deuW5rXJs6PghYiIiMiTSmj/7+xs3Tok3bhx4wZdu3ShbrZsNMueHYCvr1wmymxmckQEpoAAmDMH3n7bCF0UKwbu7pBMa08RXFyMj5pqREREREREJMubOXMm8fHxdOzYMdmL4S1btsTX1xd3d3eL9fd/nSAgIIBy5cqxbt26ZLe///77FhePCxYsSO3atfnzzz8ZP358YugCoEaNGhQrVox9+/YlrouOjmbu3LnkypWLwYMHW4zduHFjGjRowNq1a9myZQt16tQB4KWXXuL9999n7NixDBw4kGXLlmE2m5k7d26Si9bJmTJlCvHx8YwYMcIidAFGVw1vb+9HjvG4XF1dGT16dGLoAowgSrdu3dixY4fFvoUKFUpyvMlkomfPnsyYMYN169ZZBC8e9Jw+SFhYGPDg5zx79uzEx8dz69atux1Zn3Cce/d7kGfd7SLhfPdyd3d/JsELAG9vb86ePUtoaGiS4MXXX3+dZP+KFSsqeJHJKHghIiIi8qQiIoyPCl7Ifz788ENuXbvGsIKFMJlM/B0Rzi9hYXw3ciT5p083whYJ/4EuVgyCguD1161as6RjTk7Gx4TfNSIiIiIiIpIlxcfHM3PmTEwmE++8806y+7i7uz/wQnlQUBBjx45l+/bthIaGEhsbm7jNwcEh2WMqVaqUZJ2Xl9dDt23fvj3x68OHDxMZGUlAQAAuCTcW3CMgIIC1a9eyd+/exOAFwBdffEFQUBBjxowBYPTo0VSpUiXZGu/3999/A8lPtZFWSpYsmSQUYmdnR968eblx44bF+ujoaCZOnMi8efM4fPgwt2/ftpiW4sKFCxb7P+w5Te9u3rzJL7/8gpubW4qmiEkNW7duxdfX94HbT506xaxZsyzWeXh40Ldv37QtDAgJCSFfvnxpfh6xLgUvRERERJ6UyWR81Lx9Aqxdu5bp06czLG8+8tnbExkfz7DQUGrVrMl7AwcaU4vc2y5yzhxNUyMPl/C7JeF3jYiIiIiIiGRJ69at48yZM9SrV4+iRYs+1rG//PILbdq0wc3NjUaNGlGkSBFcXFwwmUzMmjWL06dPJ3tcQleDeyVMT/GgbfcGOm7evAlA3rx5kx0/IcSRsF8CR0dHXn75Zfbu3YuTk9NjdUsICwvDZDIljv0sJPe9AOP7ERcXZ7HutddeY+nSpZQsWZI2bdrg6emJvb09N27cYNy4cURFRT1VLQkhjQd1orh58yYmk4ls2bI99Tj37pecefPmERERQefOnVPUreRZOHXqFMOHD7dYV7hw4VQLXiQEZ+7tBiNZi4IXIiIiIk9K0wDIf27fvs2777yDr5sbr//3n87vr17lQmwsK2fMwOb8eWN6kXu9/bbR8ULkQRJ+tyRzZ5CIiIiIiIhkHYGBgcCTTdkwbNgwnJyc2LVrFz4+Phbb5s2blyr1JSchkHDp0qVkt1+8eNFivwTbt2/nq6++IleuXFy9epXu3bszf/78FJ3Tw8MDs9lMSEgI+fPnf4rqU9+OHTtYunQpjRo1Yvny5RbTxWzbto1x48Y99TkSnt9jx44l2RYXF0dwcDBFixZNDNA8iKurK15eXgQHBxMXF5dkapuE8e//ebrX0/zMphV/f3+LDiOp6eTJk5w9e5Y8efIkmeZGsg6bR+8iIiIiIslKmGJE0wBkeQMHDuTyxYsMz+OJyWTicGQkM25cZ/CQIZR2dTW6XZw8aUwvsmWL8fHkSWN9dLS1y5f0KiF4oemMREREREREsqyrV6+yZMkScubMScuWLR/7+BMnTlCmTJkkF8lDQkI4efJkapWZROnSpXFycmLHjh1EJPPeWdB/N6PcO23JrVu3aNeuHXZ2dgQFBdGqVSsWLFjAjBkzUnTO6tWrA7BmzZqnrj+1nThxAoAmTZokCTJs2rQpVc7h5+cHJP/4N2/eTHh4eOI+KRkrPDycLVu2JNm2evVqAOrWrZvssf/++y87duygXLlyD536IzP57LPPAGjTpg0mdS7NshS8EBEREXlS3t7GxzT8T6qkf5s2bWLSpEn0zZmTgg4OxJnNfBp6hVIlSzKgXTvL0EVQELzwgvExIXxx8KCVH4GkW/+9KZP4u0ZERERERESynDlz5hAdHc1bb72Fo6PjA/cLCwvj8OHDhISEWKwvXLgwx48ft+g8ERkZSffu3YmJiUmzuh0cHHjjjTcIDQ1l1KhRFttWrVrF6tWrKVGiBLXumZa1R48enDx5kjFjxlC+fHmmTZtGwYIF6dOnD0ePHn3kObt164atrS2DBw9OMoWK2WxOnArCGgoXLgwYAYh7HThwIMn3J8GDntMHKVWqFHXr1mX9+vWsXLkycX10dDRDhgwBknagCA0N5fDhw4SGhlqsf++99wAYMmQI0ffcNLRy5UqCgoJo2LBh4mO63/Tp0wHo3LlziurOyG7fvk3//v2ZNWsWXl5efPLJJ9YuSaxIwQsRERGRJ5UzJ5QsCVu3WrsSsZKIiAjead+e511dedMjBwA/Xr/OgYgIAqdOxaFxY8vQRcGCxoEFC94NXzzl/J2SiW3dCk5OcM/dPyIiIiIiIpK1JFzEftSUDYsXL6ZMmTIMGjTIYn3v3r25efMmlStXpk+fPvTo0YMKFSqwf/9+KlasmGZ1A4wePZpixYoxYsQI6tWrxyeffEK7du1o1qwZLi4uzJw5Exsb41Lljz/+yI8//kizZs3o2bMnADly5ODHH3/kzp07tGvX7pFBkQoVKjB27FhCQkIoV64cb731Fv/73//o3LkzJUuW5Msvv0zTx/sw1atXp3r16ixYsIC6devy8ccf07ZtW6pVq0a9evWSPeZBz+nDTJ48GXd3d1q0aEH79u0ZMGAAzz//PJs2baJXr1688MILFvtPnDiRMmXKMHHiRIv1AQEBdOnShY0bN/L8888zYMAA2rdvT4sWLciZMycTJkxI9vzR0dH8+OOPODg40L59+xTXnREEBgYybNgwhg4dSr9+/WjWrBne3t588803lCtXjjVr1uDl5WXtMsWKHj6Jj4iIiIg8XM2aCl5kYStWrOD4qVMsKVIUG5OJK7GxjL9+jdy5czN15kymenvDxYtQtSoMHZp0gKpVOXb6NJ7JjL1u3Treeecdi3X+/v6Z7j+t8hBbt0KVKuDgYO1KRERERERE0g0nWxtsTRBntnYlybM1GTWmhr///pv9+/dTvXp1KlSo8ERj9OzZE3t7eyZMmMC0adPw8PCgSZMmjBo1itdffz1V6nyQPHnysH37dj777DOWLFnCpk2bEkMBQ4cOpXz58gAEBwfTs2dPvLy8kkwrUrduXQYNGsTIkSP55JNP+Oqrrx56zl69elG+fHm+/vprVq5cye3bt/H09KRGjRq0bt06zR7ro9ja2rJs2TIGDhzIqlWr2LFjBz4+PowZM4aXX36ZhQsXpsp5ypUrx/bt2xk8eDDLly8nPDyckiVLMmnSJLp37/5YY02ZMoUKFSowdepUxo0bh5ubGy1btmTkyJEUL1482WN+++03rl69SuvWrcmVK1dqPKR0IyEEZWtrS7Zs2fD29uaVV16hRYsWNG/eHHt7eytXKNZmMpvN6fSfpvTr5s2buLu7ExYWRvbs2a1djtwjJiaGFStW0LhxY/2CE8kC9JqXdGHKFOjZE8LCwNXV2tVkeuntdf/zzz/z5ptvssunJM42NlyMieF/ly8TyWP8iW2GN7Nnp/E9f1dOvhrKlshIi93ORUWRz8eHfw4cSK3yJb0rWBDatoVHvKmUmaW317yIpC295kWyFr3mJbNJuG5w5coVrly5QtGiRXFycrJ2WZnW7ZhYIuPirV1GspxsbXCz133PIiKZRWRkJMHBwY/8t12/+UVERESeRs2aEBcHO3eCn5+1qxEry2dvz/T8+Z96nB65ctPjvnUjLl3kX2Wms45z54ylZk1rVyIiIiIiIpLuuNnb4abMloiIpCOp0+tIREREJKsqVw7c3DTdiIikrm3bjI8KXoiIiIiIiIiIiKR76nghIiIi8jRsbY1OFwsWwIABYDJZuyKxgsBrV7F/iue+nls2fBwdE7/+KzycfyLvWOyz/76pRySTW7AASpcGLy9rVyIiIiIiIiIiIiKPoOCFiIiIyNPq3Rteegk2bAB/f2tXI89QyZIlKejtzaKoKHjCaUCu3bjB2egYRt5zgX3M9Wucjosjm6vr3R1dXXlF3Q+yhlOnYNEimDDB2pWIiIiIiIiIiIhICih4ISIiIvK0GjaE8uXh668VvMhiqlatypnz559qjFq+vpgPHbJYZwa6vPsu48ePf6qxJYMaNw48PKBDB2tXIiIiIiIiIiIiIilgY+0CRERERDI8kwn69YNly+DIEWtXIyIZWVgYBAZCt25wb8cTyRAiw28TevY0V8+dJUbTA4mIiIiIiIiIZBnqeCEiIiKSGtq1g0GD4Ntv4fvvrV2NiGRU06ZBVBT06mXtSuQxhBw7ws7lv3Fs2xbM5nhjpclErvwFqfNmR4o/X926BYqIiIiIiIiISJpSxwsRERGR1ODoaFwonT0brlyxdjUikhHFxMD48UaQy8vL2tVICu1e+Ts/D+7P0a2b7oYuAMxmrp47w2+j/49v2zXn798XEh8f/+CBREREREREREQkw1LwQkRERCS1dOsG9vYwYIC1KxGRjOirr+D8eejf39qVSAod3rKB9bOmPnK/+Lg4Nv00i8ld2nHjUsgzqExERERERERERJ4lBS9EREREUkvu3DB2LMycCUuXWrsaEclI9u2DYcOM4FaFCtauRlLAHB/Pxp9mPdYxUeG3+eGjXoTfuJ42RYmIiIiIiIiIiFUoeCEiIiKSmjp1giZN4N134epVa1cjIhlBdDS0bw+lS8PQodauRlLo1D97uHX18aeWiomKYs3349KgIhERERERERERsRY7axcgIiIikqmYTDBtGpQrBz17wrx51q5I0juTiT8jImh57mziquA7d6xYkDxz//d/cPAg7NgBjo7WrkZS6Nyh/cbvfLP5sY89uXcXEWE3cHH3SP3CRERERERERETkmVPwQkRERCS1eXnB5MnwxhvQsiW0aWPtiiQdG/S//7F27dok6zt27Pjsi5Fnb/t2GDUKhg+HSpWsXY08htjo6Cc/2Gzm2N9bqdjg5dQrSERERERERERErEbBCxEREZG00KYN/Por9OgBtWtD/vzWrkjSqaZNm9K0aVNrlyHWcPs2dOgAVarAwIHWrkYek0t29yfqdpEg4uaN1CtGRERERERERESsysbaBYiIiIhkSiaT0fXC1RUaNYJr16xdkYikJ1FRRkecCxdg9mywUyY+oylVs85THW/noGllREREREREREQyCwUvRERERNJK7tywZg1cugRNmhh3t4uIxMXBm2/Cpk2wdCmUKWPtiuQJeOTzolD5ik98fIEy5VKxGhERERERERERsSYFL0RERETSUunSsHIl7N8Pr75q3OUuIlmX2Qxdu8Jvv8GCBeDnZ+2K5Ck07NoHO8fH71yRs0BBvEqUSoOKRERERERERETEGhS8EBEREUlrVavC77/Dxo3w1lvG3e4ikjUNHAjTp8OMGfDKK9auRp6Su2de3v5iPE6ubo91XMDbXdKoIhERERERERERsQYFL0RERESehYAAmD8fFi+Gbt2Mu95FJGsZPRq+/BLGjoX27a1djaSSnN756TF9Li+0fguTre3DdzaZeKnHBxSpVOXZFCciIiIiIiIiIs+EnbULEBEREckymjc37nTv2BHs7WH8eLDTn2MimZ7ZDF99ZXS7GDIE3n/f2hVJKjOZTNRs1Zaardqyb91K/l78CzdDL9/dbmODT/UXqNGyNZ5FilmxUhERERERERERSQt6p19ERETkWerQAaKjoXt3OHHC6ILh4WHtqkQkrURHG11uZs6E//0Phg+3dkWSxirWf5mK9V8m+k4Et65eBSBbrlw4OLtYuTIREREREREREUkrCl6IiIiIPGvvvgvFisFrr0HNmrBsGRQvbu2qRCS1hYbCq6/C9u3www/w9tvWrkieIQdnF3IVUNhCRERERERERCQrsLF2ASIiIiJZUr16sG0bxMVB9eqwYYO1KxKR1HTwINSoAYcPw59/KnQhIiIiIiIiIiKSiSl4ISIiImItpUoZ4YtKlaBBA5gxw9oViUhqWLXK6Gbj4gJ//w21alm7IhEREREREREREUlDCl6IiIiIWFPOnMZF2k6doHNn6N8foqOtXZWIPIn4ePj2W2jSBOrUgS1boEgRa1clIiIiIiIiIiIiaUzBCxERERFrs7eH77+HsWNh/Hhj6pF9+6xdlYg8jtOnoWFD6NcPPvgAliyB7NmtXZWIiIiIiIiIiIg8AwpeiIiIiKQHJhO8/z5s327cNV+1Kvzf/0FMjLUrE5GHMZth6lQoXx6OHoXVq2HMGLC1tXZlIiIiIiIiIiIi8owoeCEiIiKSnjz/POzcCQMHGsGLGjXg33+tXZWIJOfMGWjUCLp2hbZtjddqw4bWrkpERERERERERESeMQUvRERERNIbBwf47DPYtg2io6FKFRg5EmJjrV2ZiIDR5WL6dKPLxcGDsHIlTJsG7u7WrkxERERERERERESsQMELERERkfSqalXYtQs+/BA+/RR8feGff6xdlUjWdvo0NG4MXbrAa6/B/v3w0kvWrkpERERERERERESsSMELERERkfTM0RE+/xy2boWICKhUCd55B86ds3ZlIlnL9evw8cdQqpQRgFq+HGbMAA8Pa1cmIiIiIiIiIiIiVqbghYiIiEhGUL067N0L48bB0qXg4wOffAJhYdauTCRzi4yEr7+G4sVh0iQYOBAOHza6XoiIiIiIiIiIiIig4IWIiIhIxuHgAL17w4kT0L8/jB1rXAweNw6io61dnUjmEh8PP/0EpUvDgAHQujUcPw7DhkG2bNauTkRERERERERERNIRBS9EREREMprs2WHECDh2DFq2hH79oEwZmD/fuFgsIk9n3TqoWhXeegsqV4b9++H778HLy9qViYiIiIiIiIiISDqk4IWIiIhIRpU/P0ybBv/8A2XLQtu2UKMGrFwJZrO1qxPJeLZtg5deggYNwMkJNm+GxYuNrhciIiIiIiIiIiIiD6DghYiIiEhGV64cLF0KQUFgZweNG0PFivDjjxATY+3qRNK3+HhYtgzq1oWaNeHUKVi0CLZsgVq1rF2diIiIiIiIiIiIZAAKXoiIiIhkFn5+8NdfRgCjYEF4+20oXhzGjoVbt6xdnUj6EhUFs2fDc89Bs2YQGwu//QYHD8Krr4LJZO0KRUREREREREREJINQ8EJEREQkMzGZjADG8uXGFCQBAfDRR1CgAHzwAZw4Ye0KRazr4kUYNgwKF4aOHaFYMdi0yQgtNW8ONvovkoiIiIiIiIiIiDwevasoIiIikllVqGDc0R8cDL16wZw54ONj3N2/bp0xxYJIVmA2w44dRheYQoVgzBho1QoOHYLff4fata1doYiIiIiIiIiIiGRgCl6IiIiIZHYFCsDIkXD2LEybBqdPQ4MGUKIEfPopHDtm7QpF0saFC0bIomJFqF4dNm+GUaPg3DmYNAlKl7Z2hSIiIiIiIiIiIpIJKHghIiIiklU4O0PnzrBvH2zYAC++CGPHQsmS8MIL8P33cO2atasUeTrh4fDTT9CoERQsCIMHQ5kysHQpHD8O/fuDh4e1qxQREREREREREZFMRMELERERkazGZIK6dSEwEC5dgrlzIUcOYzoSLy9jCoYlSyA62tqViqRMfDz8+Sd07Aj58sFbb8GdO0aY6OJFmD8fmjYFW1trVyoiIiIiIiIiIiKZkJ21CxARERERK3J2hrZtjeXiRSOE8cMP0KIF5MoFb7xhXMSuVg1slNmVdMRshoMHje4WP/5oTKVTvDh89JHxM1usmLUrFBERERERERERkSxCwQsRERERMeTLBx98YCz//gtz5hgXtCdONDphNGlidA2oXx9cXa1drWRF0dGwcaMxbciyZXDypDFtSNu20L49+PoaHV1EREREREREREREniEFL0REREQkqQoV4MsvYdQo2LTJuMi9bJkxPYmjI7z4ohHCaNoUChWydrWSmV2+DCtXGmGLNWvg1i0oUACaNTPCQPXrGz+TIiIiIiLpQExMGDEx17CxccTRMS8mk6a7ExEREckKFLwQERERkQeztQV/f2MZMwaOHbsbwnj/fejZE557zghgNGtmTEliqzcW5SmYzUbHlYSfs23bjPXVq8OAAcbP2nPPqbOFiIiIiKQbZrOZq9c2cO7sD1y9thEwA+DokJcCBd4mf/622NvnsG6RIiIiIpKmFLwQERERkZTz8bk7HUlYGKxebVwcnzIFPv8c8uSBevWgTh1jKVcObGysXbWkZ2YzHD9udFbZtAn+/BPOnAE3N2jYEGbMgJdfhrx5rV2piIiIiEgSZnM8R44M5fyFnwFbEkIXAFHRlzhx8htOn5lBrpy1uBG2g7jYcOzss+OZ5yXy52+Hi0sRwsOPc+vWQczmWJycvPHwqI7JpP9HiYiIiGQkCl6IiIiIyJNxd4fWrY0lLs7oTLBsGWzYAAsXQmws5MgBtWrdDWJUqQIODtauXKwpLs7oaJEQtNi0CS5eNDpYVKwILVsaU4jUraspREREREQk3Ttx8uv/QhcAccnsEU9s7DUuXV6auCY27hZnzs7izNnpODrmIyrqosURjo7eFCrYiYIFO2iqEhEREZEMQsELEREREXl6trZGwKJWLePriAjYvv3uhfX/+z8IDwdnZ6hRwwhh1K0Lvr5GZwPJvKKiYMeOuz8LW7bAzZtGAKd6dejUyfh5eOEFI8wjIiIiIpJBREWHcubMtCc82ghp3B+6MNZd4NjxkVy/sY0K5SdhY2P/FFWKiIiIyLOg4IWIiIiIpD4XFwgIMBaAmBjYu/fuxffvvoPPPjMCG+XLQ6VKRreDhCVXLmtWL0/q1i345x/Yt894vvftM5aoKMiWzQhXfPyxEbqpVg2cnKxdsYiIiIjIE7twYT5ms/nROz6h0NA/OX7iS0r6/C/NziEiIiIiqUPBCxERERFJe/b2xoX2atWgXz8wm+HwYSOEsWuXcZF+wQK4c8fYv0AByzBGpUpQvLgVH4BYMJvhzJm7wYqEkMWJE8Z2e3soW9Z43t58E2rXNp5HW7VJFhEREZHM4/q1rUB8Gp7BzLlzP1K0SG/s7bOn4XlERERE5GkpeCEiIiIiz57JBGXKGEuCuDg4dszyQv6MGRASYmx3dYUqVYzgxsSJUKyYEcYoVszosCGpLyoKTp0yAhUnThjPT0JHixs3jH1y5TJCFc2b3w3JlC5tTCUiIiIiIpKJxcVHpPk5zOYYLl78lYIFO6b5uURERETkySl4ISIiIiLpg62tccG+dGlo0+bu+itX7oYxDhww1o0cCVev3t3Hy+tuEOPepVgxyJPHCHpI8q5fN0IVJ0/eDVgkLOfOGd0twAhSFC0Kzz0HH354tyNJ/vz6/oqIPKHQ21Es2HmW+TvOcjEsEntbE+Xzu9OhZhHql82Lva2NtUsUEZGHcHDIDdiQll0vTCZbbt8+kmbji4iIiEjqUPBCRERERNK3PHmgfn1jiYmBFSvgwgUjeHF/WODYMVi1Ci5fvnu8m5sRwsifH/LmBU9P4+P9S65cYJNJLnCZzUag4tKlu8vly5ZfX7hgfP+uX797XI4cdwMrNWtahli8vTVViIhIKlq1P4Q+8/YSGxdP/H8Zt6hY2H7yGttOXiOPmwM9A0rQqkoBsjnZW7dYERFJVl7PpoSG/pGm5zCbzcSbY9L0HCIiIiLy9BS8EBEREZGMx2Qyulx4eUGtWkm337plhAruDWaEhMChQxAUZAQPIu5rC2xjY4Q87g1j5M5tBDfc3IypThI+3vv5/evsn/LiWGwshIcby+3blh8ftC401DJgcfmyEVK5l6Pj3cfl6QmVK0OrVneDFsWLG8ELERFJc+uPXKb7T7vBDOb7tiV8feV2NMOWHmTY0oM8X8iDUa9WoFS+7M+6VBEReQhPz5c4euz/iIm5QdLf6KnH2algmo0tIiIiIqlDwQsRERERyXyyZTOmwahY8cH73L794G4Qly7BqVOwc6dl4CE6+tHntrcHJycjyHH/YjIZS3x88kt0NERFPfocdnaWgY9cuYxARfXqD+7okT27pgQREUkH4uLNDFr0T7KhiwfZfeYGL43bxLS3q1C/bL40rU9ERFLOxsaBcmW/Zu++Lv+tSYvwRTxeXq3SYFwRERERSU0KXoiIiIhI1pTQyaJ48ZQfk9CN4mGdKMLDITLSmO7jQQELW9vkgxkODinrrOHgkHbfFxERSVNBRy5z8WYKQnb3MZvhvTm7WN/fn8K5XdOgMhEReRK5cvlR8bmp7D/Ql7i426k8ui25c/nh7FwglccVERERkdSm4IWIiIiISErZ2YG7u7GIiIg8gbUHL2FnYyI2/vHvio43w7ClB5jZqXoaVCYiIk8qd+4A6tTeRkjIYo4e+wyzOQWd8h7JFmfn/JQp80UqjCUiIiIiac3G2gWIiIiIiIiIiGQVNyNjiDM/eSv6DUevEBUbl4oViYhIarC1daZAgXbUqL4Me/tcmEy2D93fw6MGefM2x8bGGQCTyQ6TyQ7jLXsTeXK/SNUqi3BwyJX2xYuIiIjIU1PHCxERERERERGRZ8TN0Q4bk+mJwxfxZjhx+TZlvdV9SUQkPXJ1LU71aksIPjWRixd/JT7+bvcLGxtH8no2pWjR93F2zg9AXFwEFy8t5fatQ8SbY3By8sYrX0ucnLyt9RBERERE5AkoeCEiIiIiIiIi8owElPJkwc5zTzXG7ajYVKpGRETSgpOTF2VKj8SnxECuX99KbOwt7OyykSNHTczmOG7dPkRExHEcHPPi5lqK/N5trF2yiIiIiDwlBS9ERERERERERJ6R+mXzksvVgavh0Y/e+QG83J1TsSIREUkrdnbZyJOnIQC3w49x5Oj/cenS75jNdwN0Li7F8PRsjGeeRjg7F8LOzs1a5YqIiIjIU7CxdgEiIiIiIiIiIlmFva0N/9e8/BMfn9vNgYI5XVKxIhERSWtXr25ix47mXLq4xCJ0ARARcZJTpyby945mbNhYlYOHBnL79hErVSoiIiIiT0rBCxERERERERGRZ6jJc158+dpz2JpMmB7z2HfrFEuTmkREJG2Ehx/nn3+7Eh8fjZm4R+wdQ0jIL2z/uwmnz0x/JvWJiIiISOpQ8EJERERERERE5BlrXbUgQR/5082/OE52KXt7pqxXNgUvREQymNNnpv/X5cL8GEeZOX78czZtrsmNGzvTqjQRERERSUUKXoiIiIiIiIiIWEHBnC4MeKk0h0e8zAf1fR7a/aJGsZws6VUbG5vH7ZEhIiLWEht7i4sXf8NsflSni+RFR19m1+62XL6yNpUrExEREZHUpuCFiIiIiIiIiIiVvV+/JPuHN6JL7aLky+6Em6MdOV3sqVfGkz/6+zH/vZrY2+ptHBGRjOR2+FHM5uinHMXMv//2IDr6aqrUJCIiIiJpw87aBYiIiIiIiIiICLg62jG4aVkGNy1r7VJERCQVmONjUmmkeI4fH03Zsl+m0ngiIiIiktp0q4SIiIiIiIiIiIiISCpzdMybamNdurws1cYSERERkdSn4IWIiIiIiIiIiIiISCpzcSlKtmwVSI234ePjozCbzU9flIiIiIikCQUvRERE5JmKuBlGyLEjXDh6mPAb161djoiIiIiIiEiaKVSwExCfSqMpeCEiIiKSXtlZuwAREasIOwfHVsDNsxAfBza24F4YSjaBbF7Wrk4kUwo5doSdyxdzbPtfmOP/e9PJZCJfMR98atSkTJ0AsuXMbd0iRURERERERFJR3ryvcPXaRi5e/O0pR7LFZNJ9lCIiIiLplYIXIpK1xMfD7kC4EXzf+li4fgK2j4dcPlCxI9joP7MiqeWfP1azdtpETCabu6ELALOZiyeOcvHEUTb9PJviVWtQvfnreJcsbb1iRURERERERO53+zZcugSXL8OtW8bX4eHG8pDPTeHhlA0Px+f6TeLu3MBkBsxmiAeTGUzx/31tBmzAbDL999Hya1zcILcvuLoai5tb0s+TW5czJ+TNC7lzg62tVb+FIiIiIpmZghcikrXs+h7Czj58n6vHYM8MqNLl2dQkkskF79nJ2qkTADCb4x6674ldf3Ny9w5e7tWfMrX8nkV5IiIiIiIikhWZzRAWZoQpHrRcvnz384iI5MexsUk+8JDwuacnJldXHFxfJM7OzK2II0RGnedO9AXiibkbsgAwW4YxjI9gijPjneMViLK7G+oICUk+7BEZ+eA6c+c2QhiPWvLkAXv7NPimi4iIiGReCl6ISNZx6d9Hhy4SXD8BV49CrpJpW5NIOnDx+FH2rVvJlTOnMMfHkyt/QSrUa0SBMuUxmUyPHuARNs+fg8lkwmxOwVy0ZjNms5kVE8bgks2dws9Veurzi4iIiIiISBYVGQnBwXDyJJw4cXc5edJYf39Iwd7eMoBQpgz4+Vmu8/SE7NnvBiwcHSGF/3e2BTz++9xsNnPw0AAuXlz0yOOKFumDQ7H3U/aY4+IsAxlXryYfKjlzBnbsMMIlN24kHcfLC4oVg+LFLZdixYxgRiq8XyAiIiKSmSh4ISJZx8l1j7f/8dUKXkimFn7jOr9/M4oLRw5isrk7BciV08Ec2hxE7kJFaPHRYNw98z3xOS6eOMbl4BOPf6DZzMKRQyhdqy7PN34FrxKlnrgGERERERERycTCwuDoUctQRcLn588bnS3ACEgUK2YsDRoYH728LEMVHh7PLFBgMpkoV/ZLsmUrw/HjozGbY5LZx54SJQZSqGDHlA9sa2sEQ7JnN7728Xn0MVFRlt09Ll2C06eN7+HRo7BqlbE9gZubZRAj4fMSJaBwYU3fKyIiIlmSghciknWEX370Pve6dSFt6hBJByJv32be0I8Ju3wJIDF0ce/noWdP88OAPrzUvS8lqvpieoI3Ti4cPWy8aZWSbhdJmDmydROHt2zgxU5dqfxSsycYQ0RERERERDIFs9noUrFvH+zda3zctw9Onbq7T86cd0MAtWtbhgK8vdNlIKBQwU4UyN+BCxfmEXJxEXGxt7G1cyNfvpYUyP9mqnSifCRHRyhY0Fge5Natu6GWe8Mtv/5qhDTi/pta1M0NKlSASpWgYkXjY/nyRncQERERkUxMwQsRyRriY61dgUi6snneD4RdvmQRuEjCbCY6IoLfv/6c7Lk9qfxyMyq/1Axbu5T/+RAXG5PyaUaSK+G/+v6cOQUXdw9K1azzROOIiIiIiIhIBnLnDuzfbxmy+OcfuHnT2J4nj3FB/7XXjI9lyhghCw8P69X8FGxsbChQoB0FCrSzdikPli2bEaSoWDHptthYY+qSY8eM52nfPti4EaZONQIZJpPReSMhjJEQyPD21pQlIiIikmkoeCEiWYPJ1toViKQbURER7A9a9/DQxX1uhl5mw48zOLp9C3kKFeXEzm1E34nA3smZEtV8qdigMZ5FiiU5ztUjx2Od52E2/jSTkjVqPVHnDREREREREUmn4uPhwAHYtAk2b4bdu+HIEWO9jQ2ULGlcpG/S5O6F+3z5dME+PbGzuzuNS6NGd9dHRhrPbUJ3kr17YfVqY3oYgFy5jOe0Rg2oUwdeeOHuFCkiIiIiGYyCFyKSNZhMYOcCsREpP8YhW9rVI2JFJ3f/TVxM9OMfaDYTcvQwIUcPJ66KiYrinz/W8M+6VZQPaECDd3thY3s36FS8Sg3s7B2IfZLz3efmlcuc/ncvRSo+/9RjiYiIiIiIiJXExBjhii1bjClAihWDCxeMi/fPPw8vvggffGBckC9XDlxcrF2xPCknJ6hSxVgSmM3G1CQJYYw9e2DaNPj8cyNoU6mSEcJIWDw9rVa+iIiIyONQ8EJEso6CvhD8Z8r3L6wpDSRzigi7gcnGJtU6UWA2xtm/fi0Xjh7mlX6DyFWgEACOLi6UC2jAP+tWPvX5bGxtOXdov4IXIiIiIiIiGUl4OGzbZnS02LTJ+DwiAnLmhBkzoGtXqFULfH3B1dXa1UpaM5mgSBFjad7cWGc2w9Gjd39GliyBceOMbSVL3g1h1K1rHKduJyIiIpIOZdpe3SaTKUWLv7+/tUsVkWelaADYOqZsXzsXKFgrbesRsRI7B4fUC13c59r5s8z+qDdHt21OXFfnjfbk8MqfKlOExEZHPfUYIiIiIiIikobi441wxeDBRpjCwwPq14fx441gxbBhsHUrnDlj7D9oENSrp9BFVmYyQalS0KULzJ4NwcFw9iz8/LPxs7F9O3TsaHRHKVgQ3nwTfvoJrl2zduUiIiIiidTxQkSyDhs78H0fto2FuIdMe2DnZOyXCheJRdKj/KXKpun45vg4lo37ktezu1OwbAUcXVxpO3w0y8d9yel/9z75uGYzztk9Uq1OERERERERSSU3b8LatbBsGSxfDleuGB0tGjaEDh2MbgVly1q+1xITY716Jf0rUADeeMNYwAhZbNlidMT44w8jlGFjY3RLadoUmjWD0qXVDUNERESsJtMHL7p3706PHj0euN1VSWqRrMU5B9QZBEdXwsU9EH/Pf/JtHcCrMpRoDHYO1qtRJI3lLlQE71JlCDl6GLPZnDYnMZvZPPcH3vjsKwCcs2XntcEjCD1zip3LFnN8xzaiIsIfb8j4eErV1BRAIiIiIiIi6cLJk0bQYtkyCAoyghTlysE77xgXwn19wS7Tv/0sz0rOnEa4olkz4+vz52HFCuPnb9gwGDDA6IjRtKmx+PmBg97fExERkWcn0//l6+npSfny5a1dhoikJ3ZOULalsYRfgahb4OQOLrmsXZnIM1O7zdv8MmKwMY9qGjCbzVw4eoj/Z++u46Sq9z+Ov2YTdunubhBUEEFAsLCxu7v72te86tV7jZ/d126vBSYWFxBEFBAVpbsbFtic3x9fYUF62eVsvJ6Px3nM7MSZz7Azy8w57/P5LJg+lZqNmqy7vEajJhx08VUALJw+lU8ff5D5UydvdX2xhAQa77IrVWrXKZJ6JUmSJElbkZsbRoT07x92dv/2W9ix3acPPPBA2NndtGnUVaqsqF8fzjsvLKtXwzffhNfl+++HsTYVK4aOK4cdBoccArVqRV2xJEkq5eyjL6lsS68J1ZoZulCZ07B9Rw659BpiCQnEEhKL5kFiMWb8+vNmr67RqAnH3XIPVevWJ7aF0T6xhARS0yuw/7mb72AlSZIkSSoiv/wC110HjRqFoRED+gAAtEhJREFUkSEvvgh77gnvvQcLF8Lnn8Nllxm6UHTKlw/hiieegGnTYPTo0AFj1qzQgaVePTj0UHjrrRDSkCRJKgIGLyRJKqPa9OjN6fc9Qoc++5OQWPjhi1gsgZysrC3eplyFCpx4x33Ubdkm3Ge9AMba81Xq1OXkf/ybyrXsdiFJkiRJO8W8efDQQ7D77rDLLvCf/8DRR8N338GcOeHno44KXQWk4iQWg06d4OabQ4eWuXPhscdg6VI48USoUwfOPRf+9z/Iy4u6WkmSVIqU+lEjkiRp82o0akLfCy6j92lnM/CZx/hj2OBCW3c8L5fylSpt9XZplatw4h33MXfieMZ8+SkLpk4hHs+jar367LLvgTTu0GmLHTEkSZIkSYVg9Wr46CN4+eXQxSIxEQ4/HG6/HQ46KIwVkUqaWrXgwgvDMmECvPoqvPIKPP88NGkCp54Kp50GrVpFXakkSSrhSn3w4p133uHtt99m6tSpJCYmUqdOHfbaay/OPPNM9tlnn6jLkySpWEhNS+fQK66jRqMmjPjgbbIzM/8cQRIHYsTzcrd7nQmJibTo0m2bbhuLxajbsjV1W7be7seRJEmSJBVQXh4MGRLCFu+8A8uXw157weOPw/HHQ9WqUVcoFZ6WLeGOO0KYaOjQ8Lp/9FG46y7o1g1OPx1OOAGqVSuUh4vH44WyHkmSFK1t/T+91Acvfvvttw1+njhxIhMnTuTll1/myCOP5MUXX6Ry5cpbXEdmZiaZmZnrfl6+fDkA2dnZZGdnF37RKrC1vw9/L1LZ4Hu+8HU+/Gh26XsIE4YNYc6k8eRm55BepSotu3Zn1OcfM+H7odu0nlhCAq279ySpXHl/PypUvu+lssX3vFS2+J6XdqKVK+G11+Dpp2HSJGjcGK6+OoxiaNYs/3ZF+H70Pa9I7blnWB54AD79FN58E667Dm68EY49Fi66CDp23K5Vrn0tJyYmEovFyMjIoHz58kVRvSRJ2okyMjKIxWIkJydv8XaxeCmNXaanp9OvXz/2228/2rRpQ4UKFViwYAGDBg3iqaeeYtGiRQD07t2bgQMHbvEf6vbbb+eOO+7Y6PLXX3+dtLS0InsOkiRJkiRJkiSp+Fu1ahUnn3wyy5YtIyMjg6VLl1KpUiUqVapEUlISsVgs6hIlSdI2isfj5OTksHz5cpYvX06VKlWoW7fuFu9TaoMXS5cupUqVKpu8bt68eRx88MGMGjUKgIcffpjLL798s+vaVMeLhg0bsnDhQiptw+x67TzZ2dkMHDiQAw44YKupI0kln+/5aCybN4/+/3cvS+bMIpaQQDwvD4CEhETy8nKp3rARh195PRWr14y4UpVGvu+lssX3vFS2+J6XitCwYfDII+HI/qpV4ayz4NxzoV69yEryPa9iKycHPvkEnnwSvvsOGjaECy+EM8+EChU2e7fly5dTo0YNli1bRsWKFVm2bBnz588nN3f7x7dKkqTiITExkVq1alG5cuWthihL7aiRzYUuAGrXrs27775LmzZtyM7O5tFHH91i8CI1NZXU1NSNLk9OTvZLQTHl70YqW3zP71w1GjTgzH89wrSxo/n5y89YNGs6EKNGw8Z0OuAQGrbfxaM4VOR830tli+95qWzxPS8Vkrw86N8f/vWvsPO4bdsQvjj5ZChG4w98z6vYSU6GY44Jy6hR8H//F8aQ3HknXHwxXH451K69ibvlv45jsRhVqlShcuXK5ObmkpOTsxOfgCRJKgxJSUnrRoht0+2LuJ5iq1mzZhxwwAF88sknTJw4kdmzZ1MvwoS3JEklSSwhgSaddqdJp92jLkWSJEmStL7cXHjlFbjvPvj9d+jZEz76CA49FBISoq5OKll22w1eegnuuisEMB55BB54IHS/uPFGaNx4i3ePxWIkJSWRlFRmd8VIklRmlOlP2u3atVt3ftasWRFWIkmSJEmSJEk7IB6Hjz+GTp3CKJFWrWDoUBg8GA4/3NCFtCMaNgyBi+nT4bbb4P33w3vs2mthyZKoq5MkScVAmf60bRt0SZIkSZIkSSXeDz/APvvAYYdBzZowYgR8+CHstVfUlUmlS9WqodPFpElw003w5JPQrBncfz+sWRN1dZIkKUJlOnjx22+/rTvvmBFJkiRJkiRJJcqkSXDiidC1KyxcGDpefP017LFH1JVJpVuFCqHzxcSJcNJJcMMN0Llz1FVJkqQIldngxZQpUxg4cCAAzZs3p379+hFXJEmSJEmSJEnbYOFCuOIKaNsWhgyB55+HMWPgkEPALr/SzlOnDjzxBPz6K+y2W9TVSJKkCJXK4EX//v3JycnZ7PXz5s3jmGOOISsrC4CLL754Z5UmSZIkSZIkSQWTlQX33gvNm8OLL8Idd8D48XD22ZCYGHV1UtnVujW8+mrUVUiSpAglRV1AUbjsssvIzs7mmGOOoXv37jRp0oTy5cuzcOFCvv32W55++mkWLlwIQM+ePbnkkksirliSJEmSJEmStmDMGDjzTBg7Fi65BG65BWrUiLoqSZIkSZTS4AXA7NmzefTRR3n00Uc3e5tjjjmG5557jtTU1J1YmSRJkiRJkiRto+zs0OXizjvDaJERI2D33aOuSpIkSdJ6SmXw4qWXXmLQoEEMGzaMyZMns3DhQpYvX06FChVo2LAhe+21F2eccQbdu3ePulRJkiRJkiRJ2rSxY0OXizFj4IYbQpcLDyKTJEmSip1SGbzo3bs3vXv3jroMSZIkSZIkSdp+OTlw331wxx3QqhUMHw5dukRdlSRJkqTNKJXBC0mSJEmSJEkqkX79NXS5+OknuP56uO02u1xIkiRJxZzBC0mSJEmSJEkqDt56K4QumjaFYcOga9eoK5IkSZK0DRKiLkCSJEmSJEmSyrR4HG6/HU48EY45JnS7MHQhSZIklRh2vJAkSZIkSZKkqKxeDWedFbpd3H033HgjxGJRVyVJkiRpOxi8kCRJkiRJkqQozJkDRxwBv/wC774bul1IkiRJKnEMXkiSJEmSJEnSzjZqFBx+eBgzMmQI7L571BVJkiRJKiCDF5IkSZIkSTsiNxcyMvKXlSshKyvsTM3L23gBSEjYcInFwmlyMlSoAOnp+UuSm2+kUuejj+Ckk6BdO/jwQ6hXL+qKJEmSJO0Av7lLkiRJkqSyLScHFiyAefM2XObPhyVL8sMU6wcr1j+/Zk3R1peaGgIY6wcy/nq+cmWoXXvjpWZNSEkp2vokbZ/PP4djjw3dLl55BdLSoq5IkiRJ0g4yeCFJkiRJkkqn3FyYMQMmT4Zp02Du3I2DFfPmwaJFoTvF+ipVglq1oFq1/JBD7dpbDj+s36UiNXXjrhZrF9h8N4zMzI27Z2zp/KJF4bktXRqey9KlG/87VK266VBG7drQqBE0bx5Ok5OL+jciadgwOPpo6NsX3nzT950kSZJUShi8kCRJkiRJJdeqVSFYMXkyTJq04TJ1KmRn59+2WrUQplgbOujQYdNhhFq1oHz5yJ7SDsnMzA+UbCpkMm8e/PrrxoGTxMT8EMZfl2bNoGLFaJ+XVBr88gsceijsvju8/bahC0mSJKkUMXghSZIkSZKKt3gc5syBMWNg9Gj444/8cMWcOfm3K18+hASaN4fDDssPDTRvDo0bhy4UpV1qKjRsGJatyc4OHUHW/luuDa8MHw6vvRa6aqxVs2Z+EKN1a+jUKSyNGkEsVnTPRyotJk8OXS4aN4b+/R0vIkmSJJUyBi8kSZIkSVLxkZ0Nv/+eH7IYMyYsCxaE6ytVgnbtQgBgn3027MxQp44hgO2RnByCKc2awQEHbHhdPB7+zTfVSeTTT2Hx4nC7KlXyQxi77hpO27cvGyEXaVvNmRPeY+np8Nln4X0jSZIkqVQxeCFJkiRJkqKxYgX8+OOGAYtff4WsrHB906ZhR/7FF+fv1G/SxHDFzhCLhZErtWpBt24bXhePw6xZG4ZjPvsMHn00XJeUBG3abBjG6Nw5jHqRypoVK+DAA8MYoCFDwjgjSZIkSaWOwQtJkiRJkrRzzJ8PgwfnL6NHQ15e6I6wyy6w++5w9tlhR33HjlC5ctQVa1NiMWjQICyHHpp/+cqV8MsvGwZpPvgAMjLC9R06QK9e+UuDBoVW0ozFq3j3x5lMW5RBTl6cBlXLc8IeDWlao0KhPYZUIH/7W+gc8/33ITgmSZIkqVQyeCFJkiRJkgpfPA5Tp4aAxf/+F07Hjw/XNWkSdrxfeCHstRe0bh26JKhkq1AhdMdYv0NGXh5MnAjDh4fXwFdfwZNPhuvWvg7WLs2abfdDLluVzXX/HcMXv86DWHjZrfXUoMnUqJDC3w9tx+Gd6pGYYKcU7WSffQbPPANPPRVG8EiSJEkqtdyqIUmSJEmSdlw8Dr//Dt98k9/RYtascF2HDrDffnD77YXe6UDFXEICtGoVltNPD5fNmxdGLqx9nbz2WghoNGwYxpU8/jj07h3GlGxhrMyy1dkc89R3TFmQQRwgvvFtFq7M4sq3RvPo1xO4av9W7N+uNuWSE4vimUobWrIEzjkH+vaF88+PuhpJkiRJRczghSRJkiRJKpjMzNDNYsCAsEyeHDpXdO4MJ58cQhY9ekC1alFXquKkdm045piwACxfDsOGwdCh4ec77oClS6FePTjssLDstx+kpW2wmjs++pUpCzLIjW8icfEXkxZkcOkbo6hULolTuzXmsn1bUj7FAIaK0OWXhzE7zz+/xQCRtFZ2djZjx47lhx9+YMaMGWRkZFCuXDkqV65Ms2bNaNu2Le3atSMx0b9dkiRJxZHBC0mSJEmStO3mz4dPPoH+/eGLL2DlytCpYO0O8t69IT096ipVklSqBAceCPvuG15bM2eG0SQffxxeZ888A+XKhfDFYYfBoYeysGotPhoze5tCF+tbviaHpwZNYsjEhbx+XjcqpLppTEXgvffg1Vfh5Zft8KMtisfjDB48mPvuu48vv/ySrKwsEhISqFohnZSkRHJy81iVmUXGmjUAVKpYkb333pujjj6aI488kmoGGyVJkooNv11KkiRJkqTNi8fh559DR4v+/WHEiHD5nnvCDTeEHeEdO3pEtwpPSkoIWey3HzzwAIwfn99V5dJL4aKLiLVsxxU1d+Gr5l0ZU7cl8VjCNq8+Lw6/zFrG394Zw1Ondi7CJ6IyacECuOACOPJIOPXUqKtRMTZq1CguuuhCvv9+BPWqVuagts1pVL0K9apUJiVpw64WqzKzmL1sBVMXLua3H4bz8Sef8PxzzzH0u+8iql6SJEl/ZfBCkiRJkiRtbMyYcLT2O+/AjBlQoULoSnDhhXDIIVCrVtQVqiyIxaB167Bccw0sWQKff86cp1/jtOEfc9l3b7EgrQqft+rOex325ad6bbYpBJQXh89/mcu0RRk0rm6HFhWiBx4IY5ieespAmjbrtdde45xzzqFGennO7tmFtnVrEdvC6yUtNYUWtarTolZ19m/Xkvd++oWlS5fuvIIlSZK0VQYvJEmSJElSMHs2vP56CFyMHQs1a8Lxx8MRR8Dee0NqatQVqqyrWhVOPJGPq+zKf76dQMcZv7H/xBEcPu5/nDr6U6ZUrct77ffl/fb7MLNKnS2uKiEhxhsjZnDDwW12UvEq9VauhKefhvPPh9q1o65GxdQtt9zCXXfdRZcmDThm9w4kr9fdIic3jz/mLWBJxipWrskiFouRlpJMrUoVqFelEhXLhf+HEzDUI0mSVNwYvJAkSZIkqSxbtQo++CCELQYOhORk6NcP7rkndLhITo66QmkjHepVJpMEfmjYgR8aduC+3mew54xfOOaXr7nw+/9yzZDX+L5Be97rsC+ftOnJitSNu1rk5sX5Y+7yCKpXqfXCC7BiBVx+edSVqJh6/PHHueuuuzh4l9bs26b5ui4XGZlZDJ80nWFTZrA0YxUpyclUr16NeByWLF1KZmYmAA2qV6Vt7RosX7MGkstH+VQkSZL0FwYvJEmSJEkqa/LyYNAgeOWVMEpk5Uro2TO0xj/uOKhSJeoKpS06oF1tqqWlsHhVFgB5CYkMa9yJYY07ccsBF3HghGEc/cvX3PP549zx5dMMbLEn73XYl8FNdiMnMX9zWG5efJPrn7d8DU8PmkT/n+eQkZlDalICuzaswk2HtKVl7Yo75TmqhMnNhf/7v/A3tFGjqKtRMTRy5EiuvOIKerVswn5tWwAQj8cZ+NtEvh0/GWIJnHbaaVx55ZW0b99+XSgjLy+PqVOnMnz4cD4eMICPPvqIlRkZtG9XNcqnI0mSpL8weCFJkiRJUlmxYAE8+2xohT99OjRvDtdeC6eeCs2aRV2dtM1SkhK4ZN8W/GPAbxtdtzqlHB+034cP2u9D7RULOeK3QRz9y9e88O4dLEirwtsdD+CV3Q5lQZWaNK6+YSeMeDzOvz77gycHTdrg8lVZuXzzxwK++WMBnRtV4fXzupGanIi0zkcfweTJ8NZbUVeiYigej3PeuedSt0olDu3Ydt1lH//8O9/+MZnrrruOa665hlq1am1034SEBJo1a0azZs04+eSTWblyJa+//jrVqlXb2U9DkiRJW2DwQpIkSZKk0m7MGHjkEXjtNYjF4JRT4OyzoXv38LNUAp3downTF2Xw0rBpm73NvIo1eGbPY3im69G0mz+F48YO5LSfPuaC7//LZ6170K7rzRBvv+59cPfH43huyJQtPu6P05fS+a4vOXq3+vRsWYN929QiKTGhUJ+bSqAHHoBevaBLl6grUTH0wQcfMHrMGC7q023d34tfZs3j2z8m89BDD3HllVdu87oqVKjA+eefX0SVSpIkqaD8VihJkiRJUmmUlwf9+0OfPrDrrvDFF3D77TBzJjz3HOy1l6ELlWixWIzb+7XnoeM7UaNCytZuzG+1m3HH/hfQ/eIXuWv/89l98RSaHXUQ7LEHvP4642Ys3mroYq2VmTm8Mnwa57/yI3vd+zUfjp5VCM9IJdYff8DQobAdO89VduTl5XHL3/9Oyzo1aV6rOgCZ2Tl89PPvHHrIIVxxxRURVyhJkqTCYPBCkiRJkqTSJCsLXngBOnSAfv3Cz2+9FVrg33ADVK8edYVSoYnFYhy1ewNG/v0AXjxrDw7uUJsKqVseAbKmfDqf9TmW2O+/w8cfQ7VqcMop1N69A2f82J/yWWu26bHjf57OX5HJFW+Opt+jQ3j0qwnMXbZt91cpMnRoCLLtv3/UlagYGjx4ML/+9hv7t22+7rJfZ89jycoMHn7kEWKGICVJkkoFgxeSJEmSJJUGGRlw//3QtGkYI9KyJQwZAt99B8cfD8nJUVcoFak+rWvx5Kld+OWOg7j7qA5UTw9dMJISYiQlxkiIhX3j+7SuxUeX9qBu1XQ45JDQDWb0aIbUbs0tXz3L0KfO5sohr1FpzcrtevyfZy3joS/Hs9e9X3HVW6NZlZVTFE9TxdHw4SHsVqlS1JWoGOrfvz9V0tNoWqPausvGzZlPp44dad68+RbuKUmSpJIkKeoCJEmSJEnSDsjJgf/8B267DRYtgtNOg7/9Ddq2jboyKTKn7NmY47s05Ktx8xg1fSmZOXnUrlSOfrvWo36V8hvdPneXjlx+2N/4V6/TOOeHDzh/xHucNfIjHut+Ai93PozMpK2MMvlT3p9tMD4cPYspCzN447xulE/ZcgcOlQLDhkH37lFXoWLqow8/pHWt6iT82dkiNy+P8fMXcfUZ50RcmSRJkgqTwQtJkiRJkkqieBz694frr4fff4dTT4V//AOaNIm6MqlYSE5M4KAOdTmoQ92t3jYhFpaZlWtzx/4X8Hj347l86JtcP+hFzvipP/fvfToftutNPLZtzWPz4vDzzKU8OPAPbj603Y4+FRVny5bBr7/C1VdHXYmKoalTpzJh4kTO7NF53WXTFy0lY00mh/btC8CyZcv46KOPGDRoEMOHfceCBQtJTUmhRvXqNGjcmBNOOIGjjz6a8uU3Do1JkiSp+HDUiCRJkiRJJc3330Pv3nDEEVC/Pvz4I7zyiqELqYBisRgta1VY9/PC9Krc2vci+p7zBGPrtOT/BjzAgBevpOeUUdu8zrw4vPb9dEeOlHYjRoQgnB0vtAm///47APWq5I+hGTdnPtUrVKDjWWdx5zXXUL9ePU4//XQ+fe+/VFyTwa61qtKqUnlSVy7l1+FDOfXUU6lTuzYXXXQRI0eOjOqpSJIkaSvseCFJkiRJUkkxYQLcdBO8+y507AiffQZ9+8Kf7cslFdyV+7fiotd+2uCyydUbcNFRN7H7zHHc+O0LvPr2LfyvyW7c2+csfqvdbKvrXJWVy8Df5nHErvWLqmxFbfhwqFoVWrWKuhIVQ5MnTyYxIYEq63WrmLNsBW1zc9l/4kRGPPQQPVo2Ye9WzaicVm6T61i4IoMfps7gzVde5qmnnuKCCy7g0UcfJTk5eWc9DUmSJG0DO15IkiRJklTcLV0Kl10G7dqFbhcvvQQ//QQHHmjoQiokfdvXoX6VTe/4/KlBW4475T7OP+pm6i9fwIAXr+CBAQ9Qc+WSLa4zMSHGnGVriqJcFRdz50LjxpDgZlZtbPLkyVSvVIGEhPz/q+cuX8mQ1asZk5zERft25/Bd260LXWTn5LJ01WrWZOcQj8cBqFExnYN3acNNB/fh6N078Nyzz3LIwQeTmZkZyXOSJEnSptnxQpIkSZKk4uzTT+G882DFCrj77hDAcM67VOgSE2IMuKwX+z/4LYsysje+QSzGF62681WLrpzw8xdcNfg19p10MbcdcAEfte29yRBUPB4nOdEd8qXaqlWQlhZ1FSqmZsyYQeVyqRtctiRjFQCX7NeDWpUqkJOby+gZcxg6aTozFuWHuapVSKdb04bs2awh6akpJCTE2KtFY2pWTOf5b7/l6quv5vHHH9+pz0eSJEmb5zc/SZIkSZKKo2XL4Jxz4JBDoEMH+OUXuO46QxdSEaqansLQG/bl+C4NSE3a9Gaz3IREXt/1YA449wn+13R3Hul/P099cA81MjbufpEXh/b1KhV12YrSqlX+XdZmrcrIIOUv3VD6tG7GhX26UatSBaYuXMw/B3zNmyPG0H7REv4DfFynDm889hj9jj2OL/+YzN0ff8P3k6evu3/L2jXo16ktTzzxBJ999tlOfkaSJEnaHIMXkiRJkiQVN198EcIW77wDzz4bul40bBh1VVKZUC45iX8d24nf/3EQr5zdlb/1bUXNCin8tZ/F0vKVuKLftVx45I10mfkbXzx/CYeN+x/8OR4gBjStnsaeTavt9OegnSgvzzEj2qzMrCwS/tIN57BObWlRqzqzly7n2cEj6di6Db8DnwJnAYf897+ceMklvPDCC8ycOZPTzjiDd0aO5cdpM9eto3vzRjSoXpVnn312pz4fSZIkbZ7fCiRJkiRJKi6WL4fzz4cDD4Q2bUKXi3PP3eQIA0lFKxaL0atVTS7dtyVfXtOH8/ZuRsXUjaf2fta6B33PeYLvGnfisY/+xRMf/JPqGUuJA1ce0IqY79/SrXx5WL066ipUTKWnp5Odl7fR5XnxOG+NHEuLpk34fPlyWq9/5WmnwYwZANSsWZNnn32WU045hfdHjWP56jVA+Pu0a4M6DBgwgGXLlu2EZyJJkqStMXghSZIkSVJx8NVXsMsu8MYb8NRToetFo0ZRVyUJqFw+mZsOacsPf9+f58/ozL5tagGQ8GemYnFaZS494nou6Xc93Wb8whfPX8yTqZM5Ytf6EVatnSItzeCFNqtixYqbDF7MWLyUWYuX8uiKlZSfOhWaNYOhQ8Pp5MnQp8+68EUsFuPRRx8lLx5n9Iw569axa8O6ZGdn8/777++kZyNJkqQtMXghSZIkSVKU4nG4/3444ABo3hzGjoULLrDLhVQMlUtOZL+2dfjPmXvw1Km706lBlQ2u/7htL667/TVye/bi4Dsvh2uvhdzcaIrVzlGlCsyfH3UVKqYqVKhAVs7GfwN+nTWPaomJ7D1nTghbfPst7LVXON1E+KJq1arsu+++/DZnwbp1VEkrT/NaNXj1lVd2zpORJEnSFm3cH1GSJEmSJO0cWVlw4YXwwgtw003wj39AgsdISCXBQR3qclCHukyYt4IpCzOIxWI0q5lO85oV4NpD4eGH4ZprYPx4ePVVqFgx6pJVFLp0gfvugzlzoG7dqKtRMVOxYkVWZ+dsdPlvM+fSLzeXxLWhi4YNwxUNG4af+/QJ4Yv99w+BzJQUjjr6aC764gsyMrNIT00BoHXt6nwzbNhOez6SJEnaPLfmSJIkSZIUhYULww6V116Dl1+Gu+82dCGVQC1rV6Rv+zoc0K52CF1A6Fhz5ZXQvz988w307AnTpkVap4pI9+7h1J3f2oRWrVqxaMVKMtcLX+TF48xbmUG3WrU2DF2stTZ80aoV3HknpISQRbdu3ciLx1m4MmPdTSuUS2XV6tVkZmbuhGcjSZKkLXGLjiRJkiRJO9tvv8Gee8Lvv4edsqedFnVFkorCIYeEHfLLl0PXru6cL43q1w87yocPj7oSFUNdunQhHo8ze+nydZdlZucQB6o+9NDGoYu1GjYMnS5OOGHdRVWqVAFgzXohjvSUZAAWL15c6LVLkiRp+xi8kCRJkiRpZ/rss3CEdFoajBgRZrpLKr3atw/v9VatwviAV1+NuiIVtm7dDNVok9q1a0dKSgozlixbd1nin92tsuPxLd/5z04Xa2VnZ/95/9i6y3Ly8gAoV65cYZQrSZKkHWDwQpIkSZKkneWFF+DQQ2HvveG776BJk6grkrQz1KwJX34JJ50UOtzcc0/UFakwde8OI0dCVlbUlaiYSU5OpuMuuzBzveBFcmICyUlJzJkzZ7vWNXfuXADS1gtkZGRmkZiYSOXKlQunYEmSJBWYwQtJkiRJknaG//4Xzj0XzjsPPvgAKlaMuiJJO1Nqaghf3XYb3HwzPPZY1BWpsHTvDmvWwA8/RF2JiqGue+7J7OUr1/0ci8VoVqMan3366Xat57PPPiO9XCq1K1VYd9n85SupU7s2CQlu5pckSYqan8gkSZIkSSpqAwfCySeHWe1PPAGJiVFXJCkKsVgIXlx1FVx2Gbz+etQVqTB06RI6GD31VNSVqBjaf//9mbtkGbPW63rRrl5NBg0axNKlS7d5Pe/997+0qV1j3aiS3Lw8xsyaxzHHHlvYJUuSJKkADF5IkiRJklSUvv8ejjoK9t8fXnoJPCpVKttiMbj/fjjzTDjjDPjkk6gr0o5KSoIrroA334SZM6OuRsXM4YcfTr26dflu4rR1l3WoV4ec3FxeeumlbVrH999/z2/jxtGhfu11l42ft5Dlq1Zz5plnFnbJkiRJKgC39kiSJEmSVFR+/RUOPhh22w3eeQeSk6OuSFJxkJAAzz4Lhx0GxxwDQ4ZEXZF21DnnQFoaPPpo1JWomElKSuKSSy9l1Mw5rFiTCUDltHJ0b96IG2+4gR+2MqJm7ty5nHLKyTSqUZV29fKDFz9OnUW7tm3Zddddi7J8SZIkbSODF5IkSZIkFYWpU6FvX2jUCPr3DzvkJGmtpCR44w3o3j0EMMaMiboi7YiKFeH88+Hpp2HlyqirUTFzwQUXkJaWzoCff1932WEd21K7Yhr79OnDrbfeypw5cza4T0ZGBk8++SRdu+7BwrlzOWmPTuvGjCzOWMWvc+Zx5llnEYvFdupzkSRJ0qYZvJAkSZIkqbCtXg2HHALly8Nnn0GVKlFXJKk4KlcOPvgAWrQI3XEWLYq6Iu2Iyy8PoYv//CfqSlTMVK9enQcefJAfp87kx6lhHE1qchLn9dyD3erV4l/33kvjRo3Yb999Ofnkkzn00EOpX68el15yCVXJ5eLee1KzYjoA2Tm5vDx8NPXq1efcc8+N8mlJkiRpPUlRFyBJkiRJUqlz880weTL89BPUqRN1NZKKs0qVQlec9u3hkkvgzTejrkgF1bAhHH88/N//wUUXOV5KGzjrrLMYPHgwL7/0Etm5eXRr3ojU5CSO3L09B3ZoxQ9TZjBl/Dim/TaW1MREOterSbfmnamWnt8xa1VmFq9+P5qFGasZ/tU3VK1aNcJnJEmSpPUZvJAkSZIkqTANGhR2ut1/P7RrF3U1kkqCunXhiSfgpJPgqKPghBOirkgFdcMNsPvucNddcMcdUVejYiQWi/Hcc8+RlpbGE088wdzlKzigXUvSU1Mon5LM3q2bsXfrTd83KyeXsbPm8OXvk8mJJfLpp5/SqVOnnfsEJEmStEUGLyRpR8TjkJUVWolmZIRlU+fXrIG8vA2XeDz/fCwGCQlhWf98QkKY+1uhAqSnh2VT59PSwm0lSZIUrRUr4KyzoGdPuOKKqKtRMbN06VJ++uknRo4cyaxZsza6fr/99qNfv34RVKZi4YQT4L334OKLYe+9QxhDJU/HjvD3v4fgxeGHQ5cuUVekYiQxMZHHHnuM5s2bc8vf/87IabPYs2lDWtepScOqlSmfkt8lJR6PM2PJMkZMnsGYWXNZnZnFPvv04bnnnqdZs2aRPQdJkiRtmsELSYIQglixAubN2/yyaFEIUqwNU6w9zc3d+vqTkiAxcdPhilgs3GZzwYzs7HB+a9LSNg5mVKkCtWtvfqlRI9QlSZKkwnHttTB/Pnz5pZ+zyrjly5evC1mMHPkjw0f8wLQpkwBISk0jpUptiOXfPmvZQoYOG27woiyLxULXiw4d4Pzz4aOP8r8vqmS5+ebw+zv99DByqly5qCtSMRKLxbj66qs57bTTuP/++3n6qacY9MdkYrEYVSukk5KYyJqcHFasXk1ubh716tblmmuv48wzz6R58+ZRly9JkqTNMHghqfTLyoJp02DSpDBne9asEKSYP3/DYMWaNRveLykJatXKDyk0bgwVK26588SmzqelhXUVVDwOq1dvuaPG5s4vWQITJ8LQoeE5rly54bpjsRC++Gsgo04daNIEmjeHZs3AmaGSJElb9/nn8PTT8NRT4TOUyqSxY8dy9LHHMXH8HwAkppQjtXYzEmu1p3q7I0it05KkavWIJWwYzFn06SMQXxpBxSpWatSAZ56BI46AF18MHXRU8iQnw8svQ+fOcMst8O9/R12RiqGaNWty33338c9//pPx48czfPhwJk2aREZGBpUqVaJmzZq0bt2affbZh0TDnJIkScWewQtJpcOyZSFYsTZcsfb8pEkwY0boHAFh40fduvkBg112gf33D+fXD1nUrh3CBsVhfEcsFsIbaWlQs+aOrWvVqvygyV+DJ/PmwcyZ8OOPMHdu+Dddq2rVEMJYuzRrln++fv3i8e8kSZIUpexsuOAC6Ns3HKmuMmv06NFMHP8H1Q66nNR6rUmu3mCjkIW0Rf36wZlnwpVXwtFHQ+XKUVekgujQIYwbuf76EKTp2TPqilRMJSQk0KZNG9q0aRN1KZIkSdoBBi8klRx5eSFUMXo0/PwzTJiQH7JYtCj/dpUr54cCunbdMCTQoEHZbvmclgZNm4Zla5Ys2TDAsvbf+rvvQkBj7fiT1NSwvrX/zu3bw667ho1M6elF+nQkSZKKjXffDV3WHA2gP1XosA+xxORNXhf/87N0zNeKNufuu+G11+C55+Caa6KuRgV19dXwwQdwxhkwahRUqhR1RZIkSZKKiMELScVTRgb88ksIWYwZE07Hjs0flVG7NrRuHXby9+u3YSeGatXc2F0YqlaFLl3C8ldr1sDUqRt3Fxk4MMwkzs0Nv4OWLUMIo1On/NN69fz9lFaZK2D1ohDKKV8NynlkniSpjIjH4cEHQye1jh2jrkbFTDweJ3f5fDLnTiRr7kRy5k8iZ94kkms1pcbxd0VdnoqrevXg5JPh4Yfh8stD90aVPImJ8NJLYeTIkUfCJ59AuXJRVyVJkiSpCBi8kBSteBxmz84PV6w9nTAhXJeYCG3ahJ32Rx0Vdtx36hSCF4pOuXLh97KpNphr1sCvv274O/388/zRJdWrbxzGaNvWDYkl2dJpMG0wLPgNiOdfXq0lNO4J1VtFVpokSTvF4MEwciR8+mnUlagYWTr4VXLmTyFn/iSyMsJn4Zq169CzS2cWVE/kl8mzIq5Qxd5VV4Wd9v/9L5x4YtTVqKBatIABA8IoqhNPDB2SktwkK0mSJJU2fsqXtHPl5oZOFoMH5y9z5oTrKlcOO+EPPDDMQO3UKXS08GiQkqVcuXA0T+fO+ZfF46H19vphjA8+CEeGQhhX0rUr9OoVlr32sgVrSTHrBxj3/p9dTOIbXrdkIiyeAM32h2b7RVKeJEk7xYMPQrt24XOsyrwaNWoAkDJlCD336MIepx9O586d6dy5M/Xq1QPgxhtv5JfJL0dZpkqCTp1CJ50HHoATTrBzYEnWq1cIXBx5JJx3Hjz/PCQkRF2VJEmSpEJk8EJS0crMDEf/rQ1ZDB0aOh8kJ8Mee8Dpp0O3bqHzQePGbkgqrWIxaNIkLEcckX/58uXw88/5r5Fnn4V77gkboDp1yg9i9Opll5PiIns1zP4RZo2A1Yshnhsuj8c3vu3ayyZ/GcaO1NvE2BpJkkq6CRPgo4/gmWf8LCsADj74YJYtW0Ylg8QqDFdfDYccAkOGhO9FKrkOPRRefBFOPTWMSL3/fv/fkCRJkkoRgxeSCteKFfDdd/lBixEjwuiJChVCF4O//S1sLOraFcqXj7paRa1SJejZMyxXXhl21I8fn//66d8fHnkk3LZly/Da2XvvcNq0aaSll0kL/4CfX4O87O2/76Qvoe7uEPOoLklSKfPkk1CjRtiRJv3J0IUKzUEHhY46jz9u8KI0OOUUWLIELrssjOG86aaoK5IkSZJUSAxeSNox8XjoWDBgQFhGjIC8PKhZM+xMv+eesKO8UydnmGrrYjFo3Tos554bLps1a8PRNP/5T7i8fn3o1y+09F69OnRRUeGKx2HOKJg2GDLmA3kFX1fmMlg0Hmq0KbTyJEkqFr79NhyN7ng8SUUhFgvjKZ5/Pnw+t0NCyXfppbBoEdx8czhI5fLLo65IkiRJUiFwL6ik7bd6NXzzTX7YYsaMsLHgwAPhqafCUTitW7tBSIWjfn048cSwQDg6aOhQ+PprGDgwvO6aNIHu3eGww8LSsGGkJZcKS6fD6BchZ3XhrC+WENZp8EKSVJpkZIQQ8gUXRF2JpNKse/dwUMPUqXb+Ky1uvRVWroQrroBJk+CBBzxYRZIkSSrh/EQvadvMng0ffxyCFl9+CatWQbNmcPTRYUf33ntDSkrUVaosqFo1P2CRnQ2ffAK33BLGklx2GVx8ceiwcthhcPjhsMcekOB4i+2yZCr8+AwQL8SVxiCeU4jrkySpGBg5EnJzw05R7VSrs3IZM3MpGZk5VElLpmODKiQn+plPpVS3buF02DCDF6VFLAb//nfYrnLZZfDHH/DWW1C5ctSVSZIkSSoggxeSNi0eh1Gj4KOPQtjixx/DzusePeD228NO7TZt7Gqh4uHSS+Gqq2DpUvj88/CaffJJuPtuqFUrtP8+/PDQHSM9Pepqi581S2Hm92EUSM4aWL2Ewg1dAPE8SHHWuSSplBk2DCpWhPbto66kzPjm9/nc/MFY5ixds8GnlerpKZzarTHn9mpKxXLFcARdVpZBdRVcjRrQsmX4m3PyyVFXo8J00UXhd3vccSHE178/NG8edVWSJEmSCsDghaQNTZ8Or70GL78Mv/8OVarAQQfB1VeH02rVoq5Q2rwqVeCEE8KSmxs2TK4difPii2EkzrHHwumnQ+/edsKI58GET2H60LUXFO3j1elYtOuXJGlnGzYMunaFxMSoKyn15i5bzZGPD2Xu8sxNXr8oI4tHv57Ax2Pn8MZ53ahZMXUnV7gFb70Vxgp8+aUj8VRw3buHvzkqffbfH4YPDwe47LknvPde6CoqSZIkqUQp43ucJAGwYkXYKb3vvtCkCdx1F3TpEjoHzJ8Pb7wRjqoxdKGSJDERevaEe++FX36BiRPhuutgyJD81/pNN4WAUVkUj8PvH8L0IYTARRGGLmIJUKsDpNrxQpJUygwf7piRIpSTm8fnv87luKe+o9s/v95s6GKtvDhMXrCSs1/8gby8Ig6UbqusrBC6GD8e+vSBGTO2fPt43k4pSyVQ9+4wZkwY+6nSp3Vr+P576NgxBDFeeCHqiiRJkiRtJ4MXUlmVmxuCFaecArVrw9lnh7EhL7wAc+fCK69A376QXAzb9EoF0bw53HJL2Oj93Xdw6KFhHEnbtuFI1cceg4ULo65y51kyGWaNKPrHiSWEwEWbfkX/WJIk7UzZ2SGkbEv4IrFwZSZHPj6UC175kR+mLtnm++XFYeysZQyeWEw+16WkhE4XzZrB5MlbD1/E3EyjzWjeHHJywt8dlU7VqoXtNGeeGbbRnHsuLF8edVWSJEmStpHf6KWy5uef4W9/Cy1uDzoIRo0KR2BNmwZffQVnnBHmVEulVSwWjhZ78skQMvrvf6FePbjqKqhbF444IlyWueUjKku8GcOKdsP+2nVXbgR7XAQpFYrusSRJisLq1eE0PT3aOkqhjMwcTn52OOPmrijQ/RNi8PJ3Uwu3qB3RsCF8++2G4YuZM0N4R9pWaWnhdO3fHpVOycnw9NPwzDNhTFGHDjBwYNRVSZIkSdoGBi+ksiArC157LRzV36kTvPQSHHcc/PAD/Por3HCDs4ZVNqWmwtFHwwcfwJw58NBDIYxx7LEhjHHDDVtvB10S5WbDgt+KppV1LAEqN4H6XWHPy6DLBY4YkSSVTmvb/ZcvH20dpdCrw6cxcf5Kcgs4LiQvDqNmLC3conbUX8MXr75apJPeVAqt/VvjqJHSLxaD886DsWOhZcvQjfTCC8OYWEmSJEnFlsELqTSbNw/uvBMaN4ZTT4WqVcMO5tmz4eGHoUuX8IVeEtSoAZdeGubqjhsX2rs+9RQ0bQrHHw9Dh0K8lGwdz1lNkWzpT6kYwhZ7XABtjoCK9Qr/MSRJKi7y/gwwJvi1ujDl5cV58bupFDBzsU5ObhEETHdUw4ZhpKNUEGv/1uQVw9e2ikaTJqHbxRNPhLDWLruETqWSJEmSiiW3EEml0S+/wFlnQaNGcN99cOSRobPF55+HMQrJyVFXKBVvbdrAAw+EFtAPPwxjxkDPnrDHHvD662G2ckmWmFK460urGYIWe10DFeoU7rolSSqu1h59btv/QjV+/grmLFuzw+upXalcIVRTyGbMgNNOi7oKlVRr/9bYZadsSUiAiy4K3S+aNoX994dLLoGVK6OuTJIkSdJfGLyQSot4HP73PzjssHAUxJdfwl13hR3HTz4J7dpFXaFU8lSoEDZqjRsHn34K1avDKadAixbw6KOQkRF1hQWTVA4q1AZ2sONNtVawz52w19XQoBskpRZKeZIklQhpaeHUtv+FasWawgm4nrBHMRulOGMG9OkTxow0axY6Etp8UNtjbfBi7d8elS1Nm4ZuF48+Ci++CB07Qv/+pacroyRJklQKGLyQSrq8PHj/fejeHXr3hmnT4OWXwwa9a68N40Uk7ZiEBDjooNA1ZvTo0P3iqqtCV5nbboOFC6OucPs17EGBx42kVoYOJ8BuZ0KiHXQkSWVUSgqkp8OcOVFXUqpUSE3a4XWkJiVwXOdiFLz4a+ji22+hQQM7EWr7rP1b43f8sishIYzH/Pnn8LekX7+wHej776OuTJIkSRIGL6SS7ZtvYM894eijITUVPv44fAE/7TQ34klFpVOnMF934sRwpOL990Pz5vDPf5asI17rdIL0WhDb2keBGFRuDG2OhHbHQq8bodcNUGdXiHmYpiSpDIvFwhiy4cOjrqRUaVW7InV2cEzIoyftRuW0YvJ9KCsrjAZYP3TRcAuhkHjeTitNJczw4dCypcELhe+fAweGroxLl0K3bnD88eE7qqToZGfDM89EXYUkSYqQwQupJBo7Fg49FPbdNxzx8O23MGgQHHKIO0KlnaVJE3j4YZg6Fc48M3S+aNUK/vMfyM2NuLhtkJgCu50N5atv5gZ//i2p0QZ2Pwca7An1OkNqpZ1WoiRJxV737jBsmK3eC1FiQozT92pMQgG+1iQnxvjPmXvQt32dwi+soFJS4M47w+fErYUuYBtCsSqzhg0Lf3MkCNt+DjoIRo0Ko0eGDYO2beGyy2D+/Kir2+ni8TxyclaQk7OSuP8na2eLx+Hdd6F9+9B9WJIklVl+o5dKkpkz4eyzwxH348fD22+Ho1569466MqnsqlkzBDDGjQsjSM45B3bdFT75pPjvhClXGbpeAq0P3ziAUaUx7HISdDrVcSKSJG1Ot24wd24Y96dCc1q3xjStkU7iNqYvkhJiHNKhDuPuPIh929Qq4uoK4IQTQnh+a6ELaXNWrYIxYwxeaGOJiXDGGWEb0V13wSuvQIsWcPfdkJERdXVFbvXq6UyY+E/+N3h3Bv1vVwb9rxNDv+vJ1KlPkZW1KOryVBYMHgx77QXHHRfee0OHRl2RJEmKkMELqSRYtgxuvDG0FR0wAB55BH79NXyot8OFVDw0bw5vvgkjRkD16vldaUaOjLqyLUtKhYZ7wV7XQM8boPvVsPffocsFULujR11KkrQl3bqF02HDoq2jlKlYLpk3zutGy1oVAEj8y1eetXmMXi1r8NLZXZl4zyE8cWpnkhKL8eeWlJSoK1BJNnIk5OQYvNDmlS8P118PkybBuefCHXeEbUiPPlpqAxhz537EsOH7M336C+TkrFh3eWbmXCZNvp8hQ3vyx/g7Wb16RoRVqtT6/nvo1w/23juMFfvyy3AATocOUVcmSZIiVIy3SkgiMzMcSd+8eQhb/O1vYWbnpZe64U4qrvbYA775JoSkFiwIP590UpjrXZzFYqEDRnpNSEmPuhpJkkqGWrXCZ3WDF4WuVqVy9L+sJ0+csjudm1QjOTFGDKialsy5vZox6No+vHLOnvRuVTPqUqWiN3w4VKjgDj1tXfXq8OCD8McfsN9+cNVV0Lgx3H47LFwYdXWFZuHCb/j1t6uJx3OBTY36jBOPZzFz5kt8N6wPo0efTUZGMf9OruIvHg/hij59Qvj299/htdfghx/C+02SJJV5Bi+k4mrECNhtN7j6ajj6aJgwAf7xD6hUKerKJG1NLBY6XowZA88/D//7X5i3e9994Ug1SZJUevToAV98UfxHjJVAyYkJHLJLXd6+oDsT7j6ESfccwqhb+3LTIW1pXN2gqMqQzz+HPfcMYyWkbdG0aRg7MnEinHIK/Pvf0KhROJBn0qSoq9sh8Xic8RP+sV33Wbx4CD+MPJoVK38voqpUqmVmwssvQ8eOYVvPmjXw3nth5OzJJ0OCu1gkSVLgpwKpuMnMDGNFuneH9HQYPRqeeQbq1Yu6MknbKzERzj47BKeuuAJuuinsnBk3LurKJElSYTn77HBk8RdfRF1JqZeQ4JhFlUFjx8LXX8M550RdiUqiJk1CJ9Xp0+GGG+Ctt8IIkn794KuvSmRocMnS4axePQ3Y9trj5JKbu4IRIw7j20GdGP79QUyf/h+ys5cVXaEq+ebNC2N7GjeGM84Ip4MGhU5nRx1lGE6SJG3E4IVUnIwcCZ07wwMPhO4Ww4bBLrtEXZWkHZWWBv/6FwwdCsuWhW42//435G6qJaokSSpR9t4bdt89tHaXpML24IPQoAEce2zUlagkq14dbr01BDCeeQamTIH99w/bnJ55BlatirrCbbZ40WBisaQC3jtObu5KMjImMmHiPQwZuhcLF35dqPWpFPjxRzj99NAl5l//Cp2If/stjJTde+/Q5VSSJGkTDF5IxUFmJvz972E+YGpq+IB/002QVNAvkpKKpW7dYNSo0N71+uuhV69whKwkSSq5YjG45prQ8WLs2KirkVSazJkDr70Gl18OyclRV6PSoHx5OPdc+Pnn0EmlRQu48EKoWzdcPmgQ5OVFXeUW5eYWRkgkDsTJy8tkzM8XsHjx0EJYp0q0uXND0G233aBLlzAy9u67YeZMeOKJMD5WkiRpKwxeSFH76afwgf5f/4Lbb4fhw+1yIZVm5cvD/ffD4MGwYAHsumv4cm/3C0mSSq7jjgtHpD/0UNSVqBiJx+NbXDZ5H7Z8n83dT6XU44+HgzPOOy/qSlTaxGKwzz7wwQcwcSJceWUYPdKnDzRrBrfcAuPHR1zkpiUlV2J7xoxsWQhgjBt3I/F48Q6cqAisXg1vvgmHHBI+x914IzRvDh9+GN4Xf/sbVK0adZWSJKkEMXghRSUvD+68E7p2DZ0tRo4MXS88ikUqG3r0gDFjwtFFf/sb9O4d2r5KkqSSJzk5HJH+2mvhiEmVebfccgsJCQmbXe677z7iCX/pcJiQyE8jf9ji/fbq0TOaJ6Sdb9UqePJJOOccqFIl6mpUmjVrBnfcAZMmhaP8DzgAHnkEWreG7t3D0f6LFkVd5Tq1ah5EPF6YBy7EWZM5i8WLBxfiOlVs5eWFzi7nnAN16sBJJ4WRsI89FroMvfsu9OtnF2JJklQgfoKQopCRAaedFo4suOUWAxdSWZWWFo6MPfro8Deha9fwd6Fbt6grkyRJ2+u880Kw+p//hIcfjroaRWzSpEmkVG9AhT2O3uxtUmo23uDnyt2PI6VOy83efvWkEUycOKnQalQx9+ijsHQpXHFF1JWorEhICOMwe/UKwYv+/eHll0Ow8Mor4bDD4PTTQ3eAlJTIyqxYsR2VKnZk+YpfgMLpUhGLJTF/wRdUr967UNanYmj8eHjllbBMmwZNm4bX9amnQsvN/98rSZK0PQxeSDvbzJlw+OGhZd2HH4bzksq2Xr1gxAg46qjQ2vWFF8JRF5IkqeSoUiUcMfy3v4VQZW933pR1SRWrU7FT322/faVaW7x97spFsHRKYZSm4u7XX+HWW8NOwaZNo65GZVH58nD88WGZNy+MY3j55fCdtXJlOOigEMQ4+GCoXn2nl9emzV2M/PE48vKyKYzwRTyeS07O8h0vTMVHbm7YzjJgQFh+/jm8do8/PgSIevQII3ckSZIKkaNGpJ1pxAjYYw9YvBiGDjV0ISlfrVrw9ddhI8DJJ4cNrXnOmJUkqUS54gro2RPOOgtWrIi6GkklUXY2nHEGNG8Od90VdTUS1K4d/n/78UcYOxauuiocTHTaaeF7bK9ecN998NtvEI/vlJIqVmzP7ru9SlJSpUJZXyyWQGJieqGsSxFavjyMCjnzTKhbF/baC556Cjp2hLffDqNEnnkmfFYzdCFJkoqAHS+kneWtt8IH/912g/ffD19cJWl9qanw0kvQrh3ceCP8/ju8+GIYSSJJkoq/xMTQuapTJ7j22rCxX2XWmtl/sOClywptfdkrl1A5LbXQ1qdi6p//hNGjYdiw0HVAKk46dAjLbbfB7NnwySehm8Cdd8INN4QOLYcfHrph7L13+I5bRCpX3p2ePYYwb94Apk1/hlWrJhd4XfF4LtWr712I1WmnmTw5jMUZMAAGDQrhtfbt4ZxzwuuwW7fw+UySJGknMHghFbV4PLQcvuMOOOUUeO45KFcu6qokFVexWNhg1bp1mDXau3cYS1SvXtSVSZKkbdG8Odx/P1x0UWjJfuCBUVekCFxyySXUrFmz0Ne72267Ffo6VYz89BP84x9w002hW6ZUnNWrB+eeG5bVq+Hbb8PO7/ffh0cegQoVoG/fMI5k772hZctC7zKQmFieevWOo16941i+/GcmTryPJUuHA2sfZ9s6cCQnV6NmjQMKtTYVkeXLQzDtq6/C623cOEhJgX32gQcfhEMPdUSTJEmKTJkIXkybNo1HHnmEjz/+mBkzZpCamkrz5s05/vjjueSSS0jzSGIVldzc0OXi1VdDi9CbbrKVnaRtc9RRMGQI9OsXNrp+9RW0aRN1VZIkaVtccEHY8XT22fDLL1C1atQVaSfr0aMHPXr0iLoMlSRr1sDpp4duAn//e9TVSNunfPkQsDj4YHjssTCSZMCA0IngggvCGM21Y0nWLp06FWoJlSp1ZPfdXyMjYzKLlwwhc81cZs56ldzc1cCWx3i2ankLCQnJhVqPCsm8eWHbyODBYRk9Orye6tSBQw6Bu++GAw4IQR9JkqSIlfrgRf/+/Tn11FNZvnz5ustWrVrFyJEjGTlyJM899xwff/wxLVq0iLBKlUrxeDjK7fXX4c034YQToq5IUkmz224wYkTYiHDAATB0KDRqFHVVkiRpa2IxeP75sAP11FPhgw8g2R06kjYjHoeLL4YJE2DkyHD0tlRSxWLQsWNYbropdCj47rv8HefXXw+ZmVCxYujweO654fo99yyUDrHp6c1IT28GQN26R/PTqNPJypr/57X5HTBisUTi8TzatP4Hder02+HHVSGIx2HKlPzXyuDBMH58uK5p0xDYueiiIuugIkmStKNKdfBi1KhRnHDCCaxevZoKFSpw4403ss8++7B69WrefPNNnn32WcaPH8+hhx7KyJEjqVixYtQlqzS56SZ49tkw49nQhaSCqlsXvvgCevQI4YvBg8ORQpIkqXhr0ADeeivMuj/rLHj5ZUhIiLoqScVNPA7XXRe2HbzyCuyyS9QVSYWrUiU46KCwQAhd/PBD+G47fHi47OCDQ9fYPfYIO9f32CN0xGjadIf+70xPb0H3bl8wd+6HzJj5EqtWTQIgMbEC9eodT4P6J5OW5liKyCxfDj//DKNGhQNNBg+G2bNDoKJDB9h//zC6uVcvqF8/6molSZK2qlQHL6644gpWr15NUlISX3zxBd27d1933b777kvLli257rrrGD9+PA888AC33357dMWqdPn3v+Hee8NswTPPjLoaSSVdvXowcCD07Bk2SH3zTdh4JUmSircDDwxjB088EapVg4cf9uhMSRu67z64//7w9+HUU6OuRip6qanhu23PnpCdDZ98EkZJrN3x/uKLYZsahK4YHTuGEMauu4bTDh1gO8ZGJyVVoEGDU2jQ4BTy8rKIx3NISChPzP+Pd554HKZNgzFjwqiQtadTpoTrk5Ohc2c45ZTQzaJHD8e0SZKkEqnUBi9GjBjB4MGDATjnnHM2CF2sdc011/DCCy8wbtw4Hn74YW6++WaSbf+qHfX88+FolZtvhquuiroaSaVFixah80Xv3tCvH3z6aZijK0mSirfjj4elS8OM++rV4bbboq5IUnHxzDNw441w661w+eVRVyNFZ5ddYPfd4bLLws9z5264k/6bb+CppyAvL3TAaNVqwzDGrrtCnTpbDTcmJKQAjvIpUmvWwK+/bvj7GzMGli0L19eoEX5nRx2V//tr08YRS5IkqVQotcGLDz74YN35s846a5O3SUhI4PTTT+fGG29k6dKlfPPNN/Tt23cnVahS6b334Pzz4cIL4R//iLoaSaVNx44wYEAYOXLCCfDf/zovXpKkkuD882HRojCOsFq1/B1Lksqud94J2w4uvRTswCptqE6dsBx4YP5lq1eHHfrrd0z49NMwrgKgcmVo3hyaNQun6y8NGkBiYhTPpHRauhQmT4ZJk/KXtT/PmBECMrFYfkDmoIPCaadOoaOn3UYkSVIpVWqDF0OGDAEgPT2dzp07b/Z2vXv3Xnd+6NChBi9UcIMGwUknhSPaHnvMLxGSikaPHiHkdfjhYSfOf/7j3xtJkkqCG24I4YvLLw/tsx0pIJVdn38eWuqffLIjiKRtVb48dOkSlrXicZg6NYQwxo/PDwH88EN+AADCAQtNmuQHMdaGM5o1g7p1QygyISGCJ1VMrV4N8+aF8SDrhyrWLosX5992beCleXPo2jWc7rJLGAmTnh7dc5AkSYpAqQ1ejBs3DoAWLVqQlLT5p9mmTZuN7iNtt2XLwobT7t3hpZdM0UsqWgcdFMYanXFGOALoxBOjrkiSJG1NLAb//nc4SvT002H2bLj2Wne4SmXNiy+GAHXfvvDCC+7slXZELAZNm4blr7Ky8oMD6y/ffhsOYFi9Ov+2SUlQsybUrr35pVatcFqzZsnb7hePw8qVIUyxqWX+/A1/XrFiw/vXrx8CFR06wBFHbBhgqVbNzzKSJEl/KpXBizVr1rBw4UIAGjRosMXbVq1alfT0dDIyMpgxY8Ymb5OZmUlmZua6n5f/2cIuOzub7OzsQqpahWHt72On/17+9jfIzAwbTWIx8HUh7RSRveeLg5NOgi++gKuvhp49wwYgqQwo0+97qQwqle/5xx8POzBuvx0mTID/+z/nmkt/KpXv+bVyc+GOO0KHi3PPDUEscPuByrQifc/HYqHLRZMmsN9+G14Xj4ewwZQp4XTtsmBBWKZPh5Ejw/mVKzdeb/XqULFi6OiQlhZO11/Wv+yv16ekhMBVQkJY19rza3/Oy8tf4vH887m5sGoVZGSE05Urw+n65zd1WUZG6FCxftAEQnikRo0QKKlZM4wF6dkz/+eaNcOIliZNIDV18//OOTmF8MsqPUrl/1+SJGmbxeLxeDzqIgrbggULqFWrFgAnnHACb7755hZvX7t2bebPn0+HDh0YO3bsRtfffvvt3HHHHRtd/vrrr5OWllY4RUuSJEmSJEmSpBJp1apVnHzyySxbtoxKlSpFXY4kSdrJSm3Hi7VStuHIodQ/U7ur/5r8/dONN97I1Vdfve7n5cuX07BhQ/r27esHqGImOzubgQMHcsABB5CcnLzhlVkZMHM4zB4JOfmvEVKrQIOuUK8LJP7lPluzaBF06wa77w5vvmlrPWkn2+J7vqz49NMwauTxx50VrzLB971UtpT69/yIEXDyyeFo2LffhvVGYUplUal8z8+cCSecAFOnhi6ZfftGXZFUbJTK9/ymZGfnd5/Iytq4m8X65xMTN+6EsXYpXx4qVIBy5dwGWUyt7ZQtSZLKplIZvChXrty681lZWVu9/doxIuXLl9/k9ampqevCGetLTk4u3V8KtteqRZC5HBISIb0WJJXb+n2KyEa/m1UL4cdnIOvPGYXrfzfJWgSTP4OFY2G3syF506+DjcTjcPnlYe7h44/bHljbJS8vj0mTJjFmzBimTZvG4sWLWbNmDZUrV6ZKlSp06NCBXr16+TdmG5Xpv8f9+oXgxRVXwD77hDagUhlQpt/3UhlUat/zPXrA//4Hhx8ezr/1Fhx8cNRVSZErNe/5YcPgyCNDuOrrr6FDh6grkoqlUvOe35zk5PB3oEaNqCtRESvVr2NJkrRVpTJ4UbFixXXnV/51Dt8mZGRkAFChQoUiq6nUisdh3liYPgSWz8i/PCEJ6u4GjXpBes1o61vwG/zyJuRtaeZgHJbPgp9fg93P2bbU+FtvwTvvhE4XdesWWskqvWbOnMnHH3/MZ59+wtdff8XyFX/+7UlNpFpaIuWTYyxbk8eSVblk5uRRtXIlDju8H0cdfTR9+/YlPT094megYuuhh+DLL+Hss8NpQkLUFUmSpG3VuDEMHQqnnAKHHQa33go33RR20kgqmfLywgEa114Le+wB770HNSPcNiJJkiRJKnKlMnhRrlw5qlevzqJFi5g5c+YWb7tkyZJ1wYuGDRvujPJKj3ge/PYezPmRDVtIEEIOs3+EOaOg0+lQvWXohrF6cbg+rQakFHHQJS8Xxr0Hc37axjvEYckkWDYNqjTZ8k2zsuCaa+CYY0LLUGkzVq1axdtvv80rL73IN4P+R0IMujdM5touMfasn0anOgnUSt9wJ3k8HuenOXl88Psa3h/4Nq+8+ioV0tP417/v58ILLyRmO0n9VeXK8PzzoW3xhx/CUUdFXZEkSdoeFSvC++/DP/4Rlg8/hJdegl12iboySdtr8uQQiB40CC69FO6/HzbRRVWSJEmSVLqUyuAFQLt27Rg8eDATJ04kJyeHpKRNP9Xff/993fm2bdvurPJKh0lf/hm6AIhvfH38zxmFo1+Eyo1g6dT1roxBzXbQuBdUaVw09f3RfztCF2vLSoAZw7cevHj7bZg9G+64o8DlqWy45ZZbePDBB+nTNIXnD0/lqLbJVCm35eBELBajc71EOtdL5B/7woRFydz/XRYXX3wx/T/8gHffe5+0tLSd9AxUYhxwAPTsCQ8+aPBCkqSSKDERbr89jB054wzo3Bluuw2uvx42831WUjGSlwdPPQXXXRe6W3z9dRgFKEmSJEkqE0ptL/KePXsCYYzIjz/+uNnbDRo0aN35Hj16FHldpUb2apj2v224YTwEMDYIXfx5+cJxMPJpmDmi8OtbtRBmfb/999tkrX+9TRweeAAOOgjaty9QeSo7Vq5cSecGqXxzejnO2i1lg9BFPB7n94W5fPRHNs/9lMWDwzL5z6gsRs3JJR7PDzO1rJ7I04eX55OTy/O/b7/iyH6Hs2bNmiiejoq7q6+GIUNgRBH8XZUkSTtH587w449hRMGtt0K3bvDLL1FXJWlLpk4NQehLLoHTToOffzZ0IUmSJEllTKkNXhx55JHrzr/wwgubvE1eXh4vv/wyAFWqVGEfvxRvuzk/Qjx3x9YRzwPi8Pv7sPD3rd58u8waGbpXFERezpav//ZbGD067OCUtsH6/S2ycuO8Py6b495ZTe2H1tD28QyOeHM15w/I5LahCZzz0Rp2fyaDNk9mcvu3a1i2Jj+AcXDLZPqfkMqgQd/ywAMP7PwnouKvXz9o3jx0vZAkSSVXaircfTcMHw6rVoUwxj//CTlb+a4iaeeKx+Hpp8NYoIkTYeBAePLJMD5IkiRJklSmlNrgRdeuXenVqxcAzz//PMOGDdvoNg888ADjxo0D4IorriA5OXmn1liiLZvBhruTd0QMJg3cvrtkroAp38BPz8MPT8LPr8H8XyDvzzDIogl/BjsKILXSlq9/4IGwUWX//Qu2fpVJCzLyuOHLNdT/v9Uc/fZqpqS24/zLr+Pzzz9nzpw5ZGVlsWLlKjIzM/nss8/Y65CTuP+HBHZ7dg3jFuSHnPZpmsRZnRJ57JH/IzMzM8JnpGIpMRGuvBLefRemTYu6GkmStKP22AN++gmuugr+/nfo3j2EMSRF79dfQ5eLCy+Ek06CsWPdTiBJkiRJZVipDV4APPzww5QvX56cnBz69u3LP//5T4YPH84333zDBRdcwHXXXQdAq1atuOaaayKutoTJywHiW73ZtonDitmwfNY23DQPJnwKQ+4NYY3FE2HZdJj/awhfDH/oz/qyCl5Ovc6bv+733+Hjj0O3i1hhBU9U2v2xIJumj67m8dGJnHbeZYwdO5aRP43mrrvuom/fvtSpU4ekP+d2p6SkcOCBB/LCiy8y9pffSK/Tgr6vZ7EgIz9IdGW3FObOX8ibb74Z1VNScXbWWVCpEjzySNSVSJKkwlCuHNx7LwwdCpmZIXxx3HEwYULUlUll06xZcO650LEjTJkCn30GzzwTPoNLkiRJksqsUh282G233XjrrbeoVKkSK1eu5KabbqJ79+7su+++PPPMM0AIXXz88cdUtA3k9kmtWPBRHpuzbCtHZ8fjMO49mPa//DEl+VeGk6xV4TSWVLAaEpKh7u6bv/7RR6FOnXA0i7QNatasSV5iKpdffR1Tp83gwQcfpEOHDtt036ZNm/L5wC9ZnJnIEz9kr7u8TY1EDm2VzAP/vo94vLACUCo10tPhggvg2WchIyPqaiRJUmHp1g1GjYIXXghdL9q1g8sug/nzo65MKhuWLYObb4aWLeHDD+Ghh2DcODjwwKgrkyRJkiQVA6U6eAFw+OGH8/PPP3PVVVfRqlUr0tLSqFKlCl26dOG+++5j1KhRtGjRIuoyS546uxV8lMcmxfLHhKy1Yg5MGwyTv4TpQ2H2SJj941bW8+dO6OyVBauhwwmQXH7zNxk4EI49NsxclrbB7bffzoKFi7jnnnuoXr36dt+/Xr16nHHGmTz5Ux5ZufkhizM7JTH213HMnTu3MMtVaXHyybBiBYwYEXUlkiSpMCUmwplnwvjxcNdd8Mor0Lx5OG/gUioaWVmhm1zz5iFscdVVMHEiXH45pKREXZ0kSZIkqZgo9cELgMaNG/Pggw/yxx9/kJGRwZIlS/jhhx+47rrrSEtLi7q8kqlyI0ivDRTWuI146KIBsHQqjHgCvn8kjBWZ8g2M/zh0u9hWeTnbV1tiKnQ6DWq13/xtFi4M7Xy7d9/29arMS0pKonz5LYR5tsF555/PvBXZfDcjP5zUqHL48z1v3rwdWrdKqXbtoGJFGDYs6kokSVJRKF8err8eJk2C886DO+8MR+E/+yzk5ERdnVQ6xOPw9tvQtm0IWxx5ZNgmcPfdULly1NVJkiRJkoqZMhG8UBGIxWCXkyAxhUJ5GSUkQ422sPB3+PFZWD7zzyvimxgrsk0FQlrNbbtp5Uaw99+hZtst32748HBq8EI7WbNmzQCYuzL/fVClXDhdsmRJFCWpuEtMhD33NHghSVJpV706PPgg/PEH9OkD558Pu+wCL78cjtKXtP1yc+G996BrVzjhhBC8GDMGnnsO6tePujpJkiRJUjFl8EIFV6E27HEhpP05PiG2/stpezphxKB+F8hZDT+/VsCgxV/FISEBWh32Zy1/qWdtrXV3h87nQWLS1lc5bBjUrg1NmuxgbdL2WbRoEQDVyue/jheuCu+RmjW3MWCksqd79xAYi+/o31NJklTsNW0Kr78OI0eGcQhnnBFOH3wwjB+TtHVr1oSuMe3awTHHQHo6fP01DBgAHTpEXZ0kSZIkqZgzeKEdU6EOdL8Kdj8P6uwGVZtD9dbQbF/Y83IoV/UvgYy/ikF6TWjeF2aOgLzcLdx2OyUkQaMe0OsGaLY/pNeC5PRQU/2u0O0KaH9cuN22GDYs7MiMFdZ4FZVpWzsCcb3rx4wZA0CLavnvpSlLws70evXqFX5tKh26dw8jkiZNiroSSZK0s3TuHHYSjx0L++0XxpE0agQ33QQzZ279/lJZtHAh3HNPOMjiggtC15jhw+Hbb2GffaKuTpIkSZJUQhi80I6LxaBaM2h/LHQ+F3Y7MwQdKtaFPS4KozxgwwDG2vPVW0KXC8PIklnfs+OdLtY9AFQN4xlIrRSCIN2vgt5/h57XQZsjQmhkW+XkwIgRjhlR4XjrrbAxb8aMTV8/Y0a4/q23AHjpxRfYvX4Kzarmv4c+m5TDLu3bUq1atZ1RsUqibt3CqeNGJEkqezp0gBdfhMmT4Zxz4LHHQleME08Mnw3siCXBzz/DuedCw4Zw553Qrx/8/ju8+24Y2ydJkiRJ0nYweKGilVoRulwAe14WukxUawHVWkLD7iEIsdtZkFwecjIhe1UhPnA8PF5hmTQJMjJgjz0Kb50qm7Ky4NZbYfz4MIf7r+GLGTPC5ePHw6238sN339F/wAAu2C3/z/XyzDgDJsY54qhjdmrpKmGqVoUWLWDUqKgrkSRJUWnYEO6/P3S7eOAB+PFH2GuvsFP5lVdgVWF+B5NKgKwseP/90MmiUyf47LPw/WzmTHjmGWjVKuoKJUmSJEkl1DbOWJB2UMV6ocvEzpJSASjEkSDLl4dTuwtoR6WkwJdfhnDF5Mnh9Ntvw0bxtaGLyZOhWTOyP/2U847sR6c6yZy9W/K6Vfx7aCZrchO48MILI3oSKjGqVXOuuyRJgkqV4PLL4dJL4dNP4ZFH4PTT4ZJL4LjjwvlevSDBYzNUCsXj8MMPIWz0xhuwaFEIIL35Jhx9NCQnb30dklTCZGbOY9bst5g3bwDZ2UtJSkqnevV9aFD/FNLTm0ddniRJUqnkVhUVD0mpkJxWeOvLyoAfHodVCwtnfWuPBCtfvnDWp7KtYcMQtmjWLD988d13G4Qu+PZbrn34YX759TeePTSZpIQQJJq6NI8Hv8/lyiuvon79+lE+C5UE5ct7JKskScqXkACHHgqffw4TJ8LVV4fPpX36hM+gf/87/PFH1FVKhWP6dLjnHmjbNnR5ee89OPvsMGJk6FA44QRDF5JKnXg8zrTpzzJkaE+mTHmUVasmkZ29iNWrpzNz5ksM/74vw4btz6JFQ4g7ekySJKlQGbxQ8RBLgAZ7UnhdKuKQswbGvFI484tXrw6nBi9UWP4avujRY4PQxfNffMHDjzzCIwel0rleIgDZuXFOfC+LWnXqcsONN0Zbv0qG8uXz/35JkiStr3lzuP32EMAYMgQOPBAeewzatIFu3eCJJ0JnAKkkWb4cXnghjBJp3BjuvjuMDP3iixDE+Ne/YJddoq5SkorM9BnPMXHivUDen8vGVq2ewugxZzB4SFemz3iRvLzsnVqjJElSaWXwQsVH/T0hIbHw1hfPg4z5sGTKjq9rbcvdvE1/YZEKpGHD0O52fa+8wjcTJ3LRhRdyQedkLuqSfwTWzV9n8uOcXN56579Urlx5JxerEikvz5bhkiRpy2KxEAJ++mmYOxfefhtq1gyjSerWhaOOgnffdXyZiq/Vq+Hjj+GUU6BOHTjnHEhMhJdeCq/pV16BAw4Il0lSKbZmzRwmTvzXNt8+O3sxEyb8g8FD9mTatGeIx93uKUmStCOSoi5AWqdcZeh4Kox5+c8uFYXQqSKWALN/gGrNdmw9aX+OQfHIcRWmGTPgtNM2uGjEccfRb+li9mmSwCMHpxKLhS4wz/6Yxb+/y+Lf//43Xbt2jaJalUSrV0Pt2lFXIUmSSopy5eC448Iyfz68+Sa8/HL4OSUljCQ57DA4/HBo0iTqalWWzZ4dwhYDBsCXX4bxem3bwq23hgBGw4ZRVyhJO92s2W8W6H45OcuYOOk+Vq78g3bt/k0s5gEckiRJBeGnKBUvNVpDlwugSuM/L4iF8ERBxfNgVSG0x10bvFi1asfXJUEIXfTpkz9eZOhQfmnQgIPnzKZj1WzeOy6VlMQQunjn12wu/CSTiy+6iGuuuSbaulWyrFqV//dLkiRpe9SqFbpejBwZxpH8+9+hm9Y110DTptChA9xwAwwdCrm5UVer0i4vD378MYzH6dIF6teHCy+EJUvgttvg11/DcsMNhi4klVnz5vVnc+NFtsXceR8wY+ZLhVeQJElSGWPHCxU/lRuF8MXKebB4IuRkQkoaZK6AKV9v//oKI6Vds2Y4nTkTdt99x9ensu2voYtvv2XcypXst2oljWomMOCUNNJTQuii/x/ZnPz+Gk468UQefeyxdR0wpK2Kx2HWLDjooKgrkSRJJV3z5iGEcfnlsHw5DBwYOg385z9w331QvTocfHDohHHggeBYPBWGjAz46ivo3z90t5gzJ7y2Dj4YrroqfM6tXj3qKiWp2MjOXrbD65g27RkaNjidWMzxTJIkSdvL4IWKrwq1w7LWiMcLsJIEqFhvx2tp0CDMih0+HPr12/H1qezKyoL9998gdPHHqlXs22dvaqdkMPC0NKqWD+GKgZNyOPbdTI444khefOllEhJsUqTtMG1amGm9555RVyJJkkqTSpXgmGPCkpsLP/wQQhgDBsCrr0JSEnTtCr16haVHD6hSJeqqVRKsXAnDhoXzhx8O334LmZnQujWcfHIYc9OjByQnR1qmJBVXiYnlyclZukPryMqaz6LFg6lRvQ8AOTkZLF36PdnZy0hKSqdKlT1JTjZgKUmStCkGL1RyZK0swJ3yoEHXHX/sWAy6d8/fCCQVVEoK3HlnmD385ZdMzMxk3z57Uy22nC9PTaVGWghXDJqawxFvrWH/A/ry+htvkpTkn2ttp7V/rwxeSJKkopKYCN26heWuu2D6dPjkE/jmG3j55dANIxaDXXbJD2L06gX1CiEcr5Jv4UIYMgQGDw7LTz+F70tvvBECPvfeC4ceCi1bRl2pJJUINWrsw+zZbxGP78gIsARWrZpCVsUOTJn6OLNnv0Ne3up118ZiKdSp04+mTS6jfPkGO160JElSKeKePJUciSnbf5+qzaFCncJ5/O7dwzzZnJxwFJdUUCecAEcdxZRZs9i3z95UzF3CV6enUis9hC6+m5HDoW9m0qNXb/773vukpBTgtS8NGxbagteqFXUlkiSprGjUCC68MCzxeOjytnan+uefw+N/djFs1gz23js/iNGiRQhoqHSbNi3/9TB4MIwbFy5v1Ci8Ds45J3S0mDQJXnvNzhaStJ3q1z+FWbNe3+H1ZGcvY8QPR5KZOR/YMMQRj2cxZ857zJs3gEYNz6VGjT5UqrSro3ElSZIweKGSpHpLWLUQ4nnbdvtYIuxycuE9fvfusGoVjB0Lu+1WeOtVmTR19mz67N2T1MyFfH16KnUqhNDFD7NyOfiNTLp07c6H/QdQrly5iCtViTVsWPi7JUmSFIVYLIRAmzeHM88Ml82du+GO95deCgGNGjWgUyfYdddw2qkTtG3rjveSKjcXxo+HMWPCMnp0OJ0zJ1zfrl0I3tx8cwhcNGqUf9/s7BC8kCRtt4oV2lCnztHMnfs+EC/gWvKYM+ddsrI2Dl2sf5u8vDVMnfYYU6c9Rnp6S5o2uZTatQ8r4GNKkiSVDgYvVHLU3xOmD93227c8CFLSCu/xO3cOnS6GDTN4oR0yffp09undi6TVC/jm9FTqVQyhi1Fzcun7eiYdOnVhwCefkpZWiK9flS2rV4cN3GedFXUlkiRJ+erUgeOOCwvAsmXw3Xfw/fdhx/x778EDD4TrUlLCDvr1wxidOkG1apGVr01Yvhx+/nnDgMUvv4TPowANGoTf29lnwx57hI4WNWpEWrIklWZt29xNXl4W8+cPKND9k5KqkJk5Z7vuk5ExkV9+vYKMVVNo1vSyAj2uJElSaWDwQiVHek2ovwfM+mHrt02rAfW7Fu7jly8fNvoNHgwXX1y461aZMXPmTPbp3QtWzuOb01NpUCmELsbOy+WA1zJp0aYDn3z2ORUqVIi4UpVo338fxiLZ8UKSJBVnlSvDwQeHZa1lyzbekf/GG5CZGa5v2DB8L2vXLnTTaNYsnDZsCImJUTyL0i8vD2bPDp0oJk0KI2TGjQu/n8mTw22Sk8PvpFMnOOmk/KBM9eqRli5JZU1CQgod2v8fi+oexeTJD7Nixc/bdf/k5Crk5CwHtrHjMLC2u8aUKf9HhfSW1Kp10HY9piRJUmlh8EIlS+sjIDcL5o6BWMLmx450Og0SUwr/8Y8+Gu64A+bPh1q1Cn/9KtVmz57NPr17kbNsDoNOT6VR5RC6+G1BLvu9mknD5m354suvqVy5csSVqlDl5cC8X2DuaMhaEf42VW0WwmHliuh3/fTTYSdEx45Fs35JkqSiUrlyGD/Rq1f+ZTk5YXTF2iDG6NHw5pswY0YIBUDY8d+kyYZhjLVLs2ZgN7ktW7MGpkwJQYq1AYu1y5Qp+cEXgPr1oVUrOOKI/BExbduGLiWSpMjFYjFqVO9Djep9WL5iHNOnPcO8+f3Z2viROnWOZsGCgWxf6GJ9CUyd+oTBC0mSVGYZvFDJkpAI7U+AOrvC9O9g8YT869JqQv3uMHo+pFYqmse/4AK46y544gm4/faieQyVSnPnzmXfPnuzZvEsBp2eSpMqIXTxx8Jc9n0lkzqNW/Ll199QtWrViCtVoclaCRM/g9k/sdHGjaXTYMo30KAbtDo0/G0rLNOnwzvvwEMPedSnJEkqHZKSQjeFdu3g5JPzL8/KgqlT87swrA0KDBoEL7yQP+4CwpiTpk3Daa1aULv2ppeKFSEW2+lPscisXAnz5oVl/vz88+svU6fCrFkQ//Mza2pq+Ldq1gwOOGDDEEuTJqEbpCSpRKhUsS0dOjxE6+xbmTjp38ybN4Dc3AxisbC9IB7PJSW5Bo0bn0/DhmcxaMHnO/BoeaxY+SvLV/xCpYodCucJSJIklSAGL1TyxGJQo01YctZA9mpITIbk9HAk1OhPiu6xq1WDs84KwYvrr3eDk7bJggUL2H/fPqyYP51Bp6fSrGoIXUxcnMe+r2ZRvX4zvvz6W6rbhrf0WPg7jHkV4rmbucGfG7VnDoOc1dD++MLbwP/II2GHwVlnFc76JEmSiquUlNB5oVWrja+Lx2Hu3A3HY0ydGoIG33+fH0TI/cvntXLlNgxi1KoVvgdWqADp6WHZ2vm0tB0PwOblwapVkJERwhMZGVs/v3TpxqGKVas2XG9CAtSsmf/8GjeGvffesFNI/frhdpKkUiM5uSpt29xD61a3sWDhV6xeNQ2IkZ7egurV+5CQEHYTlCvXgIyM8WytO8aWZGRMNHghSZLKJIMXKtmSyoVlZ7ryyhC8ePVVOO+8nfvYKnEWL17MAfvtw8KZk/n29BRaVAsbMKcsyWPfVzKpWKsRX30ziFqOrik9Fk+G0S+zzRsp5o6Gmu2hdiFslFi+HJ59Fi66KGz4lyRJKqtiMahbNyw9e276Nnl5sHjx5jtBzJsXRpssXbph0CFvG1qwly8fgiEJCZteYrGwnk0tWVkbByY29xzXD31UrhzCFG3aQO/eG4ZH1p6vXt2uaJJUhiUkpFK71iGbvb5+vRMYP+EfO/Ygmz0IRZIkqXQzeCFtrxYtwizbBx+Ec87xSCBt0Zmnn8qsKX/w7WmptKmRv4HzyLfWMGNpDuXXzKRdm00cobcNEhIS+c+LL9GvX7/CKlc7Kh6HPz5k+44MicGM7wonePH882Ej/aWX7vi6JEmSSruEBKhRIyzt2m3bfeJxyMzcdOeJv16WlRVuv6lwRTweAhB/DWMkJEBy8rZ12ChfvnSNRZEkRa5u3aOZNPkBcnNXA9sQNNyEcuUbFW5RkiRJJYTBC6kgrrkGevWCzz6DQzafEpcmThjPaR0SaF9rw6PKbu+dzITFay/LKtC6b/9fNuPGjTN4UZwsmwYZ87fzTnFYOgUyV0BqxYI/dk4OPPwwnHgiNGhQ8PVIkiRp82KxMI6kXLkQ2JAkqRRJSqrILrs8wZgx5xCPw/aFL2KUL9+QKpW7FFF1kiRJxZvBC6kgevSAbt3guutgv/0gNTXqilSMbeoYtKPaJu/wev81vGBHHmgH5GbDgnGwamH4Ob0W1GwDf85CZcHvEEuAeAF+N1krdyx48fDDMH06XH11wdchSZIkSZLKtOrVerLbbq/y++83s2rVJMKWrW3p7BmnUaPziNmNSZIklVEGL6SCiMXg6aehSxe47Ta4996oK5JUlLJWwa9vw6IJbHS0R3IaNOoFTfaGnDUFf4yEHfgv+bff4Oab4corYbfdCr4eSZIkSZJU5lWtsgfd9vycpctGMm/ex8yb9xE5OcvZUgCjTp2jqF/vpJ1XpCRJUjFj8EIqqI4d4Y474O9/h379YK+9oq5IxVKMl8bmMnBaZqGveUlGTqGvU+uJ54UOFuM/hjWLN3+77FUw6XNYOQfKVSnYYyWnQ/lqBbtvdjaccQY0bQp3312wdUiSJEmSJK0nFotRtcoeVK2yBy2a/43xE+5i7tz3icdzicXC+Nx4PIekpIo0anQeTRpfZLcLSZJUphm8kHbEtdfCRx+FnZ6jR0N6etQVqZi57c67+O6774pk3fslJHDssccWybrLvNxsGPUCLJ2y7feZ9zPU71aAMSMxaNgNEhK3835/uvdeGDUKvvsOypcv2DokSZIkSZI2IympAu3a3kvLFtczd15/1qyeSSyWSIUKbahZ8yASEx3DLEmSZPBC2hFJSfDSS7DrrnDjjfDII1FXpGLmhBNO4IQTToi6DG2PeBxGv7R9oYu15o+FtJqwaiHbNv+UMKqkQbftfywIgYs77wx/f7p2Ldg6JEmSJEmStkFyclUaNjg96jIkSZKKpYSoC5BKvFatwhHnjz4KX38ddTWSdtTSKbBkUsHum50BdXeDbW2tmZwGnc+FlArb/1iZmXD66dC+Pdxyy/bfX5IkSZIkSZIkSYXC4IVUGC69FPr0CTtBp0+PuhpJO2LqoB24cyyMDOl0GiRsqalUDOrvCd2uhAp1tv9h4nG4/HL44w94+WVISSlowZIkSZIkSZIkSdpBBi+kwpCQAK+9BsnJ0LcvLFgQdUWSCmpxAbtdrK9GG+h5PbQ4CMpVBWJAAqTVgGYHQO9boO2RkFqxYOv/+9/hmWfg6aehY8cdr1eSJEmSJEmSJEkFtqXDcSVtj3r1YOBA6NkTDj44jB2pVCnqqiRtj3gc4rk7sgJIqxnOplSAJr3DEo9v+/iRrXngAbjnHrj/fjjrrMJZpyRJkiRJkiRJkgrMjhdSYWrRAj7/HCZOhCOPhDVroq5I0vaIxbYyImQrkitA9VabXm9heOEF+Nvf4MYb4ZprCmedkiRJkiRJkiRJ2iEGL6TC1qkTDBgAw4fDiSdCTk7UFUnaHpsKTmyrJntDQmLh1bK+99+Hc8+FCy6Au+8umseQJEmSJEmSJEnSdjN4IRWFnj3h3Xfh44/hvPMgLy/qiiRtq6b7Fex+NdtBox6FW8taX38dglzHHguPP154HTQkSZIkSZIkSZK0wwxeSEXlkEPgpZfCcv75kJ0ddUWStkWlelCzw/bdp0F36HgKxIrgv9XPP4cjjoA+feCVVyCxiDpqSJIkSZIkSZIkqUAMXkhF6eST4YUX4OWX4cADYfHiqCuStC06ngQ12m39dlWaQo/roU2/wg9dxOPw6KMhxNW7N7z3HqSkFO5jSJIkSZIkSZIkaYclRV2AVOqdcQY0bQpHHw177gkDBkDr1lFXJWlLYgmw62mweDJM/BSWzwLi4bqEJKjdCZrvD+WqFM3jZ2fD5ZfDU0/B1VfDv/5lpwtJkiRJkiRJkqRiyuCFtDPsvTeMGAGHHQbdusE778D++0ddlaStqdYMul4Suk/kZoXLElMgFiu6x1yyBI47DgYNgmefhXPPLbrHkiRJkiRJkiRJ0g5z1Ii0szRrBsOGha4XBx0ETz4ZdUWStlUsBkmpYSnK0MX48SGcNWoUDBxo6EKSJEmSJEmSJKkEMHgh7UyVK4dRI5deChdfDJddBjk5UVclqTj46qsQzEpIgO+/hz59oq5IkiRJkiRJkiRJ28DghbSzJSXB//0fPPVUWPbeOxzlLqlsysqCW26BAw+Erl1DZ5wWLaKuSpIkSZIkSZIkSdvI4IUUlQsugG+/hQULoFMneOghyM2NuipJO9NPP0GXLnDvvXDrrfDxx1ClStRVSZIkSZIkSZIkaTsYvJCi1KMHjBkTQhjXXAO9e8OECVFXJamoZWXBbbfljxb54YcQvEhKiroySZIkSZIkSZIkbSeDF1LU0tLC6JFvv4U5c0L3i4cfhry8qCuTVBTGjAkjRe65B26+GUaMgF13jboqSZIkSZIkSZIkFZDBC6m42Htv+PlnOOccuPJK2GcfmDQp6qokFZbsbLjzzjBaJC8Pvv8ebr8dUlKirkySJEmSJEmSJEk7wOCFVJykp8Ojj8LXX8P06dCxIzz4YBhLIKnk+v576NYtBC9uuAFGjoTdd4+6KkmSJEmSJEmSJBUCgxdScbTPPjB2LJx5Jlx7LbRtC2+95fgRqaSZMAGOOy6ELnJyYPhw+Mc/7HIhSZIkSZIkSZJUihi8kIqrChXg8cfD+JF27eDEE2HPPeHbb6OuTNLWzJ8Pl10W3rvDh8OLL8JPP4UxI5IkSZIkSZIkSSpVDF5IxV379tC/fwhcxGKhG8Zhh8Evv0RdmaS/ysiAu+6C5s3hlVfC+fHj4YwzIDEx6uokSZIkSZIkSZJUBAxeSCVF797w/fdh5Mi4cdCpE5xzDsyaFXVlknJy4NlnoWVLuPNOOO88mDQJrr8eypePujpJkiRJkiRJkiQVIYMXUkkSi8Hxx4fgxf/9H3z0UdjRe9NNsHBh1NVJZU9eHrz/PnTsCOefHzrS/PEHPPggVK8edXWSJEmSJEmSJEnaCQxeSCVRSgpcdhlMnAhXXRVCGI0bw+WXw9SpUVcnlX6ZmfD889CuHRx9NNStCyNHwmuvQdOmUVcnSZIkSZIkSZKkncjghVSSVa4Md98N06fDtdfC669DixZw8skwalTU1Umlz7JlcN99IVxx3nnQti0MHQpffQWdO0ddnSRJkiRJkiRJkiJg8EIqDWrUgNtvh2nTQveLYcNg991hv/3gww8hNzfqCqWSbeJEuOIKaNgQbr0VDj0UfvstjBnZa6+oq5MkSZIkSZIkSVKEDF5IpUl6Olx6KUyYAG+8AatWwZFHQqtW8NBD4Wh9SdsmHoeBA+Hww8N76LXXwoifKVPg2WehTZuoK5QkSVIxtGx1Nq9/P537PvudB774g49/nkNWTl7UZUmSJEmSpCKUFHUBkopAUhKceGJYRoyAhx+G666DW26B006DM86APfeEWCzqSqXiZ968EFx69tnQ1aJjR3juOTjpJChfPurqJEmSVEytysrhn5/8ztsjZ5CVk0dSQow4kJMXp2paMhf1ac55vZoR83uYJEmSJEmljh0vpNKua9dwpP60aXD11dC/P3TvDq1bw113wdSpUVcoRW/1anjrLTjsMKhfPwSV2raFb76B0aPh7LMNXUiSJGmzVmXlcOIzw3nt+2lk5uQRB7Lz4uTkxQFYsiqbez75nROeHsaHo2cxa+nqaAuWJEmSJEmFyuCFVFbUqwd33hkCGAMHhvDFvfdC06bQuzc8/7yjSFS25OXB4MFw3nlQp07oELNoETz6KMyZA+++C3362BlGkiRJW3X7R7/yy6xl/Jmz2KwRU5dwxZuj6Xnf15z70g/8MsvvYJIkSZIklQYGL6SyJjER9t8fXnoJ5s6Fl1+G1NQNdz5/8gnk5ERdqVQ0JkyAW2+F5s1h773hyy/hiivgjz9g2DC46CKoXj3qKiVJklRCLFqZyXs/zdpq6GJ98Th88/sCjnpiKN/8Mb/oipMkSZIkSTtFUtQFSIpQhQpw2mlhmTkTXn89BDEOPRRq1YKTT4ZjjgndMRITo65WKrjp08OYnVdfheHDoVIlOP748Nrv2RMSzCFKUlmXl5fHS8Om8eaIGaxYk01KUgJ7Na/O9Qe1oXJaStTlSSrG3h81i7z4dqQu/pQbj5OXC+e9NJKjdqtPpfLJNK9ZgcM71aViueQiqFSSJEmSJBUVgxeSggYN4Lrr4NprYfToEMB4/XX4v/+DatXgkEPgsMPgoIOgcuWoq5W2LDcXfvgBBgwIgYuffw7hoQMPhDffhH79oHz5qKuUJBUTb4+cwc3vjyU7d8Mdp1MXreL1ETM4Ytd6PHzibhFVJ6m4m7oog4RYrEDhiziQkxfnvz/NJCEWIzcvzp0DfuW0bo259sA2pCQZEJYkSZIkqSQweCFpQ7EY7LZbWO6/P3/n9YABoVtAUhL06hVCGIcfDi1bRl2xFCxfDgMHhtfqxx/DggX5oaGbbgqhiypVoq5SklTMvDZ8Kjd/8OsWb/Ph6NkszsjilXP23ElVSSpJYsR2eB15cdYFN9Zk5/HckCn8MXcFz5+5B8mJhi8kSZIkSSruDF5I2rzEROjWLSx33RXGNXz8cdixfdNNcM010KpVfgijRw9ItiWudqKpU8PpkUeG0EV2NrRvD2efHV6T3bo5JkeStFkr1mTz962ELtYaPGEhb/4wnRP3aFTEVUkqaVrWrkBu3vZ3u9iSeDz83TnjPyNoW7cSKUkJ7N6oKvu2qUViwo4HPSRJkiRJUuEyeCFp2zVqBBddFJaMDPjqqxDCeOMNePDBMIJkv/1CR4xevaBTp9AhQyoss2fD4MFh+frrELx44w1ISAivwUMPhaZNo65SklRC/OuzP9ieXaWPfT3R4IWkjRyxa33u/ngcmTl5hbreOPDdpEWMmLIIiJGTF6d2xVSu6dua4/doWKiPJUmSJEmSdox7RCUVTHo69OsXlrw8GDUqhDC+/hpuuAEyM6FiRdhrr/wgRteuUK5c1JWrpIjHYcKE/KDF4MEweXK4rmVL2HtvuPvu8PN779ltRZK03T4cPWu7bj9zyWoWrlxDjQp+npGUr3L5ZE7ZszEvfDeFeOE2vgAg5DnCiuetyOS6//7MvOVruGw/xz5KkiRJklRcGLyQtOMSEqBz57DcdlsIXYwcGXaU/+9/8K9/wd//DikpsMce+UGMHj1ClwwJIDcXxozJD1kMGQLz5oXXV6dOYaRNr17QsyfUqRPuk50Nn3wSbd2SpBIrIyt3u+8zaX6GwQtJG7nh4DZMmL+CIRMXFkn44q8eGDieXRtVoVfLmkX/YJIkSZIkaasMXkgqfKmpIVTRo0fofpGbC2PH5u9Qf/FFuPdeiMWgY0fo3j3sWN91V9hll9BNQ6VbXh5MmgSjR4ewxciR8N13sGJFCOh07QrnnBOCFt27G9CRJBWJhBhsb/SifEpikdQiqWRLSUrgP2fuwePfTOSl76ayZFV2kT5eYkKM54dMMXghSZIkSVIxYfBCUtFLTAyhil13hcsuCyMkJk3asLPBs8+GgEYsBi1ahNuuDWN06gT164frVPJkZITgzdqQxejR4eeMjHB93brh93zDDSFosccejqSRJO0UdSuXY/ri1dt8+xjQqlaFoitIUomWnJjAlfu34uI+Lfj2j/mMmr6E/wydSnZuHnmF3AUjNy/OoD8WMG/5GmpX8rOzJEmSJElRM3ghaedbG65o0QLOOitctmYN/PZb/o75MWPg/vth6dJwffXqIYCxfhijZUtIS4voSWgjeXkwc+bGIYuJE0PYJjER2rYNv7tjjsn/fdaqFXXlkqQy6pJ9WnD9f8du8+27Nq1GuRS/QknaspSkBPq2r0Pf9nU4tktDrv/vz4ycuoTEhBgxIKeQUhhxYOaSVQYvJEmSJEkqBtxqKKl4KFcOdt89LGvF4zB9etiBv3Yn/kcfwUMP5d+mbl1o3hyaNQuna5dmzaBmTbtkFLbVq2HKlNCxZO0yeXI4nTIFsrLC7apUCaGKgw/OD8q0a2cnC0lSsXJc5wbc/fE4lq/J2abb33Z4uyKuSFJp07xmBd69cC/Gz1tB/zGzWbgyi0nzVzBi6pJCWX/M7zuSJEmSJBULBi8kFV+xGDRuHJZ+/fIvX74cfvkFJkzI3+k/fjx8+iksWJB/u4oV8wMZ6wcz6teH2rWhWjWDGX+1ahXMmwdz5+YHLNb+G0+aBLNn59+2XLn8f9eDDsr/923fHho18t9WklTsJSQk8PFlvTjgoUGsycnb4m3vPWYX2tWrvJMqk1TatKpdkWv6tgYgHo9z43tjefOHGcQInSsKIjEhRtPq6YVWoyRJkiRJKjiDF5JKnkqVYK+9wvJXy5dv3JFh0iR47z2YNg1yc/Nvm5QUxlzUrh2W9c//dalRI4zKKGnicVixIoQp/rrMn7/xZStXbnj/GjXywxW9e2/YUaRuXUhIiOZ5SZJUSBpWT2PIDftw+RujGTZ5EfG/7AFtWj2NfxzZgZ4ta0ZToKRSJxaL8c+jd6FD/co8PWgSM5as3u51JCbEOHSXulRNTymCCiVJkiRJ0vYyeCGpdKlUKYy16NRp4+uys8PoktmzNx06mDABhgwJ1/01gBCLhQ4ZFStCejpUqBBO1z+/pcvKlw8hhbVLLLbhz/E45OVtuKy9LCsLMjLyl5UrN326qcuWLIE1azZ8LomJG4ZMWrSAHj02Dp80aQKVPbJXklT61ahQjtfP68aarBze+GEGs5eupmK5ZI7atT4Nq6dFXZ6kUigWi3Fqt8ac3LUR309ZzJSFGcRi8M7IGYyevpQt9+AJXTPO7dV0p9QqSZIkSZK2zuCFpLIjOTm/Y8PWZGRsHM5YuHDT4Ya5czcdfvhr4KEwJCZuPuBRoUIITKx/fZUqG3fvqFrVThWSJG1CuZQkzurhjkxJO09CQozuzavTvXl1AA7tWJcTnxnO73OWk7eJGSQJsTCa5P7jOtGxQZWdWqskSZIkSdo8gxeStCnp6dC0aVgKKjc3P4yxevWmu1rk5YXbrd/94q9LUlJ+mCIlJXTLkCRJklTqVCqXzDsXdOeRrybw+vfTWZGZQ4wQtgDYvXFVrt6/FXu1qBFlmZIkSZIk6S8MXkhSUUlMDKNPKlWKuhJJkiRJJUR6ahI3HtKWqw5oxbd/zGf+ikxSkxLYrVFVWtWuGHV5kiRJkiRpEwxeSJIkSZIkFTPlkhM5qEPdqMuQJEmSJEnbICHqAiRJkiRJkiRJkiRJkkoqgxeSJEmSJEmSJEmSJEkFZPBCkiRJkiRJkiRJkiSpgAxeSJIkSZIkSZIkSZIkFZDBC0mSJEmSJEmSJEmSpAIyeCFJkiRJkiRJkiRJklRABi8kSZIkSZIkSZIkSZIKyOCFJEmSJEmSJEmSJElSARm8kCRJkiRJkiRJkiRJKiCDF5IkSZIkSZIkSZIkSQVk8EKSJEmSJEmSJEmSJKmADF5IkiRJkiRJkiRJkiQVUKkNXvTp04dYLLZNiyRJkiRJkiRJkiRJUkEkRV2AJAnIy4WFv8O8sZC1EhJToFpzqLs7JJePujpJkiRJkiRJkiRJm1HqgxddunThhRdeiLoMSdq0nDUw8XOY+T0Q3/C6heNg4mfQdD9o0hvs0CNJkiRJkiRJkiQVO6U+eJGenk6HDh2iLkOSNrZkCox6AfKyN3+bvByY9DnkrIaWB++82iRJkiRJkiRJkiRtk4SoC5D+v707D9NzPvTH/57JvkokEkuiIWSz9wjS2B17E2KLKhXEUqV1OKoOP61e59uNLur0HEJKVFG1E5SqLYTQqi3R1JZmIRLCiIRMzPz+eJohJCmTmdzPzLxe1/Vcc8/93HPPezLzmSfP3O/n84EWqWp28tSvV126+LgZD5WKGgAAAAAAAEBZafYzXgAUrqYmmflIsuDlpObDpMPaSdXM0mwWn1VFZTLz0aT7Ro2XEwAAAAAAAPjcFC8AGkttbfLCrcmcJ5LamtU8V03yxvPJh0uSVm0bJh8AAAAAAACw2pr9UiMvvPBCtt9++3Tr1i3t27dPnz59csABB+Sqq65KdfVnnOIf4POqrU2eHJfMfnz1SxcfnTRZ8l4DnQsAAAAAAABoCM1+xou5c+dm7ty5de/Pnj07s2fPzm233ZYf//jHueGGGzJ48OBVnuODDz7IBx98UPd+VVVVkqS6ulp5o8ws+374vlC4F+9J3p6ZpFXDnrcmiZ/vOsY8tDzGPbQsxjy0LMY8tCzGPM2Nn2UAaNkqamtra4sO0Rh23333VFZWZr/99stWW22VHj165N13381f/vKXXHrppZk2bVqSpHfv3pkyZUo23HDDlZ7re9/7Xs4///xP7b/mmmvSsWPHRvsaAAAAAACA8rdo0aIcccQReeedd9K1a9ei4wAAa1izLV68/fbb6dat2wrvq66uzvHHH58JEyYkSUaNGpWbbrpppeda0YwXffv2zfz58/0HqsxUV1fn3nvvzZ577pk2bdoUHYfm7MMlyRvPJXOfTT54N2nVNum+UbL+tknV7GTajQ3/OTf+92TD4Q1/3ibMmIeWx7iHlsWYh5bFmIeWxZinuamqqkrPnj0VLwCghSp0qZGKiorVPscVV1yRMWPGfGr/ykoXSdKmTZtcfvnleeyxx/K3v/0tN998c2bPnp0NNthghce3a9cu7dq1W+F5PCkoT743NKp5U5Pnrk8+/CBJRZJ/9tfem53Mejjp2Dup+LBhP2fbzknfoYmf6xUy5qHlMe6hZTHmoWUx5qFlMeZpLvwcA0DLVll0gKK0bt06xx13XN37Dz74YIFpgCZj3rTk6av/WbpI6koXH99eNLdhP2frDskXxyZtOzXseQEAAAAAAIDVVuiMF9OmTVvtc6y33nr1/tghQ4bUbc+ePXu1swDN3IfVyfPXZ/myRSNbd+tk032TdqYnBAAAAAAAgHJUaPFi0KBBRX76BlnqBGhB5j6TLH2/cc7dplNS/V5pu91aSe8tkg13StorXAAAAAAAAEA5K7R4UbSpU6fWba+//voFJgGahNf/mqQiDT7jRbuuyY7f+ei8FS12FSgAAAAAAABoclps8WLp0qX59a9/Xff+zjvvXGAaoEn44N00eOmisnUy9OtJRUVKpQ4AAAAAAACgKWmWL6u+//778/bbb6/0/urq6owdOzbTpk1LkowYMSJ9+/ZdQ+mAJqtV28//MT0GrPy+Tr2T4Wcm7bvVOxIAAAAAAABQrGY548WECRMycuTIjBw5MrvuumsGDhyYrl27ZuHChfnzn/+ccePG1S0z0qtXr1x00UUFJwaahLX7J1Wz8plnvWjbJdn66OTDJcmMh5O3X01qa5KOPZKN90zar9WYaQEAAAAAAIA1oFkWL5Jk4cKFueaaa3LNNdes9Jgtttgi1113XTbaaKM1mAxosjbYLnn1wc94cEXSd1hSUZm0bp/037NRowEAAAAAAADFaJbFi7POOitbb711Jk+enKlTp2bevHl566230q5du/Tu3TvbbrttDjnkkIwaNSqtWrUqOi7QVHTonvTZIZk1+V8cWJm061wqagAAAAAAAADNWrMsXgwePDiDBw/OaaedVnQUoLkZsH+ydHHy+l+TVOTTy45UJO26JF88Lmnbac3nAwAAAAAAANaoZlm8AGg0la2SzQ5Lem2RzHw0WfDSR/e165r0/VKywdCkTcfiMgIAAAAAAABrjOIFwOdVUZH0GlK6LXkvqX4vqWyTtF8rqagsOh0AAAAAAACwBileAKyOtp0sKQIAAAAAAAAtmJdmAwAAAAAAAADUk+IFAAAAAAAAAEA9KV4AAAAAAAAAANST4gUAAAAAAAAAQD0pXgAAAAAAAAAA1JPiBQAAAAAAAABAPSleAAAAAAAAAADUk+IFAAAAAAAAAEA9KV4AAAAAAAAAANST4gUAAAAAAAAAQD0pXgAAAAAAAAAA1JPiBQAAAAAAAABAPSleAAAAAAAAAADUk+IFAAAAAAAAAEA9KV4AAAAAAAAAANST4gUAAAAAAAAAQD0pXgAAAAAAAAAA1JPiBQAAAAAAAABAPSleAAAAAAAAAADUk+IFAAAAAAAAAEA9KV4AAAAAAAAAANST4gUAAAAAAAAAQD0pXgAAAAAAAAAA1JPiBQAAAAAAAABAPSleAAAAAAAAAADUk+IFAAAAAAAAAEA9KV4AAAAAAAAAANST4gUAAAAAAAAAQD0pXgAAAAAAAAAA1JPiBQAAAAAAAABAPSleAAAAAAAAAADUk+IFAAAAAAAAAEA9KV4AAAAAAAAAANST4gUAAAAAAAAAQD0pXgAAAAAAAAAA1JPiBQAAAAAAAABAPSleAAAAAAAAAADUk+IFAAAAAAAAAEA9KV4AAAAAAAAAANST4gUAAAAAAAAAQD0pXgAAAAAAAAAA1JPiBQAAAAAAAABAPSleAAAAAAAAAADUk+IFAAAAAAAAAEA9KV4AAAAAAAAAANST4gUAAAAAAAAAQD0pXgAAAAAAAAAA1JPiBQAAAAAAAABAPSleAAAAAAAAAADUk+IFAAAAAAAAAEA9KV4AAAAAAAAAANST4gUAAAAAAAAAQD0pXgAAAAAAAAAA1JPiBQAAAAAAAABAPSleAAAAAAAAAADUk+IFAAAAAAAAAEA9KV4AAAAAAAAAANST4gUAAAAAAAAAQD0pXgAAAAAAAAAA1FProgMAAAAAK1FTk7z1VvLmm8nChcl775Vuy7Y/+faT+z74oHSOT95qa0u3ysqPbhUVH223aZN06lS6de684rcr2tetW9KrV+njAQAAAFoIxQsAAABYk5YuTebNS+bOTd54o/T247eP75s3r3T8yrRtu+IiRKdOSY8eSbt2SatWKy5XJKXyxScLGTU1yZIlpfLGm28mM2Z8utSxaNGqv8a11y4VMHr3Xv62on0dOjTcvy0AAABAARQvAAAAoCHV1iavv5689NLyt5dfLt3mzSsd83FduixfRhg2bPn3e/QoHfPJgkXrgp7W19SUyhefLGQsWLDiIsnUqaXt+fNX/LV/4QtJ//6fvn3hC2bPAAAAAMqe4gUAAAB8Xh9+mLzySvLiiysuV3x8Roj11ks23jgZMCDZZ59kgw0+PftDU5v1obKyVP7o3PnzfdzSpaXyxceLGa+/nrz6aunf77bbStvLZvmorEw23PDThYyNN04GDkw6dmzorwwAAADgc1O8AAAAgFV5993k2WeTv/41efrp0tvnnvuoXNGmTdKvX6kQsMsuyTHHLF8QUA74SOvWybrrlm4rs3RpMnNmqcDy8VLLlCnJtdeWvh9JqZSx6abJVlslW29dervVVsn665eWVAEAAABYQxQvAAAAICktgTFz5kflimVvX3qpdH/r1smQIaWL+6NHJ1tsUbrw37dv0qpVkcmbl9atk402Kt322GP5+2prkzffLM008vzzpe/R008nP/pRUlVVOqZnz0+XMQYPtmQJAAAA0GgULwAAAGiZFi5MJk9OHn44eeSR5KmnkgULSvetvXbpgv2IER9dwB88OGnXrtDILV5FRalY0bNnssMOH+2vrU1mzPioMPP008lNNyU//Wnp/rZtk802K33MTjuVbn36FPIlAAAAAM2P4gUAAAAtw/z5yaRJpaLFQw+VihYffpj06JHsuGNy+ukflSz69LFcRVNSUVFa7qVfv+TAAz/a/847yTPPlIoYf/lLct99yf/9X+m+fv1KBYyddy69HTDA9xwAAACoF8ULAAAAmqcZM0oli2W3adNK+zfcsHSh/fjjS28HDXLBvblaa62PZrhYZu7cjwo4Dz+c/Pa3SU1N0qtXqYCz7PittiotewIAAADwL/gLAgAAAM3DokXJn/6U3HFHctddyT/+Udo/ZEhpVoNzzildUN9ww2JzUqzevZODDy7dkqSq6qMlZx5+OPnOd5IPPkg6d05226203Mz++yfrr19sbgAAAKBsKV4AAADQdM2alUycmNx+e2kZifffTzbZJBk1qnTRfPjwpGfPolNSzrp2Tfbeu3RLSqWLJ58sLUdz993JSSeVZsT44hdLJYwvf7m0XVlZbG4AAACgbCheAAAA0HTU1JQuit9+e2lmi7/+NWnVqrRExH//d+mi+MCBRaekKWvXrlTYGT48Ofvs5K23SgWMO+5ILrooOf/8ZN11S7NgjBiR/Pu/J506FZ0aAAAAKJDiBQAAAOWturp04fvmm0uzW7zxRtK9e7LffslZZ5VmKujeveiUNFdrr50ccUTpVl2dPPpoqYRx++3J+PGlosZuuyUjRyaHHmqGFQAAAGiBzIsJAABA+amtTZ56qrQ9cGDpovbkycnRR5eWgHjjjeTqq5PDD1e6YM1p0ybZZZfkgguSF15Ipk9PfvSjZMmS5JvfTNZbLznggOTGG0tLlgAAAAAtguIFAAAA5WPmzNKF7M02S3bdtbTviCNKS4pMm5b85CfJTjslrU3gSBnYdNPktNOS++5L5sxJfvaz0ttDDimVML7+9VJhqLa26KQAAABAI1K8AAAAoFjvvptMmJDssUfyhS8k3/9+ss02yU03le7/7/9Ottqq2Izwr6yzTnLqqckTTyRTpyYnnVRakuRLX0oGDCj9XL/yStEpAQAAgEageAEAAMCaV1ubPPhgctRRybrrJsccU9r3618nc+cmv/1tqYgBTdHgwckPfpDMmFGaDWPHHUvLk2y8cbLzzqWf88WLi04JAAAANBDFCwAAANacxYtLF5232aa0lMgTTyTnnpu8+mrypz8lY8YkXboUHBIaSGVlsvvuyRVXJK+/nlx9ddKhQzJ2bNK3b/Jf/5XMmlV0SgAAAGA1KV4AAADQ+ObMSc45p3SxedlF53vvTaZNS84+O9lww6ITQuPq1Cn56leTP/wh+fvfS7O9/OpXSb9+yejRyaOPFp0QAAAAqCfFCwAAABrPtGnJsceWLi5ffHFy5JHJ9OnJ7bcn//7vSUVF0QlhzevfP/n5z0uzXfziF8lTTyXDh5dut92W1NQUnRAAAAD4HBQvAAAAaHiPPpoccEAyZEjpFf4/+MFHF5k32aTodFAeunRJTjkleeGF5NZbS0WkAw5INt+8tDzJkiVFJwQAAAA+A8ULAAAAGs5TTyV77ll65f7f/578+tfJK68k//mfSdeuRaeD8lRZmYwcmUyaVLoNGFCaKWbTTZPf/MYMGAAAAFDmFC8AAABYfa++WlpG5ItfLM1scdNNyXPPJccck7RtW3Q6aDqGD09uuSWZOjXZbrvka18rjat77ik6GQAAALASihcAAADU31tvJWeckQwcmNx3XzJuXPLss8moUaVX8QP1M3hw8vvfl5bt6dIl2Xvv0mwyTz1VdDIAAADgE/wVDAAAgM9v8eLkJz9J+vcvlS3OPTd58cXk+OOT1q2LTgfNx7BhyUMPlWbBmDmzNPvFUUclM2YUnQwAAAD4J8ULAAAAPruamuSqq0ozXJxzTvLVryYvvZT8f/9f0qlT0emgeaqoSA44oLR8z6WXJvfemwwYkPznfyYLFhSdDgAAAFo8xQsAAAA+m5dfTnbbLTn66GS77ZLnn0/+53+SXr2KTgYtQ+vWyQknlGaXOeec5JJLSkuS3Hpr0ckAAACgRVO8AAAAYNVqapJf/SrZYovkH/9I7rsvueGG0ivugTWvc+fkvPOS6dOToUOTAw8sLT/y1ltFJwMAAIAWSfECAACAlXv11eTf/z055ZTSTBfPPJPsvnvRqYAkWX/95LbbkgkTkttvTzbfPLnjjqJTAQAAQItTdsWLhQsX5qGHHsqFF16Yww47LBtttFEqKipSUVGRfv36fe7zPffccznxxBPTv3//dOjQIeuss0522mmnXHLJJVm6dGnDfwEAAADNQW1taRmDLbZIXnop+eMfk//936RLl6KTAR9XUZF87WulpX+22SYZMSIZMyZ5++2ikwEAAECL0broAJ80YsSIPPDAAw1yrssuuyynnHJKlixZUrfv/fffz6RJkzJp0qRcccUVmThxYnr27Nkgnw8AAKBZmDEjGTu2VLY44YTkgguSrl2LTgWsygYblGa7uPLK5LTTSuP3ssuSffctOhkAAAA0e2U340VtbW3d9tprr5299tornTt3/tznufPOO3PSSSdlyZIl6d27d375y1/m8ccfz1133ZWDDjooSTJlypSMGjUqH374YYPlBwAAaNLuvjvZcsvkb39L/vCH5NJLlS6gqaioSI45JnnuudKyI/vtl5x5ZuLvHgAAANCoyq54ccQRR+Saa67J3//+97z55pv5wx/+kB49enyuc1RXV+fUU09NTU1NunbtmkceeSSnnnpqtttuu+yzzz658cYbc/LJJydJJk2alN/85jeN8aUAAAA0HbW1ycUXJ/vvn+y8c/Lss8leexWdCqiPvn2Tu+5Kfv7z5Gc/Sw46KHn33aJTAQAAQLNVdsWLE044IV/5yleyySab1PscN998c15++eUkydlnn53+/ft/6pgLLrgg3bt3r9sGAABosaqrk5NPTr75zeSMM5JbbknWWqvoVMDqqKgoLTlyxx3J/fcnO+5YWkYIAAAAaHBlV7xoCLfcckvd9pgxY1Z4TMeOHXPYYYclSaZOnZrp06evgWQAAABl5q23kn32ScaPL91+8pOkVauiUwENZd99k8mTSzNebLddaRsAAABoUM2yeDFp0qQkycCBA7Puuuuu9LhddtmlbvuRRx5p9FwAAABlZfr0ZIcdkqefTu69Nzn22KITAY1hs82Sxx9PBgxIdt01ufrqohMBAABAs9LsihcLFy7MzJkzkySDBg1a5bEfv3/atGmNmgsAAKCsPPxwsv32SevWpQuyHyumA83QOuskf/xj8pWvJEcdlXz3u0ltbdGpAAAAoFloXXSAhjZr1qy67T59+qzy2L59+9ZtLytrrMgHH3yQDz74oO79qqqqJEl1dXWqq6vrG5VGsOz74fsCLYMxDy2PcQ8N5K9/TQ4+uFS8+O1vk65dkzIcV8Y8NLDKymTcuGTw4OT885OOHZPTTy86VR1jHloWY57mxs8yALRsza548e6779Ztd+7ceZXHdurUqW574cKFKz3uhz/8Yc4///xP7b/nnnvSsWPHeqSksd17771FRwDWIGMeWh7jHhrAZZeV3v5zqcZyZsxDAxs0KLn22tL2nXcWm2UFjHloWYx5motFixYVHQEAKFCzK168//77ddtt27Zd5bHt2rWr2168ePFKjzv77LNz+sdeAVJVVZW+fftmr732SteuXVcjLQ2turo69957b/bcc8+0adOm6DhAIzPmoeUx7mE1zZqV7LVXaYaLu+5KuncvOtEqGfPQiGprk29/u1TCuuKKZNSoohMZ89DCGPM0N8tmygYAWqZ6FS8qKipW+xNfccUVGTNmzGqf55Pat29ft71kyZJVHvvx5UM6dOiw0uPatWu3XEljmTZt2nhSUKZ8b6BlMeah5THuoR7mzUv23TdZujS5/fakV6+iE31mxjw0kp/9LJk/PznyyNLvhb33LjpREmMeWhpjnubCzzEAtGyVRQdoaF26dKnbXtXyIUny3nvv1W3/q2VJAAAAmqyqqmSffZK3307uvTdZf/2iEwHloLKyNNvF3nsnBx2UTJ5cdCIAAABokuo148W0adNW+xOvt956q32OFdlggw3qtmfNmrXKY2fOnFm33bdv30bJAwAAUKiamuSQQ5KXXkoeeijZZJOiEwHlpE2b5PrrS+WL/fZLnnoq6dev6FQAAADQpNSreDFo0KCGztFgunTpkr59+2bmzJl54YUXVnnsx+8fPHhwY0cDAABY8371q9IsF/fck2y5ZdFpgHLUoUNy223JVlslxxyT3HdfaTYMAAAA4DNpls+id9xxxyTJ3/72t7z++usrPe7BBx+s2x4+fHij5wIAAFijpk9PzjorOeWUZM89i04DlLNu3UrLjjzwQHLxxUWnAQAAgCalXjNelLsDDzww1157bZLkyiuvzHe+851PHbNo0aJcf/31SZIhQ4ZkwIABazQjAABAo/rww+Too5MNNkh+9KOi07AGjRs3Ls8//3yjnX/dddfNd77znVRUVDTa56Agu++enHpq8p3vJPvskwwcWHQiAAAAaBKaZfFi1KhR2XjjjfPyyy/nhz/8YQ499ND0799/uWPOPPPMLFiwoG4bAACgWbnwwmTKlOThh5NOnYpOwxp05n+emfZpkx6dujf4uaveX5jZb7+eE044IT169Gjw81MGfvSj5O67S8WtSZOS1s3yT0cAAADQoMru2fOLL76YSZMmLbdv4cKFdW+vvPLK5e7bZ599su666y63r02bNrn44oszYsSIVFVVZfjw4Tn33HOz3XbbZcGCBbnsssty4403JiktS3LUUUc13hcEAACwpj37bHLeecl//mfypS8VnYY1rbY2JwwdnRO3O7zBT3339Idz/M3nNPh5KSMdOyYTJiQ77phccEFy9tlFJwIAAICyV3bFi0mTJuWYY45Z4X1vvvnmp+67//77P1W8SJL99tsvl1xySU455ZTMnTs3p5566qeO2W677XLzzTenVatWDRMeAACgaLW1yfHHJ5tumpx/ftFpaGZefusfad+ufTp27Fh0FBrTsGHJt7+dfPe7yWGHJZ+YRRQAAABYXtkVLxrS8ccfn2HDhuWXv/xl7rvvvsyZMyedOnXK4MGD89WvfjVjx45Na1NmAgAAzclDDyWPP57cdVfSvn3RaSjIX1+blt89c+dqnaNXp7WzW/8d6t6vra3N756/KwcffHA6dOiwuhEpd+edl1x+eXLRRckvf1l0GgAAAChrZdc6GDNmTMaMGdNg59t8880zbty4BjsfAABAWfvZz5IhQ5K99y46CQXZeOONc8cz9+eOF+5frfO0qmyVF8+4N60rS386eGL2s3l5/j9y+djjGiIm5a5Dh+Tkk5Of/rQ0e0737kUnAgAAgLJVWXQAAAAAGsj06cnttyenn55UVBSdhoL85a9PZenSpat122arrbN7/2F1pYskue7pidnoC/2yyy67FPjVsUadfHJSXZ14QQsAAACskuIFAABAc/GLXyTrrJN89atFJ6FAFRUVadWqVb1vzz77bJ56+q85fIv96s658INFmTj9/hw79rhUVvpTQovRu3dy5JGlpUaWLCk6DQAAAJQtfy0BAABoDt58M7nyyuSUU5L27YtOQxM2fvz49OrSI7v336Fu3+0v/CmLqz9o0KVBaSJOPz2ZMye5/vqikwAAAEDZUrwAAABoDsaPT2prk5NOKjoJTdj777+f3/7m6hw8ZK/llhn53XN3Zu+99kqfPn0KTEchNtss2Xvv0qwXAAAAwAopXgAAADQH992X7L57aakRqKdbbrklC955O6O32L9u39/nv5o/z3oux40dW2AyCjV6dPLkk8k77xSdBAAAAMqS4gUAAEBTV1OTPP54MmxY0UkoQ7W1tZn93vt5Yt47mfzG2/nz/Kq8+UH1Co8df/n4bNd3y/TvsWHdvuuemZiea/fIyJEj11Rkys2wYaUZdaZMKToJAAAAlKXW//oQAAAAytoLL5Reia54wSfMWLg4U+ZVZeHSD5fb/8yChWlfWZmtenTOoLU6pbKiIjNmzMh9f7ovF+xzVt1x1R8uzY3T7smRx30tbdu2XdPxKRcDBiTduyeTJyd77ll0GgAAACg7ihcAAABN3eTJSWVlst12RSehjPy9alEmzX277v3KJUtS87HyxPs1NXl8XlUen1eVfp3b575x49KxbYd8edCudcf88aVH8+bCBRlrmZGWrbIy2X770u8aAAAA4FMsNQIAANDUTZ6cbL550qVL0UkoE28vqc4jHytdbDTx1hw4Yo90em32Co+f+8L0TLjgwowcuHs6te1Yt/93z07Mtv+2bTbffPPGjky5GzYseeyx0tJGAAAAwHIULwAAAJq6xx6zzAjLeeHtRXXblUuWZJtfXpi1Xnk5+xx56KfKF51em532ow/IrOolOXzL/ev2v/7u/Nz/0uMZe7zZLkjpd8zbbyd/+1vRSQAAAKDsKF4AAAA0dTNnJptsUnQKykRNbW3+XrUotcveb9s2f7jyulT1/UK6zpyxXPmi02uzs8+Rh+a6efOyafc+2Wb9IXXnueG5u9OuXbscfvjhBXwVlJ0BA0pvZ80qNgcAAACUIcULAACApm7RoqRTp6JTUCaWfFiTpbW1y+17b70NcvfVv1+ufNHrL09knyMPTfXMGbm5oiKjtx6ZioqKJEltbW1+9/ydOeSQQ7LWWmsV8WVQbjr+cwmaRYtWfRwAAAC0QIoXAAAATVl1dbJ0adKhQ9FJKBPLyhOf9Mnyxf6HH5iuM2fk1926p6aiIgdvtnfdsY/PejqvvjkrY447dk3Fptwt+x2zeHGxOQAAAKAMKV4AAAA0ZTU1pbeVnt5R0rayIh1arfjn4b31NsjDF1xU935tkku6dssem3wpPTt1r9t/3TMT07tvv2yzw5caOy5NxbLfMR9+WGwOAAAAKEP+MgcAANCUtW2bVFR4FTp1KioqMmitTlnRvBedXpudnc78Vt37f0ny8j9eyVe2/HLdvnc/eC8T//ZAhh8yOi6xU2fZ75hlS44AAAAAdRQvAAAAmrKKitKFUMULPmbAWh3TunL56kWn12ZnnyMPTdeZM1LV9wuZeN0tuaRz56zbsXt22Who3XG3TbsvSz6szvBRh6ZD61ZrOjrlatnvGMsaAQAAwKcoXgAAADR1PXokc+YUnYIy0rF1q+y5/tpZVpv4ZOni7qt/n1lDNs+1NcnBW+6f1pWt6z722mcnZouddsvAfhumk+IFy7z2Wunt2msXmwMAAADKkOIFAABAUzd0aPL440WnoMz07tAuIzdcJxu0TvYec/hypYv31tsgf77nrry3aGFGb7lf3ce8MO/lPD1nWnY85PAM6da5wPSUncmTS0sbbbVV0UkAAACg7CheAAAANHXDhiVPPJFUVxedhDLTrV2b7LXR+qk8//tZuHH/utJFkky6/tpsv+HW2ah7n7rjf/fMnenarUcOHDki/Tq3Lyo25eixx5IvfjFp167oJAAAAFB2FC8AAACaumHDksWLk2eeKToJZarLUV9N52lTs9+wbdKnY7u88Y8ZmTbl0Ry+xUezXSz5sDo3Trsn+x9+eHbv2ysVFRUFJqbsTJ5c+l0DAAAAfIriBQAAQFP3xS8mbdqULozCyrRtm85tWmfPDXrk3fsnpkv7Ttl/4K51d//xxUey4L23c+6pJ6dS6YKPe/315NVXFS8AAABgJRQvAAAAmrr27Uvli8ceKzoJTcCHH36YCVdcmQMG7ZEObT5aTuS6Z+/MDtttnyFDhhSYjrK0rNSleAEAAAArpHgBAADQHAwfnvzxj8mSJUUnoczde++9mTVndkZvuX/dvteq3siDL0/JsWOPKzAZZeuuu5INN0z69Ck6CQAAAJQlxQsAAIDm4Ljjkrlzk9/9rugklLnxl1+eQb02zlbrDqrb9/vn7k779u0zevToApNRlubPT37zm+T444tOAgAAAGVL8QIAAKA5GDIk2Xff5Kc/TWpri05DmZo3b15uvfW2jN58v1RUVCRJamprcv3zd+Wwww5L165dC05I2bnkkqSiIjnppKKTAAAAQNlSvAAAAGguTj89efrp5P77i05Cmfrtb3+b1NbmoM32qtv32D/+mhlvzc6xxx1bYDLK0vvvJ//zP8nRRyc9exadBgAAAMqW4gUAAEBzscceyZZblma9gE+ora3N+Msuz16b7Ji1O3ar2/+7Z+/Mpv03yY477lhcOMrTtdeWljA67bSikwAAAEBZU7wAAABoLioqSrNe3HlnMm1a0WkoM0888USem/p8Rm+5f92+d95/N3dOfzDHjj2ubukRSFJasuhnP0u+/OVk4MCi0wAAAEBZU7wAAABoTr7ylWS99ZJzzy1dOIV/Gj9+fNZfq1d27rdt3b7bpv0p1TVLc/TRRxeYjLL0u98lzz2XnHFG0UkAAACg7CleAAAANCdt2ya/+EVy002lC6eQZNGiRbnumutyyJB90qqyVd3+3z03Mfvtu2/WW2+9AtNRdl5/PfnGN5JDD0122aXoNAAAAFD2FC8AAACam8MOS0aPTk4+OXnttaLTUAZuuOGGVC2symFb7le3b9obL+XpOS/k2OOOKzAZZae2Njn++KR16+R//7e0hBEAAACwSq2LDgAAAEAj+NWvks02K11Avf12F09buGuvuSatKlvl+FvPrdu3YNE76b1Or+y///4FJqPsXHllcscdya23Jj17Fp0GAAAAmgTFCwAAgOaoR4/kssuSkSOTK65Ijj226EQU6LixYzNg4MBP7d9zzz3Tpk2bAhJRlmbMSL71reToo0u/OwAAAIDPRPECAACguRoxIjnmmOS005I99ki+8IWiE1GQQw45JIccckjRMShnNTWlgla3bslFFxWdBgAAAJqUyqIDAAAA0Ih+/vOke/dk1KikqqroNEC5+q//Sv70p2T8+GSttYpOAwAAAE2K4gUAAEBzttZaye23J6+8Ulo6YPHiohMB5eYnP0l+/ONSUWvPPYtOAwAAAE2O4gUAAEBzt+WWyR13JFOmJKNHJ9XVRScCysXllydnnZWce25pWSIAAADgc1O8AAAAaAmGD09uuim5++7kuOOSmpqiEwFFu/HG5MQTk5NPTr7//aLTAAAAQJOleAEAANBS7LNP8pvfJFdfnZx+elJbW3QioCh//GNyxBHJYYclF1+cVFQUnQgAAACarNZFBwAAAGANGj06WbAg+frXk7XWSr73PRdcoaV59NHkwAOT3XdPJkxIKr0uBwAAAFaH4gUAAEBLc9JJyTvvJN/5TjJzZnLJJUnbtkWnAtaEa69Njjkm2X770lIjxj4AAACsNi9pAAAAaInOOiu56qrkt79N9twzmT+/6ERAY6qpSb773Y+WF/nDH5KOHYtOBQAAAM2C4gUAAEBLddRRyf33J9OmlV79PnVq0YmAxrBoUXL44cn3v5/84Ael5UXaty86FQAAADQbihcAAAAt2Ze+lEyZUnrl+7Bhyd13F50IaEhz5iS77JJMnFhaWuTss5OKiqJTAQAAQLOieAEAANDS9euXPPposvPOyf77JxdfnNTWFp0KWF1//nMydGjy+uvJpEnJQQcVnQgAAACaJcULAAAAki5dkltuSf7jP5JvfrO0LMH8+UWnAurjww+Tn/882XHHZIMNSrPabLNN0akAAACg2VK8AAAAoKRVq+TCC5Prrkv++Mdks82Sm28uOhXwebz4YrLrrsnppycnnJA8+GCy3npFpwIAAIBmTfECAACA5Y0enTz/fDJsWGlpgiOOSN58s+hUwKrU1CS//GWy5ZbJnDnJAw8kF12UdOhQdDIAAABo9loXHaApqv3nWsdVVVUFJ+GTqqurs2jRolRVVaVNmzZFxwEamTEPLY9xD2tQx47JhAnJ9dcn3/52Mnhw6SLu/vuvsQjGPHxGr7ySnHxy8uijpVkuvve9pFOnpIn93cKYh5bFmKe5WXa9YNn1AwCgZamo9b+Az23WrFnp27dv0TEAAAAAAIAyMnPmzPTp06foGADAGqZ4UQ81NTWZM2dOunTpkoqKiqLj8DFVVVXp27dvZs6cma5duxYdB2hkxjy0PMY9tCzGPLQsxjy0LMY8zU1tbW3efffdrL/++qmstMo7ALQ0lhqph8rKSo3VMte1a1dP2KAFMeah5THuoWUx5qFlMeahZTHmaU7WWmutoiMAAAVRuwQAAAAAAAAAqCfFCwAAAAAAAACAelK8oFlp165dvvvd76Zdu3ZFRwHWAGMeWh7jHloWYx5aFmMeWhZjHgCA5qSitra2tugQAAAAAAAAAABNkRkvAAAAAAAAAADqSfECAAAAAAAAAKCeFC8AAAAAAAAAAOpJ8QIAAAAAAAAAoJ4ULwAAAAAAAAAA6knxgmZh4cKFeeihh3LhhRfmsMMOy0YbbZSKiopUVFSkX79+n/t8zz33XE488cT0798/HTp0yDrrrJOddtopl1xySZYuXdrwXwDQ4Hbddde63wP/6gaUvxkzZuSMM87IoEGD0qlTp6y99toZOnRoLrjggixatKjoeEAD+KyP27vuumvRUYF/4Y033sgdd9yR8847L/vuu2969uxZN4bHjBnzuc931113ZdSoUenTp0/atWuXPn36ZNSoUbnrrrsaPjxQLw0x7q+88srP/P+BK6+8slG/HgAA+LxaFx0AGsKIESPywAMPNMi5LrvsspxyyilZsmRJ3b73338/kyZNyqRJk3LFFVdk4sSJ6dmzZ4N8PgBg1W6//fYceeSRqaqqqtu3aNGiPPnkk3nyySdz+eWXZ+LEidlkk00KTAkALNO7d+8GOU9NTU1OOOGEjB8/frn9s2fPzuzZs3PLLbdk7NixufTSS1NZ6bVFUKSGGvcAANBUKV7QLNTW1tZtr7322tl2223z6KOPZuHChZ/rPHfeeWdOOumk1NTUpHfv3jnnnHOy/fbb56233spll12Wm266KVOmTMmoUaPywAMPpFWrVg39pQANbNttt80VV1xRdAygnp566qmMHj06ixcvTufOnXP22Wdnt912y+LFi3Pdddflsssuy/Tp07P//vvnySefTJcuXYqODKymr3/96zn55JNXen+nTp3WYBpgdW244YYZNGhQ7rnnns/9seecc05d6WKbbbbJt7/97fTv3z8vvfRSfvKTn+Spp57K5ZdfnnXWWSc/+MEPGjo6UE+rM+6X+cMf/pD1119/pff36dOn3ucGAIDGoHhBs3DEEUfkxBNPzNChQ+te7dqvX7/PVbyorq7OqaeempqamnTt2jWPPPJI+vfvX3f/Pvvsk2984xv53//930yaNCm/+c1v6jVFKrBmderUKZtvvnnRMYB6+ta3vpXFixendevWueeeezJs2LC6+3bfffdsuumm+fa3v53p06fnpz/9ab73ve8VFxZoEL169fLYDU3ceeedl6FDh2bo0KHp3bt3Xn311Wy00Uaf6xzTp0/PhRdemKRUpn7ooYfSoUOHJMnQoUMzcuTI7LLLLnnyySdzwQUX5NhjjzX7FRSoIcb9xw0YMKBeywcDAEBRzMNIs3DCCSfkK1/5ymr9keXmm2/Oyy+/nCQ5++yzlytdLHPBBReke/fuddsAQOOZMmVKHn744STJcccdt1zpYpkzzjgjgwcPTpJcdNFFqa6uXqMZAYBPO//88/PlL395tZYe+MUvfpGlS5cmSS6++OK60sUyHTt2zMUXX5wkWbp0aX7+85/XPzCw2hpi3AMAQFOmeAH/dMstt9Rtr2wmi44dO+awww5LkkydOjXTp09fA8kAoGX6+GPzMcccs8JjKisr87WvfS1J8vbbb+f+++9fE9EAgEZUW1ubW2+9NUkyaNCg7LDDDis8bocddsjAgQOTJLfeeutyy5ACAADAmqR4Af80adKkJMnAgQOz7rrrrvS4XXbZpW77kUceafRcANBSLXts7tSpU/7t3/5tpcd5bAaA5uWVV17JnDlzkiz/OL8iy+6fPXt2Xn311caOBgAAACukeAFJFi5cmJkzZyYpvZpmVT5+/7Rp0xo1F7D6XnjhhWy//fbp1q1b2rdvnz59+uSAAw7IVVddZUkCKHPLHmc32WSTtG7deqXHeWyG5uX3v/99hgwZko4dO6ZLly7ZdNNNc/TRR5vRBlqQqVOn1m17jg4t0zHHHJP1118/bdu2Tc+ePbPDDjvk3HPPzezZs4uOBgAAK6R4AUlmzZpVt92nT59VHtu3b9+67WVlDaB8zZ07N1OmTMk777yTDz74ILNnz85tt92Wo48+OltvvbU/zkKZev/99zN//vwk//qxuXv37unUqVMSj83QHEydOjXTpk3L4sWLs3Dhwrz44ou56qqrsvvuu2fUqFF55513io4INDLP0YEHHnggr732Wqqrq/Pmm2/m8ccfz//7f/8vm2yySS699NKi4wEAwKes/KWD0IK8++67ddudO3de5bHLLuwkpZkygPJUWVmZPfbYI/vtt1+22mqr9OjRI++++27+8pe/5NJLL820adMyderU7LbbbpkyZUo23HDDoiMDH/N5HpuT0uPze++957EZmrCOHTtm5MiR2WOPPTJo0KB07tw58+bNy4MPPphLLrkkb775Zm655ZYccMABuffee9OmTZuiIwONxHN0aLk23njjHHTQQRk2bFhdserll1/OjTfemBtuuCHvv/9+TjrppFRUVOSEE04oOC0AAHxE8QJSelXtMm3btl3lse3atavbXrx4caNlAlbPTTfdlG7dun1q/0477ZSTTz45xx9/fCZMmJC5c+fmtNNOy0033bTmQwIr9Xkem5OPHp89NkPTNXv27BU+du+555459dRTs+++++app57Kgw8+mP/7v//LN7/5zTUfElgjPEeHlmnUqFE5+uijU1FRsdz+oUOHZvTo0bnjjjty0EEHpbq6Ov/xH/+RkSNHZt111y0oLQAALM9SI6wxFRUVq3278sorGyVb+/bt67aXLFmyymM/+OCDuu0OHTo0Sh5oKRrz98KKLtws06ZNm1x++eUZOHBgkuTmm2+2TiyUmc/z2Jx89PjssRmarlU9dvfu3Ts33HBD3SwXF1988RpKBRTBc3RomdZaa61PlS4+7stf/nLOO++8JMmiRYsyfvz4NRUNAAD+JcULSNKlS5e67X81Nel7771Xt/1Zpj4HylPr1q1z3HHH1b3/4IMPFpgG+KTP89icfPT47LEZmq+NN944e+65Z5LkxRdfzJw5cwpOBDQWz9GBlTnhhBPqyhmexwMAUE4sNcIaM23atNU+x3rrrdcAST5tgw02qNueNWvWKo+dOXNm3faytSaB+in698KQIUPqts14AeWlffv26dGjR958881/+di8YMGCuosuHpuheRsyZEjuvPPOJKXH7vXXX7/gREBj6NOnT9225+jAx/Xq1Ss9evTI/PnzPY8HAKCsKF6wxgwaNKjoCCvVpUuX9O3bNzNnzswLL7ywymM/fv/gwYMbOxo0a0X/XljVFKZA8YYMGZKHH344L774YpYuXZrWrVf8X1ePzdByeOyGluHjBWnP0YFP8v8BAADKkaVG4J923HHHJMnf/va3vP766ys97uPTGA4fPrzRcwGNZ+rUqXXbXjEL5WfZY/N7772XP//5zys9zmMztBweu6Fl2GijjerG+L9aSuChhx5KUprJsl+/fo0dDSjYvHnzMn/+/CT+LwAAQHlRvIB/OvDAA+u2r7zyyhUes2jRolx//fVJSq/AGTBgwBpIBjSGpUuX5te//nXd+zvvvHOBaYAV+fhj8xVXXLHCY2pqanLVVVclSbp165bddtttTUQDCvDKK6/k3nvvTZL0799/ueUCgealoqIiBxxwQJLSjBaPPfbYCo977LHH6ma8OOCAA7wKHlqAcePGpba2Nkmyyy67FJwGAAA+ongB/zRq1KhsvPHGSZIf/vCHeemllz51zJlnnpkFCxbUbQPl6f7778/bb7+90vurq6szduzYTJs2LUkyYsQI60FDGdpuu+2y0047JUnGjx+fyZMnf+qYn/70p3Vj+Vvf+lbatGmzRjMCDeP222/P0qVLV3r/3Llzc/DBB2fJkiVJkpNPPnlNRQMKctppp6VVq1ZJklNPPTWLFy9e7v7Fixfn1FNPTZK0bt06p5122pqOCDSgV199NU899dQqj7njjjvy/e9/P0nSoUOHHHPMMWsiGgAAfCYrXigbmpgXX3wxkyZNWm7fwoUL695+cgaLffbZJ+uuu+5y+9q0aZOLL744I0aMSFVVVYYPH55zzz032223XRYsWJDLLrssN954Y5LS1OdHHXVU431BwGqZMGFCRo4cmZEjR2bXXXfNwIED07Vr1yxcuDB//vOfM27cuLqpynv16pWLLrqo4MTAylx00UUZPnx4Fi9enL322iv/9V//ld122y2LFy/Oddddl3HjxiVJBgwYkDPOOKPgtEB9nXrqqamurs7BBx+cYcOGpV+/funQoUPmz5+fBx54IJdeemndtOI77rhjvvGNbxScGFiVSZMm5cUXX6x7f9n4TUrP3z/5HH3MmDGfOseAAQNy5pln5kc/+lGefPLJDB8+PGeddVb69++fl156KT/+8Y/rLtKeeeaZ2XTTTRvlawE+m9Ud96+++mp22223DBs2LCNGjMhWW22VXr16JUlefvnl3HDDDbnhhhvqZru48MILzX4FAEBZqahd9r9VaMKuvPLKz9Vyv//++7Prrruu8L7LLrssp5xySt2r6T5pu+22y8SJE9OzZ8/6RAXWgDFjxmTChAn/8rgtttgi1113XYYMGbIGUgH1dfvtt+fII49MVVXVCu8fMGBAJk6cmE022WQNJwMaSr9+/TJjxox/edzBBx+cyy+/PN26dWv8UEC9fdb/jy+zsj9N1dTU5Pjjj19uicBPOu644zJu3LhUVprUFYq0uuP+gQce+EzLBnbs2DE///nPc8IJJ3zujAAA0JjMeAGfcPzxx2fYsGH55S9/mfvuuy9z5sxJp06dMnjw4Hz1q1/N2LFj07q1oQPl7KyzzsrWW2+dyZMnZ+rUqZk3b17eeuuttGvXLr179862226bQw45JKNGjaqbvhgoXyNGjMgzzzyTiy66KBMnTsysWbPStm3bbLLJJjn00ENzyimnpGPHjkXHBFbDhAkT8uCDD2by5Ml5+eWXM3/+/FRVVaVz587p27dvvvSlL+Xoo4/OsGHDio4KrEGVlZUZP358Dj744IwbNy5PPPFE5s+fn549e2bo0KE58cQTs++++xYdE2gA//Zv/5arr746kydPzpNPPpnXXnst8+fPz9KlS9O9e/dsttlm2WOPPTJ27Ni6mTAAAKCcmPECAAAAAAAAAKCezMMIAAAAAAAAAFBPihcAAAAAAAAAAPWkeAEAAAAAAAAAUE+KFwAAAAAAAAAA9aR4AQAAAAAAAABQT4oXAAAAAAAAAAD1pHgBAAAAAAAAAFBPihcAAAAAAAAAAPWkeAEAAAAAAAAAUE+KFwAAAAAAAAAA9aR4AQAAAAAAAABQT4oXAAAAAAAAAAD1pHgBAAAAAAAAAFBPihcAAAAAAAAAAPX0/wPuiEy3Yl+EewAAAABJRU5ErkJggg=="
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "labels = gera_comparacao(list_preprossing, result['labels'].to_numpy())\n",
    "fig, ax = plt.subplots(figsize=figsize)\n",
    "plt.scatter(result.x, result.y, c=result.labels, s=70,cmap=color_maps)\n",
    "distances = pairwise_distances(result[['x', 'y']], centroids)\n",
    "avg_distance = np.mean(distances, axis=1)\n",
    "radius_factor = 0.2\n",
    "adjusted_radius = avg_distance * radius_factor\n",
    "for centroid, radius in zip(centroids, adjusted_radius):\n",
    "    circle = plt.Circle((centroid[0], centroid[1]), radius=radius, color='red', fill=False)\n",
    "    ax.add_artist(circle)\n",
    "    plt.scatter(centroid[0], centroid[1], c='red', s=50, marker='x')\n",
    "\n",
    "for i, c in enumerate(centroids):\n",
    "    ax.scatter(c[0], c[1], marker='$%d$' % (i+1), alpha=1,\n",
    "                s=700, edgecolor='k')\n",
    "\n",
    "legend_labels = [f\"{str(i+1)}:{label[0]}: {round(label[1], 2)} TF-IDF\" for i, label in enumerate(labels)]\n",
    "legend_colors = map_labels_to_colors(np.arange(len(legend_labels)), color_maps)\n",
    "legend_elements = [mpatches.Patch(color=color, label=label) for color, label in zip(legend_colors, legend_labels)]\n",
    "plt.xticks(fontsize=20)\n",
    "plt.yticks(fontsize=20)\n",
    "\n",
    "# Position the legend outside the plot on the right side\n",
    "plt.legend(handles=legend_elements, bbox_to_anchor=(1.001,1), loc='upper left', borderaxespad=0.0, borderpad=4.6, fontsize=14)\n",
    "plt.grid(True)\n",
    "# plt.show()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-05-24T14:35:13.293448126Z",
     "start_time": "2023-05-24T14:35:12.245601444Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "outputs": [
    {
     "data": {
      "text/plain": "<Figure size 1000x500 with 1 Axes>",
      "image/png": "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"
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from sklearn.preprocessing import MinMaxScaler\n",
    "\n",
    "variances = []\n",
    "differences = []\n",
    "\n",
    "x_clusters = 30\n",
    "cluster_selecionado = 21\n",
    "\n",
    "\n",
    "# Testar diferentes valores de k (número de clusters)\n",
    "for k in range(1, x_clusters):\n",
    "    kmeans = KMeans(n_clusters=k, n_init='auto')\n",
    "    kmeans.fit(reduce_embedding_umap)\n",
    "    variances.append(kmeans.inertia_)  # Variância explicada\n",
    "\n",
    "# Calcular as diferenças adjacentes\n",
    "for i in range(1, len(variances) - 1):\n",
    "    # diff = variances[i+1] - 2 * variances[i] + variances[i-1]\n",
    "    diff = variances[i+1] -  variances[i]\n",
    "    differences.append(diff)\n",
    "\n",
    "# Normalizar os valores de variances e differences entre 0 e 1\n",
    "scaler = MinMaxScaler()\n",
    "variances_normalized = scaler.fit_transform(np.array(variances).reshape(-1, 1)).flatten()\n",
    "differences_normalized = scaler.fit_transform(np.array(differences).reshape(-1, 1)).flatten()\n",
    "\n",
    "# Encontrar o índice com a maior diferença na aceleração\n",
    "max_diff_index = differences_normalized.argmax()\n",
    "\n",
    "# Plotar a curva do método do cotovelo\n",
    "fig, ax1= plt.subplots(1, figsize=(10,5))\n",
    "\n",
    "ax1.plot(range(1, x_clusters), variances_normalized, marker='o')\n",
    "ax1.plot(range(1, cluster_selecionado+1), [variances_normalized[i] for i in range(cluster_selecionado)], marker='x', c='r')\n",
    "ax1.scatter(cluster_selecionado, variances_normalized[cluster_selecionado], marker='x',s=500, c='r')\n",
    "ax1.scatter(7, variances_normalized[7], marker='x',s=500, c='r')\n",
    "ax1.set_xlabel('Número de clusters',fontsize=20)\n",
    "ax1.set_ylabel('Inércia (normalizada)',fontsize=20)\n",
    "# ax1.set_title('Método de Elbow (Cotovelo)',fontsize=30)\n",
    "plt.xticks(fontsize=15)\n",
    "plt.yticks(fontsize=15)\n",
    "for i, var in enumerate(variances_normalized[:x_clusters]):\n",
    "    if i == cluster_selecionado-1:\n",
    "        ax1.annotate(f'{var:.2f}', (i+1, var), textcoords=\"offset points\", xytext=(0,12), ha='center',font={'size':8},color='r')\n",
    "    else:\n",
    "        ax1.annotate(f'{var:.2f}', (i+1, var), textcoords=\"offset points\", xytext=(0,8), ha='center',font={'size':8})"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-05-24T14:30:35.234673691Z",
     "start_time": "2023-05-24T14:30:34.658394180Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "outputs": [
    {
     "data": {
      "text/plain": "Text(0.5, 0.98, 'Análise Silhouette (silhueta) n_clusters = 7')"
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": "<Figure size 900x500 with 2 Axes>",
      "image/png": "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"
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "try:\n",
    "    from matplotlib.cm import spectral as color_map\n",
    "except ImportError:\n",
    "    from matplotlib.cm import summer as color_map\n",
    "silhouette_avg = silhouette_score(reduce_embedding, result[\"labels\"].to_numpy())\n",
    "sample_silhouette_values = silhouette_samples(reduce_embedding, result[\"labels\"].to_numpy())\n",
    "\n",
    "fig, (ax1, ax2) = plt.subplots(1, 2,figsize=(20,20))\n",
    "fig.set_size_inches(9, 5)\n",
    "\n",
    "ax1.set_xlim([-0.1, 1])\n",
    "ax1.set_ylim([0, len(reduce_embedding) + (kmeans.n_clusters + 1) * 10])\n",
    "centers = kmeans.cluster_centers_\n",
    "n_clusters = centers.shape[0]\n",
    "y_lower = 10\n",
    "for i in range(n_clusters):\n",
    "    ith_cluster_silhouette_values = sample_silhouette_values[kmeans.labels_ == i]\n",
    "    ith_cluster_silhouette_values.sort()\n",
    "\n",
    "    size_cluster_i = ith_cluster_silhouette_values.shape[0]\n",
    "    y_upper = y_lower + size_cluster_i\n",
    "\n",
    "    color = color_map(float(i) / n_clusters)\n",
    "    ax1.fill_betweenx(np.arange(y_lower, y_upper),\n",
    "                      0, ith_cluster_silhouette_values,\n",
    "                      facecolor=color, edgecolor=color, alpha=0.7)\n",
    "\n",
    "    ax1.text(-0.05, y_lower + 0.5 * size_cluster_i, str(i+1))\n",
    "    y_lower = y_upper + 10\n",
    "\n",
    "ax1.set_title(\"Score silhouette / clusters.\")\n",
    "ax1.set_xlabel(\"silhouette (silhueta)\")\n",
    "ax1.set_ylabel(\"Cluster\")\n",
    "\n",
    "ax1.axvline(x=silhouette_avg, color=\"red\", linestyle=\"--\")\n",
    "ax1.text(silhouette_avg, ax1.get_ylim()[1], f\"{silhouette_avg+0.01:.2f}\", va='bottom', ha='center', fontdict={'size':10},color='g')\n",
    "ax1.set_yticks([])\n",
    "ax1.set_xticks([ 0, 0.2, 0.4, 0.6, 0.8, 1])\n",
    "\n",
    "colors = color_map(kmeans.labels_.astype(float) / n_clusters)\n",
    "ax2.scatter(reduce_embedding[:, 0], reduce_embedding[:, 1], marker='.', s=30,\n",
    "            lw=0, alpha=0.7, c=colors, edgecolor='k')\n",
    "ax2.scatter(centers[:, 0],centers[:, 1], marker='o',\n",
    "            c=\"white\", alpha=1, s=200, edgecolor='k')\n",
    "\n",
    "for i, c in enumerate(centers):\n",
    "    ax2.scatter(c[0], c[1], marker='$%d$' % (i+1), alpha=1,\n",
    "                s=50, edgecolor='k')\n",
    "\n",
    "\n",
    "plt.suptitle((\"Análise Silhouette (silhueta)\"\n",
    "              \" n_clusters = %d\" % n_clusters),\n",
    "             fontsize=14, fontweight='bold')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-05-24T14:55:41.920179949Z",
     "start_time": "2023-05-24T14:55:41.401128234Z"
    }
   }
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
